

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34711 A1

(51) International Patent Classification⁷: **C07C 229/38**, 317/22, 63/04, 257/00, C07D 333/22, 307/02, 277/30, 207/30, 207/08, 211/70, 311/78, 239/02, 265/30, 277/62, 211/70, 317/44, 231/56, A61K 31/24, 31/69, 31/38, 31/34, 31/38, 31/34, 31/255, 31/425, 31/40, 31/55, 31/495, 31/505, 31/535, 31/425, 31/415, 31/44, 31/27, 31/155

(US). **NIWAS, Shri** [US/US]; 3348 Castle Crest Drive, Birmingham, AL 35244 (US).

(74) Agents: **AMERNICK, Burton, A.** et al.; Connolly Bove Lodge & Hutz LLP, P.O. Box 19088, Washington, DC 20036 (US).

(21) International Application Number: PCT/US01/32582

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 22 October 2001 (22.10.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): **BIOCRYST PHARMACEUTICALS, INC.** [US/US]; 2910 Parkway Lake Drive, Birmingham, AL 35244 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BABU, Yarla-gadda, S.** [IN/US]; 3441 Strollway Drive, Birmingham, AL 35226 (US). **ROWLAND, Scott, R.** [US/US]; 3436 Tamasee Lane, Hoover, AL 35226 (US). **CHAND, Pooran** [US/US]; 509 Creekwood Place, Birmingham, AL 35226 (US). **KOTIAN, Pravin, L.** [IN/US]; 1313 Atkins Trimm Blvd., Birmingham, AL 35226 (US). **EL-KATTAN, Yahya** [LB/US]; 5023 Rime Village, Hoover, AL 35216



WO 02/34711 A1

(54) Title: BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS

(57) Abstract: Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS
DESCRIPTION

Cross-Reference to Related Applications

This application is a continuation-in-part of copending U. S. applications S.N. 60/241,848 filed October 20, 2000 and entitled "Inhibitors for Activated Blood Coagulation Factor VIIa (FVIIa)" and S.N. 60/281,735 filed April 6, 2001 and entitled "Biaryl Compounds as Serine Protease Inhibitors"

Technical Field

The present invention relates to the identification, through synthesis and testing, of heretofore unreported compounds which, in appropriate pharmaceutical compositions, exert a therapeutic effect through reversible inhibition of serine proteases.

Background of Invention

Serine proteases make up the largest and most extensively studied group of proteolytic enzymes. Their critical roles in physiological processes extend over such diverse areas as blood coagulation, fibrinolysis, complement activation, reproduction, digestion, and the release of physiologically active peptides. Many of these vital processes begin with cleavage of a single peptide bond or a few peptide bonds in precursor protein or peptides. Sequential limited proteolytic reactions or cascades are involved in blood clotting, fibrinolysis, and complement activation. The biological signals to start these cascades can be controlled and amplified as well. Similarly, controlled proteolysis can shut down or inactivate proteins or peptides through single bond cleavages.

While serine proteases are physiologically vital, they also can be hazardous. Their proteolytic action, if uncontrolled, can destroy cells and tissues through degradation of proteins. As a natural safeguard in normal plasma, 10% of the protein matter is composed of protease inhibitors. The major natural plasma inhibitors are specific for serine proteinases. Diseases (associated protease given in the parentheses) such as pulmonary emphysema (cathepsin G), adult respiratory distress syndrome (chymases), and pancreatitis (trypsin, chymotrypsin, and others) are characterized by uncontrolled serine proteases. Other proteases appear to be involved in tumor invasion (plasmin, plasminogen activator), viral transformation, and inflammation (kallikrein). Thus the design and synthesis of specific inhibitors for this class of proteinases could offer major therapeutic benefits.

Thrombus formation, that is blood coagulation, is normally initiated by tissue injury; its normal purpose is to slow or prevent blood loss and facilitate wound healing. There are other conditions, however, not directly connected with tissue injury that may promote the coagulation process and lead instead to harmful consequences; examples of such conditions are atherosclerosis and inflammation.

The complex pathways of blood coagulation involve a series of enzyme reactions in which plasma coagulation factors, actually enzyme precursors or zymogens, are sequentially activated by limited proteolysis. Blood coagulation, or the coagulation cascade, is viewed mechanistically as two pathways, the extrinsic and the intrinsic (Fig. 1). Each pathway proceeds through a sequence of the Roman-numeral-designated factors until they converge at the activation of factor X after merger of the pathways. Thrombin generation proceeds stepwise through a common pathway. Thrombin then acts on the solution plasma protein, fibrinogen, to convert it to stable insoluble fibrin clots, thus completing the coagulation cascade.

The extrinsic pathway is vital to the initiation phase of blood coagulation while the intrinsic pathway provides necessary factors in the maintenance and growth of fibrin. The initiation of the coagulation cascade involves the release of tissue factor (TF) from injured vessel endothelial cells and subendothelium. TF then acts upon factor VII to form 5 the TF/FVIIa complex (where VIIa designates the activated factor rather than the zymogen form). This complex initiates coagulation by activating factors IX and X. The resulting factor Xa forms a prothrombinase complex that activates prothrombin to produce the thrombin that converts fibrinogen to insoluble fibrin. In contrast, the intrinsic system is activated *in vivo* when certain coagulation proteins contact 10 subendothelial connective tissue. In the sequence that follows, contact factors XII and XI are activated. The resulting factor XIa activates factor IX; then factor IXa activates factor X thereby intersecting with the extrinsic pathway.

With time, the TF/FVIIIa complex (of the extrinsic pathway) loses activity due to 15 the action of tissue factor pathway inhibitor (TFPI), a Kunitz-type protease inhibitor protein which, when complexed with factor Xa, can inhibit the proteolytic activity of TF/FVIIa. If the extrinsic system is inhibited, additional factor Xa is produced through the thrombin-mediated action in the intrinsic pathway. Thrombin, therefore, exerts a dual 20 catalytic role in (a) the conversion of fibrinogen to fibrin and (b) mediating its own production. The autocatalytic aspect of thrombin production affords an important safeguard against excessive blood loss, and, assuming presence of a threshold level of prothrombinase, ensures that the blood coagulation process will go to completion.

While the ability to form blood clots is vital to survival, there are disease states 25 wherein the formation of blood clots within the circulatory system can cause death. When patients are afflicted with such disease states, it is not desirable to completely inhibit the clotting system because life-threatening hemorrhage would follow. Thus, it is highly desirable to develop agents that inhibit coagulation by inhibition of factor VIIa without directly inhibiting thrombin.

Need for the prevention of intravascular blood clots or for anti-coagulant treatment in many clinical situations is well known. Drugs in use today are often not satisfactory. A high percentage of patients who suffer internal injuries or undergo certain surgical procedures develop intravascular blood clots which, if unchecked, cause death.

5 In total hip replacement surgery, for example, it is reported that 50% of the patients develop deep vein thrombosis (DVT). Current approved therapies involve administration of heparin in various forms, but results are not entirely satisfactory; 10-20% of patients suffer DVT and 5-10% have bleeding complications. Along these lines, see International

10 Publication No. WO 00/15658.

Other examples of clinical situations for which better anticoagulants would be of great value are when patients undergo transluminal coronary angioplasty and treatment for myocardial infarction or crescendo angina. The present therapy for these conditions 15 is administration of heparin and aspirin, but this treatment is associated with a 6-8% abrupt vessel closure rate within 24 hours of the procedure. Transfusion therapy due to bleeding complications is required in approximately 7% of cases following the use of heparin. Occurrences of delayed vessel closures are also significant, but administration of heparin after termination of the procedure affords little beneficial effect and can be 20 detrimental.

Heparin and certain derivatives thereof are the most commonly used anti-clotting agents. These substances exert their effects mainly through inactivation of thrombin, which is inactivated 100 times faster than factor Xa. Two other thrombin-specific 25 anticoagulants, hirudin and hirulog, are in clinical trials (as of September 1999). However, bleeding complications are associated with these agents.

In preclinical studies in baboons and dogs, the targeting of enzymes involved in earlier stages of the coagulation cascade, such as factor VIIa or factor Xa, prevents clot


formation and does not produce bleeding side effects observed with direct thrombin inhibitors.

Several preclinical studies reveal that inhibition of TF/FVIIa offers the widest 5 window of therapeutic effectiveness and safety with respect to bleeding risk of any anticoagulant approach tested including thrombin, platelet, and factor Xa inhibition.

A specific inhibitor of factor VIIa would provide clinicians with a valuable and needed agent that would be safe and effective in situations where the present drugs of 10 choice, heparin and related sulfated polysaccharides, are no better than marginally effective.

There exists a need for a low molecular weight specific serine protease inhibitors 15 specific toward various enzymes, particularly for factor VIIa that does not cause unwanted side effects.


Figure 1. Pathways of Coagulation



The figure illustrates the extrinsic and intrinsic pathways of blood coagulation.

Summary of Invention

5 An aspect of the present invention relates to compounds represented by the formula:



10 Each E¹ and L individually is a 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or unsaturated hetero ring, bicyclic saturated or unsaturated 15 carbon ring, bicyclic saturated or unsaturated hetero ring, or 1-8 hydrocarbon chain which may be substituted with one or more hetero groups selected from N, O, S, S(O), and 20 S(O₂) which may be saturated or unsaturated. The bicyclic rings typically contain 7-13 atoms in the ring.

25 30 R is -CH=CH-R², -C≡C-R², -C(R²)=CH₂, -C(R²)=C(R³), -CH=NR², -C(R²)=N-R³, 4-7 membered saturated or unsaturated carbon ring system with or without substitution, 4-7 membered saturated or unsaturated hetero ring system with or without substitution, or chain of 2 to 8 carbon atoms having 1 to 5 double or triple bonds with substitutions selected from R¹, R², or R³.

R¹ is H, -R, -NO₂, -CN, -halo, -N₃, -C₁₋₈ alkyl, -(CH₂)_nCO₂R², -C₂₋₈ alkenyl-CO₂R², -O(CH₂)_nCO₂R², -C(O)NR²R³, -P(O)(OR²)₂, alkyl substituted tetrazol-5-yl, -(CH₂)_nO(CH₂)_n aryl, -NR²R³, -(CH₂)_n OR², -(CH₂)_n SR², -N(R²)C(O)R³, -S(O₂)NR²R³, -N(R²)S(O₂)R³, -(CHR²)_n NR²R³, -C(O)R³, (CH₂)_n N(R³)C(O)R³, -N(R²)CR²R³

5 substituted or unsubstituted (CH₂)_n-cycloalkyl, substituted or unsubstituted (CH₂)_n-phenyl, or substituted or unsubstituted (CH₂)_n-heterocycle which may be saturated or unsaturated.

m is 1 except that when E¹ is a cyclic ring of more than 5 atoms, then m is 1 or higher, depending upon the size of the ring.

R² is H, -halo, -alkyl, -haloalkyl, -(CH₂)_n-phenyl, -(CH₂)₁₋₃-biphenyl, -(CH₂)₁₋₄-Ph-N(SO₂-C₁₋₂-alkyl)₂, -CO(CHR¹)_n-OR¹, -(CHR¹)_n-heterocycle, -(CHR¹)_n-NH-CO-R¹, -(CHR¹)_n-NH-SO₂R¹, -(CHR¹)_n-Ph-N(SO₂-C₁₋₂-alkyl)₂, -(CHR¹)_n-C(O)(CHR¹)-NHR¹,

15 -(CHR¹)_n-C(S)(CHR¹)-NHR¹, -(CH₂)_nO(CH₂)_nCH₃, -CF₃, -C₂₋₅ acyl, -(CHR¹)_nOH, -(CHR¹)_nCO₂R¹, -(CHR¹)_n-O-alkyl, -(CHR¹)_n-O-(CH₂)_n-O-alkyl, -(CHR¹)_n-S-alkyl, -(CHR¹)_n-S(O)-alkyl, -(CHR¹)_n-S(O₂)-alkyl, -(CHR¹)_n-S(O₂)-NHR³, -(CHR³)_n-N₃, -(CHR³)_nNHR⁴, 2 to 8 carbon atom alkene chain having 1 to 5 double bonds, 2 to 8 carbon atom alkyne chain having 1 to 5 triple bonds, substituted or unsubstituted-

20 -(CHR³)_n heterocycle, or substituted or unsubstituted-(CHR³)_n cycloalkyl which may be saturated or unsaturated.

When n is more than 1, the substitutions R¹ and R³ may be same or different.

R³ is H, -OH, -CN, substituted alkyl, -C₂₋₈ alkenyl, substituted or unsubstituted cycloalkyl, -N(R¹)R², or 5-6 membered saturated substituted or unsubstituted hetero ring.

-NR²R³ may form a ring system having 4 to 7 atoms or may be bicyclic ring. The ring system may be of carbon or hetero atoms and further it may be saturated or unsaturated and also may be substituted or unsubstituted.

W is a direct bond, -CHR²-, -CH=CR²-, -CR²=CH-, -CR²=CR²-, -C≡C-, -O-CHR²-,
 -CHR²-O-, -N(R²)-C(O)-, -C(O)-N(R²)-, -N(R²)-CH-(R³)-, -CH₂-N(R²)-,
 -CH(R¹)-N(R²)-, -S-CHR²-, -CHR²-S-, -S(O₂)-N(R²)-, -C(O)N(R²)-(CHR²)n-,
 5 -C(R¹R²)n-NR²-, -N(R²)-S(O₂)-, -R²C(O)NR²-, -R²NC(O)NR²-, -CONR²CO-, -
 C(=NR²)NR²-, -NR²C(=NR²)NR²-, -NR²O-, -N=NCHR²-, or -C(O)NR²SO₂-.

E² is 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or
 unsaturated hetero ring, bicyclic ring system, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl,
 10 alkylaryl, aralkyl, aralkenyl, aralkynyl, alkoxy, alkylthio, or alkylamino.

each X individually is a direct bond, substituted or unsubstituted C₁₋₄ methylene chain; O,
 S, NR², S(O), S(O₂), or N(O) containing one or two C₁₋₄ substituted or unsubstituted
 methylene chains. X at different places may be same or different.

15 B is H, -halo, -CN, -NH₂, -(CH₂)_n-C(=NR⁴)NHR⁵, -(CH₂)_n-NHR⁴, -
 (CH₂)_nNHC(=NR⁴)NR⁵, -(CH₂)_n-OR⁴, C₁₋₈ substituted or unsubstituted alkyl, substituted
 or unsubstituted ring system having 4 to 7 carbon or hetero atoms which may be saturated
 or unsaturated.

20 B¹ is selected from B; B¹ and B may be same or different.
 There may be more than one similar or different R² groups present on E², when E² is a
 cyclic group of more than 5 atoms. In particular, p is 1 except that when E² is a cyclic
 ring of more than 5 atoms, p is 1 or higher depending upon the size of the ring.

25 n is 0-4

A is selected from R¹.

o is 1 except that when L is a cyclic ring of more than 5 atoms, o is 1 or higher depending upon the size of the ring.

Each V and V¹ individually is selected from R¹ and N-alkyl substituted carboxamidyl (-CONHR) where the alkyl group may be straight, branched, cyclic, or bicyclic; N,N-disubstituted carboxamidyl (-CONR₁R₂ where R₁ and R₂ may be substituted or unsubstituted alkyl or aryl and may be the same or different); mono- or disubstituted sulfonamides (SO₂NHR or -SO₂NR₁R₂); and methylene- or polymethylene chain-extended variants thereof.

10

Each R⁴ and R⁵ individually is H, -(CH₂)_nOH, -C(O)OR⁶, -C(O)SR⁶, -(CH₂)_nC(O)NR⁷R⁸, -O-C(O)-O-R⁷, an amino acid or a dipeptide,

Each R⁶ is H, R⁷, -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)-O-R⁹, or -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-O-R⁹,

15

Each R⁷, R⁸ and R⁹ individually is H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or CH₂CO₂alkyl.

The present invention also relates to pharmaceutical compositions containing at least one of the above disclosed compounds and their prodrugs.

20

A further aspect of the present invention relates to a method for inhibiting trypsin-like serine protease enzymes, such as thrombin, factor Xa, factor VIIa, TF/VIIa, and trypsin in a patient which comprises administering to the patient an effective serine protease inhibiting amount of at least one of the above disclosed compounds.


Still other objects and advantages of the present invention will become readily apparent by those skilled in the art from the following detailed description, wherein it is shown and described preferred embodiments of the invention, simply by way of illustration of the best mode contemplated of carrying out the invention. As will be realized the invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, without departing from the invention. Accordingly, the description is to be regarded as illustrative in nature and not as restrictive.

10

Best and Various Modes for Carrying Out Invention

An aspect of the present invention relates to compounds represented by the formula:

15



20

25

Each E^1 and L individually is a 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or unsaturated hetero ring, bicyclic saturated or unsaturated carbon ring, bicyclic saturated or unsaturated hetero ring, or 1-8 hydrocarbon chain which may be substituted with one or more hetero groups selected from N, O, S, S(O), and S(O₂) which may be saturated or unsaturated.

R is -CH=CH-R², -C≡C-R², -C(R²)=CH₂, -C(R²)=C(R³), -CH=NR², -C(R²)=N-R³, 4-7 membered saturated or unsaturated carbon ring system with or without substitution, 4-7 membered saturated or unsaturated hetero ring system with or without substitution, or chain of 2 to 8 carbon atoms having 1 to 5 double or triple bonds with substitutions selected from R¹, R², or R³. Preferably, these R, R¹, R², or R³ do not include -(C₂₋₄ alkenyl)-CO₂-C₁₋₈ alkyl, -(C₂₋₄ alkenyl)-CO₂-C₁₋₈ alkyl-phenyl, and -(C₂₋₄ alkenyl)-CO₂-C₁₋₈ alkyl-O-C₁₋₄ alkyl.

R¹ is H, -R, -NO₂, -CN, -halo, -N₃, -C₁₋₈ alkyl, -(CH₂)_nCO₂R², -C₂₋₈ alkenyl-CO₂R², -O(CH₂)_nCO₂R², -C(O)NR²R³, -P(O)(OR²)₂, alkyl substituted tetrazol-5-yl, -(CH₂)_nO(CH₂)_n aryl, -NR²R³, -(CH₂)_n OR², -(CH₂)_n SR², -N(R²)C(O)R³, -S(O₂)NR²R³, -N(R²)S(O₂)R³, -(CHR²)_n NR²R³, -C(O)R³, (CH₂)_n N(R³)C(O)R³, -N(R²)CR²R³ substituted or unsubstituted (CH₂)_n-cycloalkyl, substituted or unsubstituted (CH₂)_n-phenyl, or substituted or unsubstituted (CH₂)_n-heterocycle which may be saturated or unsaturated.

m is 1 except that when E¹ is a cyclic ring of more than 5 atoms, then m is 1 or higher, depending upon the size of the ring. For instance if the ring is 6 atoms, m can be 1 or 2.

R² is H, -halo, -alkyl, -haloalkyl, -(CH₂)_n-phenyl, -(CH₂)₁₋₃-biphenyl, -(CH₂)₁₋₄-Ph-N(SO₂-C₁₋₂-alkyl)₂, -CO(CHR¹)_n-OR¹, -(CHR¹)_n-heterocycle, -(CHR¹)_n-NH-CO-R¹, -(CHR¹)_n-NH-SO₂R¹, -(CHR¹)_n-Ph-N(SO₂-C₁₋₂-alkyl)₂, -(CHR¹)_n-C(O)(CHR¹)-NHR¹, -(CHR¹)_n-C(S)(CHR¹)-NHR¹, -(CH₂)_nO(CH₂)_nCH₃, -CF₃, -C₂₋₅ acyl, -(CHR¹)_nOH, -(CHR¹)_nCO₂R¹, -(CHR¹)_n-O-alkyl, -(CHR¹)_n-O-(CH₂)_n-O-alkyl, -(CHR¹)_n-S-alkyl, -(CHR¹)_n-S(O)-alkyl, -(CHR¹)_n-S(O₂)-alkyl, -(CHR¹)_n-S(O₂)-NHR³, -(CHR³)_n-N₃, -(CHR³)_nNHR⁴, 2 to 8 carbon atom alkene chain having 1 to 5 double bonds, 2 to 8 carbon atom alkyne chain having 1 to 5 triple bonds, substituted or unsubstituted-(CHR³)_n heterocycle, or substituted or unsubstituted-(CHR³)_n cycloalkyl which may be saturated or unsaturated.

When n is more than 1, the substitutions R¹ and R³ may be same or different.

R³ is H, -OH, -CN, substituted alkyl, -C₂₋₈ alkenyl, substituted or unsubstituted cycloalkyl, -N(R¹)R², or 5-6 membered saturated substituted or unsubstituted hetero ring.

5

-NR²R³ may form a ring system having 4 to 7 atoms or may be bicyclic ring. The ring system may be of carbon or hetero atoms and further it may saturated or unsaturated and also may be substituted or unsubstituted.

10 W is a direct bond, -CHR²-, -CH=CR²-, -CR²=CH-, -CR²=CR²-, -C=C-, -O-CHR²-, -CHR²-O-, -N(R²)-C(O)-, -C(O)-N(R²)-, -N(R²)-CH-(R³)-, -CH₂-N(R²)-, -CH(R¹)-N(R²)-, -S-CHR²-, -CHR²-S-, -S(O₂)-N(R²)-, -C(O)N(R²)-(CHR²)n-, -C(R¹R²)n-NR²-, -N(R²)-S(O₂)-, -R²C(O)NR²-, -R²NC(O)NR²-, -CONR²CO-, -C(=NR²)NR²-, -NR²C(=NR²)NR²-, -NR²O-, -N=NCHR²-, or -C(O)NR²SO₂-.

15

E² is 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or unsaturated hetero ring, bicyclic ring system, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, alkylaryl, aralkyl, aralkenyl, aralkynyl, alkoxy, alkylthio, or alkylamino.

20 each X individually is a direct bond, substituted or unsubstituted C₁₋₄ methylene chain; O, S, NR², S(O), S(O₂), or N(O) containing one or two C₁₋₄ substituted or unsubstituted methylene chains. X at different places may be same or different.

B is H, -halo, -CN, -NH₂, -(CH₂)_n-C(=NR⁴)NHR⁵, -(CH₂)_n-NHR⁴, -

25 (CH₂)_nNHC(=NR⁴)NR⁵, -(CH₂)_n-OR⁴, C₁₋₈ substituted or unsubstituted alkyl, substituted or unsubstituted ring system having 4 to 7 carbon or hetero atoms which may be saturated or unsaturated.

B¹ is selected from B; B¹ and B may be same or different.

There may be more than one similar or different R² groups present on E², when E² is a cyclic system of more than 5 atoms. p is 1 or higher if E² is a cyclic ring of more than 5 atoms. For example, if the ring is 6 atoms, p can be 1 or 2.

5 n is 0-4

A is selected from R¹.

o is 1 except that when L is a cyclic ring of more than 5 atoms, o is 1 or higher depending upon the size of the ring. For instance, if the ring is 6 atoms, o can be 1 or 2.

10 Each V and V¹ individually is selected from R¹ and N-alkyl substituted carboxamidyl (-CONHR) where the alkyl group may be straight, branched, cyclic, or bicyclic; N,N-disubstituted carboxamidyl (-CONR₁R₂ where R₁ and R₂ may be substituted or unsubstituted alkyl or aryl and may be the same or different); mono- or disubstituted sulfonamides (SO₂NHR or -SO₂NR₁R₂); and methylene- or polymethylene chain-15 extended variants thereof.

Each R⁴ and R⁵ individually is H, -(CH₂)_nOH, -C(O)OR⁶, -C(O)SR⁶, -(CH₂)_nC(O)NR⁷R⁸, -O-C(O)-O-R⁷, an amino acid or a dipeptide,

20 Each R⁶ is H, R⁷, -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)-O-R⁹, or -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-O-R⁹,

25 Each R⁷, R⁸ and R⁹ individually is H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or CH₂CO₂alkyl.

R substituent groups employed pursuant to the present invention contribute to significantly enhanced activity of the compounds of the present invention.

5 Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification, unless otherwise limited in specific instances, either individually or as part of a larger group.

10 The term "alkyl" refers to straight or branched chain unsubstituted hydrocarbon groups of 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. The expression "lower alkyl" refers to unsubstituted alkyl groups of 1 to 4 carbon atoms.

15 The terms "alkenyl" and "alkynyl" refer to straight or branched chain unsubstituted hydrocarbon groups typically having 2 to 8 carbon atoms.

20 The terms "substituted alkyl", "substituted alkenyl" or substituted alkynyl" refer to an alkyl, alkenyl or alkynyl group substituted by, for example, one to four substituents, such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or aralkyl, alkanoylamine, aroylamino, aralkanoylmino, substituted alkanolamino, substituted arylamino, substituted aralkanoylmino, thiol, alkylthio, arylthio, aralkylthio, cycloalkylthio, heterocyclothio, alkylthiono, arylthiono, aralkylthiono, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, sulfonamido (e.g. SO₂NH₂), substituted sulfonamido, nitro, cyano, carboxy, carbamyl (e.g. CONH₂), substituted carbamyl (e.g. CONH alkyl, CONH aryl, CONH aralkyl or cases where there are two substituents on the nitrogen selected from alkyl, aryl or aralkyl), alkoxycarbonyl, aryl, substituted aryl, guanidino and heterocyclos, such as indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl and the like.

Where noted above where the substituent is further substituted it will be with halogen, alkyl, alkoxy, aryl or aralkyl.

The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine.

5

The term "aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted.

10

The term "aralkyl" or "alkylaryl" refers to an aryl group bonded directly through an alkyl group, such as benzyl or phenethyl.

15

The term "substituted aryl" or "substituted alkylaryl" refers to an aryl group or alkylaryl group substituted by, for example, one to four substituents such as alkyl; substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, azido, cycloalkyloxy, heterocyclooxy, alkanoyl, alkanoyloxy, amino, alkylamino, aralkylamino, hydroxyalkyl, aminoalkyl, azidoalkyl, alkenyl, alkynyl, allenyl, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thiol, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkysulfonyl, sulfonamido, aryloxy and the like. The substituent may be further substituted by halo, hydroxy, alkyl, alkoxy, aryl, substituted aryl, substituted alkyl or aralkyl. "Substituted benzyl" refers to a benzyl group substituted by, for example, any of the groups listed above for substituted aryl.

20

The term "cycloalkyl" refers to optionally substituted, saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C₃-C₇ carbocyclic ring. Exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl and adamantyl. Exemplary substituents include one or more

alkyl groups as described above, or one or more groups described above as alkyl substituents.

The term "cycloalkenyl" refers to optionally substituted, unsaturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3-7 carbons per ring.
5 Exemplary groups include cyclopentenyl and cyclohexenyl.

The terms "heterocycle", "heterocyclic" and "heterocyclo" refer to an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic cyclic group, for example, which is 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the 10 nitrogen heteroatoms may also optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atoms.
15

Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, 20 oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, thiophenyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4-piperidonyl, pyridyl, dihydropyridyl, N-oxo-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, 25 morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1, 1-dioxothienyl, dioxanyl, isothiazolidinyl, thietanyl, thiiranyl, triazinyl and triazolyl and the like.

Exemplary bicyclic heterocyclic groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, cournarinyl, cinnolinyl, quinoxaliny, indazolyl, pyrrolapridyl, furopyridinyl (such as 5 furo[2,3-c]pyridinyl, furo[3,1-b]pyridinyl, or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), benzisothiazolyl, benzisoxazolyl, benzodiazinyl, benzofurazanyl, benzothiopyranyl, benzothrasolyl, benzpyrasolyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, dihydrobenzopyranyl, indolinyl, isochromanyl, 10 isoindolinyl, naphthyridinyl, phthalazinyl, piperonyl, purinyl, pyridopyridyl, quinazolinyl, tetrahydroquinolinyl, theinofuryl, thienopyridyl, thienothienyl, and the like.

Exemplary substituents include one or more alkyl groups as described above or one or more groups described above as alkyl substituents.

15 Within the above-described definitions, certain embodiments are preferred. Preferred alkyl groups are lower alkyl groups containing 1 to about 8 carbon, and more preferably 1 to about 5 carbon atoms, and can be straight, branched-chain or cyclic saturated aliphatic hydrocarbon groups.

20 Examples of suitable alkyl groups include methyl, ethyl and propyl. Examples of branched alkyl groups include isopropyl and t-butyl. An example of a suitable alkylaryl group is phenethyl. Examples of suitable cycloalkyl groups typically contain 3-8 carbon atoms and include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The aromatic or 25 aryl groups are preferably phenyl or alkyl substituted aromatic groups (aralkyl) such as phenyl C₁₋₃ alkyl such as benzyl.

The N-heterocyclic rings preferably contain 3-7 atoms in the ring and a heteroatom such as N, S or O in the ring. Examples of suitable preferred heterocyclic

groups are pyrrolidino, azetidino, piperidino, 3,4-didehydropiperidino, 2-methylpiperidino and 2-ethylpiperidino. In addition, the above substitutions can include halo such as F, Cl, Br, lower alkyl, lower alkoxy and halo substituted lower alkoxy.

5 Examples of some preferred B groups include $-\text{NHC}(=\text{NH})\text{NH}_2$, $-\text{C}(=\text{NH})\text{NH}_2$, NH_2 , various N-substituted variants, and assorted prodrug derivatives.

10 Prodrug forms of the compounds bearing various nitrogen functions (amino, hydroxyamino, hydrazino, guanidino, amidino, amide, etc.) may include the following types of derivatives where each R group individually may be hydrogen, substituted or unsubstituted alkyl, aryl, alkenyl, alkynyl, heterocycle, alkylaryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, or cycloalkenyl groups as defined beginning on page 7.


- 15 (a) Carboxamides, $-\text{NHC}(\text{O})\text{R}$
- (b) Carbamates, $-\text{NHC}(\text{O})\text{OR}$
- 20 (c) (Acyloxy)alkyl carbamates, $-\text{NHC}(\text{O})\text{OROC}(\text{O})\text{R}$
- (d) Enamines, $-\text{NHCR}(=\text{CHCRO}_2\text{R})$ or $-\text{NHCR}(=\text{CHCRONR}_2)$
- (e) Schiff bases, $-\text{N=CR}_2$
- 25 (f) Mannich bases (from carboximide compounds), $\text{RCONHCH}_2\text{NR}_2$

Preparations of such prodrug derivatives are discussed in various literature sources (examples are: Alexander *et al.*, J. Med. Chem. 1988, 31, 318; Aligas-Martin *et al.*, PCT WO pp/41531, p. 30). The nitrogen function converted in preparing these derivatives is one (or more) of the nitrogen atoms of a compound of the invention.

Prodrug forms of carboxyl-bearing compounds of the invention include esters (-CO₂R) where the R group corresponds to any alcohol whose release in the body through enzymatic or hydrolytic processes would be at pharmaceutically acceptable levels.

- 5 Another prodrug derived from a carboxylic acid form of the invention may be a quaternary salt type

10



of structure described by Boder *et al.*, J. Med. Chem. 1980, 23, 469.

- 15 Examples of some preferred groups for W are -CH₂CH₂-, -CH=CH-, -C≡C-, -CH₂CH₂CH₂-, -CH₂CH=CH-, -CH₂C≡C-, -CONH, -CH₂CONH-, -NHCONH-, -CONHCO-, -CONHCH₂-, -C(=NH)NH-, -CH₂C(=NH)NH-, -NHC(=NH)NH-, -NNHH-, -NHO-, -CONHSO₂-, -SO₂NH-, -NSO₂CH₂-, -SO₂NHCH₂-, -CH₂O-, -CH₂OCH₂-, -OCH₂CH₂-, -CH₂NH-, -CH₂CH₂NH-, -CH₂NHCH₂-, -CH₂S-, -SCH₂CH₂, -CH₂SCH₂-, -CH₂SO₂CH₂-, -CH₂SOCH₂-, -CH(CO₂H)O and -CH(CO₂H)OCH₂.
- 20

- 25 Examples of some preferred groups for V and V¹ are N-alkyl substituted carboxamidyl (-CONHR) where the alkyl group may be straight, branched, cyclic, or bicyclic, and typically containing up to ten carbons; N,N-disubstituted carboxamidyl (-CONR₁R₂) where R₁ and R₂ may be substituted or unsubstituted alkyl or aryl and may be the same or different; mono- or disubstituted sulfonamides (SO₂NHR or -SO₂NR₁R₂); methylene- or polymethylene chain- extended variants thereof such as -(CH₂)_nCONHR₁, -(CH₂)_nCONR₁R₂, -(CH₂)_nSO₂NHR₁, -(CH₂)_nSO₂NR₁R₂ (where n = 1-4), -NHC(O)R, N(R₁)C(O)R₂, NSO₂R, CH₂NHR, CH₂NR₁R₂.

30


Pharmaceutically acceptable salts of the compounds of the present invention include those derived from pharmaceutically acceptable, inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic, trifluoroacetic and benzenesulphonic acids.

Salts derived from appropriate bases include alkali such as sodium and ammonia.


10 It is of course understood that the compounds of the present invention relate to all optical isomers and stereo-isomers at the various possible atoms of the molecule.

The synthetic routes leading to the compounds in formula (I) are described in the following schemes.


Scheme 1




Scheme 2





Scheme 3




Scheme 4




Scheme 5

**24, R =**


24, R = (continued)




25, R =





26, R =




27, R =




27, R = (continued)




15 The reduction of the formyl group of **24ab**, **24ac**, **24ae**, and **24ad** was accomplished with NaBH₄ to give corresponding alcohols **24ab-i**, **24ac-i**, **24ae-i**, and **24ad-i**, respectively. Later, the MEM group was removed under acidic conditions to give **25ab**, **25ac**, **25ae**, and **25af**, respectively.




20 The aldehyde **24ad** was oxidized to acid **24ad-ii** which was protected as benzyl ester to give **24ad-ii**. MEM deprotection under acidic conditions produced **25ad**.





The vinyl compound **24ah** was oxidized with OsO₄ to give diol **24ah-i**, followed by acidic hydrolysis of the MEM group to produce **25ah**.




25 The vinyl compound **24ah** on dihydroxylation with OsO₄ gave diol **24ah-i**. Oxidative cleavage of the diol with NaIO₄ produced aldehyde **24ah-ii**. The aldehyde on reduction gave alcohol **24ah-iii**, which on further reaction with methane sulfonyl chloride yielded mesylate **24ah-iv**. The mesylate on further reaction with sodium azide gave the corresponding azide **24ah-v**, which on acidic hydrolysis produced **25ai**.




Scheme 6

 $29, \text{R} =$ 




Aldehyde **29g** was converted to alcohol **29g-i** by reduction with NaBH₄, followed by the reaction of methanesulfonyl chloride to give mesylate **29g-ii**. The mesyl group was displaced with azide to give **29g-iii** and finally, the MEM group was removed under acidic conditions to give **30g**.




The reduction of the formyl group of **29h** and **29i** was accomplished with NaBH₄ to give corresponding alcohols **29h-i** and **29i-i**, respectively. Later, the MEM group was removed under acidic conditions to give 40 **30h** and **30i**, respectively.

Compounds of the type **23** and **28**, where X = -Sn(Bu)₃, are prepared using the methods AG-1 or AG-2


Scheme 7




Scheme 8A




Scheme 8B




Scheme 8C




Scheme 8D








Scheme 8E







Scheme 9





62, R =




63, R =




64, R =





Scheme 10




69, R =




70, R =
















71, R =




Scheme 11






Scheme 12


Scheme 13




Scheme 14




Scheme 15




Scheme 16







Scheme 16a




Scheme 16b




Scheme 17




133, 134, R = (continued)




Scheme 17a




135, 136, R =




Scheme 18




146a - 149a, R =




146b - 149b, R =

146c - 149c, R = -CH=CH₂


Scheme 19




Scheme 19a




Scheme 20




Scheme 21




Scheme 22




Scheme 23




Scheme 24



Scheme 25


Scheme 26




190a, 192a - 195a, R = H


190b, 192b - 195b, R = CH₃

Scheme 27



Scheme 28




Scheme 29


209a, R = H

209b - 211b, R =


Scheme 30



Scheme 31



Scheme 32




231a, 232a, 233a, 234a, 235a, R = H


231b, R = CO₂CH₃

232b, 233b, 234b, R = CO₂H


Scheme 33




Scheme 34



Scheme 35



Scheme 36



General Methods of Preparation

The following abbreviations have been used:

- 5 THF: Tetrahydrofuran; DMF: Dimethylformamide
DME: 1,2-Dimethoxyethane; DMAP: 4-(Dimethylamino)pyridine
Boc anhydride: Di-tert-butyl dicarbonate; TIPS: Triisopropylsilyl
MEM: Methoxyethoxymethyl; Bn: Phenylmethyl or Benzyl
- 10 The organic extracts were dried over sodium sulfate or magnesium sulfate.

The general methods for the preparation of the compounds of formula (I) are given below:

15 **A-1: Conversion of acid to amide**

To derivative (1 mmol), was added thionyl chloride (12.6 mmol) and a few drops of DMF. The reaction mixture was refluxed for 2 h and concentrated in vacuo to obtain an oily residue. The residue was dissolved in dichloromethane (3 mL); cooled with ice water and amine (5 mmol) was added. The reaction mixture was stirred at room temperature overnight, washed with 1N HCl, saturated sodium hydrogen carbonate, water, brine, dried and concentrated in vacuo. The product obtained was purified by crystallization or flash column chromatography to furnish the desired amide.

25 **A-2: Conversion of acid to amide**

To a solution of acid derivative (1 mmol) in dichloromethane (10 mL) at 0 °C was added triethylamine (3 mmol) and ethyl chloroformate (3 mmol). The reaction mixture was stirred at the same temperature for 30 min and the corresponding amine (6

mmol) was added. The reaction mixture was stirred at room temperature overnight and quenched with 1N HCl. The organic layer was separated, washed with water, brine, dried and concentrated in vacuo. The product obtained was purified by crystallization or flash column chromatography to furnish the desired amide.

5

A-3: Conversion of acid to amide

To a solution of acid (1 mmol) in dichloromethane (5 mL) was added 2M oxalyl chloride in dichloromethane (2.5 mmol), followed by a drop of DMF. The reaction mixture was stirred for 2h at room temperature and concentrated in vacuo. The residue was co-evaporated once with dichloromethane (5 mL) and then dried in vacuo. To the residue in dichloromethane (10 mL) were further added triethylamine (3 mmol) and the corresponding amine (1.2 mmol). The reaction mixture was stirred for 16 h and washed with water, brine, dried and concentrated in vacuo. The product obtained was purified by crystallization or flash column chromatography to furnish the desired amide.

10
15
A-4: Conversion of acid to amide

To a solution of acid (1 mmol) in dichloromethane or THF (10 mL) cooled with an ice bath was added triethylamine (1.2 mmol) and ethyl chloroformate or isobutyl chloroformate (1.2 mmol). The reaction mixture was stirred at 0°C for 30 min and the corresponding amine (2.5 mmol) was added. The reaction mixture was stirred at room temperature overnight and quenched with 1N HCl. The organic layer was separated, washed with water, brine, dried and concentrated in vacuo. The product obtained was purified by crystallization or flash column chromatography to furnish the desired amide.

A-5: Conversion of acid to amide

A mixture of carboxylic acid (1 mmol), amine (1.1 mmol), 1-hydroxybenzotriazole (1 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (1.1 mmol) in pyridine (10 mL) was stirred overnight at room temperature and was concentrated *in vacuo* to dryness. The residue obtained was purified by column chromatography or used as such for the next step.

A-6: Reduction of acid to alcohol

10

To a solution of acid (1 mmol) in dichloromethane or THF (10 mL) at 0 °C was added triethylamine (1.2 mmol) and ethyl chloroformate or isobutyl chloroformate (1.2 mmol). The reaction mixture was stirred at 0 °C for 30 min and sodium borohydride (1.25 mmol) was added. The reaction mixture was stirred at room temperature overnight and quenched with 1N HCl. The reaction mixture was extracted with ethyl acetate. The organic layers were combined, washed with water, brine, dried and concentrated in *vacuo* to furnish the desired alcohol. This can be purified further, if needed, by crystallization or column chromatography.

20 **A-7: Conversion of acid to amide**

A mixture of carboxylic acid (1 mmol), amine (1 mmol), and 4-dimethylaminopyridine (0.12 mmol) in xylene (10 mL) was stirred at 80 °C for 10 min. Phosphorus trichloride (1 mmol) was added and the reaction mixture was heated with stirring at 150 °C for 2 hr. After cooling, the product was extracted with EtOAc. The organic layers were combined, washed with water, brine, dried and concentrated *in vacuo*. The product obtained was purified by flash column chromatography to furnish the desired amide.

B-1: Conversion of phenolic hydroxyl to triflate

To a phenol (1 mmol) in dichloromethane (2.5 mL) was added pyridine (5 mmol) under a nitrogen atmosphere and cooled to -10 C. To the cold reaction mixture was 5 added dropwise triflic anhydride (2 mmol) in dichloromethane (2.5 mL) over a period of 10 mins and allowed to warm to room temperature and stirred for 16 h. The reaction mixture was quenched with saturated aqueous sodium hydrogen carbonate solution and the organic layer was separated. The organic layer was washed with 1N HCl, saturated sodium hydrogen carbonate, water, brine, dried and concentrated in vacuo. The product 10 obtained was purified by crystallization or flash column chromatography to furnish the desired triflate.

B-2: Conversion of phenolic hydroxyl to triflate

15 To a solution of substituted phenol (1 mmol) in DMF (10 mL) was added N-phenylbis(trifluoromethanesulphonimide) (1.1 mmol), and triethylamine (2 mmol) and stirred at room temperature overnight. The reaction mixture was quenched with ice water and extracted twice with ether. The organic layers were combined, washed with brine, dried and concentrated *in vacuo* to furnish the desired triflate.

20

C: Conversion of acid to MEM ester

To a solution of acid derivative (1 mmol) in DMF (10 mL) was added sodium bicarbonate (1.05 mmol), and MEM-Cl (1.05 mmol) and was stirred at room temperature 25 for 24 h. The reaction mixture was quenched with ice water and extracted twice with ether. The organic layers were combined, washed with brine, dried and concentrated *in vacuo* to furnish crude product. Purification by flash column chromatography or crystallization gave the desired MEM ester.

D-1: Coupling of boronic acid with triflate

A mixture of triflate (1 mmol), aryl boronic acid (1.5 mmol), potassium phosphate (3 mmol), potassium bromide (2.4 mmol) and tetrakis(triphenylphosphine)palladium (0.05 mmol) in dioxane (10 mL) was heated at reflux overnight under an argon atmosphere. The reaction mixture was cooled, quenched with water and was extracted with ethyl acetate. The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

D-2: Coupling of boronic acid with triflate

A mixture of triflate (1 mmol), aryl boronic acid (2 mmol), sodium hydrogen carbonate (3 mmol) and tetrakis(triphenylphosphine)palladium (0.05 mmol) or bis(triphenylphosphine)palladium(II)chloride (0.05 mmol) in DME/water (9:1, 10 mL) was heated at reflux overnight. The reaction mixture was cooled, quenched with water and extracted with ethyl acetate. The organic layer was dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

D-3: Coupling of tributyltin derivative with triflate

A mixture of triflate (1 mmol), tributyltin derivative (3 mmol), tetraethylammonium chloride (6 mmol), and bis(triphenylphosphine)palladium(II)-chloride (0.05 mmol) in DMF (10 mL) was heated at 70 °C overnight under an argon atmosphere. The reaction mixture was cooled, quenched with water (20 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

D-4: Coupling of trimethyltin derivative with triflate

A mixture of triflate (1 mmol), trimethyltin derivative (3 mmol), and bis(triphenylphosphine)palladium(II)chloride (0.05 mmol) in THF (10 mL) was heated at 5 70 °C overnight under an argon atmosphere. The reaction mixture was cooled, quenched with water and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

10 D-5: Coupling of alkyne with triflate

A mixture of triflate (1 mmol), triethylamine (4.5 mmol), substituted alkyne (3.5 mmol), and bis(triphenylphosphine)palladium(II)chloride (0.05 mmol) in DMF (10 mL) was heated at 70 °C overnight under an argon atmosphere. The reaction mixture was 15 cooled, quenched with water (20 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

D-6: Coupling of boronate ester with aryl bromides

20 A mixture of boronate ester (2 mmol), aryl bromide (1 mmol), potassium phosphate (3 mmol) and bis(diphenylphosphinoferrocene)palladium(II)chloride (0.05 mmol) in DMF (10 mL) was heated at 100 °C for overnight under an argon atmosphere. The reaction mixture was cooled, quenched with water (20 mL) and extracted with ethyl 25 acetate (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the desired product.

D-7: Coupling of boronate ester with aryl bromides

A mixture of boronate ester (2 mmol), aryl bromide (1 mmol), sodium hydrogen carbonate (3 mmol) and bis(diphenylphosphinoferrocene)palladium(II)chloride (0.05 mmol) in DME/water (9:1, 10 mL) was heated at 50-70 °C for overnight under an argon atmosphere. The reaction mixture was cooled, quenched with water (20 mL) and was extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo*. Purification by flash column chromatography or crystallization gave the coupled product.

10

D-8: Coupling of phenol with boronic acid

A mixture of phenol (1 mmol), aryl boronic acid (3 mmol), molecular sieves (4A°), pyridine (5 mmol), copper(II)acetate (1 mmol) and bis(triphenylphosphine)-palladium(II)chloride (0.05 mmol) in dichloromethane (10 mL) was stirred at room temperature overnight under an argon atmosphere. The reaction mixture was cooled, filtered through a pad of Celite and concentrated *in vacuo*. Purification of the crude by flash column chromatography gave the coupled aryl ether.

20

D-9: Coupling of trimethyltin derivative with triflate

To a solution of triflate (1 mmol), LiCl (4 mmol), PPh₃ (0.15 mmol), CuBr (0.2 mmol), and bis(triphenylphosphine)palladium(II)chloride (0.07 g) in DMF (10 mL) under an atmosphere of argon was added trimethylstannyl compound (0.8 mmol) and a crystal of 2,6-di-*t*-butyl-4-methylphenol. After the mixture was stirred at 90 °C for 3 h, a second portion of aryl-trimethylstannyl compound (0.5 mmol) was added. The reaction mixture was stirred at 90 °C overnight. Water was added and extracted with ethyl acetate. The organic layer was dried (MgSO₄), concentrated and purified by flash column chromatography or crystallization to furnish the desired coupled product.

D-10: Coupling of amine with triflate

A mixture of triflate (0.75 mmol), amine (0.9 mmol), potassium phosphate (1.1 mmol), 2-(di-t-butylphosphino)biphenyl (0.015 mmol) and tris(dibenzylideneacetone)dipalladium(0) (10 mg) in DME (10 mL) was heated at reflux overnight under an argon atmosphere. The reaction mixture was concentrated *in vacuo* and the residue was purified by flash column chromatography to furnish the desired coupled product.

10 D-11: Conversion of triflate to cyano compound

To a solution of triflate (0.84 mmol), zinc cyanide (0.54 mmol), Palladium acetate (0.016 mmol), 2-(di-*tert*-butylphosphine)biphenyl (0.016 mmol) and N-methyl pyrrolidine (10 mL) was heated under argon at 160 °C for 48 h. The reaction mixture 15 was cooled to room temperature and quenched with water (50 mL). The reaction mixture was extracted with ethyl acetate (2 X 25 mL). The organic layers were combined, dried, filtered and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to furnish the desired cyano compound.

20 D-12: Coupling of tetravinyltin with triflate or halide

To a solution of aryl triflate or bromide (1 mmol) in DMF (5 mL) were added LiCl (5 mmol), tetravinyltin (2 mol), and dichlorbis(triphenylphosphine)palladium (II) (0.01 mmol). The reaction mixture was stirred at 70 °C under nitrogen for 5 h and then 25 diluted with ethyl acetate and filtered. The organic layer was washed with water and brine and dried ($MgSO_4$). After evaporating the solvent *in vacuo*, the compound was purified by flash-column chromatography to give the desired product.

E: Oxidation of aryl aldehyde to acid

A mixture of aldehyde (1 mmol), *tert*-butanol (5 mL), water (2 mL) and acetonitrile (1 mL, additional amount may be added until the reaction mixture was homogenous) was stirred at room temperature. The solution was cooled in ice-bath and 2-methyl-2-butene (1 mL), sodium chlorite (6 mmol) and sodium dihydrogenphosphate (1.6 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. If the solid separated out, the mixture was filtered to collect the solid, the desired product. If no solid separated out, then the reaction mixture was concentrated in *vacuo* to remove acetonitrile, diluted with water (10 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, washed with water, brine, dried and concentrated in *vacuo* to furnish crude acid. Purification was achieved, if needed, by crystallization or using flash column chromatography to obtain pure acid.

15 E-2: Oxidation of vinyl compound to acid

To a solution of vinyl compound (1 mmol) in acetone (5 mL) was added KMnO₄ (4 mmol). The reaction mixture was stirred for 3 h (the reaction is exothermic, and refluxed on its own during the addition of KMnO₄). The reaction mixture was diluted with methanol and water and filtered. The organic solvents were evaporated *in vacuo* and the aqueous layer was acidified to pH 1 and extracted several times with ethyl acetate/DME. The combined organic layers were dried (MgSO₄) to furnish the desired acid.

25 F: Conversion of aromatic acid to MEM ester

To a solution of aromatic acid (1 mmol) in THF (10 mL) was added diisopropylethylamine (2 mmol) and 2-methoxyethoxymethylchloride (1.1 mmol). The reaction mixture was stirred at room temperature for 3 h and diluted with ether (25 mL).

The reaction mixture was washed with water (10 mL), brine (10 mL), dried and concentrated *in vacuo* to obtain product as colorless oil. The product was purified by flash column chromatography to furnish desired product.

5 **G: Conversion of aromatic benzyl ether to aromatic phenol, benzyl ester to acid, benzyl carbamate to amine, alkene to alkane, azide to amine, nitro to amine, and oxime to amine**

To a solution of appropriate substrate (1 mmol) in ethanol (10 mL) was added 10% palladium on carbon (10-wt%). The reaction mixture was hydrogenated at 50 psi for 2 to 24 h (until all starting material disappeared as confirmed by MS and TLC analysis). The catalyst was removed by filtration through a pad of Celite under nitrogen. The filtrate was concentrated *in vacuo* to furnish the product, which was purified by flash column chromatography or crystallization.

15

H: Conversion of aromatic acid to benzyl ester

To a solution of aromatic acid (1 mmol) in DMF (10 mL) was added sodium bicarbonate (1.05 mmol), and benzyl bromide (1.05 mmol) and stirred at room 20 temperature for 24 h. The reaction mixture was quenched with ice water and extracted twice with ethyl acetate. The organic layers were combined, washed with water and brine, dried and concentrated *in vacuo* to furnish crude product. Purification by crystallization or flash column chromatography gave the desired ester.

25 **I-1: Hydrolysis of MEM ester to acid**

To a solution of MEM ester (1 mmol) in DME (8 mL) was added 6 N HCl (2 mL) and stirred at room temperature overnight. The reaction mixture was neutralized with solid sodium hydrogen carbonate (18 mmol) and concentrated *in vacuo*. The reaction

mixture was acidified with 0.5 N HCl (20 mL) and extracted with ethyl acetate (2 X 20 mL). The organic layers were combined, washed with brine (20 mL), dried and concentrated *in vacuo* to furnish crude product. Purification of the crude by flash column chromatography gave the product. Alternatively the crude reaction mixture was diluted 5 with water (10 mL) and concentrated in vacuo to remove DME. The solid obtained was collected by filtration and dried in vacuo to furnish pure acid.

I-2: Hydrolysis of ester to acid

10 To a solution of ester (1 mmol) in MeOH (10 mL) was added 1 N NaOH (10 mmol). The reaction mixture was stirred at room temperature for 2-3 h, filtered through a plug of cotton, and concentrated *in vacuo* to remove MeOH. The pH of the aqueous layer was adjusted to below 7. The solid that separated, was collected by filtration, washed with water and dried *in vacuo* to furnish the desired acid.

15

J: Coupling of acid with amino compounds

To a solution of acid (1 mmol) in DMF (5 mL) was added corresponding amine (1.1 mmol) and stirred at room temperature until homogenous. Pyridine (5 mL) was 20 added to the reaction mixture followed by 1,3-dicyclohexylcarbodiimide (1.2 mmol) and stirred overnight at room temperature. The mixture was quenched with 6 N HCl (10 mL), diluted with ice cold water (10 mL) and extracted with chloroform (2 X 10 mL). The organic layers were combined washed with brine (10 mL), dried and filtered. Purification of the crude by flash column chromatography gave the product as a solid. If 25 the product was soluble in water, then the reaction mixture was concentrated in vacuo to remove pyridine and DMF and purified by flash column chromatography.

K: Reduction of aldehyde to alcohol

To a solution of aldehyde (1 mmol) in THF (10 mL) was added sodium borohydride (0.4 mmol). The reaction mixture was stirred for 30 mins and quenched 5 with glacial acetic acid (0.3 mL). The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined and washed with brine (10 mL), dried, filtered and concentrated in vacuo to obtain crude product which was purified by flash column chromatography.

10 **L: Conversion of vinyl group to diol**

To a solution of vinyl compound (1 mmol) in THF/*tert*-butanol (1:1, 10 mL) and water (2 mL) was added 4-methylmorpholine N-oxide (2.5 mmol) and osmium tetroxide (1 mL, 2.5 wt% in *tert*-butanol, 0.1 mmol). The reaction mixture was stirred at room 15 temperature for 2 h and quenched with saturated aqueous solution of sodium sulfite (5 mL). The reaction was stirred at room temperature for 30 mins and diluted with brine (10 mL) and ethyl acetate (10 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (10 mL). The organic layers were combined and washed 20 with brine (10 mL), dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography to furnish the desired diol.

M: Conversion of diol to aldehyde

To a solution of diol (1 mmol) in DME/water (9:1, 10 mL) was added sodium 25 metaperiodate (3 mmol) and stirred at room temperature for 30 min. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined and washed with brine (10 mL), dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography to furnish the desired aldehyde.

N: Conversion of alcohol to mesylate

To a solution of alcohol (1 mmol) in DME (10 mL) was added
5 dimethylaminopyridine (0.1 mmol), methane sulfonyl chloride (3 mmol) and
diisopropylethylamine or triethylamine (5 mmol). The reaction mixture was stirred at
room temperature overnight. The reaction mixture was diluted with water (10 mL) and
extracted with ethyl acetate (2 X 10 mL). The combined organic layers were washed
with brine, dried, filtered and concentrated *in vacuo*. The residue obtained, was purified
10 by column chromatography to furnish the desired mesylate.

O: Conversion of mesylate to azide

To a solution of mesylate (1 mmol) in DMSO (10 mL) was added sodium azide
15 (25 mmol) and heated at 100 °C overnight. The reaction mixture was cooled and diluted
with cold water (25 mL). The reaction mixture was extracted with ethyl acetate (2 X 15
mL). The combined organic layers were washed with water (10 mL), brine (10 mL),
dried, filtered and concentrated *in vacuo*. The residue obtained was purified by column
chromatography to furnish the desired azido compound.

20

P: Protection of amine as benzyl carbamate

A mixture of amino compound (1 mmol), benzyl chloroformate (2 mmol) and
triethylamine (10 mL) in pyridine (10 mL) was stirred at room temperature overnight.
25 The reaction mixture was concentrated *in vacuo* to remove organic solvents and diluted
with 0.1 N HCl (10 mL). The product was extracted with chloroform (2 X 10 mL), dried,
filtered and concentrated *in vacuo*. The residue obtained was purified by column
chromatography to furnish the desired carbamate.

Q: Conversion of silyl protected amine to amine

A mixture of silyl protected amine (1 mmol), tetrabutylammonium fluoride (1.0 M in THF, 2 mmol) in THF (10 mL) was stirred at room temperature for 1.5 h. The 5 reaction mixture was concentrated *in vacuo* and purified by column chromatography to obtain the desired product.

R: Protection of amine as *tert*-butyl carbamate

To a solution of amino compound (1 mmol) in acetonitrile (5 mL) was added triethylamine (2 mmol) and BOC anhydride (1.2 mmol). The reaction mixture was stirred for 2 h and concentrated *in vacuo*. Water was added to the residue and extracted with ethyl acetate. The organic layer was washed with brine, dried (MgSO_4), and the solvent was evaporated *in vacuo* to furnish *tert*-butyl carbamate. If needed, the product 15 was purified by crystallization or column chromatography.

S: Conversion of *tert*-butyl carbamate to amine

To a solution of *tert*-butyl carbamate (1 mmol) in dichloromethane (10 mL) was 20 added trifluoroacetic acid (2 mL). The solution was stirred at room temperature for 4 h and concentrated *in vacuo*. The residue was purified by column chromatography or crystallization to give the desired amine.

S-2: Conversion of *tert*-butyl carbamate to amine

To a solution of *tert*-butyl carbamate (1 mmol) in methanol (13 mL) was added 25 6 N HCl (8.75 mL, 52 mmol) and water (4.25 mL). The reaction mixture was stirred at room temperature for 2 days. The pH was adjusted to 7 using conc. ammonium hydroxide and the solid that separated out, was collected by filtration, washed with ether,

dried in *vacuo* to furnish the desired product. If no solid separated out, the product was isolated by extraction with chloroform and evaporating the organic layer.

T: Protection of aldehyde as acetal

5

To a solution of aldehyde (1 mmol) in ethanol (5 mL) was added triethyl orthoformate (1.4 mmol), ammonium nitrate (0.2 mmol) and stirred at room temperature overnight (if reaction was not complete by TLC and NMR analysis of an aliquot, the reaction mixture was heated at 50 °C until complete). After completion of the reaction, 10 the mixture was quenched with triethylamine (0.2 mmol) and concentrated *in vacuo* to remove ethanol. The residue was dissolved in ether, filtered to remove any insoluble inorganic impurities, and evaporated to dryness. The product obtained was used as such without further purification.

15 U-1: Conversion of bromide to boronic acid

To a mixture of bromo compound (1 mmol) in ether (10 mL), cooled to -78 °C, n-butyl lithium (1.2 mmol) was added dropwise and the reaction mixture was stirred for 30 mins after the addition was completed. Tributyl borate (1.3 mmol) in ether (10 mL) was 20 added to the reaction and stirred at -78 °C for 2 h. The reaction mixture was allowed to warm to 0 °C and quenched with 2 M HCl (10 mL). The reaction mixture was stirred at room temperature for 1h and cooled with ice. The aqueous layer was separated and the organic layer was extracted twice with 1N NaOH (2 X 10 mL). The basic extracts were combined and washed with ether (10 mL). The basic layer was acidified to pH 4 using 6 N HCl and the solid that separated out was collected by filtration, washed with water and hexane and dried *in vacuo* to furnish boronic acid as a solid. If no solid product is 25 obtained then the basic layer was extracted with ether (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo* to furnish boronic acid.

U-2: Synthesis of boronic acid by ortho lithiation of aryl aldehyde

To a solution of N,N,N',N'-trimethylethylenediamine (1 mmol) in THF/ether (10 mL, 1:1) cooled to -20 °C was added dropwise, over a period of 15 mins, n-butyl lithium (1 mmol) and stirred at -20 °C for 15 mins. Aldehyde (1 mmol) at -20 °C was added dropwise over a period of 10 mins to this mixture. The reaction mixture was further stirred for 15 mins at -20 °C followed by the addition of n-butyl lithium (2.8 mmol) dropwise over a period of 15 mins and stirred at 4 °C overnight. The reaction mixture was cooled to -40 °C and tributyl borate (5.6 mmol) in ether (20 mL) was added to the reaction and stirred at 4 °C for 12 h. The reaction mixture was allowed to warm to 0 °C and quenched with 2 M HCl (3 mmol) and heated at reflux for 2 h and added to ice water (25 mL). The aqueous layer was separated and the organic layer extracted twice with 1N NaOH (2 X 10 mL). The basic extracts were combined and washed with ether (10 mL). The basic layer was acidified to pH 3 using 6 N HCl and the solid that separated out was collected by filtration, washed with water and hexane and dried *in vacuo* to furnish boronic acid as a solid. If no solid product was obtained, then the basic layer was extracted with ether (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo* to furnish boronic acid.

20 U-3: Synthesis of boronic acid by ortho lithiation of aryl acetal

To a solution of aryl acetal compound (1 mmol) in ether (10 mL) at -78 °C, *tert*-butyl lithium (1.1 mmol) was added dropwise and the reaction mixture was stirred for 3 h at -20 °C after the addition was completed. Tributyl borate (1.2 mmol) in ether (10 mL) was added to the reaction and stirred at -20 °C for 1 h. The reaction mixture was allowed to warm to 0 °C and quenched with 2 M HCl (10 mL). The reaction mixture was stirred at room temperature for 1h. The aqueous layer was separated and the organic layer was extracted twice with 1N NaOH (2 X 10 mL). The basic extracts were combined and washed with ether (10 mL). The basic layer was acidified to pH 4 using 6 N HCl and the

solid that separated out was collected by filtration, washed with water and hexane and dried *in vacuo* to furnish boronic acid as a solid. If no solid product was obtained then the mixture was extracted with ether (2 X 10 mL). The organic layers were combined, dried and concentrated *in vacuo* to furnish boronic acid.

5

V-1: Demethylation of aryl methyl ether to phenol

In a round bottom flask (50 mL), pyridine hydrochloride (10g) was heated in an oil bath at 180 °C. After the entire solid had melted, the corresponding aryl methyl ether 10 (1 mmol) was added in small portions over a period of 20 min. The reaction mixture was heated at 180 °C for 4 h, cooled and quenched with water (100 mL). The reaction mixture was extracted with ethyl acetate (3 X 10mL). The combined organic layers were washed with brine, dried over MgSO₄, concentrated to give phenol. This can be further purified if needed by crystallization or column chromatography.

15

V-2: Demethylation of aryl methyl ether to phenol

To a solution of aryl ether (1 mmol) in dichloromethane (10 mL) cooled to -78 °C was added boron tribromide (3 mmol). The reaction mixture was allowed to warm to room temperature overnight and quenched with water (10 mL). The solid obtained was 20 collected by filtration to give the desired product. More product was obtained after evaporation of the organic layer and washing the residue with water. Alternatively, if a homogenous biphasic mixture was obtained on addition of water, the organic layer was separated, washed with brine, dried over MgSO₄, and concentrated to give the desired 25 phenol. This can be further purified if needed by crystallization or column chromatography.

V-3: Demethylation of aryl methyl ether to phenol

To a solution of aryl methyl ether (1 mmol) in dichloromethane (5 mL) was added AlCl₃ (8.5 mmol). The reaction mixture was heated to reflux for 12 h under nitrogen. To 5 this mixture was added 12 mL of 1 N HCl slowly and the organic layer was separated. The aqueous layer was re-extracted several times with ethyl acetate/DME. The combined organic layers were washed with brine, dried (MgSO₄), and evaporated *in vacuo* to furnish the desired phenol, which was purified by column chromatography.

10 V-4: Demethylation of aryl methyl ether to phenol

To a stirred slurry of NaH (2 mmol) in anhydrous toluene (5 mL) under nitrogen atmosphere was added para-thiocresol (2 mmol) dissolved in toluene (40 mL). The mixture was stirred at room temperature for 30 min and hexamethylphosphoric triamide 15 (2 mmol) in toluene (5 mL) was added dropwise over a period of 30 min. A solution of aryl ether (1 mmol) in toluene (5 mL) was added in one portion. The reaction mixture was stirred at reflux for 9.5 h, cooled to room temperature and diluted with ethyl acetate (40 mL). The organic layer was extracted with 1 N aqueous NaOH solution (2 X 20 mL). The basic layer was acidified to pH 5 and extracted with ethyl acetate (2 X 20 mL). The 20 organic layers were combined, washed with water, dried (MgSO₄) and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to afford the desired phenol compound.

W: Conversion of acid to methyl ester

25 A mixture of acid (1 mmol), conc. H₂SO₄ or conc HCl (0.5 mL) and methanol (10 mL) was heated at reflux for 16 h. The mixture was concentrated to half of its volume and the residue poured into a saturated sodium bicarbonate solution. The precipitate was collected by filtration, washed with water and dried to give the desired ester. If the ester

did not come as solid, it was extracted with ethyl acetate. The organic layer was dried, filtered and concentrated to give the desired ester.

W-2: Conversion of acid to ester

5

A solution of methanolic HCl or ethanolic HCl was prepared by the addition of acetyl chloride (1 mL) to methanol/ethanol (9 mL) at 0 °C and stirred for 30 mins. To the solution of anhydrous methanolic HCl was added acid (1 mmol) and stirred at room temperature (or reflux if needed) overnight. The reaction mixture was concentrated to dryness *in vacuo* and the residue was purified by column chromatography or crystallization to furnish the desired ester.
10

X: Conversion of phenol to alkyl aryl ethers or alkylation of amines

15 To a solution phenol or amine (1 mmol) in DMF (10 mL) was added cesium carbonate (1.25 mmol) and corresponding bromide (1.1 mmol). The reaction mixture was stirred at room temperature overnight and quenched with water (25 mL). The product was extracted with ether (2 X 25 mL), the organic layers were combined and washed with water (25 mL), brine (25 mL), dried and concentrated *in vacuo* to furnish
20 crude product. The crude was purified by crystallization or flash column chromatography.

Y: Conversion of nitrile to hydroxycarbamimidoyl

25 To a solution of nitrile compound (1 mmol) in ethyl alcohol (10 mL) was added hydroxylamine (50% aqueous solution, 5 mmol). The mixture was stirred at reflux for 2-5 h. The reaction mixture was concentrated *in vacuo* to furnish the desired hydroxycarbamimidoyl compound.

Z: Opening of aromatic methylene dioxy compound with alcohol

A solution of potassium tert-butoxide (2.25 mmol) in DMSO (1.25 mL) was heated at 50 °C for 30 min. Methanol (1.25 mL) was added to it and continued heating at 5 50 °C for 30 min. To the reaction mixture was added 1,2-methylenedioxy aromatic compound (1 mmol) and continued heating at 50 °C for 30 min. The reaction mixture was cooled to room temperature and quenched with water (10 mL) and 1 N sodium hydroxide (16 mL). The reaction mixture was washed with ether (2 X 10 mL) and acidified to pH 4 using conc HCl. The solid obtained was collected by filtration to 10 furnish the desired product.

Z-1: Opening of aromatic methylene dioxy compound with alcohol

To a mixture of methylene dioxy compound (1 mmol) in HMPA (2.5 mL) were 15 added sodium methoxide (2.5 mmol) and heated with stirring at 150 °C for 12 min. The mixture was cooled and poured into ice water (20 mL), NaOH (30 mg) and stirred for 10 min. It was then extracted with ether and the aqueous layer was acidified to pH 4 with HCl and extracted with ether. The later ethereal extracts were combined, dried and concentrated. The residue was purified by crystallization or column chromatography.

20

AA: Conversion of amine to amide in the presence of a phenol

To a solution of amino compound (1 mmol) in pyridine (5 mL) was added, dropwise, acid chloride (2 mmol) at 0 °C under N₂. The mixture was stirred for 45 min 25 and was then poured into ice water and acidified with 1 N HCl. The precipitated solid was collected by filtration, washed with 1N HCl, hexane, and then dried *in vacuo* to give crude product. The crude product was added to freshly prepared sodium methoxide solution (0.1 M, 10 mL) and stirred for 30 min at room temperature. The reaction mixture was quenched with acetic acid (1 mmol) and concentrated *in vacuo*. The residue

was dissolved in ethyl acetate and washed with water. The water layer was extracted with ethyl acetate, and the combined organic layers were washed with brine, dried ($MgSO_4$) and evaporated to yield a solid. The solid was washed with hexane and dried *in vacuo* to furnish the desired amide.

5

AB-1: Conversion of amino of amidine to amino carbamate

To amidine compound (1 mmol) was added 0.1N NaOH (10 mL) and stirred at room temperature for 5 min. The reaction mixture was concentrated *in vacuo* and to the residue was added alkyl or aryl 4-nitrophenyl carbonate (2 mmol) in 20 mL of hexamethylphosphoramide and stirred at 45 °C for 24 h. The reaction was quenched with water (100 mL) and extracted with ethyl acetate (2 X 100 mL). The combined extracts were washed with water (100 mL) and brine (100 mL), dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to furnish the desired product.

AB-2: Conversion of amino of amidine to amino carbamate

To a solution of amidine compound (1 mmol) in acetonitrile (25 mL) was added triethylamine (5 mL) and aryl/alkyl chloroformate (2 mmol) or dialkyl/aryl carbonate. The reaction mixture was stirred at room temperature for 16 h and quenched with water (100 mL). The reaction mixture was extracted with ethyl acetate (2 X 100 mL). The combined extracts were washed with brine (100 mL), dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to furnish the desired product.

AC: Conversion of aldehyde to oxime

To a stirred solution of aldehyde (1 mmol) in ethanol (10 mL) was added pyridine (10 mL) and hydroxylamine hydrochloride (1.25 mmol). The reaction mixture was stirred overnight at room temperature under nitrogen and then concentrated *in vacuo* to one third of its original volume. Water (10 mL) was added and the precipitated solid was collected by filtration and dried *in vacuo*. The product was used as such for next step without further purification.

10 AD: Debenzylation in the presence of aldehyde

To a solution of phenyl methoxyaryl aldehyde (1 mmol) in dichloromethane (10 mL) cooled to -78 °C was added dropwise under a nitrogen atmosphere boron tribromide (1M solution in dichloromethane, 1.2 mmol). The reaction mixture was allowed to warm to room temperature and stirred at room temperature overnight. The reaction mixture was quenched with water (10 mL) and the layers were separated. The aqueous layer was extracted with chloroform (10 mL). The organic layers were combined, washed with brine (10 mL), dried, filtered and concentrated *in vacuo* to furnish crude product. Purification of the crude by flash column chromatography furnished the desired phenolic
20 aldehyde

AE-1: Reductive amination of aldehyde

To a stirred solution of aldehyde (1 mmol) in methanol (40 mL) was added amine (3.3 mmol) followed by the addition of glacial acetic acid (0.3 mL). The reaction mixture was stirred for 30 min under nitrogen at room temperature, and then sodium cyanoborohydride (1.5 mmol) was added. After stirring for 20 min, the solvent was evaporated *in vacuo*, and the residue was taken in ethyl acetate. The organic layer was washed with water, and the insoluble material was removed from the organic layer by

filtration. The pH of the aqueous phase was adjusted to 7 with 1N NaOH and was extracted twice with ethyl acetate. The combined organic layers were washed with brine and dried ($MgSO_4$). The solvent was evaporated *in vacuo* to furnish crude product. The crude product was purified by crystallization or flash column chromatography.

5

AE-2: Reductive amination of aldehyde

To a mixture of aminoaryl amidine (1.2 mmol), $4A^\circ$ molecular sieves, and sodium hydroxide (1 N solution in anhydrous methanol, 1.2 mL, 1.2 mmol) in methanol (10 mL) was added a solution of aldehyde (1 mmol) in THF (10 mL). The reaction mixture was heated for 15 mins at reflux temperature and was cooled to room temperature. Acetic acid (1 %) and sodium cyanoborohydride (1 M solution in THF, 5 mmol) was added to the reaction mixture and stirred at room temperature overnight. The reaction mixture was quenched with 1 N NaOH (30 mmol) and stirred for additional 2 h and concentrated in *vacuo* to remove methanol. The mixture was diluted with water (15 mL) and washed with ether (2 x 10 mL). The aqueous layer was acidified to pH 2 using 6 N HCl and the solid that separated out was collected by filtration, washed with ether, dried in *vacuo* to furnish product, which was purified by flash column chromatography, if needed.

20

AE-3: Reductive amination of aldehyde

A mixture of aminoaryl amidine (2 mmol), $4A^\circ$ molecular sieves, pyridine (6 mL) in methanol (9 mL) was heated at 50 °C for one hour. A solution of aldehyde (1 mmol) in methanol (7.5 mL) containing acetic acid (1 %) was added and continued heating for 4 h to 12 h. The reaction mixture was cooled and sodium cyanoborohydride (1 M solution in THF, 5 mmol) was added to the reaction mixture and stirred at room temperature overnight. The reaction mixture was quenched with 5 N NaOH (30 mmol) and stirred for additional 2 h. The reaction mixture was filtered through Celite (to remove molecular sieves) and concentrated to remove methanol. The mixture was diluted with water (15

mL) and washed with ether (2 X 10 mL). The aqueous layer was filtered and solid obtained was kept aside (mainly product). The aqueous layer was acidified to pH 2 using 6 N HCl and the solid that separated out was collected by filtration. The combined solid materials were purified, if needed, by flash column chromatography.

5

AE-4: Reductive amination of aldehyde

To a mixture of aldehyde (1 mmol) and aminoarylamidine (1.1 mmol) in MeOH at room temperature was added triethyl amine (2.75 mmol), sodium cyanoborohydride 10 (0.83 mmol) and zinc chloride (0.9 mmol). The reaction mixture was stirred at room temperature overnight and concentrated to remove methanol. The reaction mixture was quenched with 1 N NaOH (10 mL), diluted with water (10 mL), and extracted with EtOAc (5 X 20 mL). The combined organic extracts were washed with brine (15 mL), dried (MgSO_4), filtered through Celite and concentrated to give the product. Purification 15 of the crude by flash column chromatography gave the desired product.

AE-5: Reductive amination of aldehyde

To a solution of amine (1.2 mmol) in MeOH (10 mL) was added aldehyde (1 mmol) in THF (10 mL) containing acetic acid (0.1 mL) drop-wise. The mixture was 20 stirred at 50 °C for 4-12 h and then cooled to room temperature. Sodium cyanoborohydride (1.5 mmol) was added to the reaction mixture and stirred at room temperature overnight. Water was added and pH of the solution was adjusted to 7. The solution was extracted with ethyl acetate. The organic layer was dried (MgSO_4) and 25 evaporated *in vacuo*. The residue was purified by flash column chromatography to furnish the desired amine.

AF-1: Synthesis of amidine from nitrile

Acetyl chloride (5 mL) was added to methanol (5 mL) at 0 °C drop-wise and stirred at room temperature for 15 mins. To this solution of methanolic HCl was added 5 nitrile compound (1 mmol) and stirred at room temperature overnight. The reaction mixture was concentrated in *vacuo* and dried. The residue obtained of the resulting methyl imidate was dissolved in methanol (10 mL). Dry ammonia gas was bubbled into the reaction mixture at reflux temperature for 5 h. The reaction mixture was concentrated to furnish the required amidine.

10

AG: Addition of Grignard reagent to aryl aldehyde

To a solution of aryl aldehyde (1 mmol) in THF (15 mL) cooled to -78 °C was added drop wise under a nitrogen atmosphere, vinyl magnesium bromide (1 M solution in THF, 15 5 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 48 h. The reaction was quenched carefully with saturated aqueous ammonium chloride solution (10 mL) and extracted with ethyl acetate (2 X 10 mL). The organic layers were combined, washed with brine (10 mL), dried and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to obtain the desired addition 20 product.

AG-1: Synthesis of tributylvinyltin compounds from vinyl bromide containing hydroxyl

25 To a solution of vinyl bromide with hydroxyl (1 mmol) in dichloromethane (20 mL) was added *tert*-butyldimethylsilyl chloride (1.5 mmol) and DMAP (1.5 mmol) and stirred at room temperature overnight. The reaction mixture was quenched with water (20 mL) and the aqueous layer separated. The organic layer was washed with 0.1 N aqueous HCl (10 mL), brine (20 mL), dried and concentrated in *vacuo* to furnish

corresponding *tert*-butyldimethylsilyloxy compound as an oil which was used as such for the next step.

To a solution of the above oily residue (1 mmol) in diethyl ether (20 mL) cooled to -78 °C was added dropwise *tert*-butyllithium (1.7 M in pentane, 2 mmol) over a period of 15 mins. The reaction mixture was stirred at -78 °C for 3 h and quenched at -78 °C with 2 N aqueous sulfuric acid (2 mL) and water (18 mL). The reaction mixture was neutralized using 2 N NaOH and the organic layer was separated. The organic layer was washed with water (20 mL), brine (20 mL), dried and concentrated in vacuo. Purification of the crude residue obtained by flash column chromatography furnished the desired tributyltin compound.

AG-2: Synthesis of tributylmethyltin compounds from arylmethyl bromides or allyl bromides

To lithium clippings (10 mmol) in THF (10 mL) cooled to -40 °C was added dropwise tributyltin chloride (0.27 mL, 1 mmol) in THF (5 mL) over a period of 15 min. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The reaction mixture was filtered through glass wool to remove insoluble impurities and cooled to -40 °C. A freshly prepared solution of arylmethyl bromide or allyl bromide (1 mmol) was added dropwise over a period of 10 mins and stirred at room temperature overnight. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (10 mL) and extracted with ether (2 X 10 mL). The organic layers were combined, washed with brine (10 mL), dried, filtered and concentrated in vacuo to furnish desired tributyltinalkyl and was used as such without further purification.

AG-3: 4-Bromo-5-formyl-benzo[1,3]dioxole-2-carboxylic acid methyl ester

To a mixture of 2-bromo-3,4-dihydroxy-benzaldehyde (2.17 g, 10.0 mmol) and K₂CO₃ (5.56 g, 40.2 mmol) in *n*-propanol (25 mL) was added dibromoacetic acid (2.18, 5 10.0 mmol) and the mixture was heated at reflux temperature for 24 h. After cooling to room temperature, another portion of dibromoacetic acid (1.75 g, 8.0 mmol) was added. The mixture was stirred at reflux for 46 h. *n*-Propanol was evaporated and water (30 mL) was added. The resulting aqueous solution was acidified to pH 2 by adding 1 N HCl and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried (MgSO₄) and evaporated *in vacuo* to afford crude 4-bromo-5-formyl-benzo[1,3]dioxole-10 2-carboxylic acid (1.34 g) as a brownish solid. This crude product was dissolved in anhydrous methanol (50 mL) and conc. H₂SO₄ (5 mL) was added drop by drop. The resulting mixture was refluxed overnight and cooled to room temperature. Water (50 mL) was added and the resulting aqueous solution was extracted with ethyl acetate (100 mL X 3). The combined organic layers were dried (MgSO₄) and evaporated *in vacuo*. 15 The residue was purified by flash column chromatography (ethyl acetate:hexane = 5:95) to furnish 4-bromo-5-formyl-benzo[1,3]dioxole-2-carboxylic acid methyl ester as a white solid.

20 AH: Synthesis of tert-butyl ester of phenol

To a solution of phenol (1 mmol) in pyridine (10 mL) was added 2,2-dimethyl-propionyl chloride (1.2 mmol) dropwise. The mixture was stirred at room temperature for overnight and diluted with water (100 mL). The reaction mixture was extracted with ethyl acetate (3 X 50 mL). The organic layers were combined and washed with aqueous 25 0.5 N HCl (100 mL), water, brine, dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by flash column chromatography to furnish the desired ester.

AI: Preparation of 2-bromo-5-hydroxy benzaldehyde

To a solution 3-hydroxybenzaldehyde (Aldrich, 101.39 g, 805 mmol) in chloroform (1000 mL), was added bromine (45 mL, 845 mmol) in chloroform (200 mL) drop wise over a period of 2 h at room temperature. The reaction mixture was stirred at room temperature overnight and filtered to collect crude 2-bromo-5-hydroxy benzaldehyde (32 g) as a dark brown solid. The filtrate was concentrated to 200 mL, filtered through a pad of Celite and silica gel (40 g) and washed with ether (1000 mL). The filtrate was concentrated in vacuo to give a second crop of the crude desired aldehyde (60 g) as a dark brown solid. The above solids were combined and dissolved in glacial acetic acid (360 mL) by heating. Water (840 mL) was added and the solution was filtered hot. The solution was allowed to attain room temperature and kept in a refrigerator overnight. The crystals obtained were collected by filtration and washed with water, dried overnight in vacuo to furnish (60 g, 37%) of the desired product as a purplish brown crystalline solid, mp: 135 °C.

AJ-1: Amidine from nitrile

A mixture of nitrile (1 mmol) and hydroxylamine (aqueous 50%, 1.8 mL) in EtOH (15 mL) was refluxed for 3 h and concentrated *in vacuo*. To the residue obtained was added EtOH (20 mL), acetic acid (2 mL) and a small amount of Raney nickel. The reaction mixture was hydrogenated (50 psi) for 14-24 h, filtered and concentrated *in vacuo*. The residue obtained, was purified by flash column chromatography to obtain the corresponding amidine.

25

AJ-2: Amidine from nitrile

A mixture of nitrile (1 mmol) and saturated methanolic HCl solution (freshly prepared by bubbling HCl gas or prepared in-situ by premixing methanol and acetyl

chloride at ice cold temperature) was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* to furnish methyl imidate. To the residue of methyl imidate was added MeOH (40 mL) and ammonia gas was bubbled at reflux temperature for 16 h or till the reaction was complete. The reaction mixture was concentrated *in vacuo* and dried to furnish the desired amidine. Alternatively, the methyl imidate was dissolved in methanol and ammonium acetate (10 mmol) was added. The reaction mixture was concentrated in vacuo and purified by flash column chromatography to obtain the corresponding amidine.

10 **AJ-3: Amidine from nitrile**

To a solution of nitrile (1 mmol) dissolved in methanol (5 mL) was added N-acetyl cystein (0.1 or 1 mmol) and ammonium acetate (5 mmol) and heated at reflux till the reaction was complete. The reaction mixture was concentrated in vacuo and purified by flash column chromatography to obtain the corresponding amidine.

AK: Conversion of aryl triflates or halides to boronate ester

To dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.75 mmol) under argon in dioxane (100 mL) was added aryl triflate (25 mmol), pinacolborane (31.5 mmol) and triethylamine (75 mmol). The reaction mixture was heated under argon at 100 °C for 3h or until complete as evidenced from TLC analysis. The reaction mixture was concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to furnish the desired boronate ester.

25 Alternatively, the following method can be used.


To dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.03 mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.03 mmol) under argon in dioxane (100 mL) was added aryl triflate (1 mmol), bis(pinacolata)diboron (1.1

mmol) and potassium acetate (3 mmol). The reaction mixture was heated under argon at 100 °C for 3h or until complete as evidenced from TLC analysis. The reaction mixture was concentrated *in vacuo*. The residue obtained was purified by flash column chromatography to furnish the desired boronate ester.





5

The examples of the compounds prepared are given in the following tables. The tables describe the compounds, their method of preparation, the starting material, and the analytical data. In some cases, where analytical data have not been given, those compounds were characterized at the later step in the synthesis.






10



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
2a	-OH		1	A-1 or A-2	¹ H NMR (DMSO-d ₆): δ 10.26 (s, 1 H), 9.84 (s, 1 H), 8.15 (d, J = 3.0 Hz, 1 H), 7.64 (dd, J = 2.0 Hz and 8.9 Hz, 1 H), 6.94 (d, J = 8.9 Hz, 1 H), 3.90 (s, 3 H), 2.15 (d, J = 6.9 Hz, 2 H), 2.06 (m, J = 6.9 Hz, 1 H), 0.93 (d, J = 6.9 Hz, 1 H), 0.93 (d, J = 6 Hz, 6H); MS (ES ⁺): 252.12
2b	-OH		1	A-1 or A-2	Characterized in the next step
2c	-OH		1	A-1 or A-2	MS (ES ⁺): 294.54
2d	-OH		1	A-1 or A-2	MS (ES ⁺): 288.49 (M+Na) ⁺


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
2e	-OH		1	A-1 or A-2	Characterized in the next step
2f	-OH		1	A-1 or A-2	MS (ES ⁺): 300.40 (M+Na) ⁺
2g	-OH		1	A-1 or A-2	MS (ES ⁺): 272.48 (M+Na) ⁺ ; MS (ES ⁺): 248.66
2h	-OH		1	A-1 or A-2	MS (ES ⁺): 286.48 (M+Na) ⁺
2i	-OH		1	A-1 or A-2	MS (ES ⁺): 224.54
2j	-OH		1	A-1 or A-2	Characterized in the next step

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
3a	-OSO ₂ CF ₃		2a	B-1 or B-2	MS (ES ⁺): 384.37
3b	-OSO ₂ CF ₃		2b	B-1 or B-2	MS (ES ⁺): 370.36
3c	-OSO ₂ CF ₃		2c	B-1 or B-2	MS (ES ⁺): 426.37
3d	-OSO ₂ CF ₃		2d	B-1 or B-2	Characterized in the next step
3e	-OSO ₂ CF ₃		2e	B-1 or B-2	¹ H NMR (CDCl ₃): δ 8.41 (d, <i>J</i> = 2.3 Hz, 1 H), 8.10 (dd, <i>J</i> = 8.5, 2.4 Hz, 1 H), 7.37 (d, <i>J</i> = 8.5 Hz, 1 H), 6.48 (broad, 1 H), 3.98 (s, 3 H), 3.46 (q, <i>J</i> = 7.2 Hz, 2 H), 1.62 (m, 2 H), 1.42 (m, 2 H), 0.96 (t, <i>J</i> = 7.2 Hz, 3 H); MS (ES ⁺): 384.1
3f	-OSO ₂ CF ₃		2f	B-1 or B-2	¹ H NMR (CDCl ₃): δ 8.45 (d, <i>J</i> = 2.4 Hz, 1 H), 8.14 (dd, <i>J</i> = 8.7, 2.4 Hz, 1 H), 7.42 (d, <i>J</i> = 8.7 Hz, 1 H), 6.52 (broad, 1 H), 4.14 (m, 2 H), 4.00 (s, 3 H); MS (ES ⁺): 410.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
3g	-OSO ₂ CF ₃		2g	B-1 or B-2	¹ H NMR (CDCl ₃): δ 8.42 (d, <i>J</i> = 2.3 Hz, 1 H), 8.12 (dd, <i>J</i> = 8.5, 2.3 Hz, 1 H), 7.39 (d, <i>J</i> = 8.7 Hz, 1 H), 6.31 (broad, 1 H), 4.00 (s, 3 H), 3.34 (dd, <i>J</i> = 7.2, 5.5 Hz, 2 H), 1.07 (m, 1 H), 0.59 (m, 2 H), 0.30 (m, 2 H); MS (ES ⁺): 382.2
3h	-OSO ₂ CF ₃		2h	B-1 or B-2	MS (ES ⁺): 396.36
3i	-OSO ₂ CF ₃		2i	B-1 or B-2	¹ H NMR (DMSO-d ₆): δ 8.85 (t, <i>J</i> = 5.5 Hz, 1 H), 8.49 (d, <i>J</i> = 2.3 Hz, 1 H), 8.23 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 7.70 (d, <i>J</i> = 8.7 Hz, 1 H), 3.92 (s, 3 H), 3.31 (m, 2 H), 1.14 (t, <i>J</i> = 7.2 Hz, 3 H); MS (ES ⁺): 356.1
3j	-OSO ₂ CF ₃		2j	B-1 or B-2	¹ H NMR (DMSO-d ₆): δ 8.81 (t, <i>J</i> = 6.0 Hz, 1 H), 8.49 (d, <i>J</i> = 2.3 Hz, 1 H), 8.24 (dd, <i>J</i> = 8.7, 2.4 Hz, 1 H), 7.71 (d, <i>J</i> = 8.7 Hz, 1 H), 3.92 (s, 3 H), 3.15 (m, 2 H), 1.64 (m, 1 H), 1.41 (m, 1 H), 1.12 (m, 1 H), 0.88 (m, 6 H); MS (ES ⁺): 398.2
5	-OSO ₂ CF ₃	-CO ₂ MEM	4	B-2	¹ H NMR (DMSO-d ₆): δ 8.52 (d, <i>J</i> = 2.0 Hz, 1 H), 8.32 (dd, <i>J</i> = 2.0 and 8.9 Hz, 1 H), 7.72 (d, <i>J</i> = 7.9 Hz, 1 H), 5.50 (s, 2 H), 3.88 (s, 3 H), 3.78 (t, <i>J</i> = 4.9 Hz, 2 H), 3.44 (d, <i>J</i> = 4.9 Hz, 2 H), 3.17 (s, 3 H); MS (ES ⁺): 439.1 (M+Na) ⁺
6a			3a	AK	¹ H NMR (CDCl ₃): δ 8.29 (d, <i>J</i> = 1.6 Hz, 1 H), 7.96 (dd, <i>J</i> = 7.5 & 1.6 Hz, 1 H), 7.58 (d, <i>J</i> = 7.5 Hz, 1 H), 6.24 (bs, 1 H), 3.94 (s, 3 H), 3.30 (t, <i>J</i> = 6.5 Hz, 2 H), 1.92 (m, 1 H), 1.43 (s, 12 H), 0.99 (d, <i>J</i> = 6.5 Hz, 6 H); MS (ES ⁺): 362.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
139	-OH		138	AA	¹ H NMR (DMSO-d ₆): δ 10.26 (s, 1 H), 9.84 (s, 1 H), 8.15 (d, J = 3.0 Hz, 1 H), 7.64 (dd, J = 2.0 Hz and 8.9 Hz, 1 H), 6.94 (q, J = 8.9 Hz, 1 H), 3.90 (s, 3 H), 2.15 (d, J = 6.9 Hz, 2 H), 2.06 (m, J = 6.9 Hz, 1 H), 0.93 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 252.12
140	-OSO ₂ CF ₃		139	B-2	¹ H NMR (DMSO-d ₆): δ 10.38 (s, 1 H), 8.36 (d, J = 2.8 Hz, 1 H), 7.99 (dd, J = 2.6 and 8.9 Hz, 1 H), 7.52 (d, J = 9.0 Hz, 1 H), 3.89 (s, 3 H), 2.23 (d, J = 7.0 Hz, 2 H), 2.09 (m, J = 6.6 Hz, 1 H), 0.94 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 384.0
169	-OH		168	AC	¹ H NMR (CDCl ₃): δ 8.08 (s, 1 H), 8.00 (d, J = 2.3 Hz, 1 H), 7.75 (dd, J = 2.3 and 8.7 Hz, 1 H), 7.01 (d, J = 8.7 Hz, 1 H), 3.97 (s, 3 H), 3.50 (s, 1 H); MS (ES ⁺): 196.1
170	-OH		169	G	¹ H NMR (DMSO-d ₆): δ 7.79 (d, J = 2.0 Hz, 1 H), 7.51 (dd, J = 2.3 and 8.5 Hz, 1 H), 6.95 (d, J = 8.5 Hz, 1 H), 7.01 (d, J = 8.7 Hz, 1 H), 3.90 (s, 3 H), 3.72 (s, 2 H), 3.50 (bs, 2 H); MS (ES ⁺): 182.12
171	-OH		170	AA	MS (ES ⁺): 250.50; MS (ES ⁺): 274.50 (M+Na) ⁺

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
172	-OSO ₂ CF ₃		171	B-2	¹ H NMR (CDCl ₃): δ 7.96 (d, <i>J</i> =2.3 Hz, 1 H), 7.55 (d, <i>J</i> =2.3 and 8.3 Hz, 1 H), 7.26 (d, <i>J</i> =8.3 Hz, 1 H), 5.90 (br s, 1 H), 4.50 (d, <i>J</i> =4.1 Hz, 2 H), 3.97 (s, 3 H), 2.44 (sep, <i>J</i> =7.0 Hz, 1 H), 1.20 (d, <i>J</i> =7.0 Hz, 6 H); MS (ES ⁺): 384.1
177	-OH		168	AE-1	¹ H NMR (DMSO-d ₆): δ 10.62 (s, 1 H), 8.88 (m, 2 H), 7.99 (d, <i>J</i> =2.3 Hz, 1 H), 7.70 (dd, <i>J</i> =2.3 and 8.5 Hz, 1 H), 7.06 (d, <i>J</i> =8.7 Hz, 1 H), 4.09 (m, 2 H), 3.91 (s, 3 H), 2.70 (m, 2 H), 1.98 (m, 1 H, <i>J</i> =6.8 Hz), 0.93 (d, <i>J</i> =6.8 Hz, 6 H); MS (ES ⁺): 238.1
178	-OSO ₂ CF ₃		177	B-2	¹ H NMR (CDCl ₃): δ 8.05 (d, <i>J</i> =2.3 Hz, 1 H), 7.63 (dd, <i>J</i> =2.3 and 8.3 Hz, 1 H), 7.25 (d, <i>J</i> =8.3 Hz, 1 H), 3.96 (s, 3 H), 3.85 (s, 2 H), 2.43 (d, <i>J</i> =6.8 Hz, 2 H), 1.77 (m, <i>J</i> =6.6 Hz, 1 H), 0.93 (d, <i>J</i> =6.6 Hz, 1 H); MS (ES ⁺): 370.2
179	-OSO ₂ CF ₃		178	R	¹ H NMR (DMSO-d ₆): δ 7.93 (m, 1 H), 7.47 (m, 1 H), 7.26 (m, 1 H), 4.48 (m, 2 H), 3.96 (s, 3 H), 3.03 (m, 2 H), 1.91 (m, 1 H), 1.52 (m, 9 H), 0.89 (d, <i>J</i> =6.6 Hz, 6 H); MS (ES ⁺): 492.2 (M+Na) ⁺




Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
7	-OBn	-CHO	6 + 3a	D-2	¹ H NMR (DMSO-d6): 89.78 (s, 1H), 8.85 (t, J = 5.7 Hz, 1H), 8.50 (d, J = 2.0 Hz, 1H), 8.20 (dd, J = 8.2, 1.9 Hz, 1H), 7.55 (m, 9H), 5.35 (s, 2H), 3.69 (s, 3H), 3.23 (t, J = 6.5 Hz, 2H), 1.98 (m, 1H), 1.02 (d, J = 6.8 Hz, 6H); MS (ES+): 446.3
8	-OBn	-CO ₂ H	7	E	MS (ES ⁺): 484.33 (M+Na) ⁺
9	-OBn	-CO ₂ MEM	8	F	MS (ES ⁺): 572.2 (M+Na) ⁺
10	-OH	-CO ₂ MEM	9	G	MS (ES ⁺): 482.33 [(M-MEM) + Na] ⁺
11	-OSO ₂ CF ₃	-CO ₂ MEM	10	B-2	¹ H NMR (DMSO-d6): 88.75 (t, J = 5.6 Hz, 1H), 8.44 (d, J = 1.6 Hz, 1H), 8.11 (dd, J = 8.0, 1.9 Hz, 1H), 8.01 (d, J = 2.9 Hz, 1H), 7.84 (dd, J = 8.4, 2.6 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 5.23 (q, AB system, 2H), 3.59 (s, 3H), 3.44 (m, 2H), 3.30 (m, 2H), 3.18 (s, 3H), 3.13 (t, J = 6.6 Hz, 2H), 1.88 (m, 1H), 0.91 (d, J = 6.7 Hz, 6H); MS (ES+): 614.3 (M+Na) ⁺
29a				D-3	Characterized in the next step


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
29b		-CO ₂ MEM	11	D-3	MS (ES ⁺): 520.2 (M+Na) ⁺
29c		-CO ₂ MEM	11	D-3	MS (ES ⁺): 482.3
29d		-CO ₂ MEM	11	D-3	MS (ES ⁺): 562.3 (M+Na) ⁺
29e		-CO ₂ MEM	11	D-3	MS (ES ⁺): 556.4 (M+Na) ⁺
29f		-CO ₂ MEM	11	D-3	¹ H NMR (DMSO-d6): δ8.50 (t, J = 5.6 Hz, 1H), 8.18 (d, J = 1.9 Hz, 1H), 7.86 (dd, J = 7.9, 1.9 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.56 (dd, J = 8.0, 1.8 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 7.9 Hz, 1H), 6.67 (dd, J = 17.6, 11.1 Hz, 1H), 5.76 (d, J = 17.6 Hz, 1H), 5.19 (d, J = 11.1 Hz, 1H), 4.99 (q, AB system, 2H), 3.37 (s, 3H), 3.20 (m, 2H), 3.11 (m, 2H), 2.97 (s, 3H), 2.91 (t, J = 6.7 Hz, 2H), 1.67 (m, 1H), 0.70 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 492.3 (M+Na) ⁺
29g		-CO ₂ MEM	11	D-2	MS (ES ⁺): 576.2 (M+Na) ⁺ ; MS (ES): 552.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
29h		-CO ₂ MEM	11	D-2	MS (ES ⁺): 538.2	
29i		-CO ₂ MEM	11	D-2	MS (ES ⁺): 560.4 (M+Na) ⁺	
30a		-CO ₂ H	29a	I-1	MS (ES ⁺): 398.3 ; MS (ES): 396.3	
30b		-CO ₂ H	29b	I-1	Characterized in the next step	
30c		-CO ₂ H	29c	I-1	MS (ES): 392.1	
30d		-CO ₂ H	29d	I-1	MS (ES ⁺): 452.1	
30e		-CO ₂ H	29e	I-1	MS (ES ⁺): 446.2	


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
30f		-CO ₂ H	29f	I-1	MS (ES ⁺): 380.1
30g		-CO ₂ H	29g	K, N, O, I-1	MS (ES ⁺): 515.3 (M+Na) ⁺ ; MS (ES): 491.2
30h		-CO ₂ H	29h	K, I-1	MS (ES ⁺): 450.1
30i		-CO ₂ H	29i	K, I-1	MS (ES ⁺): 450.3
33	-OSO ₂ CF ₃	-CO ₂ H	11	I-1	Characterized in the next step
41		-CO ₂ MHM	10	D-8	MS (ES ⁺): 534.30
42		-CO ₂ H	41	I-1	MS (ES ⁺): 446.30
48	-OCH ₃	-CHO	47 + 3a	D-2	MS (ES ⁺): 392.2 (M+Na) ⁺
49	-OCH ₃	-CO ₂ H	48	E	MS (ES ⁺): 386.1; 408.1 (M+Na) ⁺



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
14	$-\text{OSO}_2\text{CF}_3$	$-\text{CHO}$	13	B-2	Characterized in the next step	
15	$-\text{OSO}_2\text{CF}_3$	$-\text{CO}_2\text{H}$	14	E	MS (ES): 403.58	
16	$-\text{OSO}_2\text{CF}_3$		15	A-3 or A-4	$^1\text{H NMR}$ (DMSO-d ₆): δ 8.83 (t, J = 6 Hz, 1 H), 8.49 (d, J = 2.6 Hz, 1 H), 8.23 (dd, J = 8.6 Hz, 1 H), 7.72 (d, J = 8.6 Hz, 1 H), 7.49 (m, 2 H), 7.41 (m, 3 H), 5.43 (s, 2 H), 3.1 (t, J = 6.9 Hz, 2 H), 2.29 (m, 1 H), 0.89 (d, J = 6.9 Hz, 6 H).	



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
17	-OBn	-CHO	16 + 6	D-2	¹ H NMR (DMSO-d ₆): δ 0.88 (d, J = 6.0 Hz, 6 H), 1.85 (m, 1 H), 3.1 (t, J = 6.0 Hz, 2 H), 5.02 (q, J = 13 and 2.5 Hz, 2 H), 5.18 (s, 2 H), 6.88 (m, 2 H), 7.17 (d, J = 8.6 Hz, 1 H), 7.26 (m, 4 H), 7.35 (m, 1 H), 7.40 (m, 4 H), 7.49 (d, J = 7.7 Hz, 2 H), 8.07 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.38 (d, J = 1.7 Hz, 1 H), 8.72 (t, J = 6 Hz, 1 H), 9.63 (s, 1 H); MS (ES ⁺) 522.89
18	-OBn	-CO ₂ H	17	E	¹ H NMR (DMSO-d ₆): δ 0.86 (d, J = 6.9 Hz, 6 H), 1.85 (m, 1 H), 3.09 (t, J = 6.9 Hz, 2 H), 5.01 (d, J = 5.01 Hz, 2 H), 5.14 (s, 2 H), 7.08 (m, 3 H), 7.14 (dd, J = 8.6 and 2.6 Hz, 1 H), 7.27 (m, 4 H), 7.34 (m, 1 H), 7.41 (m, 3 H), 7.48 (m, 2 H), 7.99 (dd, J = 6.9 and 1.8 Hz, 1 H), 8.32 (s, 1 H), 8.64 (t, J = 6 Hz, 1 H), 12.57 (s, 1 H); MS (ES ⁺) 538.86
19	-OBn	-CO ₂ MEM	18	F	¹ H NMR (DMSO-d ₆): δ 0.90 (d, J = 6.8 Hz, 6 H), 1.86 (m, 1 H), 3.10 (t, J = 6.5 Hz, 2 H), 3.16 (s, 3 H), 3.28 (dd, J = 3 and 6 Hz, 2 H), 3.36 (dd, J = 3 and 6 Hz, 2 H), 5.02 (d, J = 3.8 Hz, 2 H), 5.12 (d, J = 15 Hz, 2 H), 5.64 (s, 2 H), 7.11 (m, 3 H), 7.24 (dd, J = 8.25 and 2.75 Hz, 1 H), 7.29 (m, 4 H), 7.35 (m, 1 H), 7.42 (m, 3 H), 7.49 (m, 2 H), 8.02 (dd, J = 1.7 and 8.2 Hz, 1 H), 8.36 (d, 1.7 Hz, 1 H), 8.68 (t, J = 6 Hz, 1 H); MS (ES ⁺) 626.44

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
21	-OH	-CO ₂ MEM	19	G, H	¹ HNMR (DMSO-d ₆): δ 0.88 (d, J = 6 Hz, 6 H), 1.85 (m, 1 H) 3.10 (t, J = 6 Hz, 2 H) 3.16 (s, 3 H), 3.28 (m 2 H), 3.35 (m, 2 H), 5.04 (d, J = 3.5 Hz, 2 H) 5.11 (d, J = 14 Hz, 2 H), 6.98 (m, 2 H), 7.11 (m, 2 H), 7.29 (m, 5 H), 8.03 (dd, J = 8 and 2 Hz, 1 H), 8.32 (d, J = 2 Hz, 1 H), 8.67 (t, J = 6 Hz, 1 H), 9.9 (s, 1 H); MS (ES+) 536.30 (100%: M ⁺)
22	-OSO ₂ CF ₃	-CO ₂ MEM	21	B-2	¹ HNMR (DMSO-d ₆): δ 0.89 (d, J = 6.8 Hz, 6 H), 1.86 (m, 1 H), 3.12 (t, J = 6.5 Hz, 2 H), 3.16 (s, 3 H), 3.29 (m, 2 H), 3.40 (m, 2 H), 5.04 (s, 2 H), 5.16 (dd, J = 18 and 6 Hz, 2 H), 7.15 (m, 2 H), 7.31 (m, 3 H), 7.36 (d, J = 8.5 Hz, 1 H), 7.41 (d, J = 8.5 Hz, 1 H), 7.73 (dd, J = 8.6 and 2.6 Hz, 1 H), 7.85 (d, J = 2.6 Hz, 1 H), 8.07 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.45 (d, J = 1.7 Hz, 1 H), 8.73 (t, J = 6 Hz, 1 H); MS (ES+) 668.15
24a				D-1	¹ HNMR (DMSO-d ₆): δ 0.89 (d, J = 6.8 Hz, 6 H), 1.87 (m, 1 H), 3.12 (t, J = 6 Hz, 2 H), 3.16 (s, 3 H), 3.29 (m, 2 H), 3.39 (m, 2 H), 5.05 (d, J = 2.6 Hz, 2 H), 5.16 (d, J = 17 Hz, 2 H), 7.08 (m, 2 H), 7.21 (m, 4 H), 7.24 (d, J = 7.7 Hz, 1 H), 7.35 (d, J = 7.7 Hz, 1 H), 7.62 (d, J = 3.5 Hz, 1 H), 7.64 (d, J = 5 Hz, 1 H), 7.86 (d, J = 8.6 Hz, 1 H), 8.06 (m, 2 H), 8.42 (s, 1 H), 8.73 (t, J = 6 Hz, 1 H); MS (ES+) 602.52

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
24b		-CO ₂ MEM	22 + 23	D-1	¹ H NMR (DMSO-d ₆): δ 0.89 (d, J = 6.8 Hz, 6 H), 1.87 (m, 1 H), 3.12 (t, J = 6 and 6.8 Hz, 2 H), 3.16 (s, 3 H), 3.30 (m, 2 H), 3.39 (dd, J = 5.2 and 3.4 Hz, 2 H), 5.04 (d, J = 4.3 Hz, 2 H), 5.16 (d, J = 16 Hz, 2 H), 7.08 (m, 2 H), 7.20 (m, 3 H), 7.24 (d, J = 8.6 Hz, 1 H), 7.35 (d, J = 8.6 Hz, 1 H), 7.61 (d, J = 5 Hz, 1 H), 7.71 (dd, J = 4.8 and 3 Hz, 1 H), 7.91 (dd, J = 1.7 and 7.7 Hz, 1 H), 8.00 (m, 1 H), 8.06 (dd, J = 2 and 8 Hz, 1 H), 8.14 (d, J = 1.7 Hz, 1 H), 8.41 (d, J = 1.7 Hz, 1 H), 8.68 (t, J = 6 Hz, 1 H); MS (ES+) 602.27
24c		-CO ₂ MEM	22 + 23	D-1	¹ H NMR (DMSO-d ₆): δ 0.89 (d, J = 6.8 Hz, 6 H), 1.87 (m, 1 H), 3.12 (t, J = 6 and 6.8 Hz, 2 H), 3.16 (s, 3 H), 3.30 (m, 2 H), 3.40 (m, 2 H), 5.05 (d, J = 5 Hz, 2 H), 5.17 (d, J = 17 Hz, 2 H), 7.09 (m, 2 H), 7.21 (m, 3 H), 7.30 (d, J = 7.7 Hz, 1 H), 7.37 (d, J = 7.7 Hz, 1 H), 7.44 (m, 1 H), 7.54 (t, J = 7.7 Hz, 2 H), 7.73 (d, J = 6.8 Hz, 2 H), 7.88 (dd, J = 1.7 and 7.7 Hz, 1 H), 8.07 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.11 (d, J = 1.7 Hz, 1 H), 8.42 (d, J = 1.7 Hz, 1 H), 8.72 (t, J = 6 Hz, 1 H); MS (ES+) 596.45
24d		-CO ₂ MEM	22 + 23	D-1	MS (ES+) 616
24e		-CO ₂ MEM	22 + 23	D-1	MS (ES+) 586.4

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
24f		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	586.39
24g		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	616.63
24h		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	597.25
24i		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	597.4
24j		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	597.4
24k		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺)	644.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
24l		-CO ₂ MEM	22 + 23	D-3	Characterized at the next step
24m		-CO ₂ MEM	22 + 23	D-10	Characterized at the next step
24n		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 560.74
24o		-CO ₂ MEM	22 + 23	D-4	MS (ES ⁺): 603.72
24p		-CO ₂ MEM	22 + 23	D-5	MS (ES ⁺): 558.3
24q		-CO ₂ MEM	22 + 23	D-5	Characterized in the next step
24r		-CO ₂ MEM	22 + 23	D-5	MS (ES ⁺): 610.4 (M+Na) ⁺

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
24s		-CO ₂ MEM	22 + 23	D-3	Characterized in the next step
24t		-CO ₂ MEM	22 + 23	D-3	Characterized in the next step
24u		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 598.4 (M+Na) ⁺
24v		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 500.4 [(M-MEM)-1] ⁻
24w		-CO ₂ MEM	22 + 23	D-5	Characterized in the next step
24x		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 610.5 (M+Na) ⁺
24y		-CO ₂ MEM	22 + 23	D-5	MS (ES ⁺): 596.4 (M+Na) ⁺
24z		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 576.3 (M+Na) ⁺
24aa		-CO ₂ MEM	22 + 23	D-11	Characterized in the next step

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
24ab		-CO ₂ MEM	22 + 23	D-2	MS (ES ⁺): 630.55	
24ac		-CO ₂ MEM	22 + 23	D-2	MS (ES ⁺): 630.74	
24ad		-CO ₂ MEM	22 + 23	D-2	MS (ES ⁺): 652.3	
24ae		-CO ₂ MEM	22 + 23	D-2	Characterized in the next step	
24ag		-CO ₂ MEM	22 + 23	D-1	MS (ES ⁺): 685.01	
24ah		-CO ₂ MEM	22 + 23	D-3	MS (ES ⁺): 546.49	

Cpd. No.	R	-R'	Starting From	Method Used	Analytical Data
25a		CO ₂ H	24a	I-1	¹ H NMR (DMSO-d ₆): δ 0.91 (d, J = 6.9 Hz, 6 H), 1.88 (m, 1 H), 3.13 (t, J = 6.9 and 6 Hz, 2 H), 5.07 (d, J = 11.2 Hz, 2 H), 7.09 (m, 2 H), 7.22 (m, 5 H), 7.35 (d, 7.7 Hz, 1 H), 7.63 (d, 2.6 Hz, 1 H), 7.65 (d, J = 5.2 Hz, 1 H), 7.82 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.05 (d, J = 1.7 Hz, 1 H), 8.07 (s, 1 H), 8.40 (s, 1 H), 8.72 (t, J = 6 Hz, 1 H), 12.77 (brs, 1 H); MS (ES+) 514.19
25b		CO ₂ H	24b	I-1	¹ H NMR (DMSO-d ₆): δ 0.92 (d, J = 6.9 Hz, 6 H), 1.88 (m, 1 H), 3.12 (t, J = 6.9 and 6 Hz, 2 H), 5.07 (d, J = 13 Hz, 2 H), 7.09 (m, 2 H), 7.22 (m, 4 H), 7.35 (d, J = 8.6 Hz, 1 H), 7.63 (d, J = 5.2 Hz, 1 H), 7.70 (dd, J = 2.6 and 4.3 Hz, 1 H), 7.88 (dd, J = 7.2 and 1.7 Hz, 1 H), 8.02 (d, J = 1.7 Hz, 1 H), 8.07 (dd, J = 1.7 and 7.7 Hz, 1 H), 8.15 (m, 1 H), 8.39 (d, J = 1.7 Hz, 1 H), 8.72 (t, J = 6 Hz, 1 H), 12.70 (brs, 1 H); MS (ES+) 514.06
25c		CO ₂ H	24c	I-1	¹ H NMR (DMSO-d ₆): δ 12.73 (bs, 1 H), 8.73 (t, J = 6 Hz, 1 H), 8.41 (d, J = 1.7 Hz, 1 H), 8.12 (d, J = 1.7 Hz, 1 H), 8.07 (dd, J = 7.7 & 1.7 Hz, 1 H), 7.83 (dd, J = 7.7 & 1.7 Hz, 1 H), 7.72 (d, J = 6.9 Hz, 2 H), 7.54 (t, J = 7.7, 2 H), 7.44 (t, J = 7.7 Hz, 1 H), 7.37 (d, J = 7.7 Hz, 1 H), 7.28 (d, J = 7.7 Hz, 1 H), 7.21 (m, 3 H), 7.09 (m, 2 H), 5.08 (d, J = 14 Hz, 2 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.88 (m, 1 H), 0.91 (d, 6.8 Hz, 6 H); MS (ES+) 507.93
25d		CO ₂ H	24d	I-1	¹ H NMR (DMSO-d ₆): δ 12.75 (bs, 1 H), 8.71 (t, J = 6 Hz, 1 H), 8.39 (d, J = 1.7 Hz, 1 H), 8.05 (dd, J = 1.7 & 7.7 Hz, 1 H), 8.01 (d, J = 2.5 Hz, 1 H), 7.75 (dd, J = 2.5 & 7.7 Hz, 1 H), 7.42 (d, 3.4 Hz, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.22 (m, 3 H), 7.19 (d, J = 8.6 Hz, 1 H), 7.09 (m, 2 H), 6.95 (d, J = 3.4 Hz, 1 H), 5.06 (d, J = 11 Hz, 2 H), 3.12 (t, J = 6.5 Hz, 2 H), 2.52 (s, 3 H), 1.89 (m, 1 H), 0.81 (d, 6.8 Hz, 6 H); MS (ES+) 528.51


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
25e		CO ₂ H	24e	I-1	¹ H NMR (DMSO-d ₆): δ 0.89 (d, J = 6 Hz, 6 H), 1.86 (m, 1 H), 3.12 (t, J = 6.8 and 6.0 Hz, 2 H), 5.03 (d, J = 10 Hz, 2 H), 7.02 (s, 1 H), 7.06 (m, 2 H), 7.16 (q, J = 8.6 Hz, 1 H), 7.21 (m, 3 H), 7.31 (d, J = 7.7 Hz, 1 H), 7.75 (dd, J = 8.5 and 1.7 Hz, 1 H), 7.78 (t, J = 1.7 Hz, 1 H), 8.04 (m, 2 H), 8.29 (s, 1 H), 8.36 (d, J = 1.7 Hz, 1 H), 8.66 (t, J = 6 and 5.2 Hz, 1 H), 12.58 (bs, 1 H); MS (ES+) 498.49
25f		CO ₂ H	24f	I-1	MS (ES ⁺): 498.36
25g		CO ₂ H	24g	I-1	¹ H NMR (DMSO-d ₆): δ 12.72 (bs, 1 H), 8.69 (t, J = 6 Hz, 1 H), 8.39 (d, J = 1.7 Hz, 1 H), 8.06 (m, 2 H), 7.79 (dd, J = 1.7 & 7.7 Hz, 1 H), 7.45 (s, 1 H), 7.35 (d, J = 7.7 Hz, 1 H), 7.21 (m, 5 H), 7.1 (m, 2 H), 5.07 (q, J = 8.6 Hz, 2 H), 3.12 (t, J = 6.5 Hz, 2 H), 2.29 (s, 3 H), 1.89 (m, 1 H), 0.91 (d, 6.8 Hz, 6 H); MS (ES ⁺) 528.38
25h		CO ₂ H	24h	I-1	¹ H NMR (DMSO-d ₆): δ 12.74 (bs, 1 H), 8.73 (m, 2 H), 8.63 (d, J = 1.7 Hz, 1 H), 8.41 (d, J = 1.7 Hz, 1 H), 8.23 (dd, J = 1.7 and 7.7 Hz, 1 H), 8.08 (dd, J = 1.7 & 7.7 Hz, 1 H), 8.05 (d, J = 7.7 Hz, 1 H), 7.96 (dt, J = 7.7 & 1.7 Hz, 1 H), 7.43 (dd, J = 6 & 7 Hz, 1 H), 7.37 (d, J = 7.7 Hz, 1 H), 7.29 (d, J = 8.6 Hz, 1 H), 7.18 (m, 3 H), 7.08 (m, 2 H), 5.01 (q, J = 10 & 25 Hz, 2 H), 3.13 (t, J = 6.9 and 6 Hz, 2 H), 1.89 (m, 1 H), 0.92 (d, J = 6.9 Hz, 6 H); MS (ES ⁺) 509.58

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
25i		CO ₂ H	24i	I-1	¹ H NMR (DMSO-d ₆): δ 12.70 (bs, 1 H), 8.91 (d, J = 2.6 Hz, 1 H), 8.68 (t, J = 6 & 1 Hz, 1 H), 8.62 (d, J = 2 Hz, 1 H), 8.4 (d, J = 1.7 Hz, 1 H), 8.12 (m, 2 H), 8.05 (dd, J = 8.6 & 1.7 Hz, 1 H), 7.88 (d, 8.5 & 1.7 Hz, 1 H), 7.53 (dd, J = 8.6 & 5.2 Hz, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.28 (d, J = 8.6 Hz, 1 H), 7.18 (m, 3 H), 7.08 (m, 2 H), 5.04 (d, J = 12 Hz, 2 H), 3.11 (t, J = 6.5 Hz, 2 H), 1.87 (m, 1 H), 0.9 (d, 6.8 Hz, 6 H); MS (ES+) 509.11	
25j		CO ₂ H	24j	I-1	¹ H NMR (DMSO-d ₆): δ 0.90 (d, J = 6.9 Hz, 6 H), 1.88 (m, 1 H), 3.11 (t, J = 6.9 and 6 Hz, 2 H), 5.03 (s, 2 H), 7.06 (m, 2 H), 7.18 (m, 3 H), 7.33 (d, 8.4 Hz, 1 H), 7.30 (d, J = 8.4 Hz, 1 H), 7.75 (d, J = 6.2 Hz, 2 H), 7.85 (m, 1 H), 8.05 (dd, J = 7.6 and 1.7 Hz, 1 H), 8.18 (s, 1 H), 8.40 (d, J = 2 Hz, 1 H), 8.71 (m, 4 H); MS (ES+) 509.49	
25k		CO ₂ H	24K	I-1	Characterized in the next step	
25l		CO ₂ H	24l	I-1	MS (ES [†]): 511.54	
25m		CO ₂ H	24m	I-1	MS (ES [†]): 501.66	

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
25n		CO ₂ H	24n	I-1	MS (ES ⁺): 472.4
25o		CO ₂ H	24o	I-1	MS (ES ⁺): 515.65
25p		CO ₂ H	24p	I-1	Characterized in the next step
25q		CO ₂ H	24q	I-1	MS (ES ⁺): 536.3 (M+Na) ⁺
25r		CO ₂ H	24r	I-1	MS (ES ⁺): 500.4
25s		CO ₂ H	24s	I-1	Characterized in the next step
25t		CO ₂ H	24t	I-1	Characterized in the next step
25u		CO ₂ H	24u	I-1	MS (ES ⁺): 486.4





Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
25v		CO ₂ H	24v	I-1	MS (ES ⁺): 524.3 (M+Na) ⁺
25w		CO ₂ H	24w	I-1, Q	Characterized in the next step
25x		CO ₂ H	24x	I-1	MS (ES ⁺): 498.3
25y		CO ₂ H	24y	I-1	MS (ES ⁺): 484.3
25z		CO ₂ H	24z	I-1	MS (ES ⁺): 488.3
25aa		CO ₂ H	24aa	I-1	Characterized in the next step
25ab		CO ₂ H	24ab	K, I-1	MS (ES ⁺): 544.27

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
25ac		CO ₂ H	24ac	K, I-1	MS (ES ⁺): 544.2
25ad		CO ₂ H	24ad	E, H, I-1	MS (ES ⁺): 670.3 (M+Na) ⁺
25ae		CO ₂ H	24ae	K, I-1	¹ H NMR (DMSO-d ₆): δ 9.1 (bs, 2 H), 8.8 (bs, 2 H), 8.5 (t, J = 6 Hz, 1 H), 8.02 (s, 1 H), 7.68 (s, 1 H), 7.62 (m, 6 H), 7.53 (d, J = 5.8 Hz, 1 H), 7.15 (d, J = 6 Hz, 1 H), 7.13 (m, 1 H), 7.01 (s, 1 H), 5.5 (t, J = 5 Hz, 1 H), 4.7 (d, J = 5 Hz, 2 H), 3.01 (m, 2 H), 1.8 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H)
25af		CO ₂ H	24ad	K, I-1	MS (ES ⁺): 566.2 (M+Na) ⁺
25ag		CO ₂ H	24ag	I-1	MS (ES ⁺): 597.7
25ah		CO ₂ H	24ah	L, I-1	MS (ES ⁺): 492.54
25ai		CO ₂ H	24ai	L, M, K, N, O, I-1	Characterized in the next step



Cpd. No.	-R	Starting From	Method Used	Analytical Data	
26a		25a	J	¹ H NMR (DMSO-d ₆): δ 0.88 (d, J = 6.9 Hz, 6 H), 1.84 (m, 1 H), 3.07 (t, J = 6.9 and 6.0 Hz, 2 H), 5.05 (s, 2 H), 7.04 (d, J = 6.9 Hz, 2 H), 7.20 (m, 4 H), 7.35 (d, J = 7.7 Hz, 1 H), 7.43 (d, J = 7.7 Hz, 1 H), 7.66 (d, J = 5.2 Hz, 1 H), 7.70 (d, J = 4.3 Hz, 1 H), 7.75 (m, 4 H), 7.82 (dd, J = 7.7 and 1.7 Hz, 1 H), 7.94 (d, J = 1.7 Hz, 1 H), 8.03 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.26 (dd, J = 7.7 and 1.7 Hz, 1 H), 8.69 (t, J = 6 Hz, 1 H), 8.80 (s, 2 H), 9.17 (s, 2 H), 10.76 (s, 1 H); MS (ES+) 631.05	
26b		25b	J	¹ H NMR (DMSO-d ₆): δ 0.88 (d, J = 6.9 Hz, 6 H), 1.84 (m, 1 H), 3.07 (t, J = 6.8 and 6.0 Hz, 2 H), 5.04 (s, 2 H), 7.02 (d, J = 6.8 Hz, 2 H), 7.20 (m, 3 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.43 (d, J = 8.6 Hz, 1 H), 7.72 (m, 6 H), 7.90 (dd, J = 1.7 and 7.7 Hz, 1 H), 8.05 (m, 3 H), 8.23 (d, J = 1.7 Hz, 1 H), 8.68 (t, J = 6 and 5.2 Hz, 1 H), 8.82 (s, 2 H), 9.17 (s, 2 H), 10.73 (s, 1 H); MS (ES+) 631.82	
26c		25c	J	¹ H NMR (DMSO-d ₆): δ 10.75 (s, 1 H), 9.19 (s, 2 H), 8.89 (s, 2 H), 8.69 (t, J = 6 Hz, 1 H), 8.29 (d, J = 1.7 Hz, 1 H), 8.07 (dd, J = 7.7 & 1.7 Hz, 1 H), 7.99 (d, J = 1.7 Hz, 1 H), 7.87 (dd, J = 7.7 & 1.7 Hz, 1 H), 7.83 (d, J = 7.7 Hz, 2 H), 7.77 (m 5 H), 7.54 (t, J = 7.7, 2 H), 7.43 (m, 3 H), 7.19 (m, 3 H), 7.03 (d, J = 6.9 Hz, 2 H), 5.04 (bs, 2 H), 3.09 (t, J = 6.5 Hz, 2 H), 1.84 (m, 1 H), 0.89 (d, 6.8 Hz, 6 H); MS (ES+) 625.81	

Cpd. No.	R	Starting From	Method Used	Analytical Data
26d		25d	J	¹ H NMR (DMSO-d ₆): δ 10.7 (s, 1 H), 9.14 (s, 2 H), 8.82 (s, 2 H), 8.64 (t, J = 6 Hz, 1 H), 8.21 (s, 1 H), 7.98 (dd, J = 7.8 & 2 Hz, 1 H), 7.8 (d, J = 2 Hz, 1 H), 7.7 (m, 4 H), 7.68 (dd, J = 2 & 7.8 Hz, 1 H), 7.44 (d, J = 3 Hz, 1 H), 7.37 (d, 7.8 Hz, 1 H), 7.27 (d, J = 7.7 Hz, 1 H), 7.16 (m, 3 H), 7.0 (s, 1 H), 6.99 (s, 1 H), 6.86 (d, J = 3 Hz, 1 H), 5.0 (s, 2 H), 3.03 (t, J = 6.5 Hz, 2 H), 2.46 (s, 3 H), 1.78 (m, 1 H), 0.83 (d, 6.8 Hz, 6 H); MS (ES+) 645.77
26e		25e	J	¹ H NMR (DMSO-d ₆): δ 0.87 (d, J = 6.2 Hz, 6 H), 1.73 (m, 1 H), 3.07 (t, J = 6.7 and 6.2 Hz, 2 H), 5.05 (s, 2 H), 7.03 (dd, J = 1.7 and 8 Hz, 2 H), 7.11 (d, J 1.7 Hz, 1 H), 7.21 (m, 3 H), 7.31 (d, J = 8 Hz, 1 H), 7.42 (d, J = 8 Hz, 1 H), 7.78 (m, 5 H), 7.92 (d, J = 1.7 Hz, 1 H), 8.02 (dd, J = 8 and 1.7 Hz, 1 H), 8.25 (d, J = 1.9 Hz, 1 H), 8.33 (s, 1 H), 8.63 (t, J = 6 and 5 Hz, 1 H), 8.80 (bs, 2 H), 9.14 (bs, 2 H), 10.67 (s, 1 H); MS (ES+) 615.75
26f		25f	J	¹ H NMR (DMSO-d ₆): δ 0.87 (d, J = 6.7 Hz, 6 H), 1.83 (m, 1 H), 3.06 (t, J = 6.7 and 6.2 Hz, 2 H), 5.04 (s, 2 H), 6.67 (m, 1 H), 7.03 (m, 2 H), 7.16 (m, 3 H), 7.35 (d, J = 8.6 Hz, 1 H), 7.42 (d, J = 8 Hz, 1 H), 7.74 (m, 4 H), 7.85 (m, 2 H), 7.98 (d, J = 1.2 Hz, 1 H), 8.03 (dd, J = 1.7 and 8 Hz, 1 H), 8.25 (d, J = 1.8 Hz, 1 H), 8.67 (t, J = 6.2 and 5.5 Hz, 1 H), 8.88 (bs, 2 H), 9.12 (bs, 2 H), 10.772 (bs, 1 H); MS (ES+) 615.75
26g		25g	J	¹ H NMR (DMSO-d ₆): δ 10.67 (s, 1 H), 9.12 (s, 2 H), 8.78 (s, 2 H), 8.61 (t, J = 6 Hz, 1 H), 8.21 (s, 1 H), 7.98 (dd, J = 7.8 & 2 Hz, 1 H), 7.84 (d, J = 2 Hz, 1 H), 7.7 (m, 5 H), 7.46 (s, 1 H), 7.39 (d, 7.8 Hz, 1 H), 7.29 (d, J = 7.7 Hz, 1 H), 7.16 (m, 4H), 7.01 (s, 1 H), 6.99 (s, 1 H), 5.0 (s, 2 H), 3.03 (t, J = 6.5 Hz, 2 H), 2.23 (s, 3 H), 1.79 (m, 1 H), 0.83 (d, 6.8 Hz, 6 H); MS (ES+) 645.77




Cpd. No.	-R	Starting Material Used	Method Used	Analytical Data
26h		25h	J	¹ HNMR (DMSO-d ₆): δ 10.77 (bs, 1 H), 8.95 (bs, 4 H), 8.76 (d, J = 4.3 Hz, 1 H), 8.69 (t, J = 6 Hz, 1 H), 8.4 (s, 1 H), 8.29 (m, 2 H), 8.15 (d, J = 7.7 Hz, 1 H), 8.07 (dd, J = 1.7 and 7.7 Hz, 1 H), 7.99 (dt, J = 1.7 & 7.7 Hz, 1 H), 7.76 (m, 4 H), 7.46 (m, 2 H), 7.18 (m, 3 H), 7.05 (s, 1 H), 5.06 (s, 2 H), 3.10 (t, J = 6.9 and 6 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J = 6.9 Hz, 6 H); MS (ES+) 626.69
26i		25i	J	¹ HNMR (DMSO-d ₆): δ 10.73 (bs, 1 H), 9.16 (bs, 2 H), 9.05 (d, J = 1.9 Hz, 1 H), 8.79 (s, 2 H), 8.69 (t, J = 6 & Hz, 1 H), 8.64 (dd, J = 1.2 & 5 Hz, 1 H), 8.29 (d, J = 1.7 Hz, 1 H), 8.24 (d, J = 8 Hz, 1 H), 8.05 (m, 2 H), 7.93 (dd, 8 & 1.8 Hz, 1 H), 7.76 (m, 5 H), 7.56 (dd, J = 8 & 4.3 Hz, 1 H), 7.44 (d, J = 7.4 Hz, 2 H), 7.18 (m, 3 H), 7.0 (m, 2 H), 5.0 (s, 2 H), 3.08 (t, J = 6.5 Hz, 2 H), 1.82 (m, 1 H), 0.88 (d, 6.8 Hz, 6 H); MS (ES+) 626.44
26j		25j	J	¹ HNMR (DMSO-d ₆): δ 0.87 (d, J = 6.9 Hz, 6 H), 1.75 (m, 1 H), 3.08 (t, J = 6.9 and 6.0 Hz, 2 H), 5.03 (s, 2 H), 7.03 (m, 1 H), 7.18 (m, 3 H), 7.45 (t, J = 7.8 and 7 Hz, 2 H), 7.76 (s, 4 H), 7.87 (d, J = 6 Hz, 2 H), 7.94 (dd, J = 8 and 2 Hz, 1 H), 8.05 (dd, J = 8 and 2 Hz, 1 H), 8.08 (d, J = 2 Hz, 1 H), 8.29 (d, J = 2 Hz, 1 H), 8.70 (m, 3 H), 8.84 (s, 2 H), 9.11 (s, 2 H), 10.76 (s, 1 H); MS (ES+) 626.76
26k				¹ HNMR (DMSO-d ₆): δ 10.72 (bs, 1 H), 9.15 (bs, 2 H), 8.81 (bs, 2 H), 8.86 (t, J = 6 Hz, 1 H), 8.28 (s, 1 H), 8.03 (m, 3 H), 7.91 (d, J = 7.9 Hz, 1 H), 7.81 (d, J = 4 Hz, 1 H), 7.74 (s, 4 H), 7.42 (d, J = 7.9 Hz, 1 H), 7.38 (d, J = 7.9 Hz, 1 H), 7.18 (m, 3 H), 7.04 (m, 2 H), 5.04 (bs, 2 H), 3.07 (t, J = 6 Hz, 2 H), 2.57 (s, 3 H), 1.83 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES+) 673.7


Cpd. No.	-R	Starting From	Method Used	Analytical Data
26l		25l	J	¹ HNMR (DMSO-d ₆): δ 10.66 (s, 1 H), 9.20 (s, 2 H), 8.86 (s, 2 H), 8.66 (t, J = 6 Hz, 1 H), 8.24 (d, J = 2 Hz, 1 H), 8.15 (dd, J = 7.8 & 2 Hz, 1 H), 7.69 (m, 4 H), 7.68 (d, J = Hz, 1 H), 7.63 (d, J = 7.9 Hz, 1 H), 7.43 (d, J = 7.9 Hz, 1 H), 7.37 (d, J = 7.9 Hz, 1 H), 7.24 (m, 3 H), 7.09 (m, 2 H), 6.92 (s, 1 H), 6.40 (s, 1 H), 6.17 (t, J = 4 Hz, 1 H), 5.10 (bs, 2 H), 3.74 (s, 3 H), 3.09 (t, J = 6 Hz, 2 H), 1.83 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES+) 628.65
26m		25m	J	MS (ES+): 618.91
26n		25n	J	¹ HNMR (DMSO-d ₆): δ 10.56 (s, 1 H), 9.15 (bs, 2 H), 8.84 (bs, 2 H), 8.64 (t, J = 6 Hz, 1 H), 8.19 (d, J = 2 Hz, 1 H), 7.99 (d, J = 7 Hz, 1 H), 7.70 (m, 4 H), 7.46 (s, 1 H), 7.36 (m, 2 H), 7.24 (m, 3 H), 7.05 (s, 1 H), 7.00 (s, 1 H), 6.0 (m, 1 H), 5.18 (d, J = 16 Hz, 1 H), 5.10 (d, J = 11 Hz, 1 H), 5.0 (s, 2 H), 3.47 (d, J = 6 Hz, 1 H), 3.03 (t, J = 6 Hz, 2 H), 1.79 (m, 1 H), 0.83 (d, J = 6.8 Hz, 6 H); MS (ES+) 589.5
26o		25o	J	¹ HNMR (DMSO-d ₆): δ 10.84 (s, 1 H), 9.16 (s, 2 H), 8.78 (s, 2 H), 8.69 (t, J = 6 Hz, 1 H), 8.27 (d, J = 2 Hz, 1 H), 8.19 (s, 1 H), 8.09 (dd, J = 2 & 7.7 Hz, 1 H), 8.04 (dd, J = 2 & 7.7 Hz, 1 H), 8.01 (d, J = 4 Hz, 1 H), 7.89 (d, J = 3 Hz, 1 H), 7.73 (m, 4 H), 7.44 (dd, J = 3 & 7.8 Hz, 2 H), 7.16 (m, 3 H), 7.30 (s, 1 H), 7.05 (s, 1 H), 5.03 (bs, 2 H), 3.06 (t, J = 6.5 Hz, 2 H), 1.82 (m, 1 H), 0.86 (d, 6.8 Hz, 6 H); MS (ES+) 632.4
26p		25p	J	MS (ES ⁺): 609.3 (M+Na) ⁺

Cpd. No.	-R	Starting From	Method Used	Analytical Data
26q		25q	J	¹ HNMR (DMSO-d ₆): δ 10.71 (s, 1 H), 9.16 (s, 2 H), 8.81 (s, 2 H), 8.68 (t, J = 6 Hz, 1 H), 8.25 (s, 1 H), 8.03 (d, J = 7.8 Hz, 1 H), 7.73 (m, 5 H), 7.69 (s, 1 H), 7.55 (d, J = 7.8 Hz, 1 H), 7.39 (d, J = 8.9 Hz, 1 H), 7.26 (m, 3 H), 7.03 (m, 2 H), 5.02 (bs, 2 H), 4.95 (t, J = 5 Hz, 1 H), 3.62 (q, J = 6 & 12.8 Hz, 2 H), 3.07 (t, J = 6 Hz, 2 H), 2.62 (t, J = 6 Hz, 2 H), 1.83 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES+) 617.4
26r		25r	J	¹ HNMR (DMSO-d ₆): δ 10.71 (s, 1 H), 9.16 (s, 2 H), 8.81 (s, 2 H), 8.68 (t, J = 6 Hz, 1 H), 8.25 (s, 1 H), 8.03 (d, J = 7.8 Hz, 1 H), 7.73 (m, 5 H), 7.69 (s, 1 H), 7.55 (d, J = 7.8 Hz, 1 H), 7.39 (d, J = 8.9 Hz, 1 H), 7.26 (m, 3 H), 7.03 (m, 2 H), 5.02 (bs, 2 H), 4.95 (t, J = 5 Hz, 1 H), 3.62 (q, J = 6 & 12.8 Hz, 2 H), 3.07 (t, J = 6 Hz, 2 H), 2.62 (t, J = 6 Hz, 2 H), 1.83 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES+) 617.4
26s		25s	J	¹ HNMR (DMSO-d ₆): δ 0.89 (d, J = 6.8 Hz, 2 H), 5.04 (s, 2 H), 5.18 (s, 1 H), 5.28 (s, 1 H), 6.73 (d, J = 16 Hz, 1 H), 7.04 (d, J = 6 Hz, 2 H), 7.23 (m, 5 H), 7.42 (d, J = 9 Hz, 1 H), 7.73 (m, 5 H), 7.85 (s, 1 H), 8.03 (dd, J = 9 and 2 Hz, 1 H), 8.26 (d, J = 2 Hz, 1 H), 8.69 (t, J = 6 Hz, 1 H), 8.87 (bs, 4 H), 10.91 (s, 1 H); MS (ES+) 615.4
26t		25t	J	¹ HNMR (DMSO-d ₆): δ 10.8 (br s, 1 H), 9.1 and 8.9 (2 br s, 4 H), 8.6 (m, 1 H), 8.2 (s, 1 H), 8.0 (m, 1 H), 7.8-7.6 (m, 6 H), 7.40 (s, 1 H), 6.9 Hz, 1 H), 7.3 (m, 4 H), 7.0 (d, 1 H), 5.6 (m, 1 H), 5.2 (m, 1 H), 5.0 (br s, 1 H), 3.1 (t, J = 6.8 Hz, 2 H), 2.2 (s, 3 H), 1.8 (m, 1 H), 0.95 (d, 6 H); MS (ES+) 589.4, MS (ES-) 587.5
26u		25u	J	¹ HNMR (DMSO-d ₆): δ 0.88 (d, J = 6.8 Hz, 6 H), 1.84 (m, 1 H), 3.09 (t, J = 6 Hz, 2 H), 4.33 (t, J = 5.5 Hz, 2 H), 5.02 (s, 2 H), 5.01 (t, J = 5.5 Hz, 1 H), 5.95 (m, 1 H), 6.57 (d, J = 11.5 Hz, 1 H), 7.04 (d, J = 6.7 Hz, 2 H), 7.25 (m, 3 H), 7.31 (d, J = 7.8 Hz, 1 H), 7.43 (m, 2 H), 7.54 (s, 1 H), 7.74 (s, 4 H), 8.05 (dd, J = 7.8 and 2 Hz, 1 H), 8.23 (d, J = 2 Hz, 1 H), 8.69 (t, J = 6 Hz, 1 H), 8.83 (bs, 2 H), 9.18 (bs, 2 H), 10.66 (s, 1 H); MS (ES+) 605.3

Cpd. No.	-R	Starting From	Method Used	Analytical Data
26v		25v	J	¹ H NMR (DMSO-d ₆): δ 0.88 (d, J = 6.8 Hz, 6 H), 1.84 (m, 1 H), 2.75 (t, J = 7 Hz, 2 H), 3.09 (t, J = 6 Hz, 2 H), 3.60 (m, 2 H), 4.65 (t, J = 5 Hz, 1 H), 5.05 (s, 2 H), 7.05 (d, J = 7 Hz, 2 H), 7.29 (m, 5 H), 7.42 (d, J = 7.8 Hz, 1 H), 7.66 (dd, J = 7.8 and 2 Hz, 1 H), 7.75 (m, 6 H), 8.03 (dd, J = 7.8 and 2 Hz, 1 H), 8.25 (s, 1 H), 8.68 (t, J = 6 Hz, 1 H), 8.82 (bs, 2 H), 9.18 (bs, 2 H), 10.68 (s, 1 H); MS (ES+) 619.4
26w		25w	J	¹ H NMR (DMSO-d ₆): δ 0.88 (d, J = 6.8 Hz, 6 H), 1.84 (m, 1 H), 3.09 (t, J = 6 Hz, 2 H), 4.41 (s, 1 H), 5.04 (d, J = 11 Hz, 2 H), 7.05 (d, J = 5.5 Hz, 2 H), 7.29 (m, 3 H), 7.34 (d, J = 8 Hz, 1 H), 7.40 (d, J = 8 Hz, 1 H), 7.65 (dd, J = 8 and 2 Hz, 1 H), 7.75 (s, 4 H), 7.79 (s, 1 H), 8.05 (dd, J = 8 and 2 Hz, 1 H), 8.28 (d, J = 2 Hz, 1 H), 8.71 (t, J = 6 Hz, 1 H), 8.82 (bs, 2 H), 9.17 (bs, 2 H), 10.73 (s, 1 H); MS (ES+) 573.3
26x		25x	J	¹ H NMR (DMSO-d ₆): δ 0.86 (d, J = 6.8 Hz, 6 H), 1.47 (s, 3 H), 1.74 (s, 3 H), 1.85 (m, 1 H), 3.06 (t, J = 6 Hz, 2 H), 3.43 (d, J = 8 Hz, 1 H), 5.04 (s, 2 H), 5.11 (m, 1 H), 7.03 (m, 2 H), 7.23 (m, 5 H), 7.52 (m, 2 H), 7.72 (m, 5 H), 8.02 (m, 1 H), 8.21 (s, 1 H), 8.66 (t, J = 6 Hz, 1 H), 8.81 (bs, 2 H), 9.23 (bs, 2 H), 10.52 (s, 1 H); MS (ES+) 617.6
26y		25y	J	¹ H NMR (DMSO-d ₆): δ 0.87 (d, J = 6.8 Hz, 6 H), 1.72 (m, 1 H), 3.07 (t, J = 6 Hz, 2 H), 4.36 (d, J = 6 Hz, 2 H), 5.0 (m, 2 H), 5.42 (t, J = 6 Hz, 1 H), 7.03 (d, J = 7 Hz, 2 H), 7.25 (m, 3 H), 7.31 (d, J = 8 Hz, 1 H), 7.39 (d, J = 8 Hz, 1 H), 7.58 (d, J = 8 Hz, 1 H), 7.73 (m, 5 H), 8.02 (dd, J = 10 and 2 Hz, 1 H), 8.23 (s, 1 H), 8.68 (t, J = 6 Hz, 1 H), 8.76 (bs, 2 H), 9.15 (bs, 2 H), 10.71 (s, 1 H); MS (ES+) 603.4

Cpd. No.	-R	Starting Material Used	Analytical Data	
26z		25z	J	¹ H NMR (DMSO-d ₆): δ 10.6 (s, 1 H), 9.17 (s, 1 H), 8.85 (s, 1 H), 8.68 (d, J = 5.9 Hz, 2 H), 8.25 (d, J = 1.98 Hz, 1 H), 8.05 (d, J = 1.96 Hz, 1 H), 8.03 (d, J = 1.9 Hz, 1 H), 7.75 (m, 4 H), 7.65 (m, 4 H), 7.41 (d, J = 7.87 Hz, 4 H), 7.25 (m, 1 H) 5.4 (s, 1 H), 5.2 (d, J = 5.9 Hz, 2 H), 4.44 (d, J = 5.9 Hz, 1 H), 3.09 (d, J = 6.89 Hz, 2 H), 1.89 (d, J = 6.89 Hz, 2 H) 0.88 (d, J = 5.9 Hz, 6 H); MS (ES+) 605.69
26aa	-C≡N	25aa	J	Characterized in the next step
26ab		25ab	J	¹ H NMR (DMSO-d ₆): δ 10.70 (s, 1 H) 9.15 (bs, 2 H), 8.77 (bs, 2 H), 8.67 (t, J = 6 Hz, 1 H), 8.25 (s, 1 H), 8.04 (d, J = 7 Hz, 1 H), 7.77 (d, J = 2 Hz, 1 H), 7.71 (m 4 H), 7.70 (d, J = 2 Hz, 1 H), 7.59 (d, J = 6 Hz, 1 H), 7.46 (q, J = 8 Hz, 1 H), 7.41 (d, J = 8 Hz, 1 H), 7.22 (m, 3 H), 7.05 (s, 1 H), 7.03 (d, J = 2 Hz, 1 H), 5.31 (t, J = 6 Hz, 1 H), 5.04 (bs, 2 H), 4.51 (d, J = 6 Hz, 2 H), 3.07 (t, J = 6 Hz, 2 H), 1.82 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES+) 661.74
26ac		25ac	J	¹ H NMR (DMSO-d ₆): δ 0.87 (d, J = 6.8 Hz, 6 H), 1.83 (m, 1 H), 3.07 (t, J = 6 Hz, 2 H), 4.71 (d, J = 5 Hz, 2 H), 5.04 (bs, 2 H), 5.69 (t, J = 5 Hz, 1 H), 7.03 (d, J = 5.8 Hz, 2 H), 7.21 (m, 3 H), 7.35 (d, J = 5 Hz, 1 H), 7.38 (d, J = 8 Hz, 1 H), 7.44 (m, d, J = 8 Hz, 1 H), 7.58 (d, J = 5 Hz, 1 H), 7.74 (m, 6 H), 8.03 (d, J = 8 Hz, 1 H), 8.24 (s, 1 H), 8.67 (t, J = 6 Hz, 1 H), 8.79 (bs, 2 H), 9.14 (bs, 2 H), 10.64 (s, 1 H); MS (ES+) 661.74
26ad		25ad	J	¹ H NMR (DMSO-d ₆): δ 9.65 (s, 1 H), 8.71 (t, J = 5.15 Hz, 1 H) 8.39 (d, J = 2.57 Hz, 4 H), 8.09 (d, J = 1.79 Hz, 4 H), 8.05 (d, J = 1.79 Hz, 4 H), 7.43 (d, J = 7.77 Hz, 2 H), 7.29 (s, 2 H), 7.19 (m, 2 H), 7.08 (m, 2 H), 5.03 (d, J = 2.58 Hz, 2 H) 3.29 (m, 2 H), 3.12 (s, 4 H), 2.49 (m, 2 H), 1.87 (m, 2 H), 0.90 (d, J = 6.87 Hz, 6 H); MS (ES+) 765.4









Cpd. No.	-R	Starting From	Method Used	Analytical Data
26ae		25ae	J	¹ H NMR (DMSO-d ₆): δ 9.1 (bs, 2 H), 8.8 (bs, 2 H), 8.5 (t, J = 6 Hz, 1 H), 8.02 (s, 1 H), 7.68 (s, 1 H), 7.62 (m, 6 H), 7.53 (d, J = 5.8 Hz, 1 H), 7.15 (d, J = 6 Hz, 1 H), 7.13 (m, 1 H), 7.01 (s, 1 H), 5.5 (t, J = 5 Hz, 1 H), 4.7 (d, J = 5 Hz, 2 H), 3.01 (m, 2 H), 1.8 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES+) 571.2
26af		25af	J	¹ H NMR (DMSO-d ₆): δ 10.6 (s, 1 H), 9.17 (s, 1 H), 8.85 (s, 1 H), 8.68 (d, J = 5.9 Hz, 2 H), 8.25 (d, J = 1.98 Hz, 1 H), 7.75 (m, 4 H), 7.65 (m, 4 H), 7.41 (d, J = 7.87 Hz, 4 H), 7.25 (m, 4 H), 5.4 (s, 1 H), 5.2 (d, J = 5.9 Hz, 2 H), 4.44 (d, J = 5.9 Hz, 1 H), 3.09 (d, J = 6.89 Hz, 2 H), 1.89 (d, J = 6.89 Hz, 2 H), 0.88 (d, J = 5.9 Hz, 6 H).
26ag		25ag	J	¹ H NMR (DMSO-d ₆): δ 0.90 (d, J = 6.9 Hz, 6 H), 1.41 (s, 9 H), 1.87 (m, 1 H), 3.11 (t, J = 6.9 and 6 Hz, 2 H), 5.07 (s, 2 H), 6.37 (t, J = 3.4 Hz, 1 H), 6.51 (s, 1 H), 7.11 (m, 2 H), 7.26 (m, 3 H), 7.33 (d, J = 7.7 Hz, 1 H), 7.41 (d, J = 8.6 Hz, 1 H), 7.45 (d, J = 1.7 Hz, 1 H), 7.61 (dd, J = 1.7 and 7.7, 1 H), 7.74 (m, 5 H), 8.05 (dd, J = 8.6 and 1.7 Hz, 1 H), 8.26 (d, J = 1.7 Hz, 1 H), 8.66 (t, J = 5 and 6 Hz, 1 H), 8.77 (bs, 2 H), 9.15 (bs, 2 H), 10.58 (s, 1 H); MS (ES+) 714.78
26ah		25ah	J	MS (ES ⁺): 609.6
26ai		25ai	J	¹ H NMR (DMSO-d ₆): δ 10.8 (s, 1 H), 6.2 and 8.9 (2 br s, 2 H each, 4 H), 8.7 (t, 1 H), 8.2 (s, 1 H), 8.0 (d, J = 6 Hz, 1 H), 7.7 (m, 5 H), 7.6 (d, J = 5 Hz, 1 H), 7.4 (d, J = 5.8 Hz, 1 H), 7.35 (d, J = 6.9 Hz, 1 H), 7.29 (m, 3 H), 7.0 (m, 2 H), 5.0 (m, 2 H), 4.6 (s, 2 H), 3.01 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 0.95 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 604.3



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
27a			26a	I-2	¹ H NMR (DMSO-d ₆): δ 14.95 (s, 1 H), 8.97 (s, 4 H), 8.5 (t, J = 6 Hz, 1 H), 7.97 (d, J = 2 Hz, 1 H), 7.80 (d, J = 2 Hz, 1 H), 7.73 (dd, J = 7.9 and 2 Hz, 1 H), 7.61 (m, 7 H), 7.18 (t, J = 3.9 Hz, 1 H), 7.05 (d, J = 7.9 Hz, 1 H), 6.93 (d, J = 7.9 Hz, 1 H), 3.01 (t, J = 6.9 and 6.0 Hz, 2 H), 1.81 (m, 1 H), 0.84 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 541.17	
27b			26b	I-2	¹ H NMR (DMSO-d ₆): δ 13.24 (s, 1 H), 9.05 (s, 2 H), 8.9 (s, 2 H), 8.49 (t, J = 6 and 5.2 Hz, 1 H), 7.97 (s, 1 H), 7.99 (s, 1 H), 7.87 (s, 1 H), 7.75 (d, J = 7.7 Hz, 1 H), 7.65 (m, 1 H), 7.62 (m, 6 H), 7.05 (d, J = 7.7 Hz, 1 H), 6.93 (d, J = 7.7 Hz, 1 H), 3.01 (t, J = 6.9 and 6.0 Hz, 2 H), 1.81 (m, 1 H), 0.85 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 541.42	
27c			26c	I-2	¹ H NMR (DMSO-d ₆): δ 13.28 (s, 1 H), 9.04 (s, 4 H), 8.5 (t, J = 6 Hz, 1 H), 7.97 (s, 1 H), 7.82 (s, 1 H), 7.74 (m, 3 H), 7.62 (m, 5 H), 7.5 (t, J = 7.7 Hz, 2 H), 7.4 (t, J = 7.7, 1 H), 7.1 (d, J = 7.7 Hz, 2 H), 6.97 (d, J = 7.7 Hz, 1 H), 3.01 (t, J = 6.5 Hz, 2 H), 1.8 (m, 1 H), 0.85 (d, 6.8 Hz, 6 H); MS (ES ⁺): 535.48	

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27d			26d	I-2	¹ H NMR (DMSO-d ₆): δ 9.03 (s, 2 H), 8.89 (s, 2 H), 8.49 (t, J = 6 Hz, 1 H), 7.99 (s, 1 H), 7.65 (m, 8 H), 7.37 (d, J = 3 Hz, 1 H), 7.04 (d, J = 7.7 Hz, 1 H), 6.98 (s, 1 H), 6.82 (d, J = 3 Hz, 1 H), 2.98 (t, J = 6.5 Hz, 2 H), 2.46 (s, 3 H), 1.76 (m, 1 H), 0.81 (d, 6.8 Hz, 6 H); MS (ES ⁺): 555.61
27e			26e	I-2	¹ H NMR (DMSO-d ₆): δ 14.10 (s, 1 H), 9.05 (bs, 2 H), 8.79 (bs, 2 H), 8.47 (t, J = 5.6 Hz, 1 H), 8.3 (s, 1 H), 7.96 (d, J = 2 Hz, 1 H), 7.78 (m, 1 H), 7.63 (m, 7 H), 7.05 (m, 1 H), 7.01 (d, J = 7.7 Hz, 1 H), 6.92 (d, J = 7.7 Hz, 1 H), 3.02 (t, J = 4.9 Hz, 2 H), 1.81 (m, 1 H), 0.85 (d, J = 6.3 Hz, 6 H); MS (ES ⁺): 525.36
27f			26f	I-2	¹ H NMR (DMSO-d ₆): δ 9.07 (s, 2 H), 8.86 (s, 2 H), 8.53 (t, J = 5 Hz, 1 H), 8.03 (s, 1 H), 7.89 (d, J = 1.4 Hz, 1 H), 7.78 (m, 2 H), 7.65 (m, 6 H), 7.1 (m, 2 H), 7.08 (d, J = 7 Hz, 1 H), 6.64 (dd, J = 3.5 and 2 Hz, 1 H), 3.03 (t, J = 6.9 and 6.0 Hz, 2 H), 1.81 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 525.43
27g			26g	I-2	¹ H NMR (DMSO-d ₆): δ 13.81 (s, 1 H), 8.74 (bs, 4 H), 8.43 (t, J = 6 Hz, 1 H), 7.92 (d, J = 2 Hz, 1 H), 7.69 (d, J = 2 Hz, 1 H), 7.62 (dd, J = 7.7 & 2 Hz, 1 H), 7.54 (m, 5 H), 7.38 (s, 1 H), 7.15 (s, 1 H), 6.99 (d, J = 7.8 Hz, 1 H), 6.89 (d, J = 6.8 Hz, 1 H), 2.97 (t, J = 6.5 Hz, 2 H), 2.20 (s, 3 H), 1.76 (m, 1 H), 0.8 (d, 6.8 Hz, 6 H); MS (ES ⁺): 555.67

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
27h			26h	I-2	¹ H NMR (DMSO-d ₆): δ 13.95 (bs, 1 H), 8.99 (bs, 2 H), 8.79 (bs, 2 H), 8.65 (q, J = 5 Hz, 1 H), 8.43 (t, J = 6 Hz, 1 H), 8.25 (s, 1 H), 8.09 (d, J = 7.8 Hz, 1 H), 8.00 (d, J = 7.8 Hz, 1 H), 7.94 (s, 1 H), 7.87 (t, J = 7.8 Hz, 1 H), 7.58 (m, 5 H), 7.34 (dd, J = 7.8 & 5 Hz, 1 H), 7.09 (dd, J = 7.7 Hz, 1 H), 6.90 (d, J = 7.8 Hz, 1 H), 2.97 (t, J = 5 Hz, 2 H), 1.76 (m, 1 H), 0.81 (d, 6.8 Hz, 6 H); MS (ES ⁺): 268.64 (m/z)	
27i			26i	I-2	¹ H NMR (DMSO-d ₆): δ 9.05 (bs, 2 H), 8.95 (d, J = 2.1 Hz, 1 H), 8.75 (s, 2 H), 8.65 (dd, J = 5 & 1.4 Hz, 1 H), 8.5 (t, J = 5.6 Hz, 1 H), 8.2 (dt, J = 1.8 & 7.7 Hz, 1 H), 7.99 (d, J = 2.1 Hz, 1 H), 7.9 (d, J = 2.1 Hz, 1 H), 7.85 (dd, J = 7.7 & 2.2 Hz, 2 H), 7.65 (m, 5 H), 7.55 (dd, J = 7.7 & 4.5 Hz, 1 H), 7.15 (d, J = 7.7 Hz, 1 H), 6.95 (d, J = 7.7 Hz, 1 H), 3.08 (t, J = 5 Hz, 2 H), 1.82 (m, 1 H), 0.9 (d, 6.8 Hz, 6 H); MS (ES ⁺): 268.85 (m/z)	
27j			26j	I-2	¹ H NMR (DMSO-d ₆): δ 14.19 (s, 1 H), 9.06 (bs, 2 H), 8.67 (bs, 2 H), 8.67 (d, J = 6 Hz, 2 H), 8.50 (t, J = 6 Hz, 1 H), 7.97 (m, 2 H), 7.91 (dd, J = 7.7 and 2 Hz, 1 H), 7.80 (d, J = 6 Hz, 2 H), 7.64 (m, 6 H), 7.18 (d, J = 7.7 Hz, 1 H), 6.95 (d, J = 7.7 Hz, 1 H), 3.02 (t, J = 5.0 Hz, 2 H), 1.82 (m, 1 H), 0.80 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 536.43	
27k			26k	I-2	¹ H NMR (DMSO-d ₆): δ 9.04 (bs, 2 H), 8.78 (bs, 2 H), 8.55 (t, J = 6 Hz, 1 H), 8.1 (s, 1 H), 7.98 (d, J = 4 Hz, 1 H), 7.95 (s, 1 H), 7.87 (d, J = 7.9 Hz, 1 H), 7.75 (d, J = 6.9 Hz, 1 H), 7.66 (m, 4 H), 7.2 (m, 2 H), 7.09 (s, 1 H), 3.03 (t, J = 6 Hz, 2 H), 2.55 (s, 3 H), 1.81 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 583.59	









Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27l			26l	I-2	¹ H NMR (DMSO-d ₆): δ 9.1 (s, 2 H), 8.84 (s, 2 H), 8.56 (t, J = 6 Hz, 1 H), 8.08 (bs, 1 H), 7.67 (m, J = 7 Hz), 7.58 (d, J = 7.9 Hz, 1 H), 7.11 (m, 2 H), 6.91 (bs, 1 H), 6.31 (bs, 1 H), 6.11 (t, J = 3 Hz, 1 H), 3.74 (s, 3 H), 3.05 (t, J = 6 Hz, 2 H), 1.83 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 538.64
27m			26m	I-2	¹ H NMR (DMSO-d ₆): δ 9.04 (s, 2 H), 8.94 (s, 2 H), 8.46 (t, J = 6 Hz, 1 H), 7.96 (s, 1 H), 7.63 (m, 6 H), 6.94 (s, 1 H), 6.83 (d, J = 7.7 Hz, 1 H), 6.7 (d, J = 2, 1 H), 6.62 (dd, J = 7.7 and 2 Hz, 1 H), 3.28 (m, 4 H), 3.02 (t, J = 6.5 Hz, 2 H), 1.98 (m, 4 H), 1.82 (m, 1H), 0.82 (d, 6.8 Hz, 6 H); MS (ES ⁺): 528.76
27n			26n	I-2	¹ H NMR (DMSO-d ₆): δ 13.96 (s, 1 H), 9.02 (s, 2 H), 8.85 (s, 2 H), 8.46 (t, J = 6 Hz, 1 H), 7.91 (s, 1 H), 7.58 (m, 4 H), 7.39 (s, 1 H), 7.25 (d, J = 7.8 Hz, 1 H), 6.92 (d, J = 7.7, 1 H), 6.87 (d, J = 7.7 Hz, 1 H), 6.01 (m, 1 H), 5.17 (d, J = 16.7 Hz, 1 H), 5.08 (d, J = 10 Hz, 1 H), 3.45 (d, J = 6 Hz, 2H), 2.99 (t, J = 6 Hz, 2 H), 1.78 (m, 1 H), 0.83 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 499.3
27o			26o	I-2	¹ H NMR (DMSO-d ₆): δ 14.08 (bs, 1 H), 9.06 (s, 2 H), 8.79 (s, 2 H), 8.51 (t, J = 6 Hz, 1 H), 8.11 (d, J = 2 Hz, 1 H), 8.01 (m, 3 H), 7.85 (d, J = 3 Hz, 1 H), 7.63 (m, 6 H), 7.17 (d, J = 7.8 Hz, 1 H), 6.97 (d, J = 7.8 Hz, 1 H), 3.02 (t, J = 6.5 Hz, 2 H), 1.81 (m, 1 H), 0.86 (d, 6.8 Hz, 6 H); MS (ES ⁺): 542.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27p			26p	I-2	¹ H NMR (DMSO-d ₆): δ 9.1 and 9.2 (2 br s, 4 H, NH proton), 8.6 (m, 1 H), 8.3 (m, 1 H), 8.0-7.6 (m, 8 H, aromatic proton), 7.3 (m, 2 H), 3.1 (t, 2 H), 2.2 (s, 3 H), 1.8 (m, 1 H), 0.9 (2s, 6 H); IR (KBr Pellets) 2957, 1676, 1480, 1324, 844 cm ⁻¹ . MS (ES ⁺): 497
27q			26q	I-2	¹ H NMR (DMSO-d ₆): δ 9.06 (s, 2 H), 8.77 (s, 2 H), 8.53 (t, J = 6 Hz, 1 H), 8.03 (m, 1 H), 7.64 (m, 6 H), 7.46 (d, J = 6.9 Hz, 1 H), 7.05 (s, 2 H), 6.96 (s, 1 H), 5.52 (s, 1 H), 3.02 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 1.48 (s, 6 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 539.4
27r			26r	I-2	¹ H NMR (DMSO-d ₆): δ 9.06 (s, 2 H), 8.78 (s, 2 H), 8.52 (t, J = 6 Hz, 1 H), 8.01 (d, J = 6.8 Hz, 1 H), 7.62 (m, 7 H), 7.46 (d, J = 6.8 Hz, 1 H), 7.0 (m, 2 H), 4.94 (t, J = 6 Hz, 1 H), 3.60 (q, J = 6 & 12.8 Hz, 2 H), 3.01 (t, J = 6 Hz, 2 H), 2.58 (t, J = 6 Hz, 2 H), 1.82 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 525.4
27s			26s	I-2	¹ H NMR (DMSO-d ₆): δ 9.01 (s, 2 H), 8.88 (s, 2 H), 8.5 (t, J = 6 Hz, 1 H), 8.07 (m, 1 H), 7.73 (m, 1 H), 7.63 (m, 7 H), 7.11 (d, J = 17 Hz, 1 H), 7.01 (d, J = 17 Hz, 1 H), 6.97 (m, 1 H), 6.69 (d, J = 17 Hz, 1 H), 5.24 (s, 1 H), 5.14 (s, 1 H), 3.03 (t, J = 6.9 and 6.0 Hz, 2 H), 1.92 (s, 3 H), 1.81 (m, 1 H), 0.84 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 525.4
27t			26t	I-2	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.82 (s, 2 H), 8.53 (t, J = 6 Hz, 1 H), 8.04 (m, 1 H), 7.67 (m, 7 H), 7.04 (m, 2 H), 5.55 (s, 1 H), 5.20 (s, 1 H), 3.04 (t, J = 6.9 and 6.0 Hz, 2 H), 2.19 (s, 3 H), 1.81 (m, 1 H), 0.87 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 499.4

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27u			26u	I-2	¹ H NMR (DMSO-d ₆): δ 9.11 (s, 2 H), 8.86 (s, 2 H), 8.57 (t, J = 6 Hz, 1 H), 8.13 (m, 1 H), 7.53 (m, 2 H), 7.74 (m, 6 H), 7.37 (d, J = 7 Hz, 1 H), 7.17 (m, 2 H), 6.54 (d, J = 12 Hz, 1 H), 5.91 (m, 1 H), 4.99 (m, 1 H), 4.31 (m, 2 H), 3.06 (t, J = 6.9 and 6.0 Hz, 2 H), 1.83 (m, 1 H), 0.87 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 515.4
27v			26v	I-2	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.82 (s, 2 H), 8.54 (t, J = 6 Hz, 1 H), 8.05 (m, 1 H), 7.63 (m, 8 H), 7.06 (m, 2 H), 5.52 (s, 1 H), 5.2 (s, 1 H), 4.63 (t, J = 5 Hz, 1 H), 3.56 (m, 2 H), 3.05 (t, J = 6.9 and 6.0 Hz, 2 H), 2.71 (t, J = 7 Hz, 2 H), 1.82 (m, 1 H), 0.87 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 529.4
27w			26w	I-2	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.86 (s, 2 H), 8.54 (t, J = 6 Hz, 1 H), 8.03 (m, 1 H), 7.62 (m, 7 H), 7.08 (d, J = 7.5 Hz, 1 H), 6.99 (m, 1 H), 4.32 (s, 1 H), 3.03 (t, J = 6.9 and 6.0 Hz, 2 H), 2.71 (t, J = 7 Hz, 2 H), 1.82 (m, 1 H), 0.87 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 483.3
27x			26x	I-2	¹ H NMR (DMSO-d ₆): δ 13.8 (s, 1 H), 9.04 (s, 2 H), 8.96 (s, 2 H), 8.47 (t, J = 6 Hz, 1 H), 7.93 (s, 1 H), 7.61 (m, 6 H), 7.42 (m, 1 H), 6.91 (m, 2 H), 6.07 (dd, J = 17 and 9 Hz, 1 H), 5.35 (m, 1 H), 5.09 (dd, J = 17 and 11 Hz, 1 H), 3.38 (d, J = 6.5 Hz, 1 H), 3.0 (t, J = 7 Hz, 2 H), 1.78 (m, 1 H), 1.72 (s, 3 H), 1.41 (s, 3 H), 0.84 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 527.5

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27y			26y	I-2	¹ H NMR (DMSO-d ₆): δ 8.99 (s, 2 H), 8.86 (s, 2 H), 8.52 (t, J = 6 Hz, 1 H), 8.03 (m, 1 H), 7.63 (m, 6 H), 7.50 (d, J = 7 Hz, 1 H), 7.07 (d, J = 7 Hz, 1 H), 7.12 (m, 1 H), 5.40 (t, J = 6 Hz, 1 H), 4.33 (d, J = 6.0 Hz, 2 H), 3.01 (t, J = 7 Hz, 2 H), 1.80 (m, 1 H), 0.84 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 513.4
27z			26z	I-2	¹ H NMR (DMSO-d ₆): δ 9.50 (bs, 1 H), 8.77 (bs, 2 H), 8.49 (t, J = 6 Hz, 1 H), 7.98 (m, 1 H), 7.63 (m, 6 H), 7.55 (d, J = 6.9 Hz, 1 H), 7.01 (d, J = 7.9 Hz, 1 H), 6.99 (m, 1 H), 5.55 (s, 1 H), 5.38 (s, 1 H), 5.13 (t, J = 5 Hz, 1 H), 4.39 (d, J = 5 Hz, 2 H), 3.02 (t, J = 6.9 and 6.0 Hz, 2 H), 1.81 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 515.4
27aa			26aa	I-2	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.73 (s, 2 H), 8.53 (t, J = 6 Hz, 1 H), 8.06 (s, 1 H), 8.02 (bs, 1 H), 7.94 (d, J = 7.8 Hz, 1 H), 7.62 (m, 6 H), 7.24 (d, J = 7.8 Hz, 1 H), 6.95 (d, J = 7.8 Hz, 1 H), 3.03 (t, J = 6 Hz, 2 H), 1.82 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 484.3
27ab			26ab	I-2	¹ H NMR (DMSO-d ₆): δ 9.05 (bs, 2 H), 8.81 (bs, 2 H), 8.49 (t, J = 6 Hz, 1 H), 8.02 (s, 1 H), 7.68 (s, 1 H), 7.62 (m, 6 H), 7.53 (d, J = 6 Hz, 1 H), 7.21 (d, J = 6 Hz, 1 H), 7.13 (d, J = 7 Hz, 1 H), 7.01 (s, 1 H), 5.25 (t, J = 5 Hz, 1 H), 4.51 (d, J = 5 Hz, 2 H), 3.01 (t, J = 6 Hz, 2 H), 1.81 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 571.64

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
27ac			26ac	I-2	¹ H NMR (DMSO-d ₆): δ 9.05 (bs, 2 H), 8.78 (s, 2 H), 8.52 (t, J = 6 Hz, 1 H), 8.02 (bs, 1 H), 7.65 (m, 6 H), 7.53 (d, J = 5 Hz, 1 H), 7.54 (d, J = 5 Hz, 1 H), 7.26 (d, J = 5 Hz, 1 H), 7.10 (m, 1 H), 6.99 (m, 1 H), 5.64 (t, J = 5 Hz, 1 H), 4.71 (d, J = 5 Hz, 2 H), 3.07 (t, J = 6.9 and 6.0 Hz, 2 H), 1.73 (m, 1 H), 0.84 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 571.56	
27ad			26ad	I-2	MS (ES ⁺): 585.4	
27ae			26ae	I-2	¹ H NMR (DMSO-d ₆): δ 14.11 (bs, 1 H), 9.05 (bs, 2 H), 8.75 (bs, 2 H), 8.5 (m, 1 H), 8.0 (s, 1 H), 7.8-7.6 (m, 8 H), 7.49 (d, J = 3 Hz, 1 H), 7.1 (d, J = 6.9 Hz, 1 H), 7.0 (m, 1 H), 5.5 (m, 1 H), 4.7 (m, 2 H), 3.09 (m, 2 H), 1.74 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 571.2	
27af			26af	I-2	¹ H NMR (DMSO-d ₆): δ 14.11 (bs, 1 H), 9.05 (bs, 2 H), 8.75 (bs, 2 H), 8.49 (t, J = 6 Hz, 1 H), 7.97 (s, 1 H), 7.67 (d, J = 3 Hz, 1 H), 7.61 (m, 7 H), 7.54 (d, J = 3 Hz, 1 H), 7.06 (d, J = 6.9 Hz, 1 H), 6.89 (d, J = 6.9 Hz, 1 H), 5.23 (t, J = 5 Hz, 1 H), 5.42 (d, J = 5 Hz, 2 H), 3.09 (t, J = 6.9 and 6.0 Hz, 2 H), 1.74 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 571.3	

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27ag			26ag	I-2	¹ H NMR (DMSO-d ₆): δ 11.45 (s, 1 H), 9.08 (bs, 2 H), 8.88 (bs, 2 H), 8.75 (t, J = 6 Hz, 1 H), 8.04 (bs, 1 H), 7.88 (m, 1 H), 7.7 (m, 7 H), 7.03 (m, 2 H), 6.9 (m, 1 H), 6.62 (m, 1 H), 6.17 (m, 1 H), 3.07 (t, J = 6.9 and 6.0 Hz, 2 H), 1.84 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 524.65
27ah			26ah	I-2	¹ H NMR (DMSO-d ₆): δ 13.83 (s, 1 H), 8.9 (bs, 4 H), 8.47 (t, J = 6 Hz, 1 H), 7.95 (s, 1 H), 5.3 (s, 1 H), 7.61 (m, 6 H), 7.4 (m, 1 H), 6.95 (d, J = 7.7 Hz, 1 H), 6.85 (d, J = 7.7 Hz, 1 H), 6.64 (d, J = 9 Hz, 1 H), 6.22 (s, 1 H), 4.6 (t, J = 5.1 Hz, 1 H), 3.51 (d, J = 5.6 Hz, 2 H), 3.01 (t, J = 7 Hz, 2 H), 1.8 (m, 1 H), 0.85 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 519.52
27ai			26ai	I-2	MS (ES ⁺) 514.25
27aj			26n	G	¹ H NMR (DMSO-d ₆): δ 9.05 (s, 2 H), 8.67 (s, 2 H), 8.47 (t, J = 6 and 5 Hz, 1 H), 7.95 (m, 1 H), 7.95 (m, 1 H), 7.63 (m, 5H), 7.40 (s, 1 H), 7.38 (d, J = 7.7 Hz, 1 H), 6.92 (m, 2 H), 3.02 (t, J = 6.8 Hz, 2 H), 2.64 (m, 2 H), 1.80 (m, 1 H), 1.66 (m, 2 H), 0.96 (t, J = 8 and 6.5 Hz, 3 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES-) 499.31

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
27ak			32f	G	¹ H NMR (DMSO-d ₆): δ 14.3 (bs, 1 H), 9.05 (bs, 2 H), 8.75 (bs, 2 H), 8.5 (m, 2 H), 8.0 (s, 1 H), 7.8-7.6 (m, 8 H), 7.49 (d, J = 3 Hz, 1 H), 7.1 (d, J = 6.9 Hz, 1 H), 7.0 (m, 1 H), 5.5 (m, 1 H), 4.7 (m, 2 H), 3.09 (m, 2 H), 1.74 (m, 1 H), 0.86 (d, J = 6.9 Hz, 6 H); MS (ES+) 487.2
27al			26ai	G	MS (ES+) 488.3 (100%: M ⁺¹)
27am			26u	G	¹ H NMR (DMSO-d ₆): δ 13.9 (bs, 1 H), 9.05 (2 bs, 4 H), 8.5 (m, 1 H), 7.9 (s, 1 H), 7.7-7.5 (m, 8 H), 7.3 (d, J = 3 Hz, 1 H), 6.9 (m, 2 H), 4.6 (m, 1 H), 3.5 (m, 2 H), 3.09 (m, 2 H), 2.6 (m, 2 H), 1.8 (m, 1 H) 0.85 (d, J = 6.9 Hz, 6 H); MS (ES+) 517.3
32a			31a	I-2	¹ H NMR (DMSO-d ₆): δ 9.84 (bs, 1 H), 9.07 (bs, 2 H), 8.87 (bs, 2 H), 8.51 (t, J = 6 and 5 Hz, 1 H), 8.13 (m, 1 H), 8.03 (m, 2 H), 7.65 (m, 5 H), 7.20 (d, J = 7.7 Hz, 1 H), 6.94 (d, J = 7.7 Hz, 1 H), 3.04 (t, J = 6.8 Hz, 2 H), 2.66 (s, 3 H), 1.83 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES-) 499.4, (ES+) 501.4
32b			31b	I-2	Characterized in the next step

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
32c			31c	I-2	¹ H NMR (DMSO-d ₆): δ 14.24 (s, 1 H), 9.29 (bs, 2 H), 9.01 (bs, 2 H), 8.73 (t, J = 6 Hz, 1 H), 8.2 (d, J = 2 Hz, 1 H), 7.85 (m, 5 H), 7.74 (d, 2 Hz, 1 H), 7.4 (d, J = 8 Hz, 1 H), 7.22 (d, J = 7.4 Hz, 1 H), 7.13 (d, J = 7.5, 1 H), 6.73 (t, J = 6.8 Hz, 1 H), 5.59 (d, J = 6.8 Hz, 2 H), 3.25 (t, J = 6.8 Hz, 2 H), 2.04 (m, 1 H), 1.08 (d, J = 6.8 Hz, 6 H); MS (ES-) 495.1; (ES+) : 497.2
32d			31d	I-2	MS (ES') : 553.3
32e			31e	I-2	¹ H NMR (DMSO-d ₆): δ 13.642 (bs, 1 H), 9.06 (s, 2 H), 8.89 (s, 2 H), 8.50 (t, J = 6 and 5 Hz, 1 H), 7.98 (s, 1 H), 7.62 (m, 7 H), 7.43 (s, 1 H), 7.33 (m, 4 H), 6.95 (m, 2 H), 4.04 (s, 2 H), 3.02 (t, J = 6.8 Hz, 2 H), 1.80 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES') : 547.4
32f			31f	I-2	¹ H NMR (DMSO-d ₆): δ 0.85 (d, J = 6.9 Hz, 6 H), 1.81 (m, 1 H), 3.03 (t, J = 7 Hz, 2 H), 5.35 (d, J = 11 Hz, 1 H), 5.94 (d, J = 17 Hz, 1 H), 6.84 (dd, J = 17 and 11 Hz, 2 H), 7.0 (m, 2 H), 7.64 (m, 8 H), 8.01 (s, 1 H), 8.54 (t, J = 6 Hz, 1 H), 8.77 (s, 2 H), 9.06 (s, 2 H); MS (ES+) : 485.57
32g			31g	I-2	MS (ES+) 596.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
32h			31h	I-2	¹ H NMR (DMSO-d ₆): δ 14.2 (bs, 1 H), 9.1 (bs, 4 H), 8.6 (m, 1 H), 8.15 (s, 1 H), 7.9-7.6 (m, 8 H), 7.2 (m, 2 H), 6.7 (s, 1 H), 5.3 (br s, 1 H), 4.6 (m, 2 H), 3.1 (m, 2 H), 1.9 (m, 1 H), 0.9 (d, J = 6.7 Hz, 6 H); MS (ES+) 555.1
32i			31i	I-2	¹ H NMR (DMSO-d ₆): δ 13.84 (bs, 1 H), 9.01 (bs, 2 H), 8.80 (bs, 2 H), 8.46 (t, J = 6 and 5 Hz, 1 H), 8.03 (s, 1 H), 7.95 (s, 1 H), 7.77 (s, 1 H), 7.67 (m, 2 H), 7.61 (m, 5 H), 7.02 (d, J = 7.7 Hz, 1 H), 6.94 (m, 1 H), 5.13 (t, J = 5 Hz, 1 H), 4.47 (m, 2 H), 2.97 (t, J = 6.8 Hz, 2 H), 1.78 (m, 1 H), 0.80 (d, J = 6.8 Hz, 6 H); MS (ES-) 553.3, (ES ⁺) 555.3
40			39	I-2	MS (ES+) 524.3
44			43	I-2	¹ H NMR (DMSO-d ₆): δ 13.82 (s, 1 H), 9.20 (bs, 1 H), 9.10 (bs, 1 H), 8.51 (t, J = 6 Hz, 1 H), 7.97 (s, 1 H), 7.73-7.45 (m, 5 H), 7.43-7.39 (m, 2 H), 7.20 (t, J = 8 Hz, 1 H), 7.10 (m, 6 H), 6.96 (d, J = 8 Hz, 1 H), 3.0 (t, J = 6 Hz, 2 H), 1.80 (m, 1 H), 0.68 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 551.30
46			45	I-2	¹ H NMR (DMSO-d ₆): δ 9.21 (2 bs, 2 H each, 4 H), 8.61 (m, 1 H), 8.1 (s, 1 H), 7.8-7.4 (m, 10 H), 7.3 (s, 1 H), 7.2 (d, J = 7 Hz, 1 H), 7.1 (m, 2 H), 5.2 (s, 2 H), 3.1 (m, 2 H), 1.8 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 565.27





Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
51			50	I-2	¹ H NMR (CF ₃ CO ₂ D): δ 8.43 (s, 1 H), 8.01 (d, J = 7.5 Hz, 1 H), 7.67 (q, J = 24 and 8.4 Hz, 4 H), 7.56 (d, J = 7.7 Hz, 1 H), 7.38 (s, 1 H), 7.23 (s, 2 H), 3.98 (s, 3 H), 3.43 (d, J = 7 Hz, 2 H), 2.01 (m, 1 H), 1.01 (d, J = 6.8 Hz, 6 H); MS (ES-) 487., (ES ⁺) 489.3
53			52	I-2	¹ H NMR (DMSO-d ₆): δ 14.00 (bs, 1 H), 8.52 (t, J = 6 and 5 Hz, 1 H), 7.98 (s, 1 H), 7.63 (m, 8 H), 7.07 (d, J = 7.7 Hz, 1 H), 6.96 (d, J = 7.7 Hz, 1 H), 3.83 (s, 2 H), 3.02 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES-) 568.1
70a			68a	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.84 (br s, 1 H), 9.05 (s, 2 H), 8.94 (s, 2 H), 8.48 (t, J = 5.7 Hz, 1 H), 7.97 (d, J = 1.9 Hz, 1 H), 7.70 (m, 7 H), 7.00 (d, J = 7.9 Hz, 1 H), 6.92 (d, J = 7.9 Hz, 1 H), 6.84 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.93 (d, J = 17.7 Hz, 1 H), 5.34 (d, J = 10.9 Hz, 1 H), 3.19 (m, 2 H), 1.46 (qui, J = 7.0 Hz, 2 H), 1.29 (sex, J = 7.0 Hz, 2 H), 0.87 (t, J = 7.3 Hz, 3 H); MS (ES ⁺): 485.2
70b			68b	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.71 (br s, 1 H), 9.12 (s, 2 H), 8.93 (s, 2 H), 8.20 (m, 2 H), 7.86 (m, 1 H), 7.70 (m, 6 H), 7.20 (m, 2 H), 6.87 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.99 (d, J = 17.7 Hz, 1 H), 5.40 (d, J = 10.9 Hz, 1 H), 3.97 (m, 1 H), 1.50-1.20 (m, 8 H) 0.86 (t, J = 7.2 Hz, 6 H); MS (ES ⁺): 527.3


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
70c		68c	I-2, S		¹ H NMR (DMSO-d ₆): 8.12-8.4 (br s, 1 H), 9.08 (m, 3 H), 8.36 (d, <i>J</i> =7.7 Hz, 1 H), 8.18 (s, 1 H), 7.83 (m, 1 H), 7.67 (m, 6 H), 7.15 (m, 3 H), 6.86 (dd, <i>J</i> =10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> =17.7 Hz, 1 H), 5.39 (d, <i>J</i> =10.9 Hz, 1 H), 3.74 (m, 1 H), 1.84-1.55 (m, 5 H), 1.38-1.04 (m, 5 H); MS (ES ⁺): 511.3
70d		68d	I-2, S		¹ H NMR (DMSO-d ₆): 8.9.11 (s, 2 H), 8.89 (s, 2 H), 8.81 (t, <i>J</i> =5.7 Hz, 1 H), 8.21 (s, 1 H), 7.85 (m, 1 H), 7.68 (m, 7 H), 7.17 (m, 3 H), 6.87 (dd, <i>J</i> =10.9 and 17.7 Hz, 1 H), 5.99 (d, <i>J</i> =17.7 Hz, 1 H), 5.88 (m, 1 H), 5.39 (d, <i>J</i> =10.9 Hz, 1 H), 5.12 (m, 2 H), 3.88 (t, <i>J</i> =5.0 Hz, 1 H); MS (ES ⁺): 469.2
70e		68e	I-2, S		¹ H NMR (DMSO-d ₆): 8.9.11 (s, 2 H), 9.01 (s, 2 H), 8.38 (d, <i>J</i> =7.5 Hz, 1 H), 8.18 (s, 1 H), 7.83 (m, 1 H), 7.67 (m, 6 H), 7.16 (m, 3 H), 6.86 (dd, <i>J</i> =10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> =17.7 Hz, 1 H), 5.39 (d, <i>J</i> =10.9 Hz, 1 H), 4.09 (m, 1 H), 1.15 (d, <i>J</i> =6.6 Hz, 6 H); MS (ES ⁺): 471.3
70f		68f	I-2, S		¹ H NMR (DMSO-d ₆): 8.9.11 (s, 2 H), 9.05 (s, 2 H), 8.31 (d, <i>J</i> =8.1 Hz, 1 H), 8.20 (s, 1 H), 7.85 (d, <i>J</i> =7.7 Hz, 1 H), 7.69 (m, 6 H), 7.17 (m, 3 H), 6.86 (dd, <i>J</i> =10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> =17.7 Hz, 1 H), 5.39 (d, <i>J</i> =10.9 Hz, 1 H), 3.91 (m, 1 H), 1.50 (m, 2 H), 1.12 (d, <i>J</i> =6.6 Hz, 3 H), 0.85 (t, <i>J</i> =7.3 Hz, 3 H); MS (ES ⁺): 485.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
70g			68g	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.82 (br s, 1 H), 9.25 (m, 1 H), 9.12 (s, 2 H), 8.91 (s, 2 H), 8.23 (s, 1 H), 7.87 (m, 1 H), 7.68 (m, 7 H), 7.18 (m, 3 H), 6.87 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.99 (d, <i>J</i> = 17.7 Hz, 1 H), 5.40 (d, <i>J</i> = 10.9 Hz, 1 H), 4.07 (m, 2 H); MS (ES ⁺): 511.2
70h			68h	I-2, S	¹ H NMR (DMSO-d ₆): δ 10.34 (s, 1 H), 9.05 (m, 4 H) 8.18 (s, 1 H), 7.71 (m, 11 H), 7.34 (t, <i>J</i> = 7.8 Hz, 2 H), 7.09 (m, 3 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> = 17.7 Hz, 1 H), 5.39 (d, <i>J</i> = 10.9 Hz, 1 H); MS (ES ⁺): 505.3
70i			68i	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.64 (br s, 1 H), 9.09 (m, 4 H), 8.56 (m, 1 H), 8.09 (s, 1 H), 7.66 (m, 9 H), 7.08 (m, 3 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.96 (d, <i>J</i> = 17.7 Hz, 1 H), 5.37 (d, <i>J</i> = 10.9 Hz, 1 H), 4.40 (m, 2 H) 3.39 (m, 2 H), 3.22 (m, 2 H), 1.48 (m, 4 H); MS (ES ⁺): 501.3 (100%: M ⁺)
70j			68j	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.08 (m, 4 H), 8.69 (t, <i>J</i> = 6.0 Hz, 1 H), 8.16 (s, 1 H), 7.69 (m, 5 H), 7.13 (d, <i>J</i> = 7.7 Hz, 2 H), 7.09 (m, 3 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.97 (d, <i>J</i> = 17.7 Hz, 1 H), 5.38 (d, <i>J</i> = 10.9 Hz, 1 H), 3.11 (t, <i>J</i> = 6.0 Hz, 2 H), 1.01 (m, 1 H), 0.41 (m, 2 H), 0.21 (m, 2 H); MS (ES ⁺): 483.3
70k			68k	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.11 (s, 2 H), 8.97 (s, 2 H), 8.54 (m, 1 H), 8.12 (s, 1 H), 7.68 (m, 7 H), 7.17 (m, 4 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.97 (d, <i>J</i> = 17.7 Hz, 1 H), 5.38 (d, <i>J</i> = 10.9 Hz, 1 H), 2.75 (d, <i>J</i> = 4.3 Hz, 1 H); MS (ES ⁺): 443.26

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
70l			68l	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.07 (s, 2 H), 8.92 (s, 2 H), 8.53 (t, <i>J</i> = 5.5 Hz, 1 H), 8.02 (s, 1 H), 7.62 (m, 7 H), 7.01 (m, 2 H), 6.85 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.95 (d, <i>J</i> = 17.7 Hz, 1 H), 5.36 (d, <i>J</i> = 10.9 Hz, 1 H), 3.24 (qui, <i>J</i> = 6.7 Hz, 2 H), 1.08 (t, <i>J</i> = 7.2 Hz, 3 H); MS (ES ⁺): 457.2
70m			68m	1-2, S	¹ H NMR (DMSO-d ₆): δ 12.53 (br s, 1 H), 9.10 (m, 3 H), 8.38 (d, <i>J</i> = 7.9 Hz, 1 H), 8.11 (s, 1 H), 7.68 (m, 7 H), 7.12 (m, 3 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.96 (d, <i>J</i> = 17.7 Hz, 1 H), 5.37 (d, <i>J</i> = 10.9 Hz, 1 H), 3.94 (m, 1 H), 1.88-1.33 (m, 12 H); MS (ES ⁺): 525.3
70n			68n	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.09 (m, 4 H), 8.59 (t, <i>J</i> = 5.2 Hz, 1 H), 8.17 (s, 1 H), 7.70 (m, 7 H), 7.16 (m, 4 H), 6.87 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> = 17.7 Hz, 1 H), 5.39 (d, <i>J</i> = 10.9 Hz, 1 H), 3.20 (q, <i>J</i> = 6.7 Hz, 2 H), 1.52 (sex, <i>J</i> = 7.2 Hz, 2 H), 0.87 (t, <i>J</i> = 7.3 Hz, 3 H); MS (ES ⁺): 471.3
70o			68o	1-2, S	¹ H NMR (DMSO-d ₆): δ 12.97 (br s, 1 H), 9.08 (s, 2 H), 8.99 (s, 2 H), 8.53 (t, <i>J</i> = 5.1 Hz, 1 H), 8.06 (s, 1 H), 7.64 (m, 7 H), 7.06 (m, 2 H), 6.85 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.96 (d, <i>J</i> = 17.7 Hz, 1 H), 5.36 (d, <i>J</i> = 10.9 Hz, 1 H), 3.20 (q, <i>J</i> = 6.5 Hz, 2 H), 1.49 (qui, <i>J</i> = 6.6 Hz, 2 H), 1.27 (m, 4 H), 0.86 (t, <i>J</i> = 6.6 Hz, 3 H); MS (ES ⁺): 499.3
70p			68p	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.10 (s, 2 H), 8.91 (s, 2 H), 8.55 (t, <i>J</i> = 5.5 Hz, 1 H), 8.13 (s, 1 H), 7.68 (m, 7 H), 7.12 (m, 2 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.98 (d, <i>J</i> = 17.7 Hz, 1 H), 5.38 (d, <i>J</i> = 10.9 Hz, 1 H), 3.10 (m, 2 H), 1.62 (m, 1 H), 1.39 (m, 1 H), 1.10 (m, 1 H), 0.86 (m, 6 H); MS (ES ⁺): 499.3


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
70q			68q	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.06 (s, 2 H), 8.82 (s, 2 H), 8.11 (t, <i>J</i> = 7.9 Hz, 1 H), 8.00 (s, 1 H), 7.62 (m, 7 H), 6.99 (m, 2 H), 6.85 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.95 (d, <i>J</i> = 17.7 Hz, 1 H), 5.35 (d, <i>J</i> = 10.9 Hz, 1 H), 3.81 (q, <i>J</i> = 7.5 Hz, 1 H), 1.45 (m, 4 H), 1.24 (m, 4 H), 0.82 (m, 6 H); MS (ES ⁺): 527.3
70r			68r	1-2, S	¹ H NMR (DMSO-d ₆): δ 13.81 (s, 1 H), 8.44 (m, 4 H), 7.97 (s, 1 H), 7.61 (m, 7 H), 6.90 (m, 3 H), 5.93 (d, <i>J</i> = 17.7 Hz, 1 H), 5.34 (d, <i>J</i> = 10.9 Hz, 1 H), 3.22 (m, 5 H), 2.73 (m, 2 H), 1.52 (m, 4 H); MS (ES ⁺): 500.3
70s			68s	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.09 (s, 2 H), 8.86 (s, 2 H), 8.42 (d, <i>J</i> = 7.5 Hz, 1 H), 8.11 (s, 1 H), 7.68 (m, 8 H), 7.10 (m, 2 H), 6.86 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.97 (d, <i>J</i> = 17.7 Hz, 1 H), 5.38 (d, <i>J</i> = 10.9 Hz, 1 H), 4.20 (q, <i>J</i> = 7.2 Hz, 1 H), 1.93-1.44 (m, 8 H); MS (ES ⁺): 497.2
70t			68t	1-2, S	¹ H NMR (DMSO-d ₆): δ 13.78 (br s, 1 H), 9.07 (s, 2 H), 8.87 (s, 2 H), 8.25 (d, <i>J</i> = 8.1 Hz, 1 H), 8.00 (s, 1 H), 7.62 (m, 7 H), 6.98 (m, 2 H), 6.85 (dd, <i>J</i> = 10.9 and 17.7 Hz, 1 H), 5.94 (d, <i>J</i> = 17.7 Hz, 1 H), 5.35 (d, <i>J</i> = 10.9 Hz, 1 H), 4.55 (d, <i>J</i> = 4.1 Hz, 1 H), 3.68 (m, 1 H), 3.39 (m, 1 H), 1.79 (m, 4 H), 1.28 (m, 4 H); MS (ES ⁺): 527.2
70u			68u	1-2, S	¹ H NMR (DMSO-d ₆): δ 13.36 (br s, 1 H), 9.05 (m, 3 H), 8.49 (s, 1 H), 7.98 (s, 1 H), 7.61 (m, 8 H), 6.92 (m, 3 H), 5.94 (d, <i>J</i> = 17.7 Hz, 1 H), 5.35 (d, <i>J</i> = 10.9 Hz, 1 H), 2.81 (m, 1 H), 0.69-0.48 (m, 4 H); MS (ES ⁺): 469.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
70v				I-2, S	¹ H NMR (DMSO-d ₆): δ 9.05 (m, 4 H), 8.75 (d, J = 7.5 Hz, 1 H), 8.15 (s, 1 H), 7.70 (m, 7 H), 7.14 (d, J = 7.9 Hz, 2 H), 6.86 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.97 (d, J = 17.7 Hz, 1 H), 5.39 (d, J = 10.9 Hz, 1 H), 4.40 (q, J = 8.2 Hz, 1 H), 2.12 (m, 4 H) 1.65 (m, 2 H); MS (ES ⁺): 483.3
70w				I-2, S	¹ H NMR (DMSO-d ₆): δ 13.17 (br s, 1 H), 9.05 (m, 4 H), 8.51 (t, J = 5.8 Hz, 1 H), 8.06 (s, 1 H), 7.64 (m, 7 H), 7.03 (m, 2 H), 6.85 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.95 (d, J = 17.7 Hz, 1 H), 5.36 (d, J = 10.9 Hz, 1 H), 4.72 (t, J = 5.4 Hz, 1 H) 3.47 (q, J = 5.7 Hz, 2 H), 3.28 (m, 2 H); MS (ES ⁺): 473.2
70x				I-2, S	¹ H NMR (DMSO-d ₆): δ 9.07 (s, 2 H), 8.90 (s, 2 H), 8.50 (t, J = 5.5 Hz, 1 H), 8.04 (s, 1 H), 7.63 (m, 7 H), 7.03 (m, 2 H), 6.85 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.96 (d, J = 17.7 Hz, 1 H), 5.36 (d, J = 10.9 Hz, 1 H), 3.23 (q, J = 6.5 Hz, 2 H), 1.59 (m, J = 7.0 Hz, 1 H), 1.39 (q, J = 6.8 Hz, 2 H), 0.88 (d, J = 6.6 Hz, 6 H).




Cpd. No.	-R	Starting From	Method Used	Analytical Data	
31a		30a	J	¹ H NMR (DMSO-d ₆): δ 10.85 (s, 1 H), 9.21 (s, 2 H), 8.91 (s, 2 H), 8.71 (t, J = 5.9 Hz, 1 H), 8.21 (d, J = 1.96 Hz, 1 H), 8.23 (d, J = 1.96 Hz, 1 H), 8.19 (d, J = 2.19 Hz, 1 H), 8.17 (d, J = 1.97 Hz, 1 H), 8.09 (d, J = 1.91 Hz, 1 H), 7.77 (s, 4 H), 7.53 (d, J = 7.53 Hz, 1 H), 3.57 (s, 3 H), 3.11 (q, J = 6.89 Hz, 1 H), 2.71 (s, 3 H), 1.86 (m, 1 H), 3.88 (d, 6.87 Hz, 6H); MS (ES+) 515.3	
31b		30b	J	MS (ES ⁺): 527.2	
31c		30c	J	Characterized in the next step	
31d		30d	J	¹ H NMR (DMSO-d ₆): δ 10.59 (bs, 1 H), 9.16 (s, 2 H), 8.85 (s, 2 H), 8.69 (t, J = 6 Hz, 1 H), 8.21 (s, 1 H), 8.04 (d, J = 1.5 Hz, 1 H), 7.73 (m, 4 H), 7.58 (s, 1 H), 7.50-7.38 (m, 3 H), 7.32 (m, 1 H), 7.03 (d, J = 7.5 Hz, 2 H), 4.31 (s, 2 H), 3.55 (s, 2 H), 3.07 (t, J = 6.8 Hz, 2 H), 1.85 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES-) 567.3, (ES ⁺) 569.3	
31e		30e	J	MS (ES): 561.4; MS (ES ⁺): 563.4	

Cpd. No.	-R	Starting Material Used	Method Used	Analytical Data	
31f		30f	J	¹ H NMR (DMSO-d ₆): δ 10.73 (s, 1H), 9.24 (s, 2H), 9.00 (s, 2H), 8.71 (t, J = 5.7 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.05 (dd, J = 8.0, 1.9 Hz, 1H), 7.77 (m, 5H), 7.71 (dd, J = 7.9, 1.5 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 7.9 Hz, 1H), 6.89 (dd, J = 17.6, 11.0 Hz, 1H), 6.04 (d, J = 17.6 Hz, 1H), 5.42 (d, J = 11.0 Hz, 1H), 3.56 (s, 3H), 3.10 (t, J = 6.4 Hz, 2H), 1.85 (m, 1H), 0.89 (d, J = 6.7 Hz, 6H); MS (ES+): 499.3	
31g		30g	J	¹ H NMR (DMSO-d ₆): δ 10.73 (s, 1H), 9.19 (bs, 2H), 8.88 (bs, 2H), 8.71 (t, J = 6 Hz, 1H), 8.27 (d, J = 2 Hz, 1H), 8.07 (dd, J = 7.7 and 2 Hz, 1H), 7.88 (d, 2 Hz, 1H), 7.8 (d, J = 2 Hz, 1H), 7.83 (m, 4H), 7.72 (dd, J = 2 and 7.7 Hz, 1H), 7.46 (d, J = 7.7, 1H), 7.41 (d, J = 7.7 Hz, 1H), 4.56 (s, 2H), 3.56 (s, 3H), 3.11 (t, J = 6.8 Hz, 2H), 1.87 (m, 1H), 0.92 (d, J = 6.8 Hz, 6H); MS (ES+): 608.2, (ES-) 610.3	
31h		30h	J	Characterized at the next step	
31i		30i	J	¹ H NMR (DMSO-d ₆): δ 10.68 (s, 1H), 9.17 (bs, 2H), 8.82 (bs, 2H), 8.68 (t, J = 6 Hz, 1H), 8.25 (d, J = 2 Hz, 1H), 8.16 (d, J = 2 Hz, 1H), 8.05 (dd, J = 8 and 2 Hz, 1H), 7.87 (m, 1H), 7.89 (dd, J = 8 and 2 Hz, 1H), 7.75 (m, 5H), 7.44 (d, J = 9 Hz, 1H), 7.36 (d, J = 8 Hz, 1H), 5.22 (t, J = 5 Hz, 1H), 4.54 (d, J = 5 Hz, 2 H), 3.57 (s, 3H), 3.10 (t, J = 6.8 Hz, 2H), 1.84 (m, 1H), 0.88 (d, J = 6.8 Hz, 6H); MS (ES-): 567.4, (ES+): 569.4	
43		42	J	MS (ES): 563.4	
45	-Obn	8	J	Characterized in the next step	
50	-OCH ₃	49	J	MS (ES ⁺): 503.1	


Cpd. No.	-R	Starting From	Method Used	Analytical Data	
52		31g	G	Characterized in the next step	

5









Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
34	-OSO ₂ CF ₃	-H	33	J	MS (ES ⁺)	621.2
35	-OSO ₂ CF ₃		34	P	MS (ES ⁺)	755.2; (ES ⁻) 753.3
37			35 + 36	D-2	MS (ES ⁺)	828.5
38		-H	37	G	MS (ES ⁺)	694.4; (ES ⁻) 692.4
39		-H	38	Q	Characterized in the next step	






15



Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
54	-OBn	-CHO		5 + 6 -CO ₂ MEM	D-2	¹ H NMR (DMSO-d ₆): δ 9.69 (s, 1 H), 8.49 (d, J = 2.0 Hz, 1 H), 8.22 (d, J = 6.9 Hz, 1 H), 7.53 (m, 4 H), 7.43 (m, 2 H), 7.37 (m, 2 H), 7.24 (d, J = 8.9 Hz, 1 H), 5.57 (s, 2 H), 5.26 (s, 2 H), 3.85 (t, J = 4.9 Hz, 2 H), 3.60 (s, 3 H), 3.51 (t, J = 4.9 Hz, 2 H), 3.32 (s, 3 H); MS (ES ⁺): 501.02 (M+Na) ⁺
55	-OBn	-CO ₂ H		54 -CO ₂ MEM	E	¹ H NMR (DMSO-d ₆): δ 12.65 (s, 1 H), 8.41 (d, J = 2.0 Hz, 1 H), 8.14 (dd, J = 2.0 and 7.9 Hz, 1 H), 7.50 (m, 3 H), 7.38 (m, 4 H), 7.24 (dd, J = 3.0 and 8.9 Hz, 1 H), 7.11 (d, J = 8.9 Hz, 1 H), 5.54 (s, 2 H), 5.20 (s, 2 H), 3.82 (t, J = 4.9 Hz, 2 H), 3.57 (s, 3 H), 3.49 (t, J = 4.9 Hz, 2 H), 3.23 (s, 3 H); MS (ES): 493.2
141	-OBn	-CHO		140 + 6	D-2	¹ H NMR (DMSO-d ₆): δ 10.2 (s, 1 H), 9.65 (s, 1 H), 8.25 (d, J = 2.0 Hz, 1 H), 7.85 (dd, J = 2.0 and 8.9 Hz, 1 H), 7.51 (d, J = 7.9 Hz, 2 H), 7.45 (m, 2 H), 7.35 (m, 3 H), 7.29 (d, J = 7.9 Hz, 1 H) 7.2 (d, J = 7.9 Hz, 1 H), 5.24 (s, 2 H), 3.55 (s, 3 H), 2.3 (d, J = 6.9 Hz, 2 H) 2.1 (m, J = 6.9 Hz, 1 H), 1.0 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 446.31




Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
142	-OBn	-CO ₂ H		141	E	¹ H NMR (DMSO-d ₆): δ 12.38 (s, 1 H), 10.01 (s, 1 H), 8.05 (s, 1 H), 7.68 (d, <i>J</i> = 7.9 Hz, 1 H), 7.41 (d, <i>J</i> = 7.9 Hz, 2 H), 7.35 (m, 5 H), 7.27 (m, 1 H), 7.11 (d, <i>J</i> = 8.9 Hz, 1 H), 7.04 (d, <i>J</i> = 8.9 Hz, 1 H), 6.99 (d, <i>J</i> = 8.9 Hz, 1 H), 5.11 (s, 2 H), 2.13 (d, <i>J</i> = 6.9 Hz, 2 H), 2.02 (m, <i>J</i> = 6.9 Hz, 1 H), 0.852 (d, <i>J</i> = 6.9 Hz, 6 H); MS (ES): 460.2.
143	-OBn	-CO ₂ MEM		142	F	¹ H NMR (DMSO-d ₆): δ 10.12 (s, 1 H), 8.16 (d, <i>J</i> = 1.9 Hz, 1 H), 7.80 (dd, <i>J</i> = 1.9 and 8.3 Hz, 1 H), 7.42 (m, 6 H), 7.26 (dd, <i>J</i> = 2.8 and 8.3 Hz, 1 H), 7.13 (m, 2 H), 5.21 (s, 2 H), 5.17 (s, 2 H), 3.54 (s, 3 H), 3.40 (m, 2 H), 3.32 (m, 2 H), 2.22 (d, <i>J</i> = 7.0 Hz, 2 H), 2.10 (m, 4 H), 0.95 (d, <i>J</i> = 6.4 Hz, 6 H); MS (ES ⁺): 572.3 (M+Na) ⁺
144	-OH	-CO ₂ MEM		143	G	¹ H NMR (DMSO-d ₆): δ 12.7 (br s, 1 H), 9.09 (s, 2 H), 8.91 (s, 2 H), 8.57 (m, 1 H), 8.11 (s, 1 H), 7.92 (d, <i>J</i> = 1.9 Hz, 1 H), 7.81 (m, 3 H), 7.67 (m, 5 H), 7.14 (m, 3 H), 6.66 (m, 1 H), 4.40 (t, <i>J</i> = 5.3 Hz, 1 H), 3.39 (m, 2 H), 3.22 (m, 2 H), 1.48 (m, 4 H); MS (ES): 592.2.
145	-OSO ₂ CF ₃	-CO ₂ MEM		144	B-2	MS (ES ⁺): 592.2
146a		-CO ₂ MEM		145	D-2	MS (ES ⁺): 532.5 (M+Na) ⁺


Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
146b		-CO ₂ MEM		145	D-2	¹ H NMR (DMSO-d ₆): δ 10.1 (s, 1 H), 8.21 (d, J = 2.0 Hz, 1 H), 8.10 (d, J = 2.0 Hz, 1 H), 7.89 (dd, J = 2.0 and 7.9 Hz, 1 H), 7.84 (d, J = 3.0 and 8.9 Hz, 1 H), 7.63 (m, 2 H), 7.25 (d, J = 14.8 Hz, 2 H), 3.57 (s, 3 H), 3.43 (t, J = 4.9 Hz, 2 H), 3.34 (t, J = 4.9 Hz, 2 H), 3.20 (s, 3 H), 2.23 (d, J = 6.9 Hz, 2 H), 2.11 (m, J = 6.9 Hz, 1 H), 0.96 (d, J = 5.9 Hz, 6 H); MS (ES ⁺): 526.48
146c	-CH=CH ₂	-CO ₂ MEM		145	D-3	MS (ES ⁺): 470.2 (M+Na) ⁺
147a		-CO ₂ H		146a	I-1	MS (ES ⁻): 420.29
147b		-CO ₂ H		146b	I-1	¹ H NMR (DMSO-d ₆): δ 12.65 (s, 1 H), 10.12 (s, 1 H), 8.18 (d, J = 1.9 Hz, 1 H), 8.07 (d, J = 3.0 Hz, 1 H), 7.83 (m, 2 H), 7.61 (m, 2 H), 7.19 (m, 3 H), 3.56 (s, 3 H), 2.22 (d, J = 6.9 Hz, 2 H), 2.11 (m, J = 6.9 Hz, 1 H), 0.96 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 438.52
147c	-CH=CH ₂	-CO ₂ H		146c	I-1	MS (ES ⁻): 380.32

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
173	-H	-CHO		172+ 130	D-2	¹ H NMR (DMSO-d ₆): δ 9.70 (s, 1 H), 8.42 (t, J = 6.2 Hz, 1 H), 7.90 (dd, J = 1.1 & 6.6 Hz, 1 H), 7.82 (d, J = 1.9 Hz, 1 H), 7.72-7.50 (m, 3 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.27 (dd, J = 1.3 & 6.2 Hz, 1 H), 4.38 (d, J = 6.0 Hz, 2 H), 3.53 (s, 3 H), 2.47 (m, 1 H), 1.07 (d, J = 7.0 Hz, 6 H); MS (ES ⁺): 340.05
174	-H	-CO ₂ H		173	E	¹ H NMR (DMSO-d ₆): δ 12.35 (br s, 1 H), 8.31 (t, J = 7.5 Hz, 1 H), 7.80-7.31 (m, 5 H), 7.06 (m, 2 H), 4.25 (d, J = 6.0 Hz, 2 H), 3.41 (s, 3 H), 2.37 (m, 1 H), 0.97 (d, J = 7.0 Hz, 6 H); MS (ES ⁺): 353.83
180	-H	-CHO		179+ 130	D-2	¹ H NMR (DMSO-d ₆): δ 9.70 (s, 1 H), 7.87 (m, 2 H), 7.69 (m, 1 H), 7.55 (m, 2 H), 7.35 (d, J = 7.9 Hz, 1 H), 7.27 (d, J = 7.5 Hz, 1 H), 4.51 (s, 2 H), 3.52 (s, 3 H), 3.05 (m, 2 H), 1.92 (m, 1 H), 1.40 (m, 9 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 448.3 (M+Na) ₊
181	-H	-CO ₂ H		180	E	¹ H NMR (DMSO-d ₆): δ 7.81 (m, 2 H), 7.56 (m, 1 H), 7.44 (m, 2 H), 7.16 (m, 2 H), 4.47 (s, 2 H), 3.51 (s, 3 H), 3.02 (m, 2 H), 1.92 (m, J = 7.0 Hz, 1 H), 1.41 (m, 9 H), 0.85 (d, J = 6 Hz, 6 H); MS (ES ⁺): 440.2
184a	-OBn	-CHO		3a+6	D-2	¹ H NMR (DMSO-d ₆): 89.78 (s, 1 H), 8.85 (t, J = 5.7 Hz, 1 H), 8.50 (d, J = 2.0 Hz, 1 H), 8.20 (dd, J = 8.2, 1.9 Hz, 1 H), 7.55 (m, 9 H), 5.35 (s, 2 H), 3.69 (s, 3 H), 3.23 (t, J = 6.5 Hz, 2 H), 1.98 (m, 1 H), 1.02 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 446.3

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
184b	-OBn	-CHO		3f + 6	D-2	MS (ES): 470.2
184c	-OBn	-CHO		3i + 6	D-2	MS (ES): 418.3
184d	-OBn	-CHO		3j + 6	D-2	MS (ES ⁺): 460.3
185a	-OH	-CHO		184a	AD	¹ H NMR (DMSO-d ₆): δ 10.06 (s, 1 H), 9.63 (s, 1 H), 8.73 (t, J = 6.5 Hz, 1 H), 8.36 (d, J = 2 Hz, 1 H), 8.09 (dd, J = 2 and 8 Hz, 1 H), 7.45 (d, J = 8 Hz, 1 H), 7.28 (s, 1 H), 7.11 (s, 2 H), 3.58 (s, 3 H), 3.13 (d, J = 7 Hz, 2 H), 1.87 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁻): 354.2 and (ES ⁺) 378.2 (M+Na ⁺)
185b	-OH	-CHO		184b	AD	MS (ES): 380.1
185c	-OH	-CHO		184c	AD	¹ H NMR (DMSO-d ₆): δ 10.21 (s, 1 H), 9.78 (s, 1 H), 8.87 (t, J = 5.80 Hz, 1 H), 8.51 (s, 1 H), 8.23 (d, J = 7.92 Hz, 1 H), 7.60 (d, J = 7.9 Hz, 1 H), 7.43 (s, 1 H), 7.25 (s, 2 H), 3.74 (s, 3 H), 3.46 (q, J = 5.65, 2 H), 1.32 (t, J = 7.8 Hz, 3 H)

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
185d	-OH	-CHO		184d	AD	¹ H NMR (DMSO-d ₆): δ 10.06 (s, 1 H), 9.62 (s, 1 H), 8.69 (t, J = 5.90 Hz, 1 H), 8.36 (s, 1 H), 8.08 (d, J = 7.92 Hz, 1 H), 7.45 (d, J = 8.1 Hz, 1 H), 7.28 (s, 1 H), 7.10 (s, 2 H), 3.58 (s, 3 H), 3.22 (m, 1 H), 3.11 (m, 1 H), 1.66 (m, 1 H), 1.44 (m, 1 H), 1.18 (m, 1 H), 0.89 (t, J = 6.4 Hz, 6 H).
186a	-OSO ₂ CF ₃	-CHO		185a	B-2	MS (ES ⁺): 488.24
186b	-OSO ₂ CF ₃	-CHO		185b	B-2	¹ H NMR (DMSO-d ₆): δ 9.74 (s, 1 H), 9.44 (t, J = 5.90 Hz, 1 H), 8.51 (s, 1 H), 8.11 (d, J = 7.91 Hz, 1 H), 7.54 (m, 4 H), 4.18 (m, 2 H), 3.59 (s, 3 H).
186c	-OSO ₂ CF ₃	-CHO		185c	B-2	¹ H NMR (DMSO-d ₆): δ 9.45 (s, 1 H), 8.59 (t, J = 5.90 Hz, 1 H), 8.28 (s, 1 H), 7.94 (d, J = 8.10 Hz, 1 H), 7.79 (d, J = 2.8 Hz, 1 H), 7.67 (d, J = 7.9 Hz, 1 H), 7.32 (d, J = 7.9 Hz, 2 H), 3.40 (s, 3 H), 3.12 (q, J = 7.1 Hz, 2 H), 0.97 (t, J = 7.16 Hz, 3 H).
186d	-OSO ₂ CF ₃	-CHO		185d	B-2	¹ H NMR (DMSO-d ₆): δ 9.71 (s, 1 H), 8.78 (t, J = 5.90 Hz, 1 H), 8.49 (s, 1 H), 8.18 (d, J = 7.92 Hz, 1 H), 8.00 (s, 1 H), 7.88 (d, J = 8.51 Hz, 1 H), 7.52 (q, J = 8.1 Hz, 2 H), 3.67 (s, 3 H), 3.22 (m, 1 H), 3.16 (m, 1 H), 1.68 (m, 1 H), 1.44 (m, 1 H), 1.18 (m, 1 H), 0.89 (t, J = 6.4 Hz, 6 H).

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
187a	-CH=CH ₂	-CHO		186a	D-3	¹ H NMR (DMSO-d ₆): δ 9.74 (s, 1 H), 8.76 (t, J = 6.5 Hz, 1 H), 8.42 (d, J = 2 Hz, 1 H), 8.11 (dd, J = 2 and 8 Hz, 1 H), 8.00 (d, J = 1.7 Hz, 1 H), 7.84 (dd, J = 8 and 2 Hz, 1 H), 7.47 (d, J = 8 Hz, 1 H), 7.27 (d, J = 8 Hz, 1 H), 6.90 (dd, J = 11 and 17.7 Hz, 1 H), 6.01 (d, J = 17.7 Hz, 1 H), 5.42 (d, J = 11 Hz, 1 H), 3.59 (s, 3 H), 3.14 (d, J = 7 Hz, 2 H), 1.88 (m, 1 H), 0.92 (d, J = 6.8 Hz, 6 H); MS (ES ⁻): 364.2 and (ES ⁺) 388.2 (M+Na) ⁺
187b	-CH=CH ₂	-CHO		186b	D-3	MS (ES): 390.1
187c	-CH=CH ₂	-CHO		186c	D-3	MS (ES): 336.2
187d	-CH=CH ₂	-CHO		186d	D-3	MS (ES): 378.2




10

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
56	-OBn	-H	-CO ₂ MHM	55	J	¹ H NMR (DMSO-d ₆): δ 10.67 (s, 1 H), 9.2 (s, 2 H), 8.87 (s, 2 H), 8.33 (d, <i>J</i> = 2.0 Hz, 1 H), 8.17 (dd, <i>J</i> = 2.0 and 7.9 Hz, 1 H), 7.77 (s, 4 H), 7.49 (m, 4 H), 7.39 (m, 2 H), 7.30 (s, 2 H), 5.54 (s, 2 H), 5.27 (s, 2 H), 3.83 (<i>t</i> , <i>J</i> = 4.9 Hz, 2 H), 3.57 (s, 3 H), 3.49 (<i>t</i> , <i>J</i> = 4.9 Hz, 2 H), 3.23 (s, 3 H); MS (ES ⁺): 612.4
57	-OBn	-Boc	-CO ₂ MHM	56	R	MS (ES ⁺): 712.4
58	-OH	-Boc	-CO ₂ MHM	57	G	¹ H NMR (DMSO-d ₆): δ 10.4 (s, 1 H), 10.0 (s, 1 H), 8.9 (s, 1 H), 8.28 (d, <i>J</i> = 2.0 Hz, 1 H), 8.12 (dd, <i>J</i> = 2.1 and 7.7 Hz, 1 H), 7.89 (d, <i>J</i> = 8.4 Hz, 2 H), 7.61 (d, <i>J</i> = 8.4 Hz, 2 H), 7.45 (d, <i>J</i> = 7.7 Hz, 1 H), 7.13 (d, <i>J</i> = 8.4 Hz, 1 H), 7.06 (s, 1 H), 6.98 (dd, <i>J</i> = 2.8 and 8.4 Hz, 1 H), 5.52 (s, 2 H), 3.81 (<i>t</i> , <i>J</i> = 4.9 Hz, 2 H), 3.56 (s, 3 H), 3.46 (<i>t</i> , <i>J</i> = 4.9 Hz, 2 H), 3.20 (s, 3 H), 1.43 (s, 9 H); MS (ES ⁺): 620.5

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data	
59	-OSO ₂ CF ₃	-Boc	-CO ₂ MEM	58	B-2	¹ H NMR (DMSO-d ₆): δ 10.55 (s, 1 H), 8.38 (d, <i>J</i> = 2.0 Hz, 1 H), 8.18 (dd, <i>J</i> = 2.0 and 7.9 Hz, 1 H), 7.86 (m, 4 H), 7.75 (dd, <i>J</i> = 2.0 and 8.9 Hz, 1 H), 7.54 (m, 5 H), 5.51 (s, 2 H), 3.77 (t, <i>J</i> = 4.9 Hz, 2 H), 3.55 (s, 3 H), 3.46 (t, <i>J</i> = 4.9 Hz, 2 H), 3.18 (s, 3 H) 1.41 (s, 9 H); MS (ES ⁺): 754.3	
60		-Boc	-CO ₂ MEM	59	D-2	¹ H NMR (DMSO-d ₆): δ 10.61 (s, 1 H), 8.94 (s, 1 H), 8.37 (s, 1 H), 8.19 (dd, <i>J</i> = 2.0 and 7.9 Hz, 1 H), 8.02 (s, 1 H), 7.89 (m, 5 H), 7.65 (d, <i>J</i> = 8.9 Hz, 2 H), 7.54 (d, <i>J</i> = 7.9 Hz, 1 H), 7.39 (d, <i>J</i> = 7.9 Hz, 1 H), 7.17 (d, <i>J</i> = 3.9 Hz, 1 H), 6.68 (m, 1 H), 5.54 (s, 2 H), 3.82 (t, <i>J</i> = 4.9 Hz, 2 H), 3.58 (s, 3 H), 3.49 (t, <i>J</i> = 4.9 Hz, 2 H), 3.22 (s, 3 H), 1.45 (s, 9 H); MS (ES ⁺): 672.5	
61		-Boc	-CO ₂ H	60	I-1	¹ H NMR (DMSO-d ₆): δ 10.50 (s, 1 H), 8.96 (s, 1 H), 8.32 (s, 1 H), 8.07 (d, <i>J</i> = 7.9 Hz, 1 H), 7.98 (s, 1 H), 7.87 (m, 5 H), 7.63 (d, <i>J</i> = 8.9 Hz, 2 H), 7.38 (m, 2 H), 7.15 (d, <i>J</i> = 3.0 Hz, 1 H), 6.67 (m, 1 H), 3.57 (s, 3 H), 1.45 (s, 9 H); MS (ES ⁺): 582.4	
66	-CH=CH ₂	-Boc	-CO ₂ MEM	59	D-3	¹ H NMR (DMSO-d ₆): δ 10.56 (s, 1 H), 9.02 (br s, 1 H), 8.35 (d, <i>J</i> = 1.7 Hz, 1 H), 8.18 (dd, <i>J</i> = 1.9 and 6.0 Hz, 1 H), 7.88 (d, <i>J</i> = 9.0 Hz, 2 H), 7.80 (d, <i>J</i> = 1.3 Hz, 1 H), 7.71 (dd, <i>J</i> = 1.7 and 6.2 Hz, 1 H), 7.63 (d, <i>J</i> = 8.9 Hz, 2 H), 7.50 (d, <i>J</i> = 8.3 Hz, 1 H), 7.32 (d, <i>J</i> = 8.1 Hz, 1 H), 6.89 (dd, <i>J</i> = 10.7 and 17.7 Hz, 1 H), 6.04 (d, <i>J</i> = 17.4 Hz, 1 H), 5.54 (s, 2 H), 5.43 (d, <i>J</i> = 11.7 Hz, 1 H), 3.82 (t, <i>J</i> = 4.5 Hz, 2 H), 3.57 (s, 3 H), 3.48 (t, <i>J</i> = 4.5 Hz, 2 H), 3.22 (s, 3 H), 1.44 (s, 9 H); MS (ES ⁺): 632.1	

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data	
67	-CH=CH ₂	-Boc	-CO ₂ H	66	I-1	¹ H NMR (DMSO-d ₆): δ 10.49 (s, 1 H), 8.99 (br s, 1 H), 8.31 (s, 1 H), 8.07 (d, J = 8.3 Hz, 1 H), 7.87 (d, J = 9.0 Hz, 2 H), 7.77 (m, 2 H), 7.66 (m, 3 H), 7.38 (d, J = 7.7 Hz, 1 H), 7.29 (d, J = 7.7 Hz, 1 H), 6.88 (dd, J = 10.7 and 17.7 Hz, 1 H), 6.03 (d, J = 17.4 Hz, 1 H), 5.41 (d, J = 10.9 Hz, 1 H), 3.56 (s, 3 H), 1.43 (s, 9 H); MS (ES): 542.1	







5




10


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
62a	-CH ₃			A-4	¹ H NMR (DMSO-d ₆): δ 10.57 (s, 1 H), 8.92 (s, 1 H), 8.64 (t, J = 5.4 Hz, 1 H), 8.24 (d, J = 2.0 Hz, 1 H), 8.02 (dd, J = 2.0 and 7.9 Hz, 1 H), 7.98 (s, 1 H), 7.88 (m, 3 H) 7.84 (s, 1 H), 7.64 (d, J = 8.9 Hz, 2 H), 7.42 (d, J = 7.9 Hz, 1 H), 7.36 (d, J = 7.9 Hz, 1 H), 7.14 (d, J = 3.0 Hz, 1 H), 6.67 (m, 1 H), 3.55 (s, 3 H), 3.26 (m, 2 H), 1.50 (m, J = 7.4 Hz, 2 H), 1.43 (s, 9 H), 1.32 (m, J = 7.4 Hz, 2 H), 0.89 (t, 3 H); MS (ES): 639.5
62b	-CH ₃	CH ₃	61	A-4	MS (ES ⁺): 625.5
62c	-CH ₃	CH ₂	61	A-4	MS (ES ⁺): 623.4
62d	-CH ₃	CH ₃	61	A-4	MS (ES ⁺): 687.4

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
62e	-CH ₃		61	A-4	MS (ES ⁺): 625.4
62f	-CH ₃		61	A-4	MS (ES ⁺): 653.5
62g	-CH ₃		61	A-4	MS (ES ⁺): 653.5
62h	-CH ₃		61	A-4	MS (ES ⁺): 667.3
62i	-CH ₃		61	A-4	MS (ES ⁺): 681.5
62j	-CH ₃		61	A-4	MS (ES ⁺): 637.3
62k	-CH ₃		61	A-4	MS (ES ⁺): 640.3
62l	-CH ₃		61	A-4	MS (ES ⁺): 665.4

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
62m	-CH ₃	—CH ₃	61	A-4	MS (ES ⁺): 597.3
62n	-CH ₃		61	A-4	MS (ES ⁺): 639.4
62o	-CH ₃		61	A-4	MS (ES ⁺): 695.4 (M+Na) ⁺
62p	-CH ₃	—CF ₃	61	A-4	MS (ES): 665.4
62q	-CH ₃		61	A-4	MS (ES ⁺): 653.4
62r	-CH ₃		61	A-4	MS (ES ⁺): 567.3
62s	-CH ₃		61	A-4	MS (ES ⁺): 667.5
62t	-CH ₃		61	A-4	MS (ES ⁺): 641.3
62u	-CH ₃		61	A-4	MS (ES ⁺): 655.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
62v	-CH ₃		61	A-4	MS (ES ⁺): 663.1
62w	-CH ₃		61	A-4	MS (ES ⁺): 577.2
62x	-CH ₃		61	A-4	MS (ES ⁺): 679.2
62y	-CH ₃		61	A-4	MS (ES ⁺): 621.1
62z	-CH ₃		61	A-4	MS (ES ⁺): 611.1
62aa	-CH ₃		61	A-4	MS (ES ⁺): 657.1
62ab	-CH ₃		61	A-4	MS (ES ⁺): 659.1
62ac	-CH ₃		61	A-4	MS (ES ⁺): 679.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
62ad	-CH ₃		61	A-4	MS (ES): 695.3
62ae	-CH ₃	NHR' = 	61	A-4	MS (ES ⁺): 651.3
62af	-CH ₃	NHR' = 	61	A-4	MS (ES ⁺): 679.4



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64a			62a	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.80 (s, 1 H), 9.09 (s, 2 H), 8.91 (s, 2 H), 8.57 (m, 1 H), 8.15 (s, 1 H), 7.91 (s, 1 H), 7.80 (m, 3 H), 7.67 (m, 4 H), 7.20 (m, 2 H), 7.07 (s, 1 H), 6.63 (s, 1 H) 3.21 (m, <i>J</i> = 5.9 Hz, 2 H), 1.46 (m, <i>J</i> = 7.4 Hz, 2 H), 1.28 (m, <i>J</i> = 7.4 Hz, 2 H) 0.86 (t, <i>J</i> = 7.4 Hz, 3 H); MS (ES ⁺): 525.3
64b			62b	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.76 (s, 1 H), 9.10 (s, 2 H), 8.82 (s, 2 H), 8.59 (m, 1 H), 8.20 (s, 1 H), 7.95 (s, 1 H), 7.83 (m, 3 H), 7.70 (s, 4 H), 7.25 (m, 2 H), 7.10 (s, 1 H), 6.65 (s, 1 H), 3.20 (q, <i>J</i> = 6.0 Hz, 2 H), 1.51 (m, <i>J</i> = 7.4 Hz, 2 H), 0.87 (t, <i>J</i> = 7.4 Hz, 3 H); MS (ES ⁺): 511.2
64c			62c	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.84 (s, 1 H), 9.11 (s, 2 H), 8.84 (m, 2 H), 8.26 (m, 1 H), 7.94 (m, 2 H), 7.83 (m, 3 H), 7.71 (s, 4 H), 7.28 (m, 2 H), 7.12 (s, 1 H), 6.65 (s, 1 H), 5.87 (m, 1 H), 5.15 (d, <i>J</i> = 17.2 Hz, 1 H), 5.07 (d, <i>J</i> = 10.3 Hz, 1 H) 3.88 (t, <i>J</i> = 5.2 Hz, 2 H); MS (ES ⁺): 509.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64d			62d	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.78 (s, 1 H), 9.11 (m, 2 H), 8.85 (s, 2 H), 8.22 (s, 1 H), 7.93 (s, 1 H), 7.83 (m, 3 H), 7.68 (s, 4 H), 7.19 (m, 3 H), 7.10 (m, 5 H), 6.65 (s, 1 H), 4.41 (s, 2 H), 2.27 (s, 3 H); MS (ES ⁺): 573.3
64e			62e	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.82 (s, 1 H), 9.11 (s, 2 H), 8.86 (s, 2 H), 8.39 (d, <i>J</i> =7.7 Hz, 1 H), 8.24 (s, 1 H), 7.95 (s, 1 H), 7.90 (m, 1 H), 7.84 (m, 2 H), 7.71 (s, 4 H), 7.28 (m, 2 H), 7.11 (m, 1 H), 6.65 (s, 1 H), 4.08 (m, <i>J</i> =6.9 Hz, 1 H), 1.14 (d, <i>J</i> =6.9 Hz, 6 H); MS (ES ⁺): 511.3
64f			62f	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.28 (br s, 1 H), 9.05 (m, 2 H), 8.84 (s, 2 H), 8.46 (m, 1 H), 7.99 (s, 1 H), 7.88 (s, 1 H), 7.77 (m, 2 H), 7.63 (m, 5 H), 7.07 (m, 2 H), 6.96 (m, 1 H), 6.63 (s, 1 H), 3.16–2.96 (m, 2 H), 1.65–1.03 (m, 3 H), 0.85 (m, 6 H); MS (ES ⁺): 539.3
64g			62g	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.37 (s, 1 H), 9.06 (s, 2 H), 8.84 (s, 2 H), 8.47 (m, 1 H), 8.00 (s, 1 H), 7.88 (s, 1 H), 7.78 (m, 2 H), 7.70 (m, 5 H), 7.08 (m, 2 H), 6.97 (s, 1 H), 6.63 (s, 1 H), 3.22 (m, 2 H), 1.58 (m, <i>J</i> =6.0 Hz, 1 H), 1.38 (m, <i>J</i> =6.9 Hz, 2 H), 0.87 (d, <i>J</i> =6.9 Hz, 6 H); MS (ES ⁺): 539.3
64h			62h	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.71 (br s, 1 H), 9.13 (s, 1 H), 8.75 (m, 3 H), 8.31 (m, 1 H), 7.97 (m, 2 H), 7.86 (m, 2 H), 7.73 (m, 4 H), 7.64 (m, 2 H), 7.33 (m, 2 H), 7.13 (m, 1 H), 6.67 (m, 1 H), 3.98 (m, 1 H), 3.77 (q, <i>J</i> =6.9 Hz, 1 H), 3.62 (q, <i>J</i> =6.9 Hz, 1 H), 3.29 (m, 2 H), 1.86 (m, 3 H), 1.59 (m, 1 H); MS (ES ⁺): 553.3


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64i			62i	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.81 (br s, 1 H), 9.13 (s, 2 H), 8.85 (s, 2 H), 8.26 (m, 2 H), 7.96 (m, 2 H), 7.86 (m, 2 H), 7.74 (m, 5 H), 7.32 (m, 1 H), 7.13 (m, 1 H), 6.67 (m, 1 H), 3.99 (m, 1 H), 1.5-0.85 (m, 14 H); MS (ES ⁺): 567.3
64j			62j	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.74 (br s, 1 H), 9.07 (s, 2 H), 8.92 (s, 2 H), 8.62 (t, <i>J</i> = 5.6 Hz, 1 H), 8.03 (s, 1 H), 7.89 (d, <i>J</i> = 1.7 Hz, 1 H), 7.79 (m, 2 H), 7.64 (m, 4 H), 7.10 (m, 3 H), 6.99 (d, <i>J</i> = 8.5 Hz, 1 H), 6.64 (m, 1 H), 3.08 (t, <i>J</i> = 6.0 Hz, 2 H), 1.00 (m, 1 H), 0.40 (m, 2 H), 0.20 (m, 2 H); MS (ES ⁺): 523.4
64k			62k	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.12 (s, 2 H), 8.88 (s, 2 H), 8.52 (m, 1 H), 8.12 (m, 1 H), 7.92 (m, 2 H), 7.81 (m, 3 H), 7.67 (m, 4 H), 7.14 (m, 3 H), 6.66 (m, 1 H), 4.75 (d, <i>J</i> = 4.5 Hz, 1 H), 3.77 (m, 1 H), 3.17 (m, 1 H), 1.04 (d, <i>J</i> = 6.0 Hz, 3 H); MS (ES ⁺): 527.2
64l			62l	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.91 (br s, 1 H), 9.07 (s, 2 H), 8.90 (s, 2 H), 8.29 (d, <i>J</i> = 8.1 Hz, 1 H), 8.00 (s, 1 H), 7.89 (m, 1 H), 7.78 (m, 2 H), 7.64 (m, 5 H), 7.08 (m, 2 H), 6.96 (d, <i>J</i> = 7.7 Hz, 1 H), 6.64 (m, 1 H), 3.71 (m, 1 H), 1.82-1.03 (m, 10 H); MS (ES ⁺): 551.33
64m			62m	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.87 (br s, 1 H), 9.07 (s, 2 H), 8.90 (s, 2 H), 8.48 (m, 1 H), 7.99 (s, 1 H), 7.89 (m, 1 H), 7.79 (m, 2 H), 7.62 (m, 5 H), 7.10 (m, 2 H), 6.97 (d, <i>J</i> = 7.9 Hz, 1 H), 6.64 (m, 1 H), 2.73 (d, <i>J</i> = 4.5 Hz, 3 H); MS (ES ⁺): 483.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64n			62n	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.85 (s, 2 H), 8.26 (d, <i>J</i> =8.7 Hz, 1 H), 8.07 (s, 1 H), 7.91 (s, 1 H), 7.80 (m, 2 H), 7.67 (m, 5 H), 7.09 (m, 3 H), 6.65 (m, 1 H), 3.89 (m, <i>J</i> =7.0 Hz, 1 H), 1.49 (m, <i>J</i> =6.9 Hz, 2 H), 1.10 (q, <i>J</i> =6.6 Hz, 3 H), 0.85 (t, <i>J</i> =7.2 Hz, 3 H); MS (ES ⁺): 525.2
64o			62o	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.19 (m, 2 H), 9.10 (s, 2 H), 8.82 (s, 2 H), 8.19 (m, 1 H), 7.94 (s, 1 H), 7.83 (m, 2 H), 7.68 (m, 4 H), 7.33-7.10 (m, 8 H), 6.66 (m, 1 H), 4.45 (q, <i>J</i> =5.7 Hz, 2 H); MS (ES ⁺): 559.2
64p			62p	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.22 (m, 2 H), 9.09 (s, 2 H), 8.81 (s, 2 H), 8.17 (m, 1 H), 7.95 (s, 1 H), 7.82 (m, 2 H), 7.68 (m, 4 H), 7.16 (m, 4 H), 6.66 (m, 1 H), 4.06 (m, 2 H); MS (ES ⁺): 551.22
64q			62q	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.10 (s, 2 H), 8.86 (s, 2 H), 8.56 (m, 1 H), 8.13 (m, 1 H), 7.93 (s, 1 H), 7.82 (m, 2 H), 7.67 (m, 5 H), 7.15 (m, 3 H), 6.66 (m, 1 H), 3.19 (m, 2 H), 1.50 (m, 2 H), 1.28 (m, 4 H), 0.87 (t, <i>J</i> =7.0 Hz, 3 H); MS (ES ⁺): 539.3
64r			62r	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.09 (s, 2 H), 8.90 (m, 2 H), 8.15 (m, 2 H), 7.93 (s, 1 H), 7.81 (m, 3 H), 7.68 (m, 4 H), 7.13 (m, 3 H), 6.66 (m, 1 H), 3.83 (m, 1 H), 1.47 (m, 4 H), 1.25 (m, 4 H), 0.83 (m, 6 H); MS (ES ⁺): 567.3

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64s			62s	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.08 (s, 2 H), 8.86 (s, 2 H), 8.48 (m, 1 H), 8.03 (m, 1 H), 7.90 (s, 1 H), 7.79 (m, 2 H), 7.65 (m, 5 H), 7.12 (m, 2 H), 7.02 (m, 1 H), 6.65 (m, 1 H), 3.22 (m, 2 H), 1.42 (t, <i>J</i> = 8.2 Hz, 2 H), 0.91 (s, 9 H); MS (ES ⁺): 553.4
64t			62t	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.61 (br s, 1 H), 9.07 (s, 2 H), 9.00 (s, 2 H), 8.52 (t, <i>J</i> = 5.5 Hz, 1 H), 8.02 (s, 1 H), 7.90 (d, <i>J</i> = 1.9 Hz, 1 H), 7.79 (m, 2 H), 7.64 (m, 5 H), 7.10 (m, 2 H), 7.00 (d, <i>J</i> = 7.7 Hz, 1 H), 6.64 (m, 1 H), 4.47 (t, <i>J</i> = 5.3 Hz, 1 H), 3.43 (m, 2 H), 3.27 (m, 2 H), 1.64 (qui, <i>J</i> = 6.8 Hz, 2 H); MS (ES ⁺): 527.23
64u			62u	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.7 (br s, 1 H), 9.09 (s, 2 H), 8.91 (s, 2 H), 8.57 (m, 1 H), 8.11 (s, 1 H), 7.92 (d, <i>J</i> = 1.9 Hz, 1 H), 7.81 (m, 3 H), 7.67 (m, 5 H), 7.14 (m, 2 H), 6.66 (m, 1 H), 4.40 (t, <i>J</i> = 5.3 Hz, 1 H), 3.39 (m, 2 H), 3.22 (m, 2 H), 1.48 (m, 4 H); MS (ES ⁺): 541.34
64v			62v	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.16-8.89 (m, 4 H), 8.16 (m, 1 H), 7.93 (s, 1 H), 7.81 (m, 3 H), 7.67 (m, 4 H), 7.56 (s, 1 H), 7.15 (m, 5 H), 6.65 (m, 1 H), 6.38 (m, 1 H), 6.26 (m, 1 H), 4.42 (d, <i>J</i> = 4.9 Hz, 2 H); MS (ES ⁺): 549.27
64w			62w	I-2, S	¹ H NMR (DMSO-d ₆): δ 11.59 (br s, 1 H), 9.14 (s, 2 H), 8.98 (s, 2 H), 8.70 (t, <i>J</i> = 5.7 Hz, 1 H), 8.24 (s, 1 H), 7.99 (m, 2 H), 7.87 (m, 3 H), 7.71 (m, 3 H), 7.36 (s, 1 H), 7.27 (m, 2 H), 7.10 (m, 2 H), 6.67 (m, 1 H), 4.07 (t, <i>J</i> = 6.9 Hz, 2 H), 3.24 (q, <i>J</i> = 6.5 Hz, 2 H), 1.98 (qui, <i>J</i> = 6.7 Hz, 2 H); MS (ES ⁺): 577.17

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64x			62x	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.72 (br s, 1 H), 9.13 (s, 2 H), 9.06 (s, 2 H), 8.50 (t, <i>J</i> = 5.7 Hz, 1 H), 8.00 (d, <i>J</i> = 1.3 Hz, 1 H), 7.89 (d, <i>J</i> = 1.9 Hz, 1 H), 7.78 (m, 2 H), 7.62 (m, 4 H), 7.08 (m, 2 H), 6.96 (d, <i>J</i> = 7.9 Hz, 1 H), 6.64 (m, 1 H), 3.04 (t, <i>J</i> = 6.5 Hz, 2 H), 1.72-1.43 (m, 6 H), 1.25-1.08 (m, 3 H), 0.88 (m, 2 H); MS (ES ⁺): 565.25
64y			62y	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.16-8.87 (m, 4 H), 8.09 (s, 1 H), 7.91 (s, 1 H), 7.80 (m, 2 H), 7.65 (m, 5 H), 7.12 (m, 5 H), 6.65 (m, 1 H), 4.01 (m, 2 H), 3.10 (m, 1 H); MS (ES ⁺): 507.2
64z			62z	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.10 (s, 2 H), 8.97 (s, 2 H), 8.59 (t, <i>J</i> = 5.7 Hz, 1 H), 8.13 (s, 1 H), 7.93 (s, 1 H), 7.80 (m, 3 H), 7.68 (m, 4 H), 7.16 (m, 4 H), 6.65 (m, 1 H), 3.26 (qui, <i>J</i> = 6.0 Hz, 2 H), 1.10 (t, <i>J</i> = 7.2 Hz, 3 H); MS (ES ⁺): 497.2
64aa			62aa	I-2, S	¹ H NMR (DMSO-d ₆): δ 14.1 (br s, 1 H), 9.08 (s, 2 H), 8.79 (s, 2 H), 8.45 (m, 1 H), 8.01 (s, 1 H), 7.90 (s, 1 H), 7.79 (m, 3 H), 7.63 (m, 5 H), 7.09 (m, 2 H), 6.98 (m, 1 H), 6.65 (m, 1 H), 4.80 (d, <i>J</i> = 4.7 Hz, 1 H), 4.56 (t, <i>J</i> = 6.8 Hz, 1 H), 3.60 (m, 1 H), 3.32-2.90 (m, 3 H); MS (ES ⁺): 543.2
64ab			62ab	I-2, S	¹ H NMR (DMSO-d ₆): δ 10.34 (s, 1 H), 9.07 (s, 2 H), 8.85 (s, 2 H), 8.18 (s, 1 H), 7.93 (s, 1 H), 7.80 (m, 6 H), 7.66 (m, 4 H), 7.34 (m, 2 H), 7.11 (m, 4 H), 6.65 (m, 1 H); MS (ES ⁺): 545.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
64ac			62ac	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.07 (m, 4 H), 8.38 (d, <i>J</i> =8.5 Hz, 1 H), 8.10 (s, 1 H), 7.92 (s, 1 H), 7.84-7.62 (m, 7 H), 7.11 (m, 3 H), 6.66 (m, 1 H), 3.94 (m, 1 H), 1.88-1.35 (m, 12 H); MS (ES ⁺): 565.3
64ad			62ad	I-2, S	¹ H NMR (DMSO-d ₆): δ 13.71 (m, 2 H), 9.36-8.57 (m, 4 H), 8.50 (m, 1 H), 7.98 (s, 1 H), 7.89 (s, 1 H), 7.78 (2 H), 7.61 (m, 5 H), 7.08 (m, 2 H), 6.95 (q, <i>J</i> =7.9 Hz, 1 H), 6.63 (m, 1 H), 3.19 (m, 2 H), 2.16 (t, <i>J</i> =7.2 Hz, 2 H), 1.48 (m, 4 H), 1.28 (m, 2 H); MS (ES ⁺): 581.2
64ae		NHR =	62ae	I-2, S	¹ H NMR (DMSO-d ₆): δ 9.12 (s, 2 H), 8.89 (s, 2 H), 7.91 (m, 1 H), 7.81 (m, 2 H), 7.70 (d, <i>J</i> =8.7 Hz, 2 H), 7.62 (d, <i>J</i> =8.9 Hz, 2 H), 7.48 (m, 1 H), 7.22 (m, 2 H), 7.11 (d, <i>J</i> =3.4 Hz, 1 H), 7.05 (d, <i>J</i> =7.2 Hz, 1 H), 6.65 (m, 1 H), 3.53 (m, 2 H), 3.08 (m, 2 H), 1.62-1.21 (m, 6 H); MS (ES ⁺): 537.20
64af		NHR =	62af	I-2, S	¹ H NMR (DMSO-d ₆): δ 12.81 (br s, 1 H), 9.13 (s, 2 H), 8.82 (s, 2 H), 7.95 (s, 1 H), 7.85 (m, 2 H), 7.71 (m, 5 H), 7.43 (m, 1 H), 7.29 (m, 2 H), 7.13 (m, 1 H), 6.67 (m, 1 H), 3.49-2.97 (m, 4 H), 1.67-1.37 (m, 2 H), 1.08 (m, 1 H), 0.90 (m, 3 H), 0.61-0.26 (m, 4 H); MS (ES ⁺): 565.3




10

20

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
65			61	A-4, I-2, S	¹ H NMR (DMSO-d ₆ , D ₂ O): δ 13.87 (br s, 1 H), 9.56 (m, 2 H), 9.21 (s, 1 H), 8.74 (s, 1 H), 8.47 (m, 1 H), 7.97 (m, 1 H), 7.88 (s, 1 H), 7.78 (m, 3 H), 7.58 (m, 7 H), 7.09 (m, 3 H), 6.96 (m, 1 H), 6.65 (m, 1 H), 3.14 (m, 4 H), 1.77-0.80 (m, 18 H); MS (ES ⁺): 609.4
71a	-CH=CH ₂		67	A-4, I-2, S	¹ H NMR (DMSO-d ₆): δ 13.80 (br s, 1 H), 9.91 (s, 1 H), 9.41 (s, 1 H), 8.63 (m, 2 H), 8.07 (s, 1 H), 7.98 (s, 1 H), 7.60 (m, 8 H), 6.90 (m, 3 H), 5.94 (d, <i>J</i> =17.7 Hz, 1 H), 4.37 (m, 1 H), 4.16 (m, 1 H), 2.41-1.58 (m, 12 H); MS (ES ⁺): 537.4
71b	-CH=CH ₂		67	A-4, I-2, S	¹ H NMR (DMSO-d ₆): δ 9.76 (s, 1 H), 9.41 (s, 1 H), 8.95 (s, 1 H), 8.53 (m, 1 H), 8.07 (s, 1 H), 7.65 (m, 8 H), 7.08 (m, 2 H), 6.85 (dd, <i>J</i> =10.9 and 17.7 Hz, 1 H), 6.92 (m, 3 H), 5.97 (d, <i>J</i> =17.7 Hz, 1 H), 5.37 (d, <i>J</i> =10.9 Hz, 1 H), 2.84 (m, 1 H), 2.70 (m, 1 H), 0.98-0.51 (m, 8 H); MS (ES ⁺): 509.4



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
					¹ H NMR (DMSO-d ₆): δ 12.51 (br s, 1 H), 9.59 (s, 1 H), 9.22 (s, 1 H), 8.79 (s, 1 H), 8.58 (t, J = 5.5 Hz, 1 H), 8.17 (s, 1 H), 7.67 (m, 8 H), 7.12 (m, 2 H), 6.86 (dd, J = 10.9 and 17.7 Hz, 1 H), 5.98 (d, J = 17.7 Hz, 1 H), 5.38 (d, J = 10.9 Hz, 1 H), 3.27 (m, 4 H), 1.20 (t, J = 7.2 Hz, 1 H), 1.09 (t, J = 7.2 Hz, 1 H); MS (ES ⁺): 485.3	
71c	-CH=CH ₂	—CH ₂ CH ₃	67	A-4, I-2, S		




5

10




Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
68a	-CH ₃		67	A-4	MS (ES ⁺): 599.4	
68b	-CH ₃		67	A-4	MS (ES ⁺): 641.4	
68c	-CH ₃		67	A-4	MS (ES ⁺): 625.3	
68d	-CH ₃		67	A-4	MS (ES ⁺): 583.3	
68e	-CH ₃		67	A-4	MS (ES ⁺): 585.3	
68f	-CH ₃		67	A-4	MS (ES ⁺): 599.4	








Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
68g	-CH ₃		67	A-4	MS (ES ⁺): 625.2
68h	-CH ₃		67	A-4	MS (ES ⁺): 619.2
68i	-CH ₃		67	A-4	MS (ES ⁺): 615.3
68j	-CH ₃		67	A-4	MS (ES ⁺): 597.3
68k	-CH ₃		67	A-4	MS (ES ⁺): 557.3
68l	-CH ₃		67	A-4	MS (ES ⁺): 571.4
68m	-CH ₃		67	A-4	MS (ES ⁺): 639.4
68n	-CH ₃		67	A-4	Characterized in the next step
68o	-CH ₃		67	A-4	MS (ES ⁺): 613.5

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
68p	-CH ₃		67	A-4	MS (ES ⁺); 613.5	
68q	-CH ₃		67	A-4	MS (ES ⁺); 641.5	
68r	-CH ₃		67	A-4	MS (ES ⁺); 714.5	
68s	-CH ₃		67	A-4	MS (ES ⁺); 611.4	
68t	-CH ₃		67	A-4	MS (ES ⁺); 641.4	
68u	-CH ₃		67	A-4	MS (ES ⁺); 583.3	
68v	-CH ₃		67	A-4	MS (ES ⁺); 597.4	
68w	-CH ₃		67	A-4	MS (ES ⁺); 587.4	
68x	-CH ₃		67	A-4	MS (ES ⁺); 613.5	



Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
74	-OCH ₃ (3)	-CHO	-CH ₃	73 + 3a	D-2	MS (ES): 368.2
75a	-OH (3)	-CHO	-CH ₃	74	V-2,W	MS (ES): 354.1
75b	-OH (3)	-CHO	-Bn	74	V-1,H	MS (ES): 430.2
76a	-OSO ₂ CF ₃ (3)	-CHO	-CH ₃	75a	B-2	MS (ES ⁺): 488.1
76b	-OSO ₂ CF ₃ (3)	-CHO	-Bn	75b	B-2	MS (ES): 562.3 ; MS (ES ⁺): 586.3 (M+Na) ⁺
77a	-CH=CH ₂ (3)	-CHO	-CH ₃	76a	D-3	MS (ES ⁺): 366.38
77b	-OCH ₂ CO ₂ C ₂ H ₅ (3)	-CHO	-Bn	75b	X	Characterized in the next step
77c	-OCH ₂ CONH ₂ (3)	-CHO	-Bn	75b	X	MS (ES ⁺): 487.3; MS (ES ⁺): 511.35 (M+Na) ⁺
77d	(3)	-CHO	-Bn	76b	D-2	Characterized in the next step
77e	(3)	-CHO	-Bn	75b	D-8	MS (ES ⁺): 530.3 (M+Na) ⁺ ; MS (ES ⁻): 506.3

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
77f		-CHO	-Bn	75b	X	MS (ES ⁺): 496.3 (M+Na) ⁺
77g		-CHO	-Bn	75b	X	MS (ES ⁺): 482.4 (M+Na) ⁺
77h		-CHO	-Bn	75b	X	MS (ES ⁺): 510.4 (M+Na) ⁺
77i		-CHO	-Bn	75b	X	¹ H NMR (CDCl ₃): δ 9.59 (s, 1 H), 8.39 (d, J = 2 Hz, 1 H), 8.03 (m, 2 H), 7.84 (d, J = 8.9 Hz, 1 H), 7.35 (d, J = 8 Hz, 1 H), 7.28 (m, 2 H), 7.12 (m, 2 H), 6.93 (dd, J = 2.5 and 8.8 Hz, 1 H), 6.64 (d, J = 2.5 Hz, 1 H), 6.31 (t, J = 6 and 5 Hz, 1 H), 5.06 (m, 2 H), 4.42 (t, J = 4.5 Hz, 2 H), 4.13 (m, 2 H), 3.34 (t, J = 6.8 Hz, 2 H), 2.11 (s, 3 H), 1.94 (m, 1 H), 1.01 (d, J = 6.8 Hz, 6 H)
78a	-CH=CH ₂ (3)	-CO ₂ H	-CH ₃	77a	E	MS (ES ⁺): 380.1
78b	-OSO ₃ CF ₃ (3)	-CO ₂ H	-Bn	76b	E	Characterized in the next step
78c	-OCH ₂ CO ₂ C ₂ H ₅ (3)	-CO ₂ H	-Bn	77b	E	Characterized in the next step
78d	-OCH ₂ CONH ₂ (3)	-CO ₂ H	-Bn	77c	E	MS (ES ⁺): 527.35 (M+Na) ⁺

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data	
78e		(3) -CO ₂ H	-Bn	77d	E	MS (ES ⁺): 536.4 (M+Na) ⁺	
78f		(3) -CO ₂ H	-Bn	77e	E	MS (ES ⁺): 522.3	
78g		(3) -OCH ₃	-CO ₂ H	-CH ₃	74	E	MS (ES ⁺): 384.1
78h		(3) -CH ₃	-CO ₂ H	-Bn	77f	E	MS (ES ⁺): 488.3
78i		(3) -CH ₃	-CO ₂ H	-Bn	77g	E	MS (ES ⁺): 474.4
78j		(3) -CH ₃	-CO ₂ H	-Bn	77h	E	MS (ES ⁺): 502.4
78k		(3) -OAc	-CO ₂ H	-Bn	77i	E	Characterized in the next step
90						¹ H NMR (CDCl ₃): δ 10.47 (s, 1 H), 8.36 (d, J = 2 Hz, 1 H), 7.96 (dd, J = 2.2 and 7.7 Hz, 1 H), 7.68 (m, 2 H), 7.46 (m, 5 H), 7.23 (d, J = 8 Hz, 1 H), 7.12 (d, J = 8.7 Hz, 1 H), 6.73 (d, J = 7.2 Hz, 1 H), 5.23 (q, J = 11 and 15 Hz, 2 H), 3.67 (s, 3 H), 3.31 (t, J = 6.8 Hz, 2 H), 1.94 (m, 1 H), 1.01 (d, J = 6.8 Hz, 6 H), MS (ES ⁺) 468.2 (M+Na) ⁺ (ES ⁻) 444.2	




Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
91	-OBn (5)	-CO ₂ H	-CH ₃	90	E	¹ H NMR (CDCl ₃) δ 8.22 (s, 1 H), 7.83 (d, J = 7.2 Hz, 1 H), 7.34 (m, 8 H), 7.02 (d, J = 8.1 Hz, 1 H), 6.75 (d, J = 7.4 Hz, 1 H), 5.16 (s, 2 H), 3.66 (s, 3 H), 3.21 (t, J = 6.8 Hz, 2 H), 1.85 (m, 1 H), 0.94 (d, J = 6.8 Hz, 6 H), MS (ES+) 484.1 (M+Na) ⁺
92	-OBn (5)	-CO ₂ MEM	-CH ₃	91	F	MS (ES ⁺): 572.2 (M+Na) ⁺
93	-OH (5)	-CO ₂ MEM	-CH ₃	92	G	MS (ES ⁺): 482. (M+Na) ⁺
94	-OSO ₂ CF ₃ (5)	-CO ₂ MEM	-CH ₃	93	B-2	MS (ES ⁺): 614.3 (M+Na) ⁺
95a		-CO ₂ MEM	-CH ₃	94	D-3	MS (ES+) 562.3 (M+Na) ⁺
96a		-CO ₂ H	-CH ₃	95a	I-1	MS (ES+) 452.1 (M+Na) ⁺
101	-OCH ₃ (2)	-CHO	-CH ₃	100 + 3a	D-2	MS (ES+) 370.1
102	-OCH ₃ (2)	-CO ₂ H	-CH ₃	101	E	MS (ES) 384.2; MS (ES ⁺) 386.2
108	-OBn (2)	-CHO	-CH ₃	107 + 3a	D-2	MS (ES ⁺): 446.2
109	-OBn (2)	-CO ₂ H	-CH ₃	108	E	MS (ES): 460.1

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R''	Starting From	Method Used	Analytical Data
131	-H	-CHO	-CH ₃	130 + 3a	D-2	¹ H NMR (CDCl ₃ -d ₁): δ 9.79 (s, 1 H), 8.39 (d, J = 1.88 Hz, 1 H), 8.02 (t, J = 6.0 Hz, 2 H), 7.59 (m, 2 H), 7.38 (d, J = 7.9 Hz, 1 H), 7.22 (d, J = 8.1 Hz, 1 H), 6.30 (b, 1 H), 3.72 (s, 3 H), 3.36 (t, J = 6.6 Hz, 2 H), 1.96 (m, 1 H), 1.02 (d, J = 6.8 Hz, 6 H), MS (ES ⁺): 340.1
132	-H	-CO ₂ H	-CH ₃	131	E	¹ H NMR (DMSO-d ₆): δ 12.28 (b, 1 H), 8.52 (d, J = 6.03 Hz, 1 H), 8.12 (s, 1 H), 7.86 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 7.74 Hz, 1 H), 7.41 (t, J = 8.67 Hz, 1 H), 7.31 (t, J = 7.9 Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1 H), 6.97 (d, J = 7.5 Hz, 1 H), 3.39 (s, 3 H), 2.92 (t, J = 6.0 Hz, 2 H), 1.66 (m, 1 H), 0.78 (d, J = 7.4 Hz, 6 H), MS (ES ⁺): 354.1
193a	-H			NH -NHBoc -CH ₃	192a + 6a	D-7 MS (ES ⁺): 560.5
193b	-H			NH -NHBoc -CH ₃	192b + 6a	D-7 MS (ES ⁺): 574.5

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R''	Starting From	Method Used	Analytical Data
194a	-H		-CH ₃	193a	S-2	MS (ES ⁺): 460.3
194b	-H		-CH ₃	193b	S-2	MS (ES ⁺): 474.3
195a	-H		-H	194a	I-2	¹ H NMR (DMSO-d ₆): δ 8.79 (bs, 4 H), 8.63 (t, J = 6.5 Hz, 1 H), 8.35 (s, 1 H), 7.85 (d, J = 6 Hz, 1 H), 7.62 (d, J = 8.2 Hz, 2 H), 7.26 (m, 5 H), 7.06 (m, 1 H), 5.0 (m, 2 H), 3.09 (t, J = 6.2 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J = 6.6 Hz, 6 H); MS (ES-): 444.3 and (ES ⁺) 446.3

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
195b		-H		194b	I-2	¹ H NMR (DMSO-d ₆ /DCI): δ 8.24 (d, J = 1.6 Hz, 1 H), 7.91 (dd, J = 7.7 and 1.6 Hz, 1 H), 7.56 (d, J = 8.7 Hz, 1 H), 7.48 (d, J = 8.7 Hz, 1 H), 7.32 (t, J = 8 Hz, 1 H), 7.16 (m, 3 H), 6.91 (t, J = 7.5 Hz, 1 H), 6.76 (d, J = 8.5 Hz, 1 H), 6.66 (d, J = 8.5 Hz, 1 H), 4.99 (m, 1 H), 2.92 (d, J = 6.9 Hz, 2 H), 1.68 (m, 1 H), 1.33 (d, J = 6 Hz, 1.2 H), 1.27 (d, J = 6 Hz, 1.8 H), 0.71 (d, J = 6.5 Hz, 6 H); MS (ES ⁻): 458.2 and (ES ⁺) 460.3
200	-H		-CH ₃	199 + 6a	D-7	MS (ES ⁺): 573.5


Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
201	-H		-H	200	I-2	¹ H NMR (DMSO-d ₆ /DCI): δ 8.49 (t, J = 5.6 Hz, 1 H), 8.18 (d, J = 6.9 Hz, 1 H), 7.84 (t, J = 7.8 Hz, 1 H), 7.23 (m, 4 H), 7.01 (m, 2 H), 6.82 (d, J = 7 Hz, 1 H), 6.22 (d, J = 8.5 Hz, 1 H), 6.15 (d, J = 8.5 Hz, 1 H), 3.95 (m, 1 H), 2.85 (t, J = 5.8 Hz, 1 H), 1.62 (m, 1 H), 1.23 (s, 9 H), 1.1 (d, J = 6.7 Hz, 1.2 H), 1.05 (d, J = 6.7 Hz, 1.8 H), 0.67 (d, J = 6.6 Hz, 6 H); MS (ES+): 559.4
202	-H		-H	201	S	MS (ES ⁺): 459.3
203	-OBn (4)		-CH ₃	45	R	MS (ES ⁺): 679.4
204	-OBn (4)		-H	203	I-2	MS (ES ⁺): 663.4

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
209a	-H		-CH ₃	132	A-7	MS (ES ⁺): 454.3
209b	-CH=CH ₂ (4)		-CH ₃	30f	A-7	¹ H NMR (DMSO-d ₆): δ 10.72 (s, 1 H), 8.65 (d, J = 6.03 Hz, 1 H), 8.24 (s, 1 H), 8.03 (d, J = 8.1 Hz, 1 H), 7.75 (m, 6 H), 7.40 (d, J = 7.90 Hz, 1 H), 7.34 (d, J = 8.1 Hz, 1 H), 6.88 (q, J = 11.2 Hz, 1 H), 6.04 (d, J = 7.5 Hz, 1 H), 5.41 (q, J = 11.1 Hz, 1 H), 3.55 (s, 3 H), 3.10 (t, J = 6.6 Hz, 2 H), 1.86 (m, 1 H), 0.88 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 480.3
210b	-CH=CH ₂ (4)		-CH ₃	209b	Y	¹ H NMR (DMSO-d ₆): δ 10.12 (s, 1 H), 9.37 (b, 1 H), 8.48 (t, J = 6.1 Hz, 1 H), 8.05 (d, J = 1.9 Hz, 1 H), 7.85 (d, J = 7.9 Hz, 1 H), 7.56 (d, J = 7.8 Hz, 1 H), 7.49 (d, J = 7.9 Hz, 1 H), 7.36 (s, 4 H), 7.21 (d, J = 7.9 Hz, 1 H), 7.10 (d, J = 2.8 Hz, 1 H), 6.69 (m, 1 H), 5.84 (d, J = 15.5 Hz, 1 H), 5.60 (b, 1 H), 5.22 (d, J = 11.4 Hz, 1 H), 3.38 (s, 3 H), 2.91 (t, J = 6 Hz, 2 H), 1.66 (m, 1 H), 0.71 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 515.40


Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
211b	-CH=CH ₂ (4)		-H	210b	I-2	¹ H NMR (DMSO-d ₆): δ 12.62 (bs, 1H), 10.24 (s, 1H), 8.48 (t, J=5.65 Hz, 1H), 8.15 (s, 1H), 7.81 (d, J=10.9 Hz, 1H), 7.61 (s, 1H), 7.50 (d, J=7.9 Hz, 1H), 7.49 (s, 6H), 7.16 (d, J=8.1 Hz, 1H), 7.08 (d, J=8.1 Hz, 1H), 6.72 (m, 1H), 5.85 (d, J=13.7 Hz, 1H), 5.24 (d, J=11.5 Hz, 1H), 2.93 (t, J=6 Hz, 2H), 1.68 (m, 1H), 0.72 (d, J=6.8 Hz, 6H); MS (ES+) 501.40, (ES-) 499.2
212	-CH=CH ₂ (4)		-CH ₃	187a	AE-5	¹ H NMR (DMSO): δ 8.70 (t, J=5.6 Hz, 1H), 8.36 (d, J=1.7 Hz, 1H), 8.07 (dd, J = 8.1, 1.9 Hz, 1H), 7.42 (m, 4H), 7.09 (d, J = 5.5 Hz, 1H), 7.04 (d, J = 7.7 Hz, 1H), 6.74 (dd, J = 17.5, 10.9 Hz, 1H), 6.49 (d, J = 8.8 Hz, 2H), 5.79 (d, J = 17.7 Hz, 1H), 5.27 (d, J = 10.9 Hz, 1H), 4.0 (t, J = 6.0 Hz, 2H), 3.62 (s, 3 H), 3.11 (t, J = 6.2, 2 H), 1.86 (m, 1 H), 0.90 (d, J = 6.6 Hz, 6 H)



Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
213	-CH=CH ₂ (4)		-CH ₃	212	Y	¹ H NMR (DMSO): δ 9.23 (s, 1 H), 8.71 (t, <i>J</i> =6.2 Hz, 1 H), 8.36 (d, <i>J</i> =1.9 Hz, 1 H), 8.09 (dd, <i>J</i> =7.9, 1.7 Hz, 1 H), 7.49 (d, <i>J</i> =7.9 Hz, 2 H), 7.40 (d, <i>J</i> =8.3 Hz, 1 H), 7.32 (d, <i>J</i> =8.8 Hz, 2 H), 7.04 (d, <i>J</i> =7.9 Hz, 1 H), 6.73 (dd, <i>J</i> =17.7, 11.1 Hz, 1 H), 6.40 (d, <i>J</i> =8.5 Hz, 2 H), 6.33 (t, <i>J</i> =7.0 Hz, 1 H), 5.78 (d, <i>J</i> =17.7 Hz, 1 H), 5.58 (b, 1 H), 5.26 (d, <i>J</i> =11.1 Hz, 1 H), 3.96 (m, 2 H), 3.64 (s, 3 H), 3.11 (t, <i>J</i> =6.4 Hz, 2 H), 1.86 (m,, 1 H), 0.90 (d, <i>J</i> =6.8 Hz, 6 H); MS (ES ^b): 501.3
214	-CH=CH ₂ (4)		-H	213	I-2	¹ H NMR (DMSO): δ 8.76 (t, <i>J</i> =5.8 Hz, 1 H), 8.37 (s, 1 H), 8.04 (d, <i>J</i> =8.7 Hz, 1 H), 7.39 (m, 5 H), 7.06 (d, <i>J</i> =8.3 Hz, 1 H), 6.72 (dd, <i>J</i> =17.9, 11.3 Hz, 1 H), 6.43 (d, <i>J</i> =8.5 Hz, 3 H), 5.76 (d, <i>J</i> =17.9 Hz, 1 H), 5.24 (d, <i>J</i> =11.1 Hz, 1 H), 3.98 (m, 2 H), 3.11 (t, <i>J</i> =6.6 Hz, 2 H), 1.86 (h, <i>J</i> =6.8 Hz, 1 H), 0.90 (d, <i>J</i> =6.8, 6 H); MS (ES ^b): 487.2

Cpd. No.	-R (Position with Respect to Phenyl Ring)	-R'	-R"	Starting From	Method Used	Analytical Data
238	-CH=CH ₂ (4)		-H	237 + 187a	AE-2	¹ H NMR (DMSO-d ₆): δ 8.68-8.60 (m, 1 H), 8.50 (d, J = 2.4 Hz, 1 H), 7.90-7.80 (m, 1 H), 7.76-7.70 (m, 1 H), 7.56-7.50 (m, 1 H), 7.48-7.42 (d, J = 7.7 Hz, 1 H), 7.30-7.22 (d, J = 7.9 Hz, 1 H), 7.10-7.02 (d, J = 7.7 Hz, 1 H), 6.90-6.75 (dd, J = 17, 11 Hz, 1 H), 6.5 (bs, 1 H), 5.92-5.80 (d, J = 17 Hz, 1 H), 5.40-5.30 (d, 11 Hz, 1 H), 4.50-4.20 (m, 2 H), 3.20-3.10 (t, J = 6.6 Hz, 2 H), 2.10-1.88 (m, 1 H), 1.2-0.94 (d, J = 6.6 Hz, 6 H); MS (ES ⁺) 471.3
256	-H		-CH ₃	255 + 6a	D-6	MS (ES ⁺): 573.3
257	-H		-H	256	I-2, S	MS (ES ⁺): 459.1





Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
79a	-CH=CH ₂ (3)	-CH ₃	78a	J	MS (ES ^t): 499.2	
79b	-OSO ₂ CF ₃ (3)	-CH ₂ C ₆ H ₅	78b	J	Characterized in the next step	
79c	-OCH ₂ CO ₂ C ₂ H ₅ (3)	-CH ₂ C ₆ H ₅	78c	J	Characterized in the next step	
79d	-OCH ₂ CONH ₂ (3)	-CH ₂ C ₆ H ₅	78d	J	MS (ES ^t): 622.4; (ES) 620.4	
79e		(3) -CH ₂ C ₆ H ₅	78e	J	Characterized in the next step	
79f		(3) -CH ₂ C ₆ H ₅	78f	J	Characterized in the next step	


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
79g	-OCH ₃ (3)	-CH ₃	78g	J	¹ HNMR (DMSO-d ₆): δ 10.6 (bs, 1 H), 9.29-9.32 (bs, 1 H), 9.06 (bs, 1 H), 8.82-8.75 (t, J = 5.84 Hz, 1 H), 8.32 (d, J = 1.88 Hz, 1 H), 8.13 (d, J = 1.7 Hz, 1 H), 7.83 (s, 4 H), 7.78 (d, J = 8.67 Hz, 1 H), 7.50 (d, J = 7.9 Hz, 1 H), 7.20-7.15 (dd, J = 8.67, 2.3 Hz, 1 H), 6.92 (d, J = 2.4 Hz, 1 H), 3.94 (s, 3 H), 3.64 (s, 3 H), 3.21-3.14 (t, J = 6 Hz, 2 H), 2.0-1.86 (m, 1 H), 1.0-0.94 (d, J = 6.5 Hz, 6 H); MS (ES ⁺) 503.3
79h		(3)	-Bn	78h	J MS (ES ⁺): 607.3
79i		(3)	-Bn	78i	J MS (ES ⁺): 593.4
79j		(3)	-Bn	78j	J MS (ES ⁺): 621.4
79k	-O-CH ₂ -CH ₂ -OAc (3)		-Bn	78k	J MS (ES ⁺): 651.4
80a	-CH=CH ₂ (3)	-H	79a	I-2	¹ HNMR (DMSO-d ₆): δ 9.1 (s, 2 H), 8.87 (s, 2 H), 8.53 (t, J = 6 Hz, 1 H), 8.02 (s, 1 H), 7.64 (m, 7 H), 7.1 (s, 1 H), 6.98 (d, 7.4 Hz, 1 H), 6.80 (dd, J = 11 Hz, J = 17.6 Hz, 1 H), 5.90 (d, J = 17.6 Hz, 1 H), 5.35 (d, J = 12 Hz, 1 H), 3.03 (t, 6 Hz, 2 H), 1.83 (m, 1 H), 0.86 (d, J = 6.7 Hz, 6 H); MS (ES ⁺) 485.2
80b	-OH (3)	-H	79b	I-2	¹ HNMR (DMSO-d ₆): δ 10.37 (s, 1 H), 9.20 (m, 3 H), 8.72 (t, J = 6 Hz, 1 H), 8.2 (s, 1 H), 8.85 (m, 6 H), 7.65 (d, J = 8 Hz, 1 H), 7.12 (d, 8 Hz, 1 H), 7.02 (dd, J = 2.5 Hz, J = 8 Hz, 1 H), 6.60 (d, J = 2.5 Hz, 1 H), 3.25 (t, J = 6.5 Hz, 2 H), 2.0 (m, 1 H), 1.07 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 475.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
80c	-OCH ₂ CO ₂ H (3)	-H	79c	I-2	¹ H NMR (DMSO-d ₆): δ 12.7 (2H, bs, 1 H), 9.01, 8.87 (2 bs, 4 H), 8.36 (m, 1H), 7.83 (s, 1H), 7.44 (m, 6 H), 6.75 (m, 2H), 6.31 (d, J=2.2 Hz, 1H), 4.42 (s, 2H), 2.84 (m, 2H), 1.63 (m, 1H), 0.67 (d, J=6.5 Hz, 6H); MS(ES+): 533.4
80d	-OCH ₂ CONH ₂ (3)	-H	79d	G	¹ H NMR (DMSO-d ₆): δ 9.13 (bs, 5H), 8.59 (t, J=6.28 Hz, 1H), 8.14 (d, J=1.7 Hz, 1H), 7.63 (m, 9H), 7.42 (s, 1H), 7.09 (d, J = 7.5 Hz, 1H), 7.03 (dd, J = 2.5, 12.7 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 4.48 (s, 2H), 3.05 (t, J= 6.6 Hz, 2H), 1.83 (m, 1H), 0.87 (d, J=6.8 Hz, 6H); MS(ES+): 532.4
80e		-H	79e	I-2	¹ H NMR (DMSO-d ₆): δ 12.6 (1H, bs, COOH), 8.98, 8.67 (2 bs, 4H), 8.46 (m, 1H), 8.08 (m, 1H), 7.76 (m, 1H), 7.53 (m, 6 H), 7.39 (m, 2H), 7.06 (m, 1H), 7.04 (m, 1H), 2.89 (m, 2H), 1.66 (m, 1H), 0.69 (d, J=6.5 Hz, 6H); MS(ES+): 541.4
80f		-H	79f	I-2	¹ H NMR (DMSO-d ₆): δ 9.14 (d, J = 10 Hz, 4 H), 8.60 (t, J = 6 Hz, 1 H), 8.22 (bs, 1 H), 7.87-7.62 (m, 7 H), 7.47 (t, J = 8 Hz, 2 H), 7.26 (t, 7 Hz, 1 H), 7.22 (m, 4 H), 6.70 (bs, 1 H), 3.09 (t, J = 6 Hz, 2 H), 1.83 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 551.4
80g	-OCH ₃ (3)	-H	79g	I-2	¹ H NMR (DMSO-d ₆): δ 9.13 (bs, 2 H), 8.78 (bs, 2H), 8.65 (t, J = 6 Hz, 1 H), 8.25 (bs, 1 H), 7.78 (m, 1 H), 7.76 (m, 5 H), 7.25 (s, 1 H), 7.17 (m, 1 H), 6.73 (bs, 1 H), 3.83 (s, 3 H), 3.10 (t, J = 6 Hz, 2 H), 1.80 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 489.3


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
80h		(3)	-H	79h	I-2 MS (ES ⁺): 517.7
80i		(3)	-H	79i	I-2 MS (ES ⁺): 503.4 ; MS (ES ⁻): 501.4
80j		(3)	-H	79j	I-2 MS (ES ⁺): 531.4 ; MS (ES ⁻): 529.4
80k	-O-CH ₂ -CH ₂ -OH (3)		-H	79k	¹ H NMR (DMSO-d ₆): δ 13.52 (bs, 2 H), 9.16 (bs, 1 H), 9.03 (bs, 2 H), 8.50 (t, J = 6 Hz, 1 H), 7.96 (d, J = 1.7 Hz, 1 H), 7.56 (m, 6 H), 7.00 (dd, J = 2.5 and 8.5 Hz, 1 H), 6.90 (d, J = 8 Hz, 1 H), 6.48 (d, J = 2.5 Hz, 1 H), 4.91 (t, J = 5.5 Hz, 1 H), 4.00 (t, J = 4.5 Hz, 2 H), 3.69 (q, J = 5.5 and 10 Hz, 2 H), 3.05 (t, J = 6.8 Hz, 2 H), 1.80 (m, 1 H), 0.84 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 519.3, (ES ⁻): 517.3
86a	-CH(OH)CH ₂ OH (3)		-H	82	S, I-2 ¹ H NMR (DMSO-d ₆): δ 9.15 (bs, 3 H), 8.65 (t, J = 6 Hz, 1 H), 8.12 (s, 2 H), 7.82-7.56 (m, 7 H), 7.55-6.96 (m, 4 H), 5.5 (bs, 1 H), 4.90 (bs, 1 H), 4.65 (bs, 1 H), 3.10 (t, J = 6 Hz, 2 H), 1.90 (m, 1 H), 0.92 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 519.3
86b	-CH ₂ OH (3)		-H	84	S, I-2 ¹ H NMR (DMSO-d ₆): δ 8.82 (bs, 2 H), 8.68 (bs, 2 H), 8.40 (t, J = 6 Hz, 1 H), 7.88 (bs, 1 H), 7.53 (m, 5 H), 7.45 (d, 8 Hz, 1 H), 7.25 (d, J = 8 Hz, 1 H), 6.81 (m, 2 H), 5.22 (d, J = 5.5 Hz, 1 H), 4.41 (d, J = 5.5 Hz, 2 H), 2.88 (t, J = 6 Hz, 2 H), 1.65 (m, 1 H), 0.71 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 489.2

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
86c	-CO ₂ H (3)	-H	85	S, I-2	¹ HNMR (DMSO-d ₆ -D ₂ O): δ 13.7 (bs, 1 H), 8.32 (t, J = 6 Hz, 1 H), 7.63-7.17 (m, 7 H), 6.72 (d, 7.0 Hz, 1 H), 2.81 (t, J = 6 Hz, 2 H), 1.53 (m, 1 H), 0.64 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 503.2
97a		-CH ₃	96a	J	MS (ES ⁺): 569.2
97b	-OBn (5)	-CH ₃	91	J	¹ HNMR (DMSO-d ₆): δ 10.62 (s, 1 H), 9.15 (bs, 2 H), 8.82 (bs, 2 H), 8.67 (t, J = 6 Hz, 1 H), 8.25 (d, J = 2 Hz, 1 H), 7.99 (dd, J = 8.1 and 2 Hz, 1 H), 7.69 (q, 8.8 and 16.2 Hz, 4 H), 7.44 (m, 3 H), 7.28 (m, 3 H), 6.89 (d, J = 7.7 Hz, 1 H), 5.5 (s, 2 H), 3.6 (s, 3 H), 3.08 (t, J = 5.8 and 6.8 Hz, 2 H), 1.83 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES-) 577.2, (ES ⁺) 579.3
98a		-H	97a	I-2	¹ HNMR (DMSO-d ₆): δ 13.45 (bs, 1 H), 9.06 (s, 2 H), 8.99 (s, 2 H), 8.51 (t, J = 6 and 5 Hz, 1 H), 7.99 (s, 1 H), 7.62 (m, 5 H), 7.47 (s, 1 H), 7.36 (m, 2 H), 6.99 (m, 4 H), 4.26 (s, 2 H), 3.02 (t, J = 6.8 Hz, 2 H), 1.80 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES-) 553.2, (ES ⁺) 555.2
98b	-OBn (5)	-H	97b	I-2	¹ HNMR (DMSO-d ₆): δ 13.52 (bs, 1 H), 9.09 (bs, 2 H), 9.04 (bs, 2 H), 8.48 (t, J = 6 Hz, 1 H), 7.94 (s, 1 H), 7.61 (m, 4 H), 7.49 (s, 1 H), 7.46 (s, 1 H), 7.34 (m, 5 H), 7.15 (d, J = 8.2 Hz, 1 H), 7.00 (d, J = 8.2, 1 H), 6.02 (d, J = 7.4 Hz, 1 H), 5.21 (s, 2 H), 3.01 (t, J = 6.8 Hz, 2 H), 1.80 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES-) 563.2, (ES ⁺) 565.2


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
98c	-OH (5)	-H	98b	G	¹ H NMR (DMSO-d ₆): δ 9.85 (s, 1 H), 9.07 (s, 2 H), 8.98 (s, 2 H), 8.50 (t, J = 6 and 5 Hz, 1 H), 7.99 (d, J = 1.7 Hz, 1 H), 7.63 (m, 5 H), 7.20 (t, J = 8 Hz, 2 H), 6.90 (d, J = 7.9 Hz, 1 H), 6.49 (d, J = 7.2 Hz, 1 H), 3.21 (t, J = 6.8 Hz, 2 H), 1.80 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES+) 475.2; (ES-) 473.2
103	-OCH ₃ (2)	-CH ₃	102	J	MS (ES+) 503.1
104	-OCH ₃ (2)	-H	103	I-2	¹ H NMR (DMSO-d ₆): δ 9.08 (bs, 2 H), 8.80 (bs, 2 H), 8.52 (t, J = 6 Hz, 1 H), 8.02 (s, 1 H), 7.64 (m, 5 H), 7.16 (m, 2 H), 7.03 (m, 2 H), 3.84 (s, 3 H), 3.03 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES-) 487.3, (ES+) 489.3
110	-OBn (2)	-CH ₃	109	J	MS (ES ⁺): 579.3
111	-OH (2)	-CH ₃	110	G	MS (ES ⁺): 489.3
126	-OC ₂ H ₅ (3) -OBn (4) both	-CH ₃	118b	J	Characterized in the next step
127	-OC ₂ H ₅ (3) -OBn (4) both	-H	126	I-2	¹ H NMR (DMSO-d ₆): δ 9.06-9.09 (m, 3 H), 8.56-8.50 (m, 1 H), 8.05 (s, 1 H), 7.71-7.58 (m, 6 H), 7.55-7.28 (m, 6 H), 7.10-7.01 (m, 1 H), 6.63 (s, 1 H), 5.19 (s, 2 H), 4.05-3.97 (m, 2 H), 3.05-3.01 (m, 2 H), 1.86-1.77 (m, 1 H), 1.29 (t, J=6.7 Hz, 3 H), 0.87 (d, J=6.8 Hz, 6 H)
129	-OCH ₃ (3) -CH(OH)CH ₃ (4) both	-H	128	I-2, S	¹ H NMR (DMSO-d ₆): 13.64 (br s, 1 H), 8.99 (br s, 2 H), 8.49 (t, J = 5.1 Hz, 1 H), 7.99 (s, 1 H), 7.73-7.56 (m, 5 H), 7.32-6.83 (m, 5 H), 6.50 (s, 1 H), 5.17 (d, J = 4.3 Hz, 1 H), 5.01 (m, 1 H), 3.75 (s, 3 H), 3.03 (t, J = 6.0 Hz, 1 H), 1.81 (m, 1 H), 1.32 (d, J = 6.2 Hz, 3 H), 0.86 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 533.4 (100% M ⁺¹)




Analytical Data					
Cpd. No.	-R (With Respect to Phenyl Ring)	Starting From	Method Used		
81	-CH=CH ₂ (3)	79a	R	MS (ES ⁻): 597.2	
82	-CH(OH)CH ₂ OH (3)	81	L	MS (ES ⁻): 631.3	
83	-CH=O (3)	82	M	MS (ES ⁺): 601.3	
84	-CH ₂ OH (3)	83	K	MS (ES ⁻): 601.4	
85	-CO ₂ H (3)	83	E	MS (ES ⁻): 615.3	
128	-OCH ₃ (3) -CH=CH ₂ (4)	124a both	R	MS (ES ⁺): 629.4	



Cpd. No.	-R	-R1	-R2	-R3	-R4	Starting From	Method Used	Analytical Data
88	-Br	-H	-H	-H	-OBn	87	X	¹ H NMR (CDCl ₃): δ 10.48 (s, 1 H), 7.42 – 7.25 (m, 7 H), 7.00 (dd, J = 2 and 7.4 Hz, 1 H), 5.19 (s, 2 H); IR (KBr) 1701, 1585, 1452, 1262, 1009 cm ⁻¹ ; MS (ES ⁺) 313.0, 315.0 (M+Na) ⁺
89	-B(OH) ₂	-H	-H	-H	-OBn	88	T, U-1	¹ H NMR (CDCl ₃): δ 10.61 (s, 1 H), 7.65 (d, J = 7.2 Hz, 1 H), 7.60 (t, J = 7.9 and 7.2 Hz, 1 H), 7.41 (m, 5 H), 7.19 (d, J = 7.9 Hz, 1 H), 6.81 bs, 2 H), 5.20 (s, 2 H)
100	-B(OH) ₂	-OCH ₃	-H	-H	-H	99	T, U-3	¹ H NMR (DMSO-d ₆): δ 10.2 (s, 1 H), 8.34 (s, 2 H), 7.92 (d, J = 9.4 Hz, 1 H), 7.13 (m, 2 H), 3.92 (s, 3 H); MS (ES) 179.0
107	-B(OH) ₂	-OBn	-H	-H	-H	106	T, U-1	¹ H NMR (DMSO-d ₆): δ 10.1 (s, 1 H), 7.3–7.6 (m, 8 H), 5.3 (m, 2 H)
114a	-Br	-H	-OCH ₃	-OH	-H	113	Z	MS (ES ⁺): 229.0 and 231.0
114b	-Br	-H	-OC ₂ H ₅	-OH	-H	113	Z-1	MS (ES ⁺): 242.9 and 244.9
114c	-Br	-H	-OCH(CH ₃) ₂	-OH	-H	113	Z-1	MS (ES ⁺): 257.0 and 259.0
115a	-Br	-H	-OCH ₃	-OBn	-H	114a	X	MS (ES ⁺): 321.0 and 323.0
115b	-Br	-H	-OC ₂ H ₅	-OBn	-H	114b	X	MS (ES ⁺): 335.0 and 337.0
115c	-Br	-H	-OCH(CH ₃) ₂	-OBn	-H	114c	X	MS (ES ⁺): 349.0 and 351.0


Cpd. No.	-R	-R1	-R2	-R3	-R4	Starting From	Method Used	Analytical Data
115d	-Br	-H		-OBn	-H	115a	X, V-4, AH	Characterized in the next step
116a	-B(OH) ₂	-H	-OCH ₃	-OBn	-H	115a	T, U-1	Characterized in the next step
116b	-B(OH) ₂	-H	-OC ₂ H ₅	-OBn	-H	115b	T, U-1	Characterized in the next step
116c	-B(OH) ₂	-H	-OCH(CH ₃) ₂	-OBn	-H	115c	T, U-1	Characterized in the next step



5

15

Analytical Data			
Cpd. No.	Starting From	Method Used	
112	111	I-2	¹ H NMR (DMSO-d ₆): δ 11.28 (s, 1 H), 9.31 (s, 2 H), 9.0 (s, 2 H), 8.88 (d, J = 11.30 Hz, 1 H), 8.82 (d, J = 1.88 Hz, 1 H), 8.25 (d, J = 1.88 Hz, 1 H), 8.18 (d, J = 1.88 Hz, 1 H), 8.04 (d, J = 8.47 Hz, 1 H), 7.92 (m, J = 24.48 Hz, 2 H), 7.75 (m, J = 15.82, 1 H), 7.75 (m, J = 8.28 Hz, 1 H), 7.55 (m, J = 8.66 Hz, 1 H), 3.10 (m, J = 12.6 Hz, 1 H), 2.5 (m, J = 3.5 Hz, 1 H), 1.8 (m, J = 19.9 Hz, 2 H), 0.88 (m, J = 6.6 Hz, 6 H).










Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
117a	-CH ₃	-OBn	-CHO	CH ₃ CH ₃	3a + 116a	D-2	MS (ES ⁺): 474.2
117b	-C ₂ H ₅	-OBn	-CHO	CH ₃ CH ₃	3a + 116b	D-2	MS (ES ⁺): 488.2
117c	-CH(CH ₃) ₂	-OBn	-CHO	CH ₃ CH ₃	3a + 116c	D-2	MS (ES ⁺): 502.3
117d	-CH ₃	-OBn	-CHO	CH ₃ CH ₃	3b + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.56 (s, 1 H), 8.34 (d, J = 1.7 Hz, 1 H), 8.5 (s, 1 H), 8.01 (dd, J = 7.9 and 1.9 Hz, 1 H), 7.40 (m, 7 H), 6.9 (s, 1 H), 5.24 (m, 2 H), 4.2 (m, 1 H), 3.80 (s, 3 H), 3.52 (s, 3 H), 1.02 (d, J = 7 Hz, 6 H); MS (ES ⁺): 484.3 (M+Na) ⁺

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
117e	-CH ₃	-OBn	-CHO		3c + 116a	D-2	¹ H NMR (DMSO-d ₆): δ 8.43 (d, J = 1.65 Hz, 1 H), 8.31 (d, J = 8.66 Hz, 1), 8.12 (dd, J = 1.69 Hz, 1H), 7.98 (s, 1H), 7.41 (d, J = 8 and 10 Hz, 1H), 7.19 (d, J = 8.1 Hz, 1H), 5.20 (dd, J = 6.2 Hz, 1H), 3.98 (dd, J = 7.75 Hz, 3H), 3.94 (s, 3H), 3.42 (m, 3H), 3.32 (m, 3H), 3.19 (s, 3H), 2.5 (m, 3H), 2.0 (s, 4H), 1.5 (m, 2H), 1.28 (m, 3H), 0.88 (d, J = 6.59 Hz, 3H); MS (ES+): 664.3
117f	-CH ₃	-OBn	-CHO		3d + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.50 (s, 1 H), 8.40 (d, J = 2.1 Hz, 1 H), 8.04 (dd, J = 8.1, 2.1 Hz, 1 H), 7.57 (s, 1 H), 7.48 (m, 5 H), 7.38 (m, 5 H), 6.67 (s, 1 H), 6.50 (broad, 1 H), 5.27 (d, J = 11.9 Hz, 1 H), 5.22 (dd, J = 11.7, 1 H), 4.63 (m, 3H) 4.17 (m, 4 H), 3.92 (s, 3 H), 3.66 (s, 3 H); MS (ES): 488.3
117g	-CH ₃	-OBn	-CHO		3f + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.50 (s, 1 H), 8.40 (d, J = 2.1 Hz, 1 H), 8.04 (dd, J = 8.1, 2.1 Hz, 1 H), 7.57 (s, 1 H), 6.67 (s, 1 H), 7.48 (m, 2 H), 7.38 (m, 3 H), 6.67 (s, 1 H), 6.50 (broad, 1 H), 5.27 (d, J = 11.7, 2 Hz, 1 H), 5.22 (dd, J = 11.7, 2 H), 4.17 (m, 2 H), 3.92 (s, 3 H), 3.66 (s, 3 H); MS (ES): 500

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
117h	-CH ₃	-OBn	-CHO		3e + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.56 (s, 1 H), 8.34 (d, <i>J</i> = 1.7 Hz, 1 H), 8.01 (dd, <i>J</i> = 7.9, 1.9 Hz, 1 H), 7.57 (s, 1 H), 7.50 (dd, <i>J</i> = 7.2, 1.5, 2 Hz), 7.40 (m, 4 H), 6.67 (s, 1 H), 6.21 (broad, 1 H), 5.24 (d, <i>J</i> = 2.8 Hz, 2 H), 3.92 (s, 3 H), 3.65 (s, 3 H), 3.52 (m, 2 H), 1.65 (m, 2 H), 1.46 (m, 2 H), 0.99 (t, <i>J</i> = 7.3 Hz, 3 H).
117i	-CH ₃	-OBn	-CHO		3g + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.57 (s, 1 H), 8.37 (d, <i>J</i> = 1.9 Hz, 1 H), 8.03 (dd, <i>J</i> = 7.9, 1.9 Hz, 1 H), 7.58 (s, 1 H), 7.50 (d, <i>J</i> = 7.2 Hz, 2 H), 7.38 (m, 3 H), 6.68 (s, 1 H), 6.33 (broad, 1 H), 5.26 (d, <i>J</i> = 11.5 Hz, 1 H), 5.21 (d, <i>J</i> = 11.9 Hz, 1 H), 3.92 (s, 3 H), 3.65 (s, 3 H), 3.37 (dd, <i>J</i> = 7.2, 5.3 Hz, 2 H), 1.09 (m, 1 H), 0.60 (m, 2 H), 0.32 (m, 2 H); MS (ES ⁺): 474.2
117j	-CH ₃	-OBn	-CHO		3h + 116a	D-2	¹ H NMR (CDCl ₃): δ 9.55 (s, 1 H), 8.32 (d, <i>J</i> = 1.9 Hz, 1 H), 8.00 (dd, <i>J</i> = 1.9 and 7.9 Hz, 1 H), 7.59-7.30 (m, 7 H), 6.67 (s, 1 H), 5.23 (m, 2 H), 4.45 (q, <i>J</i> = 7.0 Hz, 1 H), 3.91 (s, 3 H), 3.64 (s, 3 H), 2.21-1.46 (m, 8 H); MS (ES ⁺): 510.3 (M + Na) ⁺

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
117k	-CH ₃	-OBn	-CHO		3i+ 116a	D-2	¹ H NMR (CDCl ₃): δ 9.56 (s, 1 H), 8.35 (d, J = 1.9 Hz, 1 H), 8.02 (dd, J = 1.9 and 7.9 Hz, 1 H), 7.58-7.33 (m, 7 H), 6.68 (s, 1 H), 5.24 (m, 2 H), 3.92 (s, 3 H), 3.65 (s, 3 H), 3.56 (m, 2 H), 1.30 (t, J = 7.2 Hz, 3 H); MS (ES ⁺): 470.3 (M+ Na) ⁺
117l	-CH ₃	-OBn	-CHO		3j+ 116a	D-2	¹ H NMR (CDCl ₃): δ 9.56 (s, 1 H), 8.35 (d, J = 1.9 Hz, 1 H), 8.02 (dd, J = 1.9 and 7.9 Hz, 1 H), 7.58-7.33 (m, 7 H), 6.68 (s, 1 H), 5.24 (m, 2 H), 3.92 (s, 3 H), 3.65 (s, 3 H), 3.40 (m, 2 H), 1.80-0.94 (m, 9 H); MS (ES ⁺): 512.2 (M+ Na) ⁺
117m		-OBn	-CHO		6a+ 115d	D-6	¹ H NMR (DMSO-d ₆): δ 9.73 (s, 1 H), 8.86 (t, J = 5.7 Hz, 1 H), 8.52 (d, J = 1.5 Hz, 1 H), 8.22 (dd, J = 8 and 2 Hz, 1 H), 7.79 (s, 1 H), 7.60 (d, J = 8 Hz, 1 H), 7.5 (m, 5 H), 7.22 (s, 1 H), 5.35 (q, J = 11 and 17 Hz, 1 H), 3.70 (s, 3 H), 3.23 (t, J = 6.5 Hz, 2 H), 1.98 (m, 1 H), 1.3 (s, 9 H), 1.01 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 546.4
118a	-CH ₃	-OBn	-CO ₂ H		117a	E	MS (ES ⁺): 490.2








Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
118b	-C ₂ H ₅	-OBn	-CO ₂ H		117b	E	MS (ES ⁻): 504.2
118c	-CH(CH ₃) ₂	-OBn	-CO ₂ H		117c	E	MS (ES ⁻): 518.2
118d	-CH ₃	-OBn	-CO ₂ H		117d	E	Characterized in the next step
118e	-CH ₃	-OBn	-CO ₂ H		117e	E	MS (ES ⁺): 534.3
118f	-CH ₃	-OBn	-CO ₂ H		117f	E	MS (ES ⁺): 506.3
118g	-CH ₃	-OBn	-CO ₂ H		117g	E	Characterized in the next step
118h	-CH ₃	-OBn	-CO ₂ H		117h	E	MS (ES ⁻¹): 490.2
118i	-CH ₃	-OBn	-CO ₂ H		117i	E	MS (ES ⁻¹): 488.3

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
118j	-CH ₃	-OBn	-CO ₂ H		117j	E	¹ H NMR (DMSO-d ₆): δ 12.19 (br s, 1 H), 8.50 (d, J = 7.4 Hz, 1 H), 8.31 (d, J = 1.9 Hz, 1 H), 8.02 (dd, J = 1.7 and 7.9 Hz, 1 H), 7.58-7.29 (m, 7 H), 6.71 (s, 1 H), 5.17 (s, 2 H), 4.27 (q, J = 6.4 Hz, 1 H), 3.80 (s, 3 H), 3.57 (s, 3 H), 1.97-1.51 (m, 8 H)
118k	-CH ₃	-OBn	-CO ₂ H		117k	E	MS (ES): 462.3
118l	-CH ₃	-OBn	-CO ₂ H		117l	E	¹ H NMR (CDCl ₃): δ 8.30 (d, J = 1.9 Hz, 1 H), 7.95 (dd, J = 1.7 and 7.9 Hz, 1 H), 7.66 (s, 1 H), 7.52-7.27 (m, 6 H), 6.62 (s, 1 H), 6.49 (m, 1 H), 5.21 (s, 2 H), 3.88 (s, 3 H), 3.61 (s, 3 H), 3.38 (m, 2 H), 1.79-0.94 (m, 9 H); MS (ES): 504.4
118m		-OBn	-CO ₂ H		117m	E	Characterized in the next step
119a	-CH ₃	-OBn	-CO ₂ MEM		118a	F	MS (ES): 578.3
119b	-C ₂ H ₅	-OBn	-CO ₂ MEM		118b	F	MS (ES): 592.3




Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
119c	-CH(CH ₃) ₂	-OBn	-CO ₂ MEM		118c	F	MS (ES): 606.3
119d	-CH ₃	-OBn	-CO ₂ MEM		118d	F	MS (ES): 564.2
119e	-CH ₃	-OBn	-CO ₂ MEM		118e	F	MS (ES): 620.1
119f	-CH ₃	-OBn	-CO ₂ MEM		118f	F	MS (ES): 592.3
119g	-CH ₃	-OBn	-CO ₂ MEM		118g	F	Characterized in the next step
119h	-CH ₃	-OBn	-CO ₂ MEM		118h	F	¹ H NMR (CDCl ₃): δ 8.32 (d, J = 1.9 Hz, 1 H), 7.96 (dd, J = 7.9, 1.9 Hz, 1 H), 7.68 (s, 1 H), 7.50 (m, 2 H), 7.35 (m, 4 H), 6.62 (s, 1 H), 6.33 (t, J = 5.4 Hz, 1 H), 5.24 (m, 4 H), 3.88 (s, 3 H), 3.63 (s, 3 H), 3.46 (m, 6 H), 3.34 (s, 3 H), 1.63 (m, 2 H), 1.44 (m, 2 H), 0.98 (t, J = 7.3 Hz, 3 H)


Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
119i	-CH ₃	-OBn	-CO ₂ MEM		118i	F	¹ H NMR (CDCl ₃): δ 8.34 (d, J = 1.9 Hz, 1 H), 8.00 (dd, J = 7.9, 2.1 Hz, 1 H), 7.68 (s, 1 H), 7.50 (m, 2 H), 7.36 (m, 4 H), 6.63 (s, 1 H), 6.42 (broad, 1 H), 5.24 (m, 4 H), 3.89 (s, 3 H), 3.64 (s, 3 H), 3.45 (s, 3 H), 3.35 (m, 5 H), 1.07 (m, 1 H), 0.58 (m, 2 H), 0.30 (m, 2 H); ¹³ C NMR (DMSO-d ₆): δ 8.55 (d, J = 7.4 Hz, 1 H), 8.39 (d, J = 1.9 Hz, 1 H), 8.10 (dd, J = 1.7 and 7.9 Hz, 1 H), 7.63-7.35 (m, 7 H), 6.81 (s, 1 H), 5.25-5.12 (m, 4 H), 4.31 (q, J = 6.4 Hz, 1 H), 3.86 (s, 3 H), 3.62 (s, 3 H), 3.3 (s, 3 H), 3.23 (s, 3 H) 1.99-1.53 (m, 8 H); MS (ES ⁺): 614.3 (M+ Na) ⁺
119j	-CH ₃	-OBn	-CO ₂ MEM		118j	F	¹ H NMR (DMSO-d ₆): δ 8.70 (t, J = 5.5 Hz, 1 H), 8.35 (d, J = 1.9 Hz, 1 H), 8.05 (dd, J = 1.7 and 7.9 Hz, 1 H), 7.59-7.30 (m, 7 H), 6.77 (s, 1 H), 5.21-5.08 (m, 4 H), 3.82 (s, 3 H), 3.58 (s, 3 H), 3.40-3.29 (m, 6 H), 3.18 (s, 3 H), 1.14 (t, J = 7.2 Hz, 3 H); MS (ES ⁺): 574.3 (M+ Na) ⁺
119k	-CH ₃	-OBn	-CO ₂ MEM		118k	F	

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
119i	-CH ₃						¹ H NMR (DMSO-d ₆): δ 8.68 (t, J = 5.8 Hz, 1 H), 8.35 (d, J = 1.9 Hz, 1 H), 8.05 (dd, J = 1.7 and 7.9 Hz, 1 H), 7.63-7.33 (m, 7 H), 6.77 (s, 1 H), 5.22-5.08 (m, 4 H), 3.82 (s, 3 H), 3.58 (s, 3 H), 3.39-3.22 (m, 6 H), 3.18 (s, 3 H), 1.56 (qui, J = 7.0 Hz, 2 H), 1.27 (m, 1 H), 0.94-0.75 (m, 6 H); MS (ES ⁺): 616.3 (M+ Na) ⁺
119m						F	¹ H NMR (DMSO-d ₆): δ 8.72 (t, J = 5.6 Hz, 1 H), 8.38 (d, J = 1.8 Hz, 1 H), 8.70 (dd, J = 1.8 and 8.1 Hz, 1 H), 7.71 (s, 1 H), 7.40 (m, 6 H), 7.02 (s, 1 H), 5.20 (m, 4 H), 3.59 (s, 3 H), 3.37 (m, 2 H), 3.31 (m, 2 H), 3.17 (s, 3 H), 3.12 (t, J = 6.5 Hz, 2 H), 1.87 (m, 1 H), 1.21 (s, 9 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 650.4 and 672.3 (M+ Na) ⁺
120a	-CH ₃		-OH	-CO ₂ MEM		119a	G MS (ES): 488.1
120b	-C ₂ H ₅		-OH	-CO ₂ MEM		119b	G MS (ES): 502.2







Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
120c	-CH(CH ₃) ₂	-OH	-CO ₂ MEM		119c	G	MS (ES ⁺): 516.3
120d	-CH ₃	-OH	-CO ₂ MEM		119d	G	MS (ES ⁺): 474.3
120e	-CH ₃	-OH	-CO ₂ MEM		119e	G	MS (ES ⁺): 530.4
120f	-CH ₃	-OH	-CO ₂ MEM		119f	G	MS (ES ⁺): 502.3
120g	-CH ₃	-OH	-CO ₂ MEM		119g	G	Characterized in the next step
120h	-CH ₃	-OH	-CO ₂ MEM		119h	G	Characterized in the next step
120i	-CH ₃	-OH	-CO ₂ MEM		119i	G	MS (ES ⁺): 486.3
120j	-CH ₃	-OH	-CO ₂ MEM		119j	G	MS (ES ⁺): 524.3 (M+ Na) ⁺
120k	-CH ₃	-OH	-CO ₂ MEM		119k	G	MS (ES ⁺): 484.2 (M+ Na) ⁺

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
120l	-CH ₃	-OH	-CO ₂ MEM		119l	G	MS (ES ⁺): 502.3
120m		-OH	-CO ₂ MEM		119m	G	¹ H NMR (DMSO-d ₆): δ 10.83 (bs, 1 H), 8.77 (t, J = 5.6 Hz, 1 H), 8.42 (d, J = 1.8 Hz, 1 H), 8.12 (dd, J = 1.8 and 8.1 Hz, 1 H), 7.68 (s, 1 H), 7.41 (d, J = 8.1 Hz, 1 H), 6.73 (s, 1 H), 5.21 (q, J = 21 and 6 Hz, 2 H), 3.65 (s, 3 H), 3.48 (m, 2 H), 3.37 (m, 2 H), 3.24 (s, 3 H), 3.18 (t, J = 6.5 Hz, 2 H), 1.94 (m, 1 H), 1.39 (s, 9 H), 0.97 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 560.5 and 582.4 (M+ Na) ⁺ , (ES) 558.4
121a	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120a	B-2	MS (ES ⁺): 644.1 (M+ Na) ⁺
121b	-C ₂ H ₅	-OSO ₂ CF ₃	-CO ₂ MEM		120b	B-2	MS (ES ⁺): 658.2 (M+ Na) ⁺
121c	-CH(CH ₃) ₂	-OSO ₂ CF ₃	-CO ₂ MEM		120c	B-2	MS (ES ⁺): 672.2 (M+ Na) ⁺







Cpd. No.	-R	-R'	-R''	-R'''	Starting Material Used	Method Used	Analytical Data
121d	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120d	B-2	¹ H NMR (DMSO-d ₆): δ 8.43 (d, J = 1.9 Hz, 1 H), 8.31 (s, 1 H), 8.12 (d, J = 1.69 Hz, 1 H), 7.98 (s, 1 H), 7.41 (d, J = 8.1 Hz, 1 H), 7.19 (s, 1 H), 5.20 (m, 2 H), 3.98 (m, 1 H), 3.94 (s, 3 H), 3.42 (s, 3 H), 3.19 (s, 3 H), 2.50 (m, 2 H), 1.08 (d, J = 6.59, 6 H); MS (ES+): 608.3
121e	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120e	B-2	¹ H NMR (DMSO-d ₆): δ 8.49 (s, 1 H), 8.34 (d, J = 1.8 Hz, 1 H), 8.2 (d, J = 1.8 Hz, 1 H), 7.97 (s, 1 H), 7.4 (d, J = 7.8 Hz, 1 H), 7.2 (s, 1 H), 5.2 (q, J = 6 and 10 Hz, 2 H), 4.0 (m, 3 H), 3.6 (s, 3 H), 3.4 (m, 4 H), 3.2 (s, 3 H), 1.5 (m, 4 H), 1.3 (m, 4 H), 0.85 (m, 6 H); MS (ES+): 664.3
121f	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120f	B-2	¹ H NMR (DMSO-d ₆): δ 8.83 (d, J = 5.46, 1 H), 8.55 (d, J = 1.88 Hz, 1 H), 8.23 (dd, J = 1.88 Hz, 1 H), 8.19 (s, 1 H), 7.73 (d, J = 7.93 Hz, 1 H), 7.29 (s, 1 H), 5.29 (dd, J = 6.217 Hz, 2 H), 4.06 (s, 3 H), 3.71 (s, 2 H), 3.54 (m, 5 H), 2.62 (t, J = 3.57 Hz, 3 H), 1.66 (t, J = 6.59 Hz, 2 H), 1.42 (m, 6 H), 0.99 (t, J = 6.79 Hz, 3 H); MS (ES+): 636.6

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
121g	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120g	B-2	¹ H NMR (CDCl ₃): δ 8.43 (d, J = 1.9 Hz, 1 H), 8.03 (dd, J = 7.9 Hz, 2.1 Hz, 1 H), 8.00 (s, 1 H), 7.35 (d, J = 7.9 Hz, 1 H), 6.79 (m, 2 H), 5.29 (d, J = 6.2 Hz, 1 H), 5.26 (d, J = 6.2 Hz, 1 H), 4.16 (m, 2 H), 3.94 (s, 3 H), 3.67 (s, 3 H), 3.48 (m, 4 H), 3.36 (s, 3 H); MS (ES): 646.3
121h	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120h	B-2	¹ H NMR (CDCl ₃): δ 8.41 (s, 1 H), 7.96 (d, J = 8.3 Hz, 2 H), 7.8 (m, 1 H), 6.80 (s, 1 H), 6.34 (m, 1 H), 5.32 (m, 2 H), 3.90 (s, 3 H), 3.66 (s, 3 H), 3.55 (m, 6 H), 3.4 (s, 3 H), 1.7 (m, 2 H), 1.45 (m, 2 H), 0.98 (t, J = 7.3 Hz, 3 H); MS (ES): 620
121i	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MMFM		120i	B-2	¹ H NMR (CDCl ₃): δ 8.41 (d, J = 2.1 Hz, 1 H), 8.03 (dd, J = 7.9, 1.9 Hz, 1 H), 8.00 (s, 1 H), 7.32 (d, J = 7.9 Hz, 1 H), 6.43 (t, J = 4.9 Hz, 1 H), 5.30 (q, J = 6.0 Hz, 2 H), 3.94 (s, 3 H), 3.67 (s, 3 H), 3.55 (m, 2 H), 3.48 (m, 2 H), 3.35 (m, 5 H), 1.09 (m, 1 H), 0.59 (m, 2 H), 0.31 (m, 2 H); MS (ES): 618.4

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
121j	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120j	B-2	¹ H NMR (CDCl ₃): δ 8.35 (d, <i>J</i> =1.9 Hz, 1 H), 8.00 (m, 2 H), 7.31 (d, <i>J</i> =7.9 Hz, 1 H), 6.77 (s, 1 H), 6.27 (m, 1 H), 5.28 (m, 2 H), 4.44 (q, <i>J</i> =7.0 Hz, 1 H), 3.94 (s, 3 H), 3.66 (s, 3 H), 3.57-3.45 (m, 4 H), 3.35 (s, 3 H), 2.19-1.45 (m, 8 H); MS (ES ⁺): 656.3 (M+ Na) ⁺
121k	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120k	B-2	¹ H NMR (CDCl ₃): δ 8.38 (s, 1 H), 8.00 (m, 2 H), 7.31 (d, <i>J</i> =7.9 Hz, 1 H), 6.78 (s, 1 H), 6.37 (m, 1 H), 5.27 (m, 2 H), 3.94 (s, 3 H), 3.66 (s, 3 H), 3.59-3.43 (m, 6 H), 3.35 (s, 3 H), 1.28 (<i>t</i> , <i>J</i> =7.2 Hz, 3 H); MS (ES ⁺): 616.3 (M+ Na) ⁺
121l	-CH ₃	-OSO ₂ CF ₃	-CO ₂ MEM		120l	B-2	¹ H NMR (CDCl ₃): δ 8.38 (s, 1 H), 8.00 (m, 2 H), 7.31 (d, <i>J</i> =7.9 Hz, 1 H), 6.78 (s, 1 H), 6.37 (m, 1 H), 5.27 (m, 2 H), 3.94 (s, 3 H), 3.66 (s, 3 H), 3.57-3.25 (m, 9 H), 1.78-0.92 (m, 9 H); MS (ES ⁺): 658.4 (M+ Na) ⁺



Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
121m		-OSO ₂ CF ₃	-CO ₂ MEM		121m	B-2	¹ H NMR (DMSO-d ₆): δ 8.75 (t, J = 5.6 Hz, 1 H), 8.45 (d, J = 1.8 Hz, 1 H), 8.11 (dd, J = 1.8 and 8.1 Hz, 1 H), 8.04 (s, 1 H), 7.57 (s, 1 H), 7.42 (d, J = 8.1 Hz, 1 H), 5.23 (q, J = 21 and 6 Hz, 2 H), 3.60 (s, 3 H), 3.41 (m, 2 H), 3.32 (m, 2 H), 3.17 (s, 3 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.87 (m, 1 H), 1.37 (s, 9 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES-): 690.4
122a	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121a	D-3	Characterized in the next step
122b	-C ₂ H ₅	-CH=CH ₂	-CO ₂ MEM		121b	D-3	MS (ES ⁺): 536.3 (M+ Na) ⁺
122c	-CH(CH ₃) ₂	-CH=CH ₂	-CO ₂ MEM		121c	D-3	MS (ES ⁺): 550.3 (M+ Na) ⁺
122d	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121d	D-3	MS (ES ⁺): 486.2
122e	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121e	D-3	MS (ES ⁺): 564.5 (M+ Na) ⁺


Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
122f	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121f	D-3	MS (ES ⁺): 514.4 (M+ Na) ⁺
122g	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121g	D-3	Characterized in the next step
122h	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121h	D-3	Characterized in the next step
122i	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121i	D-3	Characterized in the next step
122j	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121j	D-3	MS (ES ⁺): 422.3 [(M-MeM)-1]
122k	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121K	D-3	MS (ES ⁺): 494.2 (M+ Na) ⁺
122l	-CH ₃	-CH=CH ₂	-CO ₂ MEM		121l	D-3	MS (ES ⁺): 536.42 (M+ Na) ⁺

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
122m						D-3 121m	¹ H NMR (DMSO-d ₆): δ 8.73 (t, J = 5.6 Hz, 1 H), 8.43 (d, J = 1.8 Hz, 1 H), 8.11 (dd, J = 1.8 and 8.1 Hz, 1 H), 7.61 (s, 1 H), 7.57 (s, 1 H), 7.42 (d, J = 8.1 Hz, 1 H), 6.72 (dd, J = 11 and 17.5 Hz, 1 H), 6.03 (d, J = 17.5 Hz, 1 H), 5.52 (d, J = 11 Hz, 1 H), 5.19 (q, J = 18 and 6 Hz, 2 H), 3.60 (s, 3 H), 3.41 (m, 2 H), 3.32 (m, 2 H), 3.18 (s, 3 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.89 (m, 1 H), 1.38 (s, 9 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES-): 480.4 [(M-MEM)-1]
123a						122a	I-1 MS (ES ⁻): 410.2
123b						122b	I-1 MS (ES ⁻): 424.2
123c						122c	I-1 MS (ES ⁻): 438.2
123d						122d	I-1 MS (ES ⁻): 396.2

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
123e	-CH ₃	-CH=CH ₂	CO ₂ H		122e	I-1	MS (ES ⁺): 454.3
123f	-CH ₃	-CH=CH ₂	CO ₂ H		122f	I-1	MS (ES ⁺): 426.3
123g	-CH ₃	-CH=CH ₂	CO ₂ H		122g	I-1	¹ H NMR (DMSO): δ 12.37 (s, 1 H), 9.35 (t, <i>J</i> =6.0 Hz, 1 H), 8.42 (d, <i>J</i> =1.7 Hz, 1 H), 8.10 (dd, <i>J</i> =8.1 Hz, 1.9 Hz, 1 H), 8.06 (s, 1 H), 7.40 (d, <i>J</i> =7.9 Hz, 1 H), 6.98 (dd, <i>J</i> =17.9, 11.5 Hz, 1 H), 6.77 (s, 1 H), 5.89 (dd, <i>J</i> =17.7, 1.3 Hz, 1 H), 5.37 (dd, <i>J</i> =11.1, 1.3 Hz, 1 H), 4.14 (m, 2 H), 3.84 (s, 3 H), 3.61 (s, 3 H); MS (ES ⁺): 436.3
123h	-CH ₃	-CH=CH ₂	CO ₂ H		122h	I-1	¹ H NMR (DMSO): δ 8.66 (t, <i>J</i> =5.5 Hz, 1 H), 8.35 (d, <i>J</i> =1.7 Hz, 1 H), 8.05 (s, 1 H), 8.03 (dd, <i>J</i> =8.1, 1.9 Hz, 1 H), 7.34 (d, <i>J</i> =7.9 Hz, 1 H), 6.98 (dd, <i>J</i> =17.9, 11.3 Hz, 1 H), 6.75 (s, 1 H), 5.88 (dd, <i>J</i> =17.7, 1.3 Hz, 1 H), 5.36 (dd, <i>J</i> =11.3, 1.3 Hz, 1 H), 3.84 (s, 3 H), 3.60 (s, 3 H), 3.30 (q, <i>J</i> =5.6 Hz, 2 H), 1.52 (m, 2 H), 1.33 (m, 2 H), 0.96 (t, <i>J</i> =7.3 Hz, 3 H); MS (ES ⁺): 410.4

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
123i	-CH ₃	-CH=CH ₂	CO ₂ H		122i	I-1	¹ H NMR (DMSO) : δ 12.34 (s, 1 H), 8.80 (t, <i>J</i> =6.1 Hz, 1 H), 8.37 (d, <i>J</i> =1.9 Hz, 1 H), 8.06 (dd, <i>J</i> =9.8, 7.9 Hz, 1 H), 8.05 (s, 1 H), 7.36 (d, <i>J</i> =7.9 Hz, 1 H), 6.98 (dd, <i>J</i> =17.9, 11.3 Hz, 1 H), 6.76 (s, 1 H), 5.89 (dd, <i>J</i> =17.9, 1.5 Hz, 1 H), 5.36 (dd, <i>J</i> =10.9, 1.5 Hz, 1 H), 3.84 (s, 3 H), 3.60 (s, 3 H), 3.18 (t, 6.2, 2 H), 1.06 (m, 1 H), 0.45 (m, 2 H), 0.25 (m, 2 H); MS (ES): 408.4
123j	-CH ₃	-CH=CH ₂	CO ₂ H		122j	I-1	¹ H NMR (DMSO- <i>d</i> ₆): δ 12.31 (br s, 1 H), 8.52 (d, <i>J</i> =7.3 Hz, 1 H), 8.34 (d, <i>J</i> =1.7 Hz, 1 H), 8.05 (m, 2 H), 7.34 (d, <i>J</i> =7.9 Hz, 1 H), 6.97 (dd, <i>J</i> =11.5 and 17.9 Hz, 1 H), 6.74 (s, 1 H), 5.89 (d, <i>J</i> =17.9 Hz, 1 H), 5.37 (d, <i>J</i> =11.5 Hz, 1 H), 4.27 (q, <i>J</i> =7.3 Hz, 1 H), 3.84 (s, 3 H), 3.60 (s, 3 H), 1.98-1.50 (m, 8 H); MS (ES): 422.3
123k	-CH ₃	-CH=CH ₂	CO ₂ H		122k	I-1	¹ H NMR (DMSO- <i>d</i> ₆): δ 12.27 (br s, 1 H), 8.58 (m, 1 H), 8.23 (s, 1 H), 7.92 (m, 2 H), 7.47 (m, 1 H), 7.22 (m, 1 H), 6.84 (m, 1 H), 6.63 (s, 1 H), 5.76 (d, <i>J</i> =17.9 Hz, 1 H), 5.24 (d, <i>J</i> =11.5 Hz, 1 H), 3.71 (s, 3 H), 3.47 (s, 3 H), 1.02 (m, 3 H); MS (ES): 382.2

Cpd. No.	-R	-R'	-R"	-R'''	Starting From	Method Used	Analytical Data
123l	-CH ₃	-CH=CH ₂	CO ₂ H		122l	I-1	¹ H NMR (DMSO-d ₆): δ 12.30 (br s, 1 H), 8.52 (q, J = 6.0 Hz, 1 H), 8.33 (d, J = 1.7 Hz, 1 H), 8.02 (m, 2 H), 7.31 (d, J = 7.9 Hz, 1 H), 6.95 (dd, J = 11.5 and 17.9 Hz, 1 H), 6.73 (s, 1 H), 5.86 (d, J = 17.9 Hz, 1 H), 5.33 (d, J = 11.5 Hz, 1 H), 3.81 (s, 3 H), 3.57 (s, 3 H), 3.14 (m, 2 H), 1.65 (m, 1 H), 1.39 (m, 1 H), 1.11 (m, 1 H), 0.87 (m, 6 H)
123m					122m	I-1	¹ H NMR (DMSO-d ₆): δ 12.81 (bs, 1 H), 8.72 (t, J = 5.6 Hz, 1 H), 8.38 (d, J = 1.8 Hz, 1 H), 8.08 (dd, J = 1.8 and 8.1 Hz, 1 H), 7.61 (s, 1 H), 7.57 (s, 1 H), 7.39 (d, J = 8 Hz, 1 H), 6.72 (dd, J = 11 and 17.5 Hz, 1 H), 5.99 (d, J = 17.5 Hz, 1 H), 5.49 (d, J = 11 Hz, 1 H), 3.57 (s, 3 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.87 (m, 1 H), 1.37 (s, 9 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES-): 480.3




Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data	
124a	-CH ₃	-CH ₃	CH ₃ —CH ₂ —CH ₃	123a	J	MS (ES ⁺): 529.3	
124b	-C ₂ H ₅	-CH ₃	CH ₃ —CH ₂ —CH ₃	123b	J	MS (ES ⁺): 543.3	
124c	-CH(CH ₃) ₂	-CH ₃	CH ₃ —CH ₂ —CH ₃	123c	J	MS (ES ⁺): 557.3	
124d	-CH ₃	-CH ₃	CH ₃ —CH ₂ —CH ₃	123d	J	Characterized in the next step	
124e	-CH ₃	-CH ₃	—CH ₂ —CH ₂ —CH ₃	123e	J	MS (ES ⁺): 571.6	


Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data
124f	-CH ₃	-CH ₃		123f	J	MS (ES ⁺): 543.6
124g	-CH ₃	-CH ₃		123g	J	¹ H NMR (DMSO): δ 10.62 (s, 1 H), 9.35 (t, <i>J</i> = 6.6 Hz, 1 H), 9.20 (s, 2 H), 8.90 (s, 2 H), 8.30 (d, <i>J</i> = 1.9 Hz, 1 H), 8.11 (dd, <i>J</i> = 8.1, 1.9 Hz, 1 H), 7.86 (s, 1 H), 7.76 (s, 4 H), 7.50 (d, <i>J</i> = 8.1 Hz, 1 H), 7.04 (dd, <i>J</i> = 17.9, 11.5 Hz, 1 H), 6.94 (s, 1 H), 6.01 (dd, <i>J</i> = 17.7, 1.3, 1 H), 5.42 (dd, <i>J</i> = 11.3, 1.3 Hz, 1 H), 4.11 (m, 2 H), 3.89 (s, 3 H), 3.57 (s, 3 H)
124h	-CH ₃	-CH ₃		123h	J	¹ H NMR (DMSO): δ 9.03 (broad, 3 H), 8.49 (broad, 1 H), 8.04 (s, 1 H), 7.65 (m, 6 H), 6.99 (m, 2 H), 6.61 (s, 1 H), 5.90 (d, <i>J</i> = 17.5 Hz, 1 H), 5.35 (d, <i>J</i> = 11.5 Hz, 1 H), 3.78 (s, 3 H), 3.20 (m, 2 H), 1.46 (m, 2 H), 1.28 (m, 2 H), 0.87 (t, <i>J</i> = 7.3 Hz, 3 H)
124i	-CH ₃	-CH ₃		123i	J	MS (ES ⁺): 527.4
124j	-CH ₃	-CH ₃		123j	J	MS (ES ⁺): 541.4
124k	-CH ₃	-CH ₃		123K	J	MS (ES ⁺): 501.3
124l	-CH ₃	-CH ₃		123l	J	MS (ES ⁺): 543.3

Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data	
124m				123m	J	¹ H NMR (DMSO-d ₆): δ 10.67 (s, 1H), 9.19 (bs, 2H), 8.88 (bs, 2H), 8.71 (t, J = 5.6 Hz, 1H), 8.25 (d, J = 1.8 Hz, 1H), 8.07 (dd, J = 1.8 and 8.1 Hz, 1H), 7.73 (m, 4H), 7.65 (s, 1H), 7.50 (d, J = 8 Hz, 1H), 7.45 (s, 1H), 6.73 (dd, J = 11 and 17.5 Hz, 1H), 6.03 (d, J = 17.5 Hz, 1H), 5.49 (d, J = 11 Hz, 1H), 3.56 (s, 3H), 3.09 (t, J = 6.5 Hz, 2H), 1.85 (m, 1H), 1.37 (s, 9H), 0.89 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 597.3 and (ES ⁺) 599.5	¹ H NMR (DMSO): δ 13.40 (bs, 1H), 9.26 and 9.03 (2s, 4H), 8.53-8.49 (t, J = 6 Hz, 1H), 8.02 (d, J = 1.28 Hz, 1H), 7.71-7.53 (m, 6H), 7.0-6.9 (m, 2H), 6.5 (s, 1H), 5.89 (d, J = 17.6 Hz, 1H), 5.33 (d, J = 12.4 Hz, 1H), 3.77 (s, 3H), 3.04-2.99 (m, 2H), 1.85-1.75 (m, 1H), 0.86-0.84 (d, J = 76.8 Hz, 6H); MS (ES ⁺): 515.3
125a	-CH ₃	-H		124a	I-2	¹ H NMR (DMSO): δ 9.17 and 8.92 (s, 3H), 8.67-8.63 (m, 1H), 8.28 (s, 1H), 7.95-7.93 (m, 1H), 7.83 (s, 1H), 7.73 (s, 5H), 7.29 (d, J = 8.1 Hz, 1H), 7.02 (dd, J = 17.7 Hz, 11.3 Hz, 1H), 6.82 (s, 1H), 6.00 (d, 17.7 Hz, 1H), 5.38 (d, 11.3 Hz, 1H), 4.14-4.06 (m, 2H), 3.11-3.04 (q, J = 6.8 Hz, 2H), 1.89-1.80 (m, 1H), 1.35 (t, J = 6.8 Hz, 3H), 0.88 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 529.2	¹ H NMR (DMSO): δ 9.17 and 8.92 (s, 3H), 8.67-8.63 (m, 1H), 8.28 (s, 1H), 7.95-7.93 (m, 1H), 7.83 (s, 1H), 7.73 (s, 5H), 7.29 (d, J = 8.1 Hz, 1H), 7.02 (dd, J = 17.7 Hz, 11.3 Hz, 1H), 6.82 (s, 1H), 6.00 (d, 17.7 Hz, 1H), 5.38 (d, 11.3 Hz, 1H), 4.14-4.06 (m, 2H), 3.11-3.04 (q, J = 6.8 Hz, 2H), 1.89-1.80 (m, 1H), 1.35 (t, J = 6.8 Hz, 3H), 0.88 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 529.2
125b	-C ₂ H ₅	-H		124b	I-2	¹ H NMR (DMSO): δ 13.74 (s, 1H), 8.99 (s, 3H), 8.59-8.41 (m, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.65-7.53 (m, 6H), 7.06-6.91 (m, 2H), 6.53 (s, 1H), 5.89 (d, J = 17.7 Hz, 1H), 5.32 (d, J = 11.5 Hz, 1H), 4.62-4.54 (m, 1H), 3.03-2.99 (m, 2H), 1.87-1.71 (m, 1H), 1.25 (d, J = 6.1 Hz, 6H), 0.85 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 541.2	¹ H NMR (DMSO): δ 13.74 (s, 1H), 8.99 (s, 3H), 8.59-8.41 (m, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.65-7.53 (m, 6H), 7.06-6.91 (m, 2H), 6.53 (s, 1H), 5.89 (d, J = 17.7 Hz, 1H), 5.32 (d, J = 11.5 Hz, 1H), 4.62-4.54 (m, 1H), 3.03-2.99 (m, 2H), 1.87-1.71 (m, 1H), 1.25 (d, J = 6.1 Hz, 6H), 0.85 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 541.2
125c	-CH(CH ₃) ₂	-H		124c	I-2	¹ H NMR (DMSO): δ 13.74 (s, 1H), 8.99 (s, 3H), 8.59-8.41 (m, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.65-7.53 (m, 6H), 7.06-6.91 (m, 2H), 6.53 (s, 1H), 5.89 (d, J = 17.7 Hz, 1H), 5.32 (d, J = 11.5 Hz, 1H), 4.62-4.54 (m, 1H), 3.03-2.99 (m, 2H), 1.87-1.71 (m, 1H), 1.25 (d, J = 6.1 Hz, 6H), 0.85 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 541.2	¹ H NMR (DMSO): δ 13.74 (s, 1H), 8.99 (s, 3H), 8.59-8.41 (m, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.65-7.53 (m, 6H), 7.06-6.91 (m, 2H), 6.53 (s, 1H), 5.89 (d, J = 17.7 Hz, 1H), 5.32 (d, J = 11.5 Hz, 1H), 4.62-4.54 (m, 1H), 3.03-2.99 (m, 2H), 1.87-1.71 (m, 1H), 1.25 (d, J = 6.1 Hz, 6H), 0.85 (d, J = 6.8 Hz, 6H); MS (ES ⁺): 541.2

Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data
125d	-CH ₃	-H	CH ₃ CH ₃	124d	I-2	¹ H NMR (DMSO-d ₆): δ 8.9 (d, J = 33.74, 4 H), 8.08 (d, J = 7.91, 1 H), 7.81 (s, 1 H), 7.51 (s, 1 H), 7.41 (s, 4 H), 6.78 (s, 1 H), 6.3 (s, 2 H), 5.70 (d, J = 7.78 Hz, 1 H), 5.15 (d, J = 11.8 Hz, 2 H), 3.82 (m, J = 20.34 Hz, 2 H), 3.56 (bs, 3 H) 0.92 (d, 6H); MS (ES+) 501.3
125e	-CH ₃	-H	CH ₃ CH ₃ CH ₃	124e	I-2	¹ H NMR (DMSO-d ₆): δ 9.05 (s, 2 H), 8.85 (s, 2 H), 7.96 (d, J = 9.04 Hz, 1 H), 7.88 (s, 1 H), 6.86 (m, J = 17.8 Hz, 3 H), 7.62 (m, 1 H), 7.24 (d, J = 7.8 Hz, 1 H), 6.95 (d, J = 7.8 Hz, 1 H), 7.45 (m, J = 28.63 Hz, 5 H), 7.55 (s, 1 H), 5.75 (d, J = 17.5 Hz, 1 H); 5.61 (d, J = 11.11, 1 H) 3.61 (s, 3 H) 1.30 (bs, 3 H) 1.05 (s, 4 H) 0.66 (m, 6 H); MS (ES+) 555.3 (100% M ⁺)
125f	-CH ₃	-H	CH ₃ CH ₃ CH ₃	124f	I-2	¹ H NMR (DMSO-d ₆): δ 12.7 (bs, 1H), 9.01 (bs, 2H), 8.87 (bs, 2H), 8.36 (t, J = 6 Hz, 1H), 7.83 (s, 1H), 7.44 (m, 6H), 6.75 (m, 2H), 6.31 (d, J = 2.2 Hz, 1H), 5.7 (d, J = 17 Hz, 1H), 5.1 (d, J = 11 Hz, 1H), 3.5 (s, 3H), 2.84 (m, 2H), 1.3 (m, 2H), 1.1 (m, 4H), 0.7 (m, 3H); MS (ES+) : 529.4
125g	-CH ₃	-H	CF ₃	124g	I-2	¹ H NMR (DMSO): δ 9.22 (broad, 1 H), 9.09 (s, 2 H), 8.9 (s, 2 H), 8.18 (s, 1 H), 7.80 (m, 2 H), 7.66 (m, 4 H), 7.16 (s, 1 H), 7.00 (dd, J = 17.7, 11.1 Hz, 1 H), 6.70 (s, 1 H), 5.94 (d, J = 17.7 Hz, 1 H), 5.37 (d, J = 10.9 Hz, 1 H), 4.07 (m, 2 H), 3.81 (s, 3 H); MS (ES+) 539.3

Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data
125h	-CH ₃	-H		124h	I-2	¹ H NMR (DMSO): δ 9.03 (bs, 4 H), 8.49 (bs, 1 H), 8.04 (s, 1 H), 7.65 (m, 6 H), 6.99 (m, 2 H), 6.61 (s, 1 H), 5.90 (d, <i>J</i> =17.5 Hz, 1 H), 5.35 (d, <i>J</i> =11.5 Hz, 1 H), 3.78 (s, 3 H), 3.20 (m, 2 H), 1.46 (m, 2 H), 1.28 (m, 2 H), 0.87 (t, <i>J</i> =7.3 Hz, 3 H); MS (ES ⁺): 515.4
125i	-CH ₃	-H		124i	I-2	¹ H NMR (DMSO): δ 8.86 (s, 2 H), 8.78 (s, 2 H), 8.44 (broad, 1 H), 7.89 (s, 1 H), 7.53 (m, 2 H), 7.43 (m, 4 H), 6.86 (s, 1 H), 6.78 (dd, <i>J</i> =17.5, 11.3 Hz, 1 H), 6.44 (s, 1 H), 5.71 (d, <i>J</i> =17.5 Hz, 1 H), 5.14 (d, <i>J</i> =11.1 Hz, 1 H), 3.59 (s, 3 H), 2.89 (m, 2 H), 0.79 (m, 1 H), 0.20 (m, 2 H), 0.01 (m, 2 H); MS (ES): 513.4
125j	-CH ₃	-H		124j	I-2	¹ H NMR (DMSO): δ 13.14 (br s, 1 H), 8.84 (m, 3 H), 8.12 (d, <i>J</i> =7.3 Hz, 1 H), 7.79 (s, 1 H), 7.40 (m, 8 H), 6.74 (m, 2 H), 6.33 (s, 1 H), 5.66 (d, <i>J</i> =19.2 Hz, 1 H), 5.10 (d, <i>J</i> =11.7 Hz, 1 H), 3.94 (m, 1 H), 3.54 (s, 3 H), 1.66-0.93 (m, 8 H); MS (ES ⁺): 527.4
125k	-CH ₃	-H		124k	I-2	¹ H NMR (DMSO): δ 9.25 (m, 4 H), 8.73 (t, <i>J</i> =5.7 Hz, 1 H), 8.28 (s, 1 H), 7.86 (m, 7 H), 6.84 (s, 1 H), 6.10 (d, <i>J</i> =17.7 Hz, 1 H), 5.55 (d, <i>J</i> =11.3 Hz, 1 H), 3.99 (s, 3 H), 3.43 (qui, <i>J</i> =6.2 Hz, 2 H), 1.28 (t, <i>J</i> =7.2 Hz, 3 H); MS (ES ⁺): 487.2
125l	-CH ₃	-H		124l	I-2	¹ H NMR (DMSO): δ 8.91 (m, 4 H), 8.38 (t, <i>J</i> =5.5 Hz, 1 H), 7.96 (s, 1 H), 7.53 (m, 5 H), 6.86 (m, 2 H), 6.52 (s, 1 H), 5.77 (d, <i>J</i> =17.7 Hz, 1 H), 5.21 (d, <i>J</i> =11.5 Hz, 1 H), 3.65 (s, 3 H), 2.94 (m, 1 H), 1.57-0.56 (m, 11 H); MS (ES ⁺): 529.3

Cpd. No.	-R	-R'	R"	Starting From	Method Used	Analytical Data
125m	-H	-H		124m	I-2	¹ H NMR (DMSO-d ₆): δ 10.07 (bs, 1H), 9.05 (bs, 2H), 8.98 (bs, 2H), 8.49 (t, J = 5.6 Hz, 1H), 7.96 (s, 1H), 7.62 (m, 5H), 7.06 (s, 1H), 7.03 (s, 1H), 6.94 (dd, J = 11 and 18 Hz, 1H), 5.78 (d, J = 18 Hz, 1H), 5.26 (d, J = 11 Hz, 1H), 3.02 (t, J = 5.7 Hz, 2H), 1.81 (m, 1H), 0.85 (d, J = 6.8 Hz, 6H); MS (ES-): 499.2 and (ES ⁺) 501.3



5

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
133a			-H	-CH ₃	132	A-5 MS (ES ⁺): 506.4
133b			-H	-CH ₃	132	J MS (ES ⁺): 499.3
133c			-H	-CH ₃	132	A-5 Characterized in the next step
133d			-H	-CH ₃	132	A-5 Characterized in the next step
133e			-H	-CH ₃	132	A-5 Characterized in the next step

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
133f		-H	-CH ₃	132	A-5	Characterized in the next step
133g		-H	-CH ₃	132	A-5	Characterized in the next step
133h		-H	-CH ₃	132	A-5	Characterized in the next step
133i		-H	-CH ₃	132	A-5	Characterized in the next step
133j		-H	-CH ₃	132	A-5	Characterized in the next step
133k		-H	-CH ₃	132	J	MS (ES ⁺): 502.3

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
133l			-H	-CH ₃	132 J	MS (ES ⁺): 470.2
133m			-H	-CH ₃	132 J	MS (ES ⁺): 437.3
133n			-H	-CH ₃	132 J	MS (ES ⁺): 518.2
133o			-H	-CH ₃	132 J	MS (ES ⁺): 501.3
133p			-H	-CH ₃	132 J	MS (ES ⁺): 469.1
133q			-H	-CH ₃	132 J	MS (ES ⁺): 469.1; MS (ES ⁺): 471.2
133r			-H	-CH ₃	132 A-5	Characterized in the next step

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
133s		-H	-CH ₃	132	A-5	MS (ES ⁺): 483.2 (M+Na)
133u		-H	-CH ₃	132	A-5	MS (ES ⁺): 432.2
133v		-H	-CH ₃	132	A-5	MS (ES ⁺): 432.2
133w		-H	-CH ₃	132	A-5	MS (ES ⁺): 447.2
133x		-H	-CH ₃	132	A-5	Characterized in the next step
133y		-H	-CH ₃	132	A-5	MS (ES ⁺): 446.3
133z		-H	-CH ₃	132	A-5	MS (ES ⁺): 446.2

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
133aa		-H	-CH ₃	132	A-4	MS (ES ⁺): 475.3
133ab		-H	-CH ₃	132	J	MS (ES ⁺): 499.3 (M+Na)
133ac		-H	-CH ₃	132	A-4	MS (ES): 483.2; MS (ES ⁺): 485.2
133ad		-H	-CH ₃	132	A-4	MS (ES ⁺): 497.2; MS (ES): 495.2
133ae		-H	-CH ₃	132	A-4	MS (ES): 483.2; MS (ES ⁺): 485.2
133af		-H	-CH ₃	132	J	MS (ES ⁺): 511.3 (M+Na) ⁺ ; MS (ES): 487.3

Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
133ag		-H	-CH ₃	132	J	MS (ES ⁺): 451.3
133ai		-H	-CH ₃	132	J	MS (ES ⁺): 584.4
134a		-H	-H	133a	I-2	¹ H NMR (DMSO-d ₆): δ 13.13 (bs, 1 H), 8.76 (t, J = 6 and 5 Hz, 1 H), 8.32 (m, 2 H), 8.02 (dd, J = 1.9 and 8.1 Hz, 1 H), 7.42 (m, 4 H), 7.25 (m, 1 H), 3.62-3.19 (m, 12 H), 3.11 (t, J = 6.8 Hz, 2 H), 1.87 (m, 1 H), 1.76 (m, 2 H), 0.90 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 490.3; (ES ⁺) 492.3
134b		-H	-H	133b	I-2	¹ H NMR (DMSO-d ₆): δ 13.82 (bs, 1 H), 10.57 (bs, 2 H), 8.50 (t, J = 6 and 5 Hz, 1 H), 7.99 (d, J = 1.5 Hz, 1 H), 7.83 (s, 1 H), 7.8 (s, 1 H), 7.59 (m, 4 H), 7.46 (m, 2 H), 7.03 (m, 1 H), 6.92 (d, J = 7.9 Hz, 1 H), 3.89 (s, 4 H), 3.02 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 0.8 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 483.3; MS (ES ⁺) 485.4
134c		-H	-H	133c	I-2	¹ H NMR (DMSO-d ₆): δ 8.71 (t, J = 5.5 Hz, 1 H), 8.40 (t, J = 5.3 Hz, 1 H), 8.30 (s, 1 H), 8.00 (d, J = 7.8 Hz, 1 H), 7.63 (d, J = 4.3 Hz, 2 H), 7.40 (d, J = 7.4 Hz, 4 H), 7.27 (d, J = 8.1 Hz, 1 H), 7.18 (s, 1 H), 6.91 (d, J = 7.1 Hz, 1 H), 4.42 (b, 2 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.93 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 497.3

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data	
						1H NMR (DMSO-d ₆): δ 10.45 (s, 1 H), 8.63 (s, 1 H), 8.27 (s, 1 H), 7.93 (d, J=8.1 Hz, 1 H), 7.67 (t, J=6.8 Hz, 2 H), 7.55 (m, 2 H), 7.27 (m, 3 H), 7.12 (m, 2 H), 3.06 (t, J = 6 Hz, 2 H), 1.82 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS(ES-) 483.3	1H NMR (DMSO-d ₆): δ 12.92 (bs, 1 H), 8.71 (t, J=5.8Hz, 1 H), 8.49(t, J=6.2 Hz, 1 H), 8.32 (s, 1 H), 8.01 (d, J = 7.8 Hz, 1 H), 7.52 (m, 5 H), 7.27 (d, J=7.9 Hz, 1 H), 7.18 (m, 1 H), 7.08 (d, J=8.2 Hz, 2 H), 4.32 (d, J=4.2 Hz, 2 H), 3.12 (t, J = 6.5 Hz, 2 H), 1.88 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS(ES-) 498.2
134d		-H	-H	133d	I-2		
134e		-H	-H	133e	I-2		
134f		-H	-H	133f	I-2		
134g		-H	-H	133g	I-2		
134h		-H	-H	133h	I-2		

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
134i		-H		133i	I-2	¹ H NMR (DMSO-d ₆): δ 8.71 (t, J=5.7 Hz, 1 H), 8.31 (s, 1 H), 8.01 (d, J=7.9 Hz, 1 H), 7.39 (m, 2 H), 7.24 (s, 1 H), 3.38 (b, 8 H), 3.11 (t, J=6.5 Hz, 2 H), 1.86 (m, 1 H), 0.91 (d, J=6.8 Hz, 6 H); MS(ES-) 409.3
134j		-H		133j	I-2	¹ H NMR (DMSO-d ₆): δ 9.61 (s, 1 H), 8.67 (t, J=5.5 Hz, 1 H), 8.32 (s, 1 H), 7.98 (d, J=7.9 Hz, 1 H), 7.71 (m, 2 H), 7.54 (m, 2 H), 7.29 (d, J=7.9 Hz, 1 H), 7.04 (m, 4 H), 3.10 (t, J=6.5 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J=6.8 Hz, 6 H); MS (ES-) 433.3
134k		-H		133k	I-2	¹ H NMR (DMSO-d ₆): δ 8.59 (t, J=6 and 5 Hz, 1 H), 8.3 (d, J=5 Hz, 2 H), 8.18 (s, 1 H), 7.86 (d, J=8 Hz, 1 H), 7.36 (m, 5 H), 6.6 (t, J=4.7 Hz, 1 H), 4.0 (m, 1 H), 3.75 (m, 2 H), 3.37 (m, 5 H), 3.07 (t, J=6.8 Hz, 2 H), 1.81 (m, 1 H), 0.85 (d, J=6.8 Hz, 6 H)
134l		-H		133l	I-2	¹ H NMR (DMSO-d ₆): δ 10.92 (bs, 1 H), 8.55 (t, J=6 and 5 Hz, 1 H), 8.14 (s, 1 H), 7.76 (d, J=7 Hz, 1 H), 7.68 (m, 1 H), 7.62 (m, 1 H), 7.45 (m, 2 H), 7.24 (t, J=2.6 Hz, 1 H), 7.19 (s, 1 H), 7.15 (s, 1 H), 7.10 (m, 2 H), 6.95 (dd, J=1.5 and 8.7 Hz, 1 H), 6.28 (s, 1 H), 3.04 (t, J=6.8 Hz, 2 H), 1.82 (m, 1 H), 0.86 (d, J=6.8 Hz, 6 H); MS (ES-) 454.3; (ES+) 456.3
134m		-H		133m	I-2	¹ H NMR (DMSO-d ₆): δ 13.30 (bs, 1 H), 8.62 (t, J=6 and 5 Hz, 1 H), 8.18 (s, 1 H), 7.87 (d, J=7.9 Hz, 1 H), 7.42 (m, 3 H), 7.09 (m, 2 H), 3.03 (m, 1 H), 3.1 (t, J=6.8 Hz, 2 H), 1.86 (m, 1 H), 1.4 (m, 4 H), 1.09 (m, 1 H), 0.89 (d, J=6.8 Hz, 6 H); MS (ES-) 421.2; (ES+) 423.2

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
134n		-H	-H	133n	I-2	¹ H NMR (DMSO-d ₆): δ 15.89 (bs, 1 H), 8.56 (t, J = 6 and 5 Hz, 1 H), 8.06 (s, 1 H), 7.67 (m, 2 H), 7.54 (d, J = 8.8 Hz, 1 H), 7.48 (m, 4 H), 7.05 (m, 1 H), 6.96 (m, 2 H), 3.77 (s, 3 H), 3.03 (t, J = 6.8 Hz, 2 H), 1.81 (m, 1 H), 0.84 (d, J = 6.8 Hz, 6 H); MS (ES-) 502.3; (ES+) 504.3
134o		-H	-H	133o	I-2	¹ H NMR (DMSO-d ₆): δ 13.07 (bs, 1 H), 8.63 (t, J = 6 and 5 Hz, 1 H), 8.26 (s, 1 H), 8.05 (d, J = 4 Hz, 1 H), 7.94 (d, J = 8 Hz, 1 H), 7.43 (m, 5 H), 7.28 (m, 1 H), 6.72 (d, J = 8.8 Hz, 1 H), 6.62 (dd, J = 5.5 and 6.5 Hz, 1 H), 3.72 (d, J = 8.8 Hz, 1 H), 3.34 (m, 8 H), 3.07 (t, J = 6.8 Hz, 2 H), 1.82 (m, 1 H), 0.85 (d, J = 6.8 Hz, 6 H); MS (ES-) 486.3; (ES+) 488.3
134p		-H	-H	133p	I-2	¹ H NMR (DMSO-d ₆): δ 12.94 (bs, 1 H), 10.20 (bs, 1 H), 8.63 (t, J = 6 and 5 Hz, 1 H), 8.28 (d, J = 1.5 Hz, 1 H), 7.96 (m, 2 H), 7.92 (d, J = 8.3 Hz, 1 H), 7.68 (m, 1 H), 7.52 (m, 2 H), 7.4 (m, 1 H), 7.3 (m, 2 H), 7.24 (m, 1 H), 3.08 (t, J = 6.8 Hz, 2 H), 1.84 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES-) 455.2; (ES+) 479.2 (M+Na)
134q		-H	-H	133q	I-2	¹ H NMR (DMSO-d ₆): δ 12.84 (bs, 1 H), 10.45 (bs, 1 H), 8.62 (t, J = 6 and 5 Hz, 1 H), 8.27 (d, J = 1.5 Hz, 1 H), 8.01 (s, 1 H), 7.93 (s, 2 H), 7.9 (d, J = 1.5 Hz, 1 H), 7.69 (m, 1 H), 7.57 (d, J = 8.7 Hz, 1 H), 7.52 (m, 2 H), 7.29 (d, J = 8 Hz, 1 H), 7.23 (m, 1 H), 7.02 (dd, J = 1.5 and 8.7 Hz, 1 H), 3.07 (t, J = 6.8 Hz, 2 H), 1.83 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES-) 455.2; (ES+) 479.3 (M+Na)

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
134r		-H	-H	133r	I-2	¹ H NMR (DMSO-d ₆): δ 8.64 (t, J=5.5 Hz, 1 H), 8.16 (s, 1 H), 7.87 (d, J=7.1 Hz, 1 H), 7.50 (m, 1 H), 7.40 (d, J=4.1 Hz, 2 H), 7.19 (b, 3 H), 7.07 (m, 2 H), 6.51 (m, 2 H), 6.35 (d, J=7.8 Hz, 2 H), 3.97 (d, J=5.6 Hz, 2 H), 3.13 (t, J=6.5 Hz, 2 H), 1.90 (m, 1 H), 0.91 (d, J=6.8 Hz, 6 H)
134s		-H	-H	133s	I-2	¹ H NMR (DMSO-d ₆): δ 9.53 (bs, 1 H), 8.67 (t, J=4.7 Hz, 1 H), 8.32 (s, 1 H), 7.99 (d, J=8.1 Hz, 1 H), 7.70 (d, J=7.6 Hz, 1 H), 7.52 (m, 2 H), 7.46 (d, J=11.5 Hz, 1 H), 7.32 (m, 3 H), 7.18 (m, 3 H), 4.33 (s, 2 H), 3.10 (t, J=6.5 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J=6.8 Hz, 6 H); MS (ES-) 445.2
134t	—OH	-H	-H	132	I-2	¹ H NMR (DMSO-d ₆): δ 12.57 (b, 1 H), 8.69 (t, J=5.6 Hz, 1 H), 8.36 (s, 1 H), 7.99 (d, J=7.9 Hz, 1 H), 7.92 (d, J=7.7 Hz, 1 H), 7.57 (t, J=7.5 Hz, 1 H), 7.46 (t, J=7.7 Hz, 1 H), 7.23 (d, J=5.2 Hz, 1 H), 7.17 (d, J=7.5 Hz, 1 H), 3.12 (t, J=6.5 Hz, 2 H), 1.88 (m, 1 H), 0.91 (d, J=6.8 Hz, 6 H); MS (ES-) 340.2
134u		-H	-H	133u	I-2	¹ H NMR (DMSO-d ₆): δ 8.56 (t, J=5.0 Hz, 1 H), 8.16 (d, J=7.0 Hz, 2 H), 7.94 (d, J=8.4 Hz, 1 H), 7.75 (d, J=7.4 Hz, 1 H), 7.63 (m, 2 H), 7.46 (m, 2 H), 7.21 (b, 1 H), 7.07 (s, 2 H), 6.99 (t, J=5.1 Hz, 1 H), 3.05 (t, J=6.5 Hz, 2 H), 1.83 (m, 1 H), 0.86 (d, J=6.8 Hz, 6 H); MS (ES-) 416.3
134v		-H	-H	133v	I-2	¹ H NMR (DMSO-d ₆): δ 8.60 (t, J=5.6 Hz, 1 H), 8.32 (d, J=5.3 Hz, 2 H), 8.11 (s, 1 H), 7.78 (d, J=7.7 Hz, 1 H), 7.65 (d, J=5.5 Hz, 1 H), 7.55 (m, 2 H), 7.43 (d, J=4.5 Hz, 2 H), 7.14 (m, 3 H), 3.06 (t, J=6.5 Hz, 2 H), 1.83 (m, 1 H), 0.86 (d, J=6.8 Hz, 6 H); MS (ES-) 416.2




Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
134w		-H	-H	133w	I-2	¹ H NMR (DMSO-d ₆): δ 10.10 (bs, 1 H), 9.31 (s, 1 H), 8.65 (t, J=5.7 Hz, 1 H), 8.27 (s, 1 H), 7.93 (d, J=8.1 Hz, 1 H), 7.62 (d, J=5.3 Hz, 1 H), 7.48 (m, 2 H), 7.28 (s, 1 H), 7.20 (d, J=12.0 Hz, 1 H), 7.09 (s, 1 H), 6.98 (d, J=7.0 Hz, 1 H), 6.81 (d, J=7.3 Hz, 1 H), 6.37 (t, J=7.6 Hz, 1 H), 3.09 (t, J = 6.5 Hz, 2 H), 1.85 (m, 1 H), 0.90 (d, J = 6.8 Hz, 6 H); MS (ES-) 431.1
134x		-H	-H	133x	I-2	¹ H NMR (DMSO-d ₆): δ 10.28 (bs, 1 H), 8.63 (t, J=5.3 Hz, 1 H), 8.34 (d, J=4.7 Hz, 1 H), 8.06 (s, 1 H), 7.82 (d, J=6.6 Hz, 1 H), 7.53 (m, 1 H), 7.42 (m, 2 H), 7.34 (t, J=8.6 Hz, 1 H), 7.18 (s, 1 H), 7.07 (d, J=2.7 Hz, 2 H), 6.10 (b, 1 H), 4.43 (b, 1 H), 4.12 (b, 1 H), 3.12 (t, J = 6.5 Hz, 2 H), 1.89 (m, 1 H), 0.90 (d, J = 6.8 Hz, 6 H); MS (ES+) 432.3, (ES-) 430.2
134y		-H	-H	133y	I-2	¹ H NMR (DMSO-d ₆): δ 9.79 (bs, 1 H), 8.62 (t, J=6.0 Hz, 1 H), 8.31 (d, J=4.5 Hz, 1 H), 8.20 (s, 1 H), 8.08 (s, 1 H), 7.78 (d, J=2.1 Hz, 1 H), 7.51 (m, 1 H), 7.42 (m, 2 H), 7.06 (m, 3 H), 6.88 (m, 1 H), 4.02 (b, 2 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.90 (m, 1 H), 0.93 (d, J = 6.8 Hz, 6 H); MS (ES+) 432.3, (ES-) 430.3
134z		-H	-H	133z	I-2	¹ H NMR (DMSO-d ₆): δ 10.71 (bs, 1 H), 8.64 (t, J=5.9 Hz, 1 H), 8.21 (d, J=5.2 Hz, 2 H), 8.05 (s, 1 H), 7.81 (d, J=7.7 Hz, 1 H), 7.51 (m, 1 H), 7.42 (m, 2 H), 7.18 (s, 1 H), 7.04 (t, J=1.4Hz, 2 H), 6.51 (b, 2H), 4.41 (b, 1 H), 4.01 (b, 1 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.91 (m, 1 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES+) 432.2, (ES-) 430.2

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
134aa		-H	-H	133aa	I-2	¹ HNMR (DMSO-d ₆): δ 10.02 (bs, 1 H), 8.65 (t, J = 5.7 Hz, 1 H), 8.26 (s, 1 H), 7.94 (d, J = 7.7 Hz, 1 H), 7.66 (d, J = 5.8 Hz, 1 H), 7.51 (m, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 7.29 (d, J = 7.9 Hz, 1 H), 7.22 (d, J = 5.5 Hz, 1 H), 7.07 (d, J = 8.3 Hz, 2 H), 4.57 (t, J = 9.0 Hz, 1 H), 3.51 (m, 2 H), 3.09 (t, J = 6.5 Hz, 2 H), 2.62 (t, J = 6.6 Hz, 2 H), 1.85 (m, 1 H), 0.90 (d, J = 6.8 Hz, 6 H), MS(ES-) 459.2
134ab		-H	-H	133ab	I-2	¹ HNMR (DMSO-d ₆): δ 9.05 (s, 1 H), 8.70 (t, J = 5.7 Hz, 1 H), 8.56 (s, 1 H), 8.36 (s, 1 H), 8.12 (m, 2 H), 7.79 (m, 1 H), 7.60 (m, 1 H), 7.44 (s, 2 H), 7.09 (m, 2 H), 6.56 (d, J = 8.9 Hz, 1 H), 4.89 (t, J = 4.4 Hz, 1 H), 4.38 (d, J = 5.6 Hz, 2 H), 3.11 (t, J = 6.5 Hz, 2 H), 1.84 (m, 1 H), 0.90 (d, J = 6.8 Hz, 6 H), MS(ES-) 461.1
134ac		-H	-H	133ac	I-2	¹ HNMR (DMSO-d ₆): δ 8.60 (t, J = 6 and 5 Hz, 1 H), 8.13 (s, 2 H), 7.85 (d, J = 2 Hz, 1 H), 7.46 (m, 4 H), 7.36 (d, J = 7.7 Hz, 1 H), 7.16 (m, 4 H), 7.10 (m, 1 H), 3.17 (s, 3 H), 3.08 (t, J = 6.8 Hz, 2 H), 1.85 (m, 1 H), 0.89 (d, J = 6.8 Hz, 6 H), MS(ES-) 469.2; (ES+) 471.3
134ad		-H	-H	133ad	I-2	¹ HNMR (DMSO-d ₆): δ 8.855 (t, J = 6 and 5 Hz, 1 H), 8.10 (s, 2 H), 7.73 (d, J = 7.2 Hz, 1 H), 7.54 (m, 4 H), 7.46 (m, 5 H), 7.08 (m, 3 H), 3.04 (t, J = 6.8 Hz, 2 H), 1.82 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H), MS(ES-) 481.1; (ES+) 483.3


Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
134ae		-H	-H	133ae	I-2	¹ H NMR (DMSO-d ₆): δ 9.66 (bs, 1H), 8.54 (t, J = 6 and 5 Hz, 1H), 8.12 (s, 2H), 7.77 (dd, J = 8 and 2 Hz, 1H), 7.6 (dd, J = 7 and 2 Hz, 1H), 7.45 (m, 5H), 7.10 (m, 4H), 4.36 (bs, 2H), 3.09 (t, J = 6.8 Hz, 2H), 1.86 (m, 1H), 0.89 (d, J = 6.8 Hz, 6H); MS (ES-) 469.2; (ES+) 471.3
134af		-H	-H	133af	I-2	¹ H NMR (DMSO-d ₆): δ 9.76 (s, 1H), 9.17 (s, 1H), 8.63 (t, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.60 (s, 1H), 7.51 (d, J = 8 Hz, 1H), 7.30 (d, J = 3.6 Hz, 2H), 7.28 (d, J = 8.2 Hz, 1H), 7.22 (t, 3H), 6.60 (d, J = 8.9 Hz, 1H), 3.06 (t, J = 6 Hz, 2H), 1.85 (m, 1H), 0.86 (d, J = 6.8 Hz, 6H); MS (ES-) 431.2
134ag		-H	-H	133ag	I-2	¹ H NMR (DMSO-d ₆): δ 9.64 (s, 1H), 9.06 (s, 1H), 8.66 (t, J = 5.6 Hz, 1H), 8.29 (s, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.63 (m, 2H), 7.50 (m, 2H), 7.29 (d, J = 3.1 Hz, 1H), 7.20 (d, J = 8.9 Hz, 1H), 7.11 (m, 1H), 7.03 (m, 1H), 6.60 (d, J = 8.9 Hz, 1H), 3.08 (t, J = 6 Hz, 2H), 2.05 (s, 3H), 1.85 (m, 1H), 0.86 (d, J = 6.8 Hz, 6H); MS (ES-) 445.2; MS (ES+) 469.3 (M+Na)
134ai		-H	-H	133ai	I-2, S	MS (ES ⁺): 472.2; MS (ES): 470.2
135a					A-4	MS (ES ⁺): 489.3

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
135b		-CH=CH ₂	-CH ₃	30f	A-4	MS (ES ⁺): 475.3; MS (ES): 473.3
135c		-CH=CH ₂	-CH ₃	30f	J	MS (ES ⁺): 573.5; MS (ES): 571.3
135d		-CH=CH ₂	-CH ₃	30f	A-4	MS (ES ⁺): 472.2
135e		-CH=CH ₂	-CH ₃	30f	J	MS (ES ⁺): 489.1
135f		-CH=CH ₂	-NH ₂	30f	J	MS (ES ⁺): 498.1
135g		-CH=CH ₂	-CH ₃	30f	J	MS (ES ⁺): 494.3
135h		-CH=CH ₂	-CH ₃	30f	J	MS (ES ⁺): 584.2

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
136a		-CH=CH ₂	-H	135a	I-2	¹ H NMR (DMSO-d ₆): δ 8.66 (t, J = .55 Hz, 1 H), 8.35 (t, J = 4 and 6.4 Hz, 1 H), 8.28 (d, J = 2 Hz, 1 H), 7.95 (dd, J = 7.9 and 2 Hz, 1 H), 7.69 (s, 1 H), 7.59 (m, 2 H), 7.25 (d, J = 8.1 Hz, 2 H), 7.15 (m, 2 H), 6.93 (s, 1 H), 6.88 (dd, J = 17.7 and 11.5 Hz, 1 H), 5.95 (d, J = 17.7 Hz, 1 H), 5.37 (d, J = 11.5 Hz, 1 H), 3.76 (t, J = 6.8 Hz, 2 H), 3.10 (t, J = 6.4 Hz, 2 H), 2.96 (m, 2 H), 1.86 (m, 1 H), 1.67 (m, 2 H), 0.89 (d, J = 6.8 Hz, 6 H); MS (ES-) 473.3; (ES+) 475.3
136b		-CH=CH ₂	-H	135b	I-2	¹ H NMR (DMSO-d ₆): δ 8.64 (t, 1 H), 8.51 (s, 1 H), 8.21 (s, 1 H), 7.88 (q, J = 7.8 Hz, 1 H), 7.74 (s, 1 H), 7.56 (s, 2 H), 7.15 (m, 2 H), 6.80 (t, 2 H), 5.90 (d, J = 17 Hz, 1 H), 5.36 (d, J = 11.0 Hz, 1 H), 3.18 (m, 2 H), 3.06 (t, J = 6 Hz, 2 H), 2.43 (m, 2 H), 1.85 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES+) 461.2, MS (ES-) 459.2
136c		-CH=CH ₂	-H	135c	I-2, S	¹ H NMR (DMSO-d ₆ /D ₂ O): δ 8.71 (t, 1 H), 8.27 (d, J = 3 Hz, 1 H), 8.21 (d, J = 3 Hz, 1 H), 7.96 (q, 1 H), 7.79 (q, 1 H), 7.72 (s, 1 H), 7.63 (d, J = 8 Hz, 1 H), 7.30 (d, J = 6 Hz, 1 H), 7.24 (d, J = 7 Hz, 1 H), 6.87 (q, 2 H), 6.00 (d, J = 8 Hz, 1 H), 5.41 (d, J = 8 Hz, 1 H), 3.06 (t, J = 6 Hz, 2 H), 1.85 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES+) 459.2


Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
136d		-CH=CH ₂	-H	135d	I-2	¹ H NMR (DMSO-d ₆): δ 12.86 (bs, 1 H), 9.17 (s, 1 H), 8.65 (t, J = 6 Hz, 1 H), 8.29 (d, J = 2 Hz, 1 H), 8.26 (s, 2 H), 7.97 (dd, J = 8 and 2 Hz, 1 H), 7.76 (s, 1 H), 7.63 (d, 8 Hz, 1 H), 7.31 (d, J = 8 Hz, 1 H), 7.24 (d, J = 8 Hz, 1 H), 6.86 (dd, J = 10.7 and 17.5 Hz, 1 H), 6.49 (s, 1 H), 5.99 (d, J = 17.5, 1 H), 5.40 (d, J = 10.7 Hz, 1 H), 3.10 (t, J = 6.8 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J = 6.8 Hz, 6 H); MS (ES-) 458.2, (ES+) 460.3
136e		-CH=CH ₂	-H	135e	I-2	¹ H NMR (DMSO-d ₆): δ 12.72 (s, broad, 1 H), 8.65 (t, J = 5.7 Hz, 1 H), 8.29 (s, 1 H), 7.93 (q, J = 7.9 Hz, 1 H), 7.74 (m, 2 H), 7.65 (d, J = 6 Hz, 1 H), 7.42 (d, J = 7.9 Hz, 1 H), 7.24 (m, 3 H), 7.11 (m, 1 H), 6.84 (q, J = 11.1, 17.8 Hz, 1 H), 5.97 (q, J = 18 Hz, 1 H), 5.58 (d, 1 H), 5.41 (d, 1 H), 3.08 (t, J = 6 Hz, 2 H), 1.85 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES-) 475.1
136f		-CH=CH ₂	-H	135f	I-2	¹ H NMR (DMSO-d ₆): δ 8.67 (t, J = 6.06 Hz, 1 H), 8.28 (s, 1 H), 7.90 (d, J = 7.7 Hz, 1 H), 7.67 (m, 4 H), 7.32 (m, 5 H), 7.09 (d, J = 7.9 Hz, 1 H), 6.89 (q, J = 10.9 & 18.0 Hz, 1 H), 5.99 (d, J = 17.5 Hz, 1 H), 5.42 (d, J = 11 Hz, 1 H), 3.08 (t, J = 6.3 Hz, 2 H), 1.88 (m, 1 H), 0.87 (d, J = 6.8 Hz, 6 H); MS (ES-) 484.2


Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
136g		-CH=CH ₂	-H	135g	I-2	¹ H NMR (DMSO-d ₆): δ 10.38 (s, 1 H), 8.66 (t, J=6.0 Hz, 1 H), 8.29 (s, 1 H), 7.95 (d, J=6.1 Hz, 1 H), 7.75 (s, 1 H), 7.63 (d, 2 H), 7.43 (d, 2 H), 7.26 (m, 3 H), 7.00 (d, J=7.7 Hz, 1 H), 6.85 (q, J=10.9 & 18.0 Hz, 1 H), 5.98 (d, J=17.5 Hz, 1 H), 5.40 (d, J=11 Hz, 1 H), 3.98 (s, 2 H), 3.08 (t, J=6.3 Hz, 2 H), 1.86 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H); MS (ES-) 480.2
136h		-CH=CH ₂	-H	135h	S, I-2	¹ H NMR (DMSO-d ₆): δ 8.55 (t, J=6.06 Hz, 1 H), 8.02 (s, 1 H), 7.60 (m, 4 H), 7.21 (t, J=7.1, 2 H), 6.99 (m, 2 H), 6.83 (d, J=6.8 Hz, 1 H), 6.81 (q, J=10.9 & 18.0 Hz, 1 H), 5.92 (d, J=17.5 Hz, 1 H), 5.35 (d, J=11 Hz, 1 H), 3.89 (s, 2 H), 3.03 (t, J=6.3 Hz, 2 H), 1.36 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H)



Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
148a				147a	J	¹ H NMR (DMSO-d ₆): δ 10.65 (s, 1 H), 10.15 (s, 1 H), 9.19 (s, 2 H), 8.88 (s, 2 H), 8.10 (d, J = 2.1 Hz, 1 H), 7.92 (s, 1 H), 7.93-7.75 (m, 6 H), 7.31 (dd, J = 8.4 and 23.9 Hz, 1 H), 7.12 (d, J = 3.5 Hz, 1 H), 6.67 (m, 1 H), 3.53 (s, 3 H), 2.20 (d, J = 7.0 Hz, 2 H), 2.07 (m, 1 H), 0.94 (d, J = 6.3 Hz, 6 H).
148b				147b	J	¹ H NMR (DMSO-d ₆): δ 10.65 (s, 1 H), 10.09 (s, 1 H), 9.17 (s, 1 H), 8.83 (s, 1 H), 8.10 (d, J = 2.0 Hz, 1 H), 7.85 (d, J = 2.0 Hz, 2 H), 7.81 (d, J = 2.0 and 7.9 Hz, 2 H), 7.76 (m, 5 H), 7.66 (d, J = 3.9 Hz, 1 H), 7.62 (d, J = 4.9 Hz, 1 H), 7.31 (d, J = 7.9 Hz, 1 H), 7.26 (d, J = 7.9 Hz, 1 H), 7.19 (t, J = 3.9 Hz, 1 H), 3.53 (s, 1 H), 2.19 (d, J = 6.9 Hz, 2 H), 2.06 (m, J = 6.9 Hz, 1 H), 0.92 (d, J = 6.9 Hz, 6 H); MS (ES ⁺): 555.67
148c				147c	J	Characterized in the next step


Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data	
149a		-H		148a	I-2	MS (ES ⁺): 525.3	
149b		-H		148b	I-2	¹ H NMR (DMSO-d ₆): δ 13.95 (s, 1 H), 9.79 (s, 1 H), 8.87 (s, 4 H), 7.76 (s, 1 H), 7.65 (m, 8 H), 7.46 (dd, J = 2.1 and 8.4 Hz, 1 H), 7.16 (t, J = 4.2 Hz, 1 H), 7.04 (d, J = 7.7 Hz, 1 H), 6.76 (d, J = 8.4 Hz, 1 H), 2.13 (d, J = 7.0 Hz, 2 H), 2.03 (m, J = 6.3 and 7.0 Hz, 1 H), 0.90 (d, J = 6.3 Hz, 6 H); MS (ES ⁺): 541.62	
149c	-CH=CH ₂	-H		148c	I-2	MS (ES ⁺): 485.6	
175	-H	-CH ₃		174	J	¹ H NMR (DMSO-d ₆): δ 8.81 (m, 4 H), 8.37 (t, J = 6.0 Hz, 1 H), 7.74-7.23 (m, 11 H), 4.31 (d, J = 6.2 Hz, 2 H), 3.51 (s, 3 H), 2.44 (m, 1 H), 1.04 (d, J = 7.0 Hz, 6 H); MS (ES ⁺): 473.3	
176	-H	-H		175	I-2	¹ H NMR (DMSO-d ₆): δ 13.79 (br s, 1 H), 9.03 (m, 3 H), 8.25 (m, 1 H), 7.78-7.35 (m, 7 H), 6.99 (m, 2 H), 6.79 (m, 1 H), 4.20 (br s, 2 H), 3.51 (s, 3 H), 2.39 (m, 1 H), 1.00 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 459.3	
182	-H	-CH ₃		178	J	¹ H NMR (DMSO-d ₆): δ 8.96 (m, 2 H), 7.79-7.38 (m, 9 H), 7.29 (dd, J = 7.5 and 1.7 Hz, 2 H), 4.42 (s, 2 H), 3.50 (s, 3 H), 2.97 (s, 2 H), 1.87 (m, 1 H), 1.36 (m, 9 H), 0.81 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 559.5	

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data	
						Chemical Structure	
183	-H	-H		182	1-2, S	¹ H NMR (DMSO-d ₆): δ 9.11 (m, 4 H), 7.86 (s, 1 H), 7.66 (m, 5 H), 7.49 (m, 2 H), 7.38 (m, 1 H), 7.08 (m, 2 H), 4.12 (s, 2 H), 2.59 (m, 2 H), 1.87 (m, 1 H), 0.81 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 445.32	



Cpd. No.	N (in Ring With Respect to Phenyl)	-R	-R'	Starting From	Method Used	Analytical Data
151	3	-CHO	-CH ₃	150 + 3a	D-9	MS (ES'): 339.3
152	3	-CO ₂ H	-CH ₃	151	E	¹ H NMR (CDCl ₃): δ 8.69 (t, J = 5.8 Hz, 1 H), 8.50 (d, J = 4.9 Hz, 1 H), 8.33 (d, J = 1.7 Hz, 1 H), 8.24 (s, 1 H), 8.01 (dd, J = 7.9, 1.9 Hz, 1 H), 7.53 (d, J = 5.1 Hz, 1 H), 7.34 (d, J = 8.1 Hz, 1 H), 3.56 (s, 3 H), 3.12 (m, 2 H), 1.87 (m, 1 H), 0.91 (d, J = 6.6 Hz, 6 H)
153	3				J	¹ H NMR (CD ₃ OD): δ 8.75 (d, J = 4.7 Hz, 2 H), 8.55 (s, 1 H), 8.42 (d, J = 1.9 Hz, 1 H), 8.07 (qd, J = 8.1, 1.9, 1 H), 7.74 (s, 3 H), 7.70 (d, J = 5.1 Hz, 1 H), 7.51 (d, J = 8.1 Hz, 1 H), 3.69 (s, 3 H), 3.21 (m, 2 H), 1.94 (m, 1 H), 0.98 (d, J = 6.6 Hz, 6 H); MS (ES'): 474



Cpd. No.	N (in Ring With Respect to Phenyl)	-R	-R'	Starting From	Method Used	Analytical Data
154	3		-H	153	I-2	¹ H NMR (DMSO): δ 11.18 (s, 1 H), 9.31 (s, 2 H), 9.10 (s, 2 H), 8.92 (d, <i>J</i> =5.1 Hz, 1 H), 8.78 (m, 2 H), 8.43 (d, <i>J</i> =1.5 Hz, 1 H), 8.07 (dd, <i>J</i> =7.9, 1.3 Hz, 1 H), 7.97 (d, <i>J</i> =5.3 Hz, 1 H), 7.82 (d, <i>J</i> =8.7 Hz, 2 H), 7.72 (d, <i>J</i> =8.8 Hz, 2 H), 7.50 (d, <i>J</i> =7.9 Hz, 1 H), 3.10 (t, <i>J</i> =6.0 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, <i>J</i> =6.6 Hz, 6 H); MS (ES ⁺) 460
156	4	-CHO	-CH ₃	155+ 3a	D-9	MS (ES ⁺): 341.4
157	4	-CO ₂ H	-CH ₃	156	E	¹ H NMR (CDCl ₃): δ 8.80 (s, 1 H), 8.46 (d, <i>J</i> =5.1 Hz, 1 H), 8.29 (s, 1 H), 7.85 (d, <i>J</i> =7.9 Hz, 1 H), 7.13 (d, <i>J</i> =7.9 Hz, 1 H), 7.00 (d, <i>J</i> =5.1 Hz, 1 H), 6.83 (bs, 2 H), 3.45 (s, 3 H), 3.15 (m, 2 H), 1.84 (m, 1 H), 0.90 (d, <i>J</i> =6.6 Hz, 6 H); MS (ES ⁻): 355.2
158	4		-CH ₃	157	J	¹ H NMR (CD ₃ OD): δ 8.85 (s, 1 H), 8.75 (d, <i>J</i> =5.3 Hz, 1 H), 8.41 (d, <i>J</i> =1.9 Hz, 1 H), 8.07 (dd, <i>J</i> =8.1, 2.1, 1 H), 7.74 (s, 4 H), 7.48 (d, <i>J</i> =8.1 Hz, 1 H), 7.45 (d, <i>J</i> =5.1 Hz, 1 H), 3.69 (s, 3 H), 3.21 (m, 2 H), 1.94 (m, 1 H), 0.97 (d, <i>J</i> =6.8 Hz, 6 H); MS (ES ⁺): 472.4
159	4		-H	158	I-2	¹ H NMR (DMSO): δ 10.97 (s, 1 H), 9.24 (s, 2 H), 8.96 (s, 3 H), 8.79 (m, 2 H), 8.40 (d, <i>J</i> =1.8 Hz, 1 H), 8.06 (d, <i>J</i> =7.7 Hz, 1 H), 7.77 (s, 4 H), 7.52 (m, 1 H), 7.38 (d, <i>J</i> =7.5 Hz, 1 H), 3.10 (m, 2 H), 1.85 (m, 1 H), 0.89 (d, <i>J</i> =5.3, 6 H); MS (ES ⁺) 460.2



5


10

Cpd. No.	-R	-R'	Starting Material Used	Analytical Data
161a	-CH ₃	-CH ₃	AB-2	¹ H NMR (DMSO-d6): δ 10.55 (s, 1H), 9.00 (bs, 2H), 8.68 (t, J = 5.8 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 1.3 Hz, 1H), 7.67 (m, 3H), 7.40 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 6.90 (dd, J = 17.7, 11.0 Hz, 1H), 6.03 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.0 Hz, 1H), 3.61 (s, 3H), 3.56 (s, 3H), 3.10 (t, J = 6.4 Hz, 2H), 1.85 (m, 1H), 0.90 (d, J = 6.5 Hz, 6H); MS (ES+): 557.3
161b	-C ₂ H ₅	-CH ₃	AB-2	¹ H NMR (DMSO-d6): δ 10.54 (s, 1H), 9.20 (bs, 4H), 8.67 (t, J = 6 Hz, 1H), 8.24 (1H), 8.02 (1H), 7.91 (2H), 7.77 (1H), 7.66 (m, 3H), 7.40 (1H), 7.29 (1H), 6.88 (dd, J = 17.3, 10.7 Hz, 1H), 6.03 (d, J = 17.3 Hz, 1H), 5.42 (d, J = 10.7 Hz, 1H), 3.56 (s, 3H), 3.5 (m, 3H), 3.09 (2H), 1.85 (m, 1H), 0.89 (6H); MS (ES+): 571.3
161c	-CH ₂ C ₆ H ₅	-CH ₃	AB-2	¹ H NMR (DMSO-d6): δ 10.54 (s, 1H), 9.20 (bs, 2H), 8.68 (t, J = 5.8 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.8 Hz, 2H), 7.77 (s, 1H), 7.68 (m, 4H), 7.36(m, 6H), 6.89 (dd, J = 17.7, 11.2 Hz, 1H), 5.05 (s, 2H), 6.03 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.2 Hz, 1H), 3.56 (s, 3H), 3.09 (t, J = 6.6 Hz, 6H); MS (ES+): 633.3


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
161d	-C(CH ₃) ₃	-CH ₃	31f	AB-2	MS (ES ⁺): 599.3 and 499.3	
161e	-CH ₂ -CCl ₃	-CH ₃	31f	AB-2	¹ H NMR (DMSO-d6): δ 10.59 (s, 1H), 9.24 (s, 2H), 8.68 (t, J = 5.6 Hz, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 8.9, 1.9 Hz, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.79 (d, J = 1.5 Hz, 1H), 7.69 (m, 3H), 7.41 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 6.89 (dd, J = 17.7, 11.1 Hz, 1H), 6.03 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.1 Hz, 1H), 4.88 (s, 2H), 3.56 (s, 3H), 3.10 (t, J = 6.6 Hz, 2H), 1.85 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 674.97	
161f		-CH ₃	31f	AB-2	¹ H NMR (DMSO-d6): δ 10.58 (s, 1H), 9.15 (s, 2H), 8.69 (t, J = 5.4 Hz, 1H), 8.25 (d, J = 1.8 Hz, 1H), 8.04 (dd, J = 8.1, 1.9 Hz, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.78 (s, 1H), 7.68 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.89 (dd, J = 17.7, 11.1 Hz, 1H), 6.03 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.1 Hz, 1H), 3.75 (s, 3H), 3.57 (s, 3H), 3.10 (t, J = 6.6 Hz, 2H), 1.85 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 649.3	
161g		-CH ₃	31f	AB-2	¹ H NMR (DMSO-d6): δ 10.59 (s, 1H), 9.19 (s, 2H), 8.68 (t, J = 5.7 Hz, 1H), 8.25 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 8.1, 1.9 Hz, 1H), 7.95 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 1.7 Hz, 1H), 7.70 (m, 3H), 7.41 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.20 (m, 4H), 6.90 (dd, J = 17.9, 11.1 Hz, 1H), 6.03 (d, J = 17.9 Hz, 1H), 5.42 (d, J = 11.1 Hz, 1H), 3.57 (s, 3H), 3.10 (t, J = 6.8 Hz, 2H), 1.85 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 637.5	

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
161h			31f	AB-1	¹ H NMR (DMSO-d6): δ 10.58 (s, 1H), 9.00 (bs, 2H), 8.68 (t, J = 5.9 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.68 (m, 3H), 7.40 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 6.89 (dd, J = 17.5, 11.0 Hz, 1H), 6.03 (d, J = 17.5 Hz, 1H), 5.71 (s, 2H), 5.42 (d, J = 11.0 Hz, 1H), 3.56 (s, 3H), 3.10 (t, J = 6.2 Hz, 2H), 2.07 (s, 3H), 1.85 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H); MS (ES+): 615.3	
161i			31f	AB-1	¹ H NMR (DMSO-d6): δ 10.57 (s, 1H), 9.22 (s, 2H), 8.67 (t, J = 5.9 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.03 (dd, J = 8.1, 1.9 Hz, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.69 (m, 3H), 7.41 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 6.89 (dd, J = 17.7, 11.1 Hz, 1H), 6.03 (d, J = 17.7 Hz, 1H), 5.73 (s, 2H), 5.42 (d, J = 11.1 Hz, 1H), 3.56 (s, 3H), 3.09 (t, J = 6.6 Hz, 2H), 1.85 (m, 1H), 1.14 (s, 9H), 0.89 (d, J = 6.7 Hz, 6H); MS (ES+): 657.52	
161j			31f	AB-1	¹ H NMR (DMSO-d6): δ 10.57 (s, 1H), 9.24 (s, 1H), 9.17 (s, 1H), 8.68 (t, J = 6.2 Hz, 1H), 8.25 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 7.5 Hz, 2H), 7.67 (s, 1H), 7.67 (m, 3H), 7.40 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 6.90 (dd, J = 17.8, 11.1 Hz, 1H), 6.71 (q, J = 5.5 Hz, 1H), 6.03 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.1 Hz, 1H), 3.56 (s, 3H), 3.10 (t, J = 6.6 Hz, 2H), 2.00 (s, 3H), 1.85 (m, 1H), 1.43 (d, J = 5.5 Hz, 3H), 0.89 (d, J = 6.7 Hz, 6H); MS (ES+): 629.4	

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
162a	-CH ₃	-H	161a	I-2	¹ H NMR (DMSO-d6): δ 9.04 (bs, 3H), 8.57 (t, J = 5.4 Hz, 1H), 8.16 (s, 1H), 7.86 (d, J = 8.5 Hz, 2H), 7.79 (d, J = 7.9 Hz, 1H), 7.72 (s, 1H), 7.58 (m, 3H), 7.12 (d, J = 8.0 Hz, 2H), 6.87 (dd, J = 17.7, 11.0 Hz, 1H), 5.97 (d, J = 17.7 Hz, 1H), 5.37 (d, J = 11.0 Hz, 1H), 3.59 (s, 3H), 3.05 (t, J = 6.6 Hz, 2H), 1.83 (m, 1H), 0.87 (d, J = 6.6 Hz, 6H); MS (ES+): 543.38
162b	-C ₂ H ₅	-H	161b	I-2	¹ H NMR (DMSO-d6): δ 12.8 (bs, 1H), 10.8 (bs, 1H), 9.20 (bs, 2H), 8.68 (t, J = 5.9 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 7.91 (m, 3H), 7.77 (d, J = 1.5 Hz, 1H), 7.64 (m, 3H), 7.28 (d, J = 8.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 6.87 (dd, J = 17.7, 11.4 Hz, 1H), 6.01 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.4 Hz, 1H), 4.05 (q, J = 7.2 Hz, 2H), 3.08 (t, J = 6.4 Hz, 2H), 1.84 (m, 1H), 1.21 (t, J = 7.2 Hz, 3H), 0.88 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 555.2
162c	-CH ₂ C ₆ H ₅	-H	161c	I-2	¹ H NMR (DMSO-d6): δ 12.7 (bs, 1H), 10.75 (bs, 1H), 9.15 (b, 2H), 8.63 (t, J = 5.8 Hz, 1H), 8.27 (bs, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.77 (s, 1H), 7.43-7.15 (m, 8H), 7.40 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 6.87 (dd, J = 17.4, 11.0 Hz, 1H), 6.03 (d, J = 17.5 Hz, 1H), 5.71 (s, 2H), 5.42 (d, J = 11.0 Hz, 1H), 5.09 (s, 2H), 3.08 (t, J = 6.4 Hz, 2H), 1.85 (m, 1H), 0.88 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 619.2
162d	-C(CH ₃) ₃	-H	161d	I-2	¹ H NMR (DMSO-d6): δ 12.6 (bs, 1H), 11.0 (bs, 1H), 9.04 (b, 2H), 8.62 (t, J = 5.4 Hz, 1H), 8.24 (s, 1H), 7.86 (m, 3H), 7.77 (s, 1H), 7.62 (m, 3H), 7.24 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.87 (dd, J = 17.2, 11.0 Hz, 1H), 6.00 (d, J = 17.7 Hz, 1H), 5.40 (d, J = 11.0 Hz, 1H), 3.07 (t, J = 6.3 Hz, 2H), 1.84 (m, 1H), 1.44 (s, 9H), 0.88 (d, J = 6.6 Hz, 6H); MS (ES ⁺): 585.4



Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
164	-CHO		-CH ₃	163 + 130 D-2	¹ H NMR (DMSO-d ₆): δ 9.58 (s, 1 H), 7.91 (dd, J = 1.2, 8.0 Hz, 1 H), 7.71 (dt, J = 1.2 and 7.4 Hz, 1 H), 7.58 (t, J = 7.4 Hz, 1 H), 7.41 (m, 2 H), 7.38 (m, 1 H), 7.32 (d, J = 8 Hz, 1 H), 7.24 (d, J = 7.4 Hz, 1 H), 3.52 (q, J = 16 and 26 Hz, 2 H), 3.35 (s, 3 H); MS (ES+): 255.32
165	-CO ₂ H		-CH ₃	164 E	Characterized in the next step
166		NH C(=NH) C ₆ H ₄ NHC(=O)CH ₃	-CH ₃	165 J	¹ H NMR (DMSO-d ₆): δ 10.34 (s, 1 H), 9.18 (s, 2 H), 8.92 (s, 2 H), 7.72-7.5 (m, 7 H), 7.34-7.14 (m, 5 H), 3.60 (q, J = 17 & 40 Hz, 2 H), 3.48 (s, 3 H); MS (ES+): 388.67
167		NH C(=NH) C ₆ H ₄ NHC(=O)CH ₃	-H	166 I-2	¹ H NMR (DMSO-d ₆): δ 11.74 (bs, 1 H), 9.90 (s, 1 H), 8.79 (bs, 2 H), 7.64 (m, 1 H), 7.50 (m, 7 H), 7.33 (d, J = 8.6 Hz, 1 H), 7.26 (d, J = 7.4 Hz, 1 H), 7.12 (t, J = 7.4 Hz, 1 H), 7.02 (t, J = 7.4 Hz, 1 H), 6.89 (d, J = 6.8 Hz, 1 H), 3.83 (d, J = 1.5 Hz, 2 H); MS (ES+): 374.79




Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
188a	-CH=CH ₂ (4)	NH C(=NH) Ar	CH ₃ CH ₂	-H	187a	AE-3	MS (ES ⁺): 485.4 (100% M ⁺)
188b	-CH=CH ₂ (4)	NH C(=NH) Ar	CF ₃ CH ₂	-H	187b	AE-3	¹ H NMR (DMSO-d ₆ /D ₂ O): δ 8.5 (d, J = 2 Hz, 1 H), 8.17 (dd, J = 8 Hz, 2 H), 7.65 (s, 1 H), 7.63 (s, 1 H), 7.54 (d, J = 8 Hz, 1 H), 7.49 (bs, 2 H), 7.14 (d, J = 7.7 Hz, 1 H), 6.78 (dd, J = 11 and 17 Hz, 1 H), 6.62 (d, J = 9 Hz, 1 H), 5.83 (d, J = 17 Hz, 1 H), 5.33 (d, J = 11 Hz, 1 H), 4.17 (d, J = 9 Hz, 1 H), 4.12 (s, 2 H); MS (ES ⁺): 497.3

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
188c -CH=CH ₂ (4)		2 group at position 4 and an -NH ₂ group at position 2."/>	2 group at position 4 and an -NH ₂ group at position 2."/>	258			

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data
189b	-OBn (4)			-H	184a	AE-3	¹ H NMR (DMSO-d ₆ /D ₂ O): δ 8.24 (d, J = 1.5 Hz, 1 H), 7.86 (d, J = 7 Hz, 1 H), 7.49 (m, 2 H), 7.36 (m, 4 H), 7.26 (d, J = 8.3 Hz, 1 H), 6.94 (m, 3 H), 6.66 (d, J = 8.7 Hz, 2 Hz, 2 H), 5.03 (s, 2 H), 4.06 (q, J = 16 and 21 Hz, 2 H), 3.02 (d, J = 7 Hz, 2 H), 1.86 (m, 1 H), 0.89 (d, J = 6.8 Hz, 6 H); MS (ES-): 549.2 and (ES ⁺) 551.4
189c	-OH (4)			-H	189b	G	¹ H NMR (DMSO-d ₆): δ 11.3 (bs, 1 H), 9.07 (s, 1 H), 8.46 (t, J = 6 Hz, 1 H), 8.27 (bs, 2 H), 8.15 (bs, 2 H), 7.66 (d, J = 7.7 Hz, 1 H), 7.36 (d, J = 8.5 Hz, 2 H), 7.03 (d, J = 8.1 Hz, 1 H), 6.77 (m, 2 H), 6.68 (d, J = 8.3 Hz, 2 Hz, 2 H), 6.6 (s, 1 H), 6.47 9d, J = 8.2 Hz, 1 H), 4.05 (d, J = 14 Hz, 1 H), 3.09 (d, J = 14 Hz, 1 H), 3.01 (t, J = 7 Hz, 2 H), 1.79 (m, 1 H), 0.82 (d, J = 6.8 Hz, 6 H); MS (ES-): 459.2 and (ES ⁺) 461.4
189d	-H			-H	131	AE-3	MS (ES ⁺): 445.4; MS (ES ⁻): 443.3

Cpd. No.	-R	-R'	-R''	-R'''	Starting From	Method Used	Analytical Data	
189e	-H			-H	131	AB-3	MS (ES ⁺): 446.46; MS (ES): 444.45	





10

20


Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data
205	O C NH ₂	-Boc	204	A-4	¹ HNMR (DMSO-d ₆): δ 11.04 (s, 0.6 H), 10.97 (bs, 0.4 H), 8.66 (t, J = 5.6 Hz, 0.6 H), 8.56 (t, J = 5.6 Hz, 0.4 H), 8.22 (s, 1 H), 8.11 (d, J = 2 Hz, 0.6 H), 8.03 (d, J = 2 Hz, 0.4 H), 7.94 (dd, J = 2 and 8 Hz, 1 H), 7.82 (m, 4 H), 7.40 (m, 8 H), 7.18 (m, 2 H), 7.04 (m, 2 H), 5.21 (s, 0.8 H), 5.11 (s, 1.2 H), 3.11 (t, J = 6.2 Hz, 1.2 H), 3.06 (t, J = 6.2 Hz, 0.8 H), 1.84 (m, 1 H), 1.43 (s, 5.4 H), 1.42 (s, 3.6 H), 0.91 (d, J = 6.8 Hz, 3.6 H), 0.88 (d, J = 6.8 Hz, 2.4 H); MS (ES ⁺): 665.5
206	-CH ₂ OH	-Boc	204	A-6	¹ HNMR (DMSO-d ₆): δ 12.15 (bs, 1 H), 11.07 (bs, 1 H), 10.69 (s, 1 H), 10.38 (bs, 1 H), 8.68 (t, J = 5.6 Hz, 1 H), 8.12 (d, J = 1.7 Hz, 1 H), 8.00 (dd, 1.8, 8 Hz, 1 H), 7.68 (m, 4 H), 7.46-7.30 (m, 6 H), 7.16 (d, J = 2.8 Hz, 1 H), 7.01 (d, J = 8.5 Hz, 1 H), 6.86 (dd, J = 8.5 and 2.8 Hz, 1 H), 5.07 (s, 2 H), 4.30 (d, J = 7.4 Hz, 2 H), 3.15 (t, J = 6.2 Hz, 2 H), 1.86 (m, 1 H), 1.53 (s, 9 H), 0.89 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 649.4
207	-CH ₂ OH	-H	206	S-2	¹ HNMR (DMSO-d ₆ /D ₂ O): δ 10.66 (s, 1 H), 9.19 (bs, 2 H), 8.86 (bs, 2 H), 8.69 (t, J = 5.5 Hz, 1 H), 8.13 (d, J = 2 Hz, 1 H), 8.02 (dd, J = 8 and 2 Hz, 1 H), 7.72 (m, 4 H), 7.38 (m, 6 H), 7.17 (d, J = 2.6 Hz, 1 H), 7.03 (d, J = 8.5 Hz, 1 H), 6.87 (dd, J = 8.5 and 2.5 Hz, 1 H), 5.39 (t, J = 4.7 Hz, 1 H), 5.08 (s, 2 H), 4.30 (m, 2 H), 3.13 (t, J = 6.5 Hz, 2 H), 1.87 (m, 1 H), 0.91 (d, J = 6.5 Hz, 6 H); MS (ES ⁺): 551.4

261

Cpd. No.	-R	-R'	Starting From	Method Used	Analytical Data	
					¹ H NMR (DMSO-d ₆): δ 11.26 (s, 0.6 H), 11.20 (bs, 0.4 H), 9.15 (bs, 1.2 H),	
208		-H	205	S-2	¹ H NMR (DMSO-d ₆): δ 11.26 (s, 0.6 H), 11.20 (bs, 0.4 H), 9.15 (bs, 1.2 H), 9.11 (bs, 0.8 H), 8.84 (bs, 1.2 H), 8.82 (bs, 0.8 H), 8.67 (t, J = 5.6 Hz, 0.6 H), 8.58 (t, J = 5.6 Hz, 0.4 H), 8.3 (s, 1 H), 8.12 (d, J = 2 Hz, 0.6 H), 8.04 (d, J = 2 Hz, 0.4 H), 7.96 (dd, J = 2 and 8 Hz, 1 H), 7.84 (m, 1 H), 7.70 (m, 2 H), 7.57 (m, 3 H), 7.40 (m, 4 H), 7.22 (m, 2 H), 7.02 (m, 2 H), 5.21 (s, 0.8 H), 5.11 (s, 1.2 H), 3.12 (t, J = 6.5 Hz, 1.2 H), 3.06 (t, J = 6.5 Hz, 0.8 H), 1.84 (m, 1 H), 0.90 (d, J = 6.5 Hz, 3.6 H), 0.86 (d, J = 6.5 Hz, 2.4 H); MS (ES+): 564.5	




Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
217	-OCH ₃		-Br	216	A-3	¹ H NMR (DMSO-d ₆): δ 8.48 (t, J = 6.2 Hz, 1 H), 8.06 (d, J = 8.3 Hz, 1 H), 7.69 (d, J = 8.5 Hz, 1 H), 4.01 (s, 3 H), 3.15 (t, J = 6.5 Hz, 2 H), 1.91 (m, 1 H), 0.91 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 287.1
218	-OCH ₃		-CH=CH ₂	217	D-12	¹ H NMR (CDCl ₃): δ 8.08 (m, 2 H), 7.20 (m, 2 H), 6.39 (dd, J = 2.0 and 17.3 Hz, 1 H), 5.53 (dd, J = 2.0 and 10.9 Hz, 1 H), 4.01 (s, 3 H), 3.15 (t, J = 6.5 Hz, 2 H), 1.91 (m, 1 H), 0.91 (d, J = 6.6 Hz, 6 H)
219	-OH		-CO ₂ CH ₃	218	E-2, V-3, W-2	¹ H NMR (DMSO-d ₆): δ 11.05 (s, 1 H), 8.48 (t, J = 6.2 Hz, 1 H), 8.06 (d, J = 8.7 Hz, 1 H), 7.53 (d, J = 8.5 Hz, 1 H), 3.90 (s, 3 H), 3.12 (t, J = 6.6 Hz, 2 H), 1.85 (m, 1 H), 0.86 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 253.2
220	-OSO ₂ CF ₃		-CO ₂ CH ₃	219	B-2	MS (ES ⁺): 407.2 (M+Na) ⁺
237			-NH ₂	-H	236	AF-1
						MS (ES ⁺): 137.1




Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
221						¹ H NMR (CDCl ₃): δ 9.77 (s, 1 H), 8.40 (d, J = 7.9 Hz, 1 H), 8.13 (d, J = 6.8 Hz, 1 H), 7.83 (d, J = 7.9 Hz, 1 H), 7.61 (d, J = 2.60 Hz, 1 H), 7.20 (m, 5 H), 7.21 (m, 1 H), 7.18 (d, J = 8.3 Hz, 1 H), 5.18 (s, 2 H), 3.72 (s, 3 H), 3.35 (q, J = 5.8 Hz, 2 H), 1.96 (m, 1 H), 1.01 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 447.4
222	-CO ₂ H	-OBn	-CH ₃	220 + 6	D-2	MS (ES): 461.3
223	-CO ₂ MEM	-OBn	-CH ₃	222	F	MS (ES ⁺): 573.33 (M+Na) ⁺
224	-CO ₂ MEM	-OH	-CH ₃	223	G	MS (ES ⁺): 461.36
225	-CO ₂ MEM	-OSO ₂ CF ₃	-CH ₃	224	B-2	MS (ES ⁺): 615.58 (M+Na) ⁺
226	-CO ₂ MEM	-CH=CH ₂	-CH ₃	225	D-3 or D-12	MS (ES): 381.35 [(M-MEM)-1]
227	-CO ₂ H	-CH=CH ₂	-CH ₃	226	I-1	MS (ES): 381.35

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
228		NH -CH=CH ₂	-CH ₃	227	J	MS (ES ⁺): 500.35
229		NH -CH=CH ₂	-H	228	I-2	MS (ES ⁺): 486.32
245	-CHO	-OH	-CH ₃	221	AD	MS (ES ⁺): 357.40
246	-CHO	-OSO ₂ CF ₃	-CH ₃	245	B-2	Characterized in the next step
247	-CHO	-CH=CH ₂	-CH ₃	246	D-3	MS (ES ⁺): 367.42
248		NH -CH=CH ₂	-H	247	AE-3	MS (ES ⁺): 472.39
249		NH -OBn	-CH ₃	222	J	MS (ES ⁺): 580.4




Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
250		-NH C(=O) N	-OBn	-H	249 I-2	MS (ES ⁺): 566.4 MS (ES): 564.3
251		NH C(=O) N	-OH	-H	250 G	MS (ES ⁺): 476.3 MS (ES): 474.2
252		NH C(=O) N	-CH=CH ₂	-H	247 AE-3	MS (ES ⁺): 473.44 MS (ES): 471.43




Cpd. No.	-R	Starting From	Method Used	Analytical Data
231b	-CO ₂ CH ₃	230	AG-3	¹ H NMR (CDCl ₃): δ 10.17 (d, J = 0.75 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 6.94 (dd, J = 8.3, 0.75 Hz, 1 H), 6.51 (s, 1 H), 3.90 (s, 3 H)



Cpd. No.	-R	-R'	-R''	Starting From	Method Used	Analytical Data
232a	-H	-CHO	-CH ₃	231a + 6a	D-6 or D-7	¹ H NMR (CDCl ₃): δ 9.64 (s, 1 H), 8.44 (d, J = 2 Hz, 1 H), 8.02 (dd, J = 8 and 2 Hz, 1 H), 7.60 (d, J = 8.3 Hz, 1 H), 7.40 (d, J = 8 Hz, 1 H), 6.96 (d, J = 8 Hz, 1 H), 6.32 (t, J = 6 and 5 Hz, 1 H), 6.01 (s, 2 H), 3.72 (s, 3 H), 3.33 (t, J = 6.5 Hz, 2 H), 1.93 (m, 1 H), 1.00 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 384.3 and 406.3 (M+Na) ⁺
232b	-CO ₂ H	-CHO	-CH ₃	231b + 6a	D-6 or D-7	¹ H NMR (DMSO-d ₆): δ 9.87 (s, 1 H), 9.49 (s, 1 H), 8.64 (d, J = 2 Hz, 1 H), 8.3 (s, 1 H), 7.97 (d, J = 8 Hz, 1 H), 7.43 (dd, J = 8 and 2.6 Hz, 1 H), 7.35 (m, 2 H), 6.94 (m, 1 H), 6.05 (s, 0.4 H), 5.98 (s, 0.6 H), 3.55 (s, 1.8 H), 3.52 (s, 1.2 H), 3.02 (t, J = 6.5 Hz, 2 H), 1.78 (m, 1 H), 0.81 (d, J = 6.6 Hz, 6 H); MS (ES ⁺): 426.2
233a	-H	-CO ₂ H	-CH ₃	232a	E	¹ H NMR (DMSO-d ₆): δ 12.29 (bs, 1 H), 8.69 (t, J = 5.5 Hz, 1 H), 8.38 (d, J = 2 Hz, 1 H), 8.03 (dd, J = 8 and 2 Hz, 1 H), 7.58 (d, J = 8.5 Hz, 1 H), 7.36 (d, J = 8 Hz, 1 H), 7.00 (d, J = 8.5 Hz, 1 H), 6.02 (s, 2 H), 3.64 (s, 3 H), 3.12 (t, J = 6.5 Hz, 2 H), 1.87 (m, 2 H), 0.91 (d, J = 6.8 Hz, 6 H); MS (ES ⁺): 398.2


Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
233b	-CO ₂ H	-CO ₂ H	-CH ₃	232b	E	¹ H NMR (DMSO-d ₆): δ 8.64 (t, J = 5.5 Hz, 1 H), 8.38 (d, J = 4 Hz, 1 H), 8.00 (dd, J = 8.5 and 4 Hz, 1 H), 7.30 (dd, J = 8 and 2.5 Hz, 1 H), 6.52 (s, 0.5 H), 6.48 (s, 0.5 H), 3.60 (s, 1.5 H), 3.58 (s, 1.5 H), 3.08 (t, J = 6.5 Hz, 2 H), 1.84 (m, 1 H), 0.88 (d, J = 6.8 Hz, 6 H)
234a	-H		-CH ₃	233a	J	MS (ES ⁺): 517.4
234b	-CO ₂ H		-CH ₃	233b	J	¹ H NMR (DMSO-d ₆): δ 12.41 (bs, 1 H), 11.09 (s, 1 H), 10.96 (s, 1 H), 9.22 (bs, 2 H), 8.96 (bs, 2 H), 8.70 (m, 1 H), 8.38 (dd, J = 2 and 13 Hz, 1 H), 8.04 (d, J = 8 Hz, 1 H), 7.82 (m, 4 H), 7.65 (dd, J = 8 and 5 Hz, 1 H), 7.39 (dd, J = 8 and 2.5 Hz, 1 H), 7.11 (dd, J = 8.5 and 1.7 Hz, 1 H), 6.05 (s, 1 H), 3.67 (s, 1.5 H), 3.50 (s, 1.5 H), 3.10 (t, J = 6.5 Hz, 2 H), 1.88 (m, 1 H), 0.90 (d, J = 6.8 Hz, 6 H)
235a	-H		-H	234a	I-2	¹ H NMR (DMSO-d ₆ +DCl one drop): δ 8.34 (d, J = 2 Hz, 1 H), 7.97 (dd, J = 8 and 2 Hz, 1 H), 7.75 (m, 4 H), 7.33 (dd, J = 3.8 and 8.1 Hz, 2 H), 7.04 (d, J = 8.1 Hz, 1 H), 6.01 (d, J = 6 Hz, 2 H), 3.07 (t, J = 6.5 Hz, 2 H), 1.83 (m, 1 H), 0.86 (d, J = 6.8 Hz, 6 H); MS (ES ⁺) 501.3; (ES ⁺) 503.3



10

Cpd. No.	-R	-R'	-R"	Starting From	Method Used	Analytical Data
240	-CH(OH)-CH ₂ OH	-Boc	-CH ₃	161d	L	¹ H NMR (DMSO-d6): δ 10.47 (s, 1H), 9.07 (s, 2H), 8.72 (t, J = 5.7 Hz, 1H), 8.29 (d, J = 2 Hz, 1H), 8.08 (dd, J = 8.0, 2 Hz, 1H), 7.95 (s, 1H), 7.92 (s, 1H), 7.67 (m, 2 H), 7.62 (d, J = 6.5 Hz, 1 H), 7.46 (d, J = 8 Hz, 1H), 7.31 (d, J = 8 Hz, 1H), 5.50 (d, J = 4.5 Hz, 1H), 4.91 (t, J = 5.7 Hz, 1H), 4.74 (m, 1 H), 4.25 (s, 1 H), 3.63 (s, 3H), 3.15 (t, J = 6.4 Hz, 2H), 1.91 (m, 1H), 1.50 (s, 9 H), 0.95 (d, J = 6.7 Hz, 6H)
241	-CHO	-Boc	-CH ₃	240	M	¹ H NMR (DMSO-d6): δ 10.69 (s, 1H), 10.17 (s, 1H), 9.10 (bs, 2 H), 8.72 (t, J = 5.7 Hz, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.22 (d, J = 1.5 Hz, 1H), 8.22 (dd, J = 1.5 and 8 Hz, 1 H), 8.07 (dd, J = 1.5 and 8 Hz, 1 H), 7.89 (s, 1H), 7.86 (s, 1 H), 7.65 (s, 1 H), 7.62 (s, 1 H), 7.57 (d, J = 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 3.57 (s, 3H), 3.11 (t, J = 6.4 Hz, 2H), 1.85 (m, 1H), 1.44 (s, 9 H), 0.89 (d, J = 6.7 Hz, 6H)
242	-CH(OH)-CH=CH ₂	-Boc	-CH ₃	241	AG	MS (ES ^b): 629.39
243	-CH(OH)-CH=CH ₂	-H	-CH ₃	242	S	MS (ES ^b): 529.38
244	-CH(OH)-CH=CH ₂	-H	-H	243	I-2	MS (ES): 515.35

5



Cpd. No.	-R	Starting From	Method Used	Analytical Data	
254		253	AE-3	MS (ES ⁺)	318.2, 320.2
255		254	R	MS (ES ⁺)	418

The following non-limiting examples are presented to further illustrate the present invention.

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-4'-thien-2-yl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-4'-thien-3-yl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-1,1':4',1"-terphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-(3-furyl)-4-[isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-4'-pyridin-4-yl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-4'- (1H-pyrrol-2-yl)-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-[2-(hydroxymethyl)thien-3-yl]-4-[isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-[3-(hydroxymethyl)thien-2-yl]-4-[isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[isobutylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

4'-Allyl-2'-[({4-[amino(imino)methyl]phenyl} amino)carbonyl]-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylate

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-(1,3-thiazol-2-yl)-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4'-[3-(hydroxymethyl)-2-furyl]-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-prop-1-ynyl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4'-(3-hydroxy-3-methylbut-1-ynyl)-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4-[(3-methylbutanoyl)amino]-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4'-(4-hydroxybut-1-ynyl)-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-[{(1E)-3-methylbuta-1,3-dienyl}-1,1'-biphenyl-2-carboxylic acid]

2'-[({4-[Amino(imino)methyl]phenyl} amino)carbonyl]-4'-(3-hydroxyprop-1-ynyl)-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-(2-furyl)-4-[(propylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(sec-butylamino)carbonyl]-4'-(2-furyl)-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-(2-furyl)-4-{{(2,2,2-trifluoroethyl)amino}carbonyl}-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-(2-furyl)-4-{{(4-hydroxybutyl)amino}carbonyl}-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(ethylamino)carbonyl]-4'-(2-furyl)-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-5'-methoxy-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-(thien-2-ylmethyl)-1,1'-biphenyl-2-carboxylic acid

2-{3-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]pyridin-4-yl}-5-[(isobutylamino)carbonyl]benzoic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(cyclopentylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-5'-ethoxy-4-[(isobutylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

Methyl 2'-[({4-[{[(acetyloxy)methoxy]carbonyl}amino)(imino)methyl]phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylate

Methyl 2'-[({4-[{(benzyloxy)carbonyl}amino](imino)methyl]phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylate

N¹-{4-[Amino(imino)methyl]phenyl}-N8-isobutyl-6-oxo-6H-benzo[c]chromene-1,8-dicarboxamide

2'-[({4-[Amino(imino)methyl]phenyl}amino)methyl]-4-[(isobutylamino)carbonyl]-4'-vinyl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-[(isobutylamino)carbonyl]-5'-thien-2-yl-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-5'-(2-amino-2-oxoethoxy)-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2'-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4'-ethoxy-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

2-{5-[({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-1,3-benzodioxol-4-yl}-5-[(isobutylamino)carbonyl]benzoic acid

2'-[1-({4-[Amino(imino)methyl]phenyl}amino)ethyl]-4-[(isobutylamino)carbonyl]-1,1'-biphenyl-2-carboxylic acid

3-[2-{({4-[Amino(imino)methyl]phenyl}amino)carbonyl]-4-(benzyloxy)phenyl]-6-[(isobutylamino)carbonyl]pyridine-2-carboxylic acid

3-[2-(4-Carbamimidoyl-phenylcarbamoyl)-4-vinyl-phenyl]-6-isobutylcarbamoyl-pyridine-2-carboxylic acid

2'-[{5-Carbamimidoyl-pyridin-2-ylamino)-methyl}-4-isobutylcarbamoyl-4'-vinyl-biphenyl-2-carboxylic acid

2'-[{4-(N-Hydroxycarbamimidoyl)-phenylamino]-methyl}-4-isobutylcarbamoyl-4'-vinyl-biphenyl-2-carboxylic acid methyl ester

2'-[{4-(N-Hydroxycarbamimidoyl)-phenylamino]-methyl}-4-isobutylcarbamoyl-4'-vinyl-biphenyl-2-carboxylic acid methyl ester

3-{2-[(4-Carbamimidoyl-phenylamino)-methyl]-4-vinyl-phenyl}-6-isobutylcarbamoyl-pyridine-2-carboxylic acid

Biological Assay Methods

In Vitro Assay for Inhibition of TF/FVIIa

5 To assess the inhibition of the test compounds against the target enzyme, TF/FVIIa, an amidolytic assay based upon the absorbance of p-Nitroanalide (pNA) at OD₄₀₅ was utilized. The IC₅₀ of the test compounds was determined by using KC4A data reduction software (Bio-Tek Instruments) to interpolate percent inhibition from observed Vmax values.

10

TF/FVIIa assay reactions were performed in a 200 µL mixture containing 4 nM FVIIa, 10 nM lipidated tissue factor, in an assay buffer containing 100 mM Tris, pH 7.2, 150 mM NaCl, 5 mM calcium chloride, 0.1 % bovine serum albumin (BSA), and 10% dimethyl sulfoxide (DMSO). TF and FVIIa were allowed to equilibrate at room 15 temperature for 15 minutes. Test compounds dissolved in DMSO were incubated at varied concentrations with TF/FVIIa for 10 minutes, followed by addition of 500 nM substrate Spectrozyme-FVIIa. Reactions were incubated for 5 minutes at room temperature prior to measuring the change in OD₄₀₅ nm for 10 minutes at 21 second intervals with a Powerwave X (Bio-Tek Instruments) microplate reader.

20

In Vitro Assay for Human Thrombin

This colorimetric assay was used to assess the ability of the test compounds to inhibit the human thrombin enzyme. IC₅₀ of the test compounds was determined by 25 using KC4A data reduction software (Bio-Tek Instruments) to interpolate percent inhibition from observed Vmax values.

Thrombin assay reactions were performed in a 200 µL mixture containing human thrombin at (1 U/mL) in an assay buffer containing 100 mM HEPES, 10 mM calcium

chloride, and 10 % DMSO, pH 7.5. Test compounds dissolved in DMSO were added to thrombin enzyme reactions at varied concentrations, followed by the addition of substrate Na-Benzoyl-Phe-Val-Arg p-Nitroanilide at a final concentration of 1 mM. Reactions were incubated for 5 minutes at room temperature prior to measuring the change in OD₄₀₅ 5 nm for 10 minutes at 21 second intervals with a Powerwave x (Bio-Tek Instruments) microplate reader.

In Vitro Assay for Human Trypsin


10 This enzymatic assay was employed to evaluate the ability of the test compounds to inhibit human pancreatic trypsin. IC₅₀ of the test compounds was determined by using KC4A data reduction software (Bio-Tek Instruments) to interpolate percent inhibition from observed Vmax values.

15 Trypsin assay reactions were performed in a 200 µL mixture containing human pancreatic trypsin at 1 µg/mL in an assay buffer containing 200 mM triethanolamine (TEA), 10 mM calcium chloride, 10 % DMSO, pH 7.8. Test compounds dissolved in DMSO were added to trypsin enzyme reactions at varied concentrations, followed by the addition of substrate Na-Benzoyl-L-Arginine p-Nitroanilide (L-BAPNA) at a final 20 concentration of (0.25 mg/mL). Reactions were incubated for 5 minutes at room temperature prior to measuring the change in OD₄₀₅ nm for 10 minutes at 21 second intervals with a Powerwave x (Bio-Tek Instruments) microplate reader.

Biological Data

IC₅₀ Values of Some Selected Compounds on Different Serine Protease Enzymes






5



15

25

R (With Respect to Phenyl Ring)	R'	TF/FVIIa	Trypsin	Thrombin
		++	+	+
		++	+	+
		++	+	+
		++	-	-
		+	-	-
		++	-	-
		+++	++	+

 (4)		+++	++	+
 (4)		+++	++	+
 (4)		+++	++	+

IC₅₀ values: + means >1 μM; ++ means >100 nM; +++ means <100 nM

A comparison of Examples with R group and without R group illustrates the greatly-enhanced activity achieved pursuant to the present invention.

Compounds of the present invention are useful as inhibitors of trypsin-like serine
5 protease enzymes such as thrombin, factor VIIa, TF/FVIIa, and trypsin.

These compounds may be employed to inhibit the coagulation cascade and prevent or limit coagulation.

10 These compounds may be used to inhibit the formation of emboli or thromboli in blood vessels.

These compounds may be used to treat thrombolymphangitis, thrombosinusitis, thromboendocarditis, thromboangitis, and thromboarteritis.

15 These compounds may be used to inhibit thrombus formation following angioplasty. These may be used in combination with other antithrombotic agents such as tissue plasminogen activators and their derivatives, streptokinase and its derivatives, or urokinase and its derivatives to prevent arterial occlusion following thrombolytic therapy.

20 These compounds may also be used in metastatic diseases, or for any disease where inhibition of coagulation is indicated.

25 These compounds may be used as diagnostic reagents in vitro for inhibiting clotting of blood in the tubes.

These compounds may be used alone or in combination with other compounds such as heparin, aspirin, or warfarin and any other anticoagulant agents.

These compounds may be used as anti-inflammatory agents.

According to a further aspect of the invention, compounds may be employed in preventing ex vivo coagulation such as that encountered in the extracorporeal perfusion 5 of blood through for example artificial valves, prothesis, stents or catheters. According to this aspect of the invention the extracorporeal device may be coated with the compositions of the invention resulting in a lower risk of clot formation due to extrinsic pathway activation.

10

Dosage and Formulation

The compounds of this invention can be administered by any means that produces contact of the active agent's site of action with factor VIIa and other serine proteases in the body of a human, mammal, bird, or other animal. They can be administered by any 15 conventional means, such as oral, topical, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal, available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. Parenteral infusion includes intramuscular, intravenous, and intraarterial. They can be administered alone, but generally administered with a pharmaceutical carrier 20 elected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will, or course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and 25 route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms, the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.0001 to 1000 milligram (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg.

Dosage forms (compositions suitable for administration) contain from about mg to about 500 mg of compound per unit. In these pharmaceutical compositions, the compound of the present invention will ordinarily be present in an amount of about 0.5-
5 95% by weight based on the total weight of the composition.

The daily dose of the compounds of the invention that is to be administered can be a single daily dose or can be divided into several, for example, two, three or four, part administrations. The pharmaceutical compositions or medicaments of the invention can
10 be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion
15 solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.

Gelatin capsules contain a compound of the present invention and powdered
20 carriers, such as lactose, starch, cellulose derivatives, biocompatible polymers, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated to mask by unpleasant taste and protect the tablet
25 from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. They may also contain buffering agents, surfactants and

preservatives. Liquid oral products can be developed to have sustained-release properties. They may also contain cyclodextrin derivatives to enhance the solubility of the active ingredient and to promote its oral uptake.

5 In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffering agents. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.

10 Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company and in the Handbook of Pharmaceuticals Excipients, American Pharmaceutical Association, both standard reference texts in this field.

15 Useful pharmaceutical dosage forms for administration of the compounds according to the present invention can be illustrated as follows:

Hard Shell Capsules

20 A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered 1500 mg of lactose, 50 mg of cellulose, and 6 mg of magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement pump into
5 molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The prodrug can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.

Tablets

10

A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 9.98 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase
15 palatability improve elegance and stability or delay absorption.

Immediate Release Tablets/Capsules

These are solid oral dosage forms made by conventional and novel processes.
20 These units are taken orally without water for immediate dissolution and delivery of the medication. The drug is mixed containing ingredient such as sugar, gelatin, pectin, and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.

25

Moreover, the compounds of the present invention can be administered in the form of nose drops, metered dose nasal or buccal inhalers. The drug is delivered from a nasal solution as a fine mist or from a powder as an aerosol.

In another embodiment of the invention, a compound of the invention can be used in an assay to identify the presence of factor VIIa and other serine protease or to isolate factor VIIa and other serine protease in a substantially purified form. For example, the compound of the invention can be labeled with, for example, a radioisotope, and the


- 5 labeled compound is detected using a routine method useful for detecting the particular label. In addition, a compound of the invention can be used advantageously as a probe to detect the location or amount of factor VIIa and other serine protease activity in vivo, in vitro or ex vivo.

10 Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The foregoing disclosure includes all the information deemed essential to enable 15 those skilled in the art to practice the claimed invention. The foregoing description of the invention illustrates and describes the present invention. Additionally, the disclosure shows and describes only the preferred embodiments of the invention but, as mentioned above, it is to be understood that the invention is capable of use in various other combinations, modifications, and environments and is capable of changes or 20 modifications within the scope of the inventive concept as expressed herein, commensurate with the above teachings and/or the skill or knowledge of the relevant art. The embodiments described hereinabove are further intended to explain best modes known of practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with the various modifications required by 25 the particular applications or uses of the invention. Accordingly, the description is not intended to limit the invention to the form disclosed herein. Also, it is intended that the appended claims be construed to include alternative embodiments.

What is claimed is

1. Compound having the structure (I) shown below:



- 15 Each E¹ and L individually is a 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or unsaturated hetero ring, bicyclic saturated or unsaturated carbon ring, bicyclic saturated or unsaturated hetero ring, or 1-8 hydrocarbon chain which may be substituted with one or more hetero groups selected from N, O, S, S(O), and S(O₂) which may be saturated or unsaturated;

20 R is $-\text{CH}=\text{CH}-\text{R}^2$, $-\text{C}\equiv\text{C}-\text{R}^2$, $-\text{C}(\text{R}^2)=\text{CH}_2$, $-\text{C}(\text{R}^2)=\text{C}(\text{R}^3)$, $-\text{CH}=\text{NR}^2$, $-\text{C}(\text{R}^2)=\text{N}-\text{R}^3$, 4-7 membered saturated or unsaturated carbon ring system with or without substitution, 4-7 membered saturated or unsaturated hetero ring system with or without substitution, or chain of 2 to 8 carbon atoms having 1 to 5 double or triple bonds with substitutions
25 selected from R^1 , R^2 , or R^3 . Preferably, these R , R^1 , R^2 , or R^3 do not include $-(\text{C}_{2-4}$ alkenyl)- CO_2 - C_{1-8} alkyl, $-(\text{C}_{2-4}$ alkenyl)- CO_2 - C_{1-8} alkyl-phenyl, and $-(\text{C}_{2-4}$ alkenyl)- CO_2 - C_{1-8} alkyl-O- C_{1-4} alkyl;

³⁰ R¹ is H, -R, -NO₂, -CN, -halo, -N₃, -C₁₋₈ alkyl, -(CH₂)_nCO₂R², -C₂₋₈ alkenyl-CO₂R², -O(CH₂)_nCO₂R², -C(O)NR²R³, -P(O)(OR²)₂, alkyl substituted tetrazol-5-yl,

- $(CH_2)_nO(CH_2)_n$ aryl, $-NR^2R^3$, $-(CH_2)_nOR^2$, $-(CH_2)_nSR^2$, $-N(R^2)C(O)R^3$, $-S(O_2)NR^2R^3$,
 $-N(R^2)S(O_2)R^3$, $-(CHR^2)_nNR^2R^3$, $-C(O)R^3$, $(CH_2)_nN(R^3)C(O)R^3$, $-N(R^2)CR^2R^3$
 substituted or unsubstituted $(CH_2)_n$ -cycloalkyl, substituted or unsubstituted $(CH_2)_n$ -phenyl, or substituted or unsubstituted $(CH_2)_n$ -heterocycle which may be saturated or
 5 unsaturated;

m is 1 except that when E¹ is a cyclic ring of more than 5 atoms, then m is 1 or higher, depending upon the size of the ring;

- 10 R² is H, -halo, -alkyl, -haloalkyl, $-(CH_2)_n$ -phenyl, $-(CH_2)_{1-3}$ -biphenyl, $-(CH_2)_{1-4}Ph$ -
 $N(SO_2-C_{1-2}-alkyl)_2$, $-CO(CHR^1)_nOR^1$, $-(CHR^1)_n$ -heterocycle, $-(CHR^1)_n-NH-CO-R^1$,
 $-(CHR^1)_n-NH-SO_2R^1$, $-(CHR^1)_n-Ph-N(SO_2-C_{1-2}-alkyl)_2$, $-(CHR^1)_n-C(O)(CHR^1)-NHR^1$,
 $-(CHR^1)_n-C(S)(CHR^1)-NHR^1$, $-(CH_2)_nO(CH_2)_nCH_3$, $-CF_3$, $-C_{2-5}$ acyl, $-(CHR^1)_nOH$,
 $-(CHR^1)_nCO_2R^1$, $-(CHR^1)_n-O$ -alkyl, $-(CHR^1)_n-O-(CH_2)_n-O$ -alkyl, $-(CHR^1)_n-S$ -alkyl,
 15 $-(CHR^1)_n-S(O)$ -alkyl, $-(CHR^1)_n-S(O_2)$ -alkyl, $-(CHR^1)_n-S(O_2)-NHR^3$, $-(CHR^3)_n-N_3$,
 $-(CHR^3)_nNHR^4$, 2 to 8 carbon atom alkene chain having 1 to 5 double bonds, 2 to 8
 carbon atom alkyne chain having 1 to 5 triple bonds, substituted or unsubstituted-
 $(CHR^3)_n$ heterocycle, or substituted or unsubstituted- $(CHR^3)_n$ cycloalkyl which may be
 saturated or unsaturated;
- 20 When n is more than 1, the substitutions R¹ and R³ may be same or different;

R³ is H, -OH, -CN, substituted alkyl, C_{2-8} alkenyl, substituted or unsubstituted
 cycloalkyl, $-N(R^1)R^2$, or 5-6 membered saturated substituted or unsubstituted hetero ring;

- 25 $-NR^2R^3$ may form a ring system having 4 to 7 atoms or may be bicyclic ring; wherein
 said ring system comprises carbon or hetero atoms and further it may be saturated or
 unsaturated and also may be substituted or unsubstituted;

W is a direct bond, -CHR²-, -CH=CR²-, -CR²=CH-, -CR²=CR²-, -C=C-, -O-CHR²-,
 -CHR²-O-, -N(R²)-C(O)-, -C(O)-N(R²)-, -N(R²)-CH-(R³)-, -CH₂-N(R²)-,
 -CH(R¹)-N(R²)-, -S-CHR²-, -CHR²-S-, -S(O₂)-N(R²)-, -C(O)N(R²)-(CHR²)n-,
 -C(R¹R²)n-NR²-, -N(R²)-S(O₂)-, -R²C(O)NR²-, -R²NC(O)NR²-, -CONR²CO-,
 5 -C(=NR²)NR²-, -NR²C(=NR²)NR²-, -NR²O-, -N=NCHR²-, or -C(O)NR²SO₂-;

E² is 5 to 7 membered saturated or unsaturated carbon ring, 5 to 7 membered saturated or
 unsaturated hetero ring, bicyclic ring system, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl,
 alkylaryl, aralkyl, aralkenyl, aralkynyl, alkoxy, alkylthio, or alkylamino;

10

each X individually is a direct bond, substituted or unsubstituted C₁₋₄ methylene chain, O,
 S, NR², S(O), S(O₂), or N(O) containing one or two C₁₋₄ substituted or unsubstituted
 methylene chains; X at different places may be same or different;

15

B is H, -halo, -CN, -NH₂, -(CH₂)_n-C(=NR⁴)NHR⁵, -(CH₂)_n-NHR⁴, -
 (CH₂)_nNHC(=NR⁴)NR⁵, -(CH₂)_n-OR⁴, C₁₋₈ substituted or unsubstituted alkyl, substituted
 or unsubstituted ring system having 4 to 7 carbon or hetero atoms which may be saturated
 or unsaturated;

20

B¹ is selected from B; B¹ and B may be same or different;

There may be more than one similar or different R² groups present on E², when E² is a
 cyclic group of more than 5 atoms; p is 1 except that when E² is a cyclic ring of more
 than 5 atoms, p is 1 or higher depending upon the size of the ring;

25

n is 0-4;


A is selected from R¹;

o is 1 except that when L is a cyclic ring of more than 5 atoms, o is 1 or higher depending
 30 upon the size of the ring;

- Each V and V¹ individually is selected from R¹ and N-alkyl substituted carboxamidyl (-CONHR) where the alkyl group may be straight, branched, cyclic, or bicyclic; N,N-disubstituted carboxamidyl of the formula -CONR₁R₂ where R₁ and R₂ may be
- 5 substituted or unsubstituted alkyl or aryl and may be the same or different; mono- or disubstituted sulfonamides of the formula SO₂NHR or -SO₂NR₁R₂; and methylene- or polymethylene chain-extended variants thereof;
- Each R⁴ and R⁵ individually is H, -(CH₂)_nOH, -C(O)OR⁶, -C(O)SR⁶, -(CH₂)_n
- 10 C(O)NR⁷R⁸, -O-C(O)-O-R⁷, an amino acid or a dipeptide;
- Each R⁶ is H, R⁷, -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)R⁹, -(CH₂)_n-C(R⁷)(R⁸)-O-C(O)-O-R⁹, or -C(R⁷)(R⁸)-(CH₂)_n-O-C(O)-O-R⁹; and
- 15 Each R⁷, R⁸ and R⁹ individually is H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or CH₂CO₂alkyl.


2. The compound of claim 1 represented by the structure

5



wherein R is selected from the group consisting of


10




15

and R' is selected from the group consisting of


20




25




30



35




40




pharmaceutically acceptable salts thereof; and prodrugs thereof.


3. The compound of claim 1 represented by the structure




10 wherein R is selected from the group consisting of



20



25




-OCH₃;

and R' is selected from the group consisting of -CHO, -CO₂H, and -CO₂MEM; and
30 pharmaceutically acceptable salts thereof; and prodrugs thereof.

4. The compound of claim 1 represented by the structure

5




wherein R is $-\text{OSO}_2\text{CF}_3$; and R' is selected from the group consisting of

10


$-\text{CHO}$, $-\text{CO}_2\text{H}$, $-\text{CH}_2\text{NHCH}_3$; and pharmaceutically acceptable salts thereof;


15 and prodrugs thereof.

5. The compound of claim 1 represented by the structure




10 wherein R is selected from the group consisting of








6. The compound of claim 1 represented by the structure




wherein R is selected from the group consisting of







15 and  ; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

7. The compound of claim 1 represented by the structure





wherein R is selected from the group consisting of





and R' is selected from the group consisting of







and pharmaceutically acceptable salts thereof; and prodrugs thereof.

25


8. The compound of claim 1 represented by the structure



wherein R is selected from the group consisting of




9. The compound of claim 1 represented by the structure



wherein R is selected from the group consisting of

15




20

and R' is -H or ; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

25

10. The compound of claim 1 represented by the structure

5




wherein R is selected from the group consisting of
10




15 R' is selected from the group consisting of -CHO, -CO₂H, and -CO₂MEM;

and R'' is selected from the group consisting of


20




25



30




35



and pharmaceutically acceptable salts thereof; and prodrugs thereof.

11. The compound of claim 1 represented by the structure


5



10


wherein R is selected from the group consisting of

15




20 R' is -H or -Boc; and R'' is -CO₂MEM or -CO₂H; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

12. The compound of claim 1 represented by the structure




wherein R is -CH₃ and R' is selected from the group consisting of


15




20




25




30




35




40



5




10




and pharmaceutically acceptable salts thereof; and prodrugs thereof.

13. The compound of claim 1 represented by the structure




wherein R is ; and R' is selected from the group consisting of


15




20




25




30




35




40





5




10

and pharmaceutically acceptable salts thereof; and prodrugs thereof.

14. The compound of claim 1 represented by the structure

5




10

15

wherein R is and -CH=CH₂ and R' is selected from the group consisting of


20



25


and pharmaceutically acceptable salts thereof; and prodrugs thereof.

15. The compound of claim 1 represented by the structure




wherein R is $-\text{CH}_3$ and R' is selected from the group consisting of


15




20




25



30




35







40

and pharmaceutically acceptable salts thereof; and prodrugs thereof.

16. The compound of claim 1 represented by the structure




10 wherein at least one R is selected from the group consisting of




R' is selected from the group consisting of


35

-CHO, -CO₂H, -CO₂MEM,




40






and R" is selected from the group consisting of -H, -CH₃ and -Bn; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

17. The compound of claim 1 represented by the structure



wherein at least one R is selected from the group consisting of

-CH=CH₂, -OSO₂CF₃, -OCH₂CO₂C₂H₅, -OCH₂CONH₂,



25

-OCH₂CO₂H, -O-CH₂-CH₂-OH, -CH(OH)CH₂OH, -CH₂OH, -CO₂H,

30

A chemical structure showing a thienothiophene ring system with a propyl group (-CH₂-CH₂-CH₃) attached to the 2-position.


-OBn, -OH, -OCH₃, -OBn, -OH, -OC₂H₅,

35

-OBn, -OCH₃, and -CH(OH)CH₃; and R' is selected from the group consisting of -CH₃, -CH₂C₆H₅, -Bn, -H; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

18. The compound of claim 1 represented by the structure


5
10



wherein at least one R is selected from the group consisting of -CH=CH₂,
15 -CH(OH)CH₂OH, -CH=O, -CH₂OH, -CO₂H, -OCH₃, -CH=CH₂; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

19. The compound of claim 1 represented by the structure


5



10 wherein R is selected from the group consisting of halo and -B(OH)₂; R1 is selected from the group consisting of -H, -OCH₃, -OBn; R2 is selected from the group consisting of

15


-H, -OCH₃, -OC₂H₅, -OCH(CH₃)₂, and



R3 is selected from the group consisting of -H, -OH, -OBn; and R4 is -OBn or -H; and pharmaceutically acceptable salts thereof; and prodrugs thereof.


20 20. The compound of claim 19 wherein said halo is -Br.

21. The compound of claim 1 represented by the structure




22. The compound of claim 1 represented by the structure

5



10 wherein R is selected from the group consisting of

15



15

R' is selected from the group consisting of -OBn, -OH, -OSO₂CF₃, and -CH=CH₂;


20

R'' is selected from the group consisting of -CO₂H, -CO₂MEM, or -CHO;


20

and R''' is selected from the group consisting of


25



30




35



and prodrugs thereof.

23. The compound of claim 1 represented by the structure

5




10

15 wherein R is selected from the group consisting of


20

R' is -H or alkyl; and R'' is selected from the group consisting of

25



30




35


thereof; and prodrugs thereof.


24. The compound of claim 23 wherein said alkyl is -CH₃.


25. The compound of claim 1 represented by the structure




wherein R is selected from the group consisting of







5




and ;

10


R' is -H, -CH=CH₂; and R" is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

26. The compound of claim 25 wherein said alkyl is -CH₃.


27. The compound of claim 1 represented by the structure



wherein R is selected from the group consisting of



20 from the group consisting of




and ; and pharmaceutically acceptable salts thereof; and prodrugs
30 thereof.

28. The compound of claim 27 wherein said alkyl is -CH₃.

29. The compound of claim 1 represented by the structure


5



10

wherein N is located at position 3 or 4 in the phenyl ring; R is selected from the group consisting of -CHO, -CO₂H, and

15




20

and R' is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.


30. The compound of claim 29 wherein said alkyl is -CH₃.

31. The compound of claim 1 represented by the structure




wherein R is selected from the group consisting of

15



20



25


and R' is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

32. The compound of claim 31 wherein alkyl is CH₃.

30

33. The compound of claim 1 represented by the structure

5




wherein R is selected from the group consisting of

10

15

-CHO, -CO₂H, and



; and R' is -H or alkyl; and


pharmaceutically acceptable salts thereof; and prodrugs thereof.

20

34. The compound of claim 33 wherein said alkyl is -CH₃.

35. The compound of claim 1 represented by the structure


5



10

wherein at least one R is selected from the group consisting of -CH=CH₂, -OCH₃, -OBn, -OH, and -H; R' is

15



20

R'' is selected from the group consisting of


25

, , and ; and R''' is -H; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

30

36. The compound of claim 1 represented by the structure

5



10

15


20

wherein R is -CH₂OH or ;

and R' is -Boc, or -H; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

37. The compound of claim 1 represented by the structure

5



wherein R is -OCH₃, -OH, -OSO₂CF₃, -C(=NH)NH₂, and -H;

10 R' is Alkyl or -NH₂;

15 and R'' is halo, -CH=CH₂, -CO₂CH₃, and


and pharmaceutically acceptable salts thereof; and prodrugs thereof.

38. The compound of claim 37 wherein said halo is -Br.

20


39. The compound of claim 1 represented by the structure

5



10 wherein R is selected from the group consisting of -CHO, -CO₂H, -CO₂MEM,

15




20 R' is selected from the group consisting of -OBn, -OH, -OSO₂CF₃, and -CH=CH₂;

and R'' is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

25 40. The compound of claim 39 wherein said alkyl is -CH₃.

41. The compound of claim 1 represented by the structure


5



wherein R is -CO₂CH₃; and pharmaceutically acceptable salts thereof; and prodrugs
10 thereof.

42. The compound of claim 1 represented by the structure


5



10 wherein R is -H or -CO₂H;

R' is selected from the group consisting of -CHO, -CO₂H, and

15



20

and R" is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.


43. The compound of claim 42 wherein said alkyl is -CH₃.

25

44. The compound of claim 1 represented by the structure

5

10



wherein R is selected from the group consisting of -CH(OH)-CH₂OH, -CHO, and
15 -CH(OH)-CH=CH₂;


R' is -Boc or -H; and R'' is -H or alkyl; and pharmaceutically acceptable salts thereof; and prodrugs thereof.

20

45. The compound of claim 44 wherein said alkyl is -CH₃.


46. The compound of claim 1 represented by the structure

5



wherein R is

10



and pharmaceutically acceptable salts thereof; and prodrugs thereof.

15

47. A pharmaceutical composition containing at least one compound according to claim 1.

20

48. A method for inhibiting serine protease in a patient which comprises administering to the patient an effective serine protease inhibiting amount of at least one compound according to claim 1.

25

49. A method for inhibiting the coagulation cascade and preventing or limiting coagulation by administering to a patient an effective amount of at least one compound according to claim 1.

30

50. A method for inhibiting the formation of emboli or thromboli in blood vessels by administering to a patient an effective amount of at least one compound according to claim 1.

51. A method for treating at least one condition selected from the group consisting of thrombolympangitis, thrombosinusitis, thromboendocarditis, thromboangitis, and thromboarteritis which comprises administering to a patient an effective amount of at least one compound according to claim 1.

52. A method for inhibiting thrombus formation following angioplasty which comprises administering to a patient an effective amount of at least one compound according to claim 1.

5

53. A method for preventing arteria occlusion following thrombolytic therapy which comprises administering to a patient an effective amount of at least one compound according to claim 1 and an effective amount of at least another antithrombolytic agent.

10 54. The method of claim 53 wherein said other antithrombolytic agent is selected from the group consisting of tissue plasminogen activators, streptokinase and urokinase, and functional derivatives thereof.

15 55. A method for treating metastatic diseases which comprises administering to a patient an effective amount of at least one compound according to claim 1.

56. A method of claim 49 which further comprises administering a further anticoagulant agent to said patient.

20 57. The method of claim 56 wherein said further anticoagulant agent is selected from the group consisting of heparin, aspirin, and warfarin.

25 58. A methof for treating a patient in need of an anti-inflammatory agent which comprises administering to said patient an effective amount of at least one of the compounds according to claim 1.

59. A method for inhibiting *in vitro* clotting of blood which comprises contacting said blood with at least one compound according to claim 1.

60. The method of claim 59 which comprises inhibiting said blood in tubes.

61. An extraarpereal device having a coating therein which comprises a compound according to claim 1.

5


62. A method for detecting future presence of a serine protease which comprises contacting a sample with a compound according to claim 1.

10

63. The compound of claim 1 represented by the structure


15

20




wherein R is alkyl and R' is selected from the group consisting of


25




30



35



40



and pharmaceutically acceptable salts thereof; and prodrugs thereof.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/32582

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :Please See Extra Sheet.
US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CASONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,551,279 A (MUELLER et al) 05 November 1985, see various examples in column 5-29.	1, 2, 47-62
Y	WO 99/41231 A1 (ONO PHARMACEUTICAL CO. LTD.) 19 August 1999, page 21-51, pages 97-610.	1-63
Y	PRYOR K.E. et al. The activated Core Approach to Combinatorial chemistry: A selection of new Core Molecules. Tetrahedron. 1998, Vol. 54, pages 4107-4124, especially page 4111.	1, 10-18, 22-26, 31, 32, 35, 44, 45

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 MARCH 2002

Date of mailing of the international search report

20 MAR 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-8230

Authorized officer
SHAILENDRA KUMAR

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/32582

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/32582

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (7):

C07C 229/38, 317/22, 68/04, 257/00; C07D 883/22, 807/02, 277/80, 207/80, 207/08, 211/70, 311/78, 289/02, 265/30, 277/62, 211/70, 317/44, 231/56; A61K 31/24, 31/69, 31/88, 31/84, 31/255, 31/425, 31/40, 31/55, 31/495, 31/505, 31/585, 31/425, 31/415, 31/44, 31/27, 31/155

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/64, 588, 438, 472, 517, 365, 427, 428, 568, 455, 255, 256, 231.2, 367, 403, 357, 485, 687, 560/35, 39, 11, 12, 14, 38;
549/213, 76, 496, 280, 436; 548/204, 561, 567, 152, 361.1;
546/335, 337; 544/335, 106; 562/469; 564/246

B. FIELDS SEARCHED

Minimum documentation searched
Classification System: U.S.

514/64, 588, 438, 472, 517, 365, 427, 428, 568, 455, 255, 256, 231.2, 367, 403, 357, 485, 687, 560/35, 39, 11, 12, 14, 38;
549/213, 76, 496, 280, 436; 548/204, 561, 567, 152, 361.1; 546/335, 337; 544/335, 106; 562/469; 564/246

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-8(in part), 4, 5-7(in part), 8-11, 13-14(in part), 15, 16-17(in part), 18-20, 22-24, 25-28(in part) 29-30, 31-34, 35(in part), 36, 44-45 and 47-62(in part), drawn to compounds which are non heterocyclic, and are ester or acids.

Group II, claim(s) 1-2(in part), 47-62(in part) drawn to boron containing compounds.

Group III, claim(s) 1(in part), 3, 5-7, 8, 10, 11-14, 16-17(in part), 21, 27-28(in part), 41-43, 47-63(in part) drawn to oxygen or sulfur containing five membered heterocyclic ring compounds.

Group IV, claims 1(in part), 5-7(in part), 9(in part), 12-13(in part), 25-26(in part), 47-63(in part), drawn to five membered nitrogen containing heterocyclic compounds.

Group V, claim 1(in part), 5-7(in part), 12-13(in part), 25-26(in part) 35(in part), 37-40, 47-63(in part), drawn to six membered nitrogen containing heterocyclic compounds.

Group VI, claims 1, 46(in part) and 47-62(in part), drawn to non heterocyclic amidino containing compounds.

Group VII, claim 1(in part), 46(in part), 47-62(in part), drawn to non heterocyclic carbamates.

The inventions listed as Groups I to VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The various chemical compounds claimed in the various groups are chemically divergent and have functionally different entity. Thus there lacks the same or corresponding special technical features.